

AUTHOR INDEX*

Volume 62

A

A, D., 6485
Aalders, M. C. G., 2024
Aalders, T. W., 2695
Aaltonen, L. A., 1166, 4352, 4554, 5989
Aarts, W. M., 5770
Abate-Shen, C., 2999
Abbaszadegan, M., 2654
Abbey, N. W., 5536
Abbruzzese, J., 6070
Abdelmohsen, K., 4922
Abdrabbo, M. K., 6823
Abecassis, J., 6211
Abel, J., 99
Abello, J., 4829
Aboagye, E. O., 5912
Abou-Khalil, E., 4325
Abraham, D., 5317
Abraham, J. M., 1148, 3493, 3641, 5637, 6820
Abri, H., 5317
Abrosimov, A. Y., 7031
Aburatani, H., 233
Accardi, L., 3654
Achermann, R., 2962
Ackerman, J. J. H., 1555
Adam, B.-L., 3609
Adam, R. M., 1549
Adams, A. W., 4109
Adams, D. M., 3159, 6552
Adams, J., 4996
Adams, M., 3289
Adams, S., 6717
Adem, C., 3587
Adesomoju, A. A., 4007
Adeyanju, M. O., 1481
Adigun, Y. E., 4115
Adini, A., 2749
Agarwal, C., 3063
Agarwal, R., 3063, 5280
Agata, N., 789
Aggarwal, B. B., 4945
Aguilar-Cordova, E., 4968
Aguzzi, A., 2592
Aharinejad, S., 5317
Ahmad, N., 6659
Ahmadian, M.-R., 1718
Ahmed, A., 5495, 6566
Ahmed, F., 7166
Ahn, D., 4514
Ahn, E., 6385
Ahn, K. Y., 1809
Ahn, W.-S., 7234
Ahrnovitz, N., 2654
Aicher, L. D., 5645
Aimes, R. T., 7083
Aittomäki, K., 4554
Aizu, W., 3667
Akagi, T., 6390
Akaike, T., 3138
Akasaka, T., 6224
Akel, N. S., 5571
Akgul, C., 6500
Akhand, A. A., 2414
Akhurst, R. J., 5627
Akiyama, M., 3876
Akiyama, S. K., 6837
Akiyama, S.-i., 2834
Akiyama, T., 3322

Akiyama, Y., 4894
Akslen, L. A., 6808
Akunda, J., 3395
Alain, T., 1696
Alam, M., 2493
Alaoui-Jamali, M. A., 5457
Alazawi, W., 6959
Albanese, C., 3997
Albar, J. P., 3167
Albelda, S. M., 6997
Albert, M., 3466
Albertson, D. G., 3636
Albini, A., 2406
Albor, A., 3264
Aldape, K. D., 6205
Aldaz, C. M., 4054
Alder, H., 2258
Ale-Agha, N., 4922
Alemany, R., 1266, 4663, 5736
Alexander, H. R., 3581
Alexander, R. L., 1730
Alfonso-De Matte, M. Y., 4575
Alfthan, H., 5210
Ali, S. Z., 135
Alison, M., 5698
Alitalo, K., 5580
Allegrini, P. R., 4015
Allen, J. C., 2660
Allen, J. D., 2294
Allen, T. M., 7190
Allen, W. L., 2644
Alli, E., 6864
Allred, C. D., 2474
Allred, K. F., 2474
Aloyz, R., 5457
Alpaugh, M. L., 3826
Alpaugh, R. K., 4767
Alson, S., 2761
Al-Tassan, N., 363
Altieri, D. C., 2462, 3093
Álvarez, A., 5013
Alvarez, R. D., 1266
Álvarez-Tejado, M., 2929
Alvey, R. F., 2423
Alvord, W. G., 7305
Alyea, E. P., 5517
Al-Zoghaibi, F., 397
Amadori, A., 6099
Amalfitano, A., 801
Aman, M. J., 1103
Āman, P., 512
Amann, G., 2986
Ambros, I. M., 2986
Ambros, P. F., 2986
Ames, S. J., 7154
Amin, K. M., 3438
Amin, S., 2
Amos, C. I., 3782
Anastasi, J., 5523
Ancelin, M., 4977
Andenoro, J., 5974
Anderson, D. W., 1439
Anderson, G. R., 6350, 6351
Anderson, K. C., 2300, 3876, 4996, 5019
Andersson, T., 409
Ando, A., 1246
Ando, T., 2385
André, T., 4879
Andreeff, M., 3603, 7264
Andrew, S. E., 359

Andrews, J., 6070
Ang, K. K., 6414, 7350
Angeletti, C. A., 2535
Angelo, L. S., 932
Angulo, J. F., 5425
Angus, S. P., 6587
Anisimov, S. V., 3257
Anklesaria, P., 6712
Ansel, J. C., 4109
Antel, J., 2131
Antonescu, C. R., 135
Anttila, M., 6410
Anttonen, A., 5210
Anver, M. R., 6724, 6944, 7305
Aoki, H., 3850
Aplenc, R., 4212
Appella, E., 3521
Arai, Y., 3850
Arakawa, H., 1246, 2883
Araki, N., 5859
Arañes, M. J., 4791
Arango, D., 4791, 6006
Arap, W., 867
Aras, R. A., 2385
Arch, B., 6959
Archer, D. R., 4109
Archer, G. E., 3335
Arden, K. C., 6981
Ardini, E., 1321
Argani, P., 5351
Ariazi, E. A., 6510
Arimori, K., 179
Arlinghaus, R. B., 386
Arlt, A., 910
Arlt, M., 5543
Armatis, P., 781
Armes, J. E., 1289
Armstrong, C. A., 4109
Armstrong, E. A., 4300
Arnold, B., 1462
Arnold, H., 3920
Arnold, J. T., 79, 986
Arola, J., 4554
Aronow, B. J., 6587
Arrigoni, G., 867, 941
Arteaga, C., 5627
Arteaga, C. L., 4132
Arteaga, J. R., 5204
Arús, C., 5672
Aryee, D. N. T., 4583
Asaki, E., 3581
Asano, T., 4176, 4176
Asemissen, A. M., 1743
Ashfaq, R., 4985
Ashmun, R. A., 5001
Ashton, S. E., 5749
Ashworth, L. K., 4100
Asmann, Y. W., 3308
Atencio, I., 6045
Atkinson, E. N., 2715, 7264
Atkinson, M. J., 3048
Atsumi, T., 5881
Attaix, D., 2771
Attanucci, J., 2583
Attoub, S., 4879
Au, T., 4089
Aubert, G., 764
Auborn, K. J., 433
Audoynaud, C., 3646
Auer, G., 2365
Augenlicht, L. H., 4791, 6006

Aughton, K., 5158
Aune, G., 4899
Astrup, H. N., 4339
Avanzini, J., 6045
Aventin, A., 5408
Avet-Loiseau, H., 2861
Ávila, P., 2929
Avila, S., 4519
Avilés, M. J., 5013
Avril, M. F., 7186
Avula, R., 262
Axworthy, D. B., 5755
Ayala, G. E., 3298
Ayres, M., 3100
Azenshtein, E., 1093
Aziz, R., 6857
Azuhata, T., 3093
Azuma, H., 1410
Azuma, K., 3351
Azumi, N., 3340
Azzam, E. I., 5436

B

Baas, F., 2024
Baba, I., 5668
Baba, M., 7004
Bachelder, R. E., 7203
Backlund, M., 901
Badia, E., 6519
Badizadegan, K., 682
Baetens, D., 603
Bagnato, A., 6381
Bai, R., 4007
Bai, R.-K., 972
Bai, Y. X., 3226
Bailey, E. C., 5867
Bailey, R. J., 715
Bailly, C., 7219
Baird, A., 977
Bais, A. J., 4599
Baker, A. H., 1271
Baker, C., 5106
Baker, C. H., 1996
Bakker, A., 2681
Bakst, R., 6385
Balachandran, S., 2239
Balagué, C., 4663
Balaguer, P., 6519
Balas, A., 5013
Baldwin, W. M., 1868
Bales, E., 6231
Bali, P., 5761
Balibrea, J. L., 3855
Balish, E., 6362
Balkwill, F. R., 5930
Baluk, P., 5381
Bamberg, M., 789
Banach-Petrosky, W. A., 2999
Band, H., 3315
Band, V., 3315, 4736
Bandyopadhyay, A., 4690
Bandyopadhyay, D., 6231
Banerjee, D., 6909
Banerjee, S., 4945
Banerji, S., 1315
Bange, J., 840
Bankert, R. B., 2611, 7254
Bansal, R., 3789
Bao, J.-J., 7264
Bapat, E., 3663, 4095

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX*

Volume 62

A

A, D., 6485
Aalders, M. C. G., 2024
Aalders, T. W., 2695
Aaltonen, L. A., 1166, 4352, 4554, 5989
Aarts, W. M., 5770
Abate-Shen, C., 2999
Abbaszadegan, M., 2654
Abbey, N. W., 5536
Abbruzzese, J., 6070
Abdelmohsen, K., 4922
Abdrabbo, M. K., 6823
Abecassis, J., 6211
Abel, J., 99
Abello, J., 4829
Aboagye, E. O., 5912
Abou-Khalil, E., 4325
Abraham, D., 5317
Abraham, J. M., 1148, 3493, 3641, 5637, 6820
Abri, H., 5317
Abrosimov, A. Y., 7031
Aburatani, H., 233
Accardi, L., 3654
Achermann, R., 2962
Ackerman, J. J. H., 1555
Adam, B.-L., 3609
Adam, R. M., 1549
Adams, A. W., 4109
Adams, D. M., 3159, 6552
Adams, J., 4996
Adams, M., 3289
Adams, S., 6717
Adem, C., 3587
Adesomoju, A. A., 4007
Adeyanju, M. O., 1481
Adigun, Y. E., 4115
Adini, A., 2749
Agarwal, C., 3063
Agarwal, R., 3063, 5280
Agata, N., 789
Aggarwal, B. B., 4945
Aguilar-Cordova, E., 4968
Aguzzi, A., 2592
Aharinejad, S., 5317
Ahmad, N., 6659
Ahmadian, M.-R., 1718
Ahmed, A., 5495, 6566
Ahmed, F., 7166
Ahn, D., 4514
Ahn, E., 6385
Ahn, K. Y., 1809
Ahn, W.-S., 7234
Ahrnovitz, N., 2654
Aicher, L. D., 5645
Aimes, R. T., 7083
Aittomäki, K., 4554
Aizu, W., 3667
Akagi, T., 6390
Akaike, T., 3138
Akasaka, T., 6224
Akel, N. S., 5571
Akgul, C., 6500
Akhand, A. A., 2414
Akhurst, R. J., 5627
Akiyama, M., 3876
Akiyama, S. K., 6837
Akiyama, S.-i., 2834
Akiyama, T., 3322

Akiyama, Y., 4894
Akslen, L. A., 6808
Akunda, J., 3395
Alain, T., 1696
Alam, M., 2493
Alaoui-Jamali, M. A., 5457
Alazawi, W., 6959
Albanese, C., 3997
Albar, J. P., 3167
Albelda, S. M., 6997
Albert, M., 3466
Albertson, D. G., 3636
Albini, A., 2406
Albor, A., 3264
Aldape, K. D., 6205
Aldaz, C. M., 4054
Alder, H., 2258
Ale-Agha, N., 4922
Alemany, R., 1266, 4663, 5736
Alexander, H. R., 3581
Alexander, R. L., 1730
Alfonso-De Matte, M. Y., 4575
Alfthan, H., 5210
Ali, S. Z., 135
Alison, M., 5698
Alitalo, K., 5580
Allegrini, P. R., 4015
Allen, J. C., 2660
Allen, J. D., 2294
Allen, T. M., 7190
Allen, W. L., 2644
Alli, E., 6864
Allred, C. D., 2474
Allred, K. F., 2474
Aloyz, R., 5457
Alpaugh, M. L., 3826
Alpaugh, R. K., 4767
Alson, S., 2761
Al-Tassan, N., 363
Altieri, D. C., 2462, 3093
Álvarez, A., 5013
Alvarez, R. D., 1266
Álvarez-Tejado, M., 2929
Alvey, R. F., 2423
Alvord, W. G., 7305
Alyea, E. P., 5517
Al-Zoghaibi, F., 397
Amadori, A., 6099
Amalfitano, A., 801
Aman, M. J., 1103
Āman, P., 512
Amann, G., 2986
Ambros, I. M., 2986
Ambros, P. F., 2986
Ames, S. J., 7154
Amin, K. M., 3438
Amin, S., 2
Amos, C. I., 3782
Anastasi, J., 5523
Ancelin, M., 4977
Andenoro, J., 5974
Anderson, D. W., 1439
Anderson, G. R., 6350, 6351
Anderson, K. C., 2300, 3876, 4996, 5019
Andersson, T., 409
Ando, A., 1246
Ando, T., 2385
André, T., 4879
Andreëff, M., 3603, 7264
Andrew, S. E., 359

Andrews, J., 6070
Ang, K. K., 6414, 7350
Angeletti, C. A., 2535
Angelo, L. S., 932
Angulo, J. F., 5425
Angus, S. P., 6587
Anisimov, S. V., 3257
Anklesaria, P., 6712
Ansel, J. C., 4109
Antel, J., 2131
Antonescu, C. R., 135
Anttila, M., 6410
Anttonen, A., 5210
Anver, M. R., 6724, 6944, 7305
Aoki, H., 3850
Aplenc, R., 4212
Appella, E., 3521
Arai, Y., 3850
Arakawa, H., 1246, 2883
Araki, N., 5859
Arañes, M. J., 4791
Arango, D., 4791, 6006
Arap, W., 867
Aras, R. A., 2385
Arch, B., 6959
Archer, D. R., 4109
Archer, G. E., 3335
Arden, K. C., 6981
Ardini, E., 1321
Argani, P., 5351
Ariazi, E. A., 6510
Arimori, K., 179
Arlinghaus, R. B., 386
Arlt, A., 910
Arlt, M., 5543
Armatis, P., 781
Armes, J. E., 1289
Armstrong, C. A., 4109
Armstrong, E. A., 4300
Arnold, B., 1462
Arnold, H., 3920
Arnold, J. T., 79, 986
Arola, J., 4554
Aronow, B. J., 6587
Arrigoni, G., 867, 941
Arteaga, C., 5627
Arteaga, C. L., 4132
Arteaga, J. R., 5204
Arús, C., 5672
Aryee, D. N. T., 4583
Asaki, E., 3581
Asano, T., 4176, 4176
Asemissen, A. M., 1743
Ashfaq, R., 4985
Ashmun, R. A., 5001
Ashton, S. E., 5749
Ashworth, L. K., 4100
Asmann, Y. W., 3308
Atencio, I., 6045
Atkinson, E. N., 2715, 7264
Atkinson, M. J., 3048
Atsumi, T., 5881
Attaix, D., 2771
Attanucci, J., 2583
Attoub, S., 4879
Au, T., 4089
Aubert, G., 764
Auborn, K. J., 433
Audoynaud, C., 3646
Auer, G., 2365
Augenlicht, L. H., 4791, 6006

Aughton, K., 5158
Aune, G., 4899
Astrup, H. N., 4339
Avanzini, J., 6045
Aventin, A., 5408
Avet-Loiseau, H., 2861
Ávila, P., 2929
Avila, S., 4519
Avilés, M. J., 5013
Avril, M. F., 7186
Avula, R., 262
Axworthy, D. B., 5755
Ayala, G. E., 3298
Ayres, M., 3100
Azenshtein, E., 1093
Aziz, R., 6857
Azuhata, T., 3093
Azuma, H., 1410
Azuma, K., 3351
Azumi, N., 3340
Azzam, E. I., 5436

B

Baas, F., 2024
Baba, I., 5668
Baba, M., 7004
Bachelder, R. E., 7203
Backlund, M., 901
Badia, E., 6519
Badizadegan, K., 682
Baetens, D., 603
Bagnato, A., 6381
Bai, R., 4007
Bai, R.-K., 972
Bai, Y. X., 3226
Bailey, E. C., 5867
Bailey, R. J., 715
Bailly, C., 7219
Baird, A., 977
Bais, A. J., 4599
Baker, A. H., 1271
Baker, C., 5106
Baker, C. H., 1996
Bakker, A., 2681
Bakst, R., 6385
Balachandran, S., 2239
Balagué, C., 4663
Balaguer, P., 6519
Balas, A., 5013
Baldwin, W. M., 1868
Bales, E., 6231
Bali, P., 5761
Balibrea, J. L., 3855
Balish, E., 6362
Balkwill, F. R., 5930
Baluk, P., 5381
Bamberg, M., 789
Banach-Petrosky, W. A., 2999
Band, H., 3315
Band, V., 3315, 4736
Bandyopadhyay, A., 4690
Bandyopadhyay, D., 6231
Banerjee, D., 6909
Banerjee, S., 4945
Banerji, S., 1315
Bange, J., 840
Bankert, R. B., 2611, 7254
Bansal, R., 3789
Bao, J.-J., 7264
Bapat, E., 3663, 4095

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Baranov, E., 1534
 Barazi, H. O., 1541
 Barber, G. N., 2239
 Barber, I., 1184
 Barbera-Guillem, E., 7042
 Barbieux, I., 1050
 Barcellos-Hoff, M. H., 5627
 Bardelmeijer, H. A., 6158
 Bar-Eli, M., 5106
 Barker, A. J., 5749
 Barnadas, R., 5672
 Barnes, C. J., 1251
 Barnes, M. N., 1266
 Barnhart, K., 43
 Barr, F. G., 135, 4711
 Barr, V., 6529
 Barrack, E. R., 2488
 Barraclough, R., 3417
 Barrett, B. S., 6850
 Barrett, J. C., 367, 6784
 Barrette, T. R., 4427
 Barrois, M., 764
 Bar-Shira, A., 6803
 Barsky, S. H., 3826
 Bartels, K. E., 4295
 Bartelt, B., 1503
 Barth, R. F., 3159, 6552
 Barthel, B., 6850
 Barthel, H., 5912
 Bartholomew, C., 6712
 Bartolazzi, A., 3861
 Barton, K., 4968
 Basak, S., 5267
 Bash-Babula, J., 6864
 Bassi, R., 2567
 Basso, A. D., 3132
 Bast, R. C., Jr., 7264
 Bastian, B. C., 3200
 Batchu, R. B., 2982
 Bateman, A., 5495, 5590
 Bateman, A. R., 6566
 Bates, D. O., 4123
 Bates, S. E., 4331, 6108
 Batrla, R., 2052
 Battaglia, R., 2332
 Bauer, A. J., 2437
 Bauer, A. K., 6850
 Bauer, A. L., 1682
 Bauerschmitz, G. J., 1266, 1271
 Baum, C., 1768
 Bayani, J., 3466
 Baylin, S. B., 2157, 5902, 7213
 Bea, S., 619
 Bearss, D. J., 2077, 2890
 Beasley, N. J. P., 1315, 2493
 Beatty, J., 7175
 Beaudenon, S., 3315
 Beaulieu, C., 4325
 Bechberger, J. F., 3544
 Becker, H., 1014
 Becker, J. C., 5664
 Becker, K. G., 2923
 Beckers, T., 3113
 Beckler, A., 4061
 Bedford, J. S., 6400
 Bedford, M. T., 6475
 Bedi, A., 1583, 4180
 Bedin, M., 4879
 Bedolla, R., 2630
 Bee, J., 4562
 Beems, R. B., 1338
 Beer, D. G., 5273
 Bégin, L. R., 6808
 Beheshti, B., 3466
 Behnam, M., 18
 Beier, C., 2592
 Beijnen, J. H., 6158
 Beissert, T., 7050
 Bekesi, G., 6080
 Beland, F. A., 1978
 Belbin, T. J., 1184
 Belenkov, A. I., 5888
 Belinsky, M. G., 6172
 Belinsky, S. A., 2248, 2370
 Béliveau, R., 381
 Bell, A., 2064
 Bell, A. K., 2072
 Bell, C., 6750
 Bell, D. W., 2741
 Bell, S. C., 3289
 Bellamy, W. T., 5089
 Bello, L., 6884
 Bello, V., 5457
 Bellone, M., 1116
 Belon, J.-P., 1815
 Benali, N., 6124
 Ben-Aroya, N., 1036
 Ben-Baruch, A., 1093
 Bendahl, P.-O., 409
 Bendall, L. J., 283
 Bendre, M. S., 5571
 Benimetskaya, L., 2175
 Benito, M., 3855
 Benjamin, L. E., 2749, 6731
 Bennett, C. J., 2220, 6405
 Bennett, L. M., 990
 Bennett, P. F., 356
 Bennewith, K. L., 6827
 Benning, C. M., 597
 Bennouna, J., 213
 Bensasson, R. V., 6506
 Benson, D., 6717
 Bentley, D. L., 1420
 Ben-Ze'ev, A., 5947
 Beppu, H., 5955
 Beran, M., 5995
 Berencsi, K., 5267
 Berger, L., 721
 Berger, M., 1477
 Bergeron, C., 3646
 Bergeron, J., 5457
 Bergers, G., 2731
 Bergoglio, V., 3511
 Bergsmedh, A., 575
 Berkey, B. A., 7350
 Berkowitz, R. S., 3058
 Berklanger, I., 4169
 Bernard, M.-A., 1158
 Bernardin, F., 3904
 Bernassola, F., 5158
 Bernhard, E. J., 7316
 Bernhard, H., 2244
 Berns, A., 1862
 Bernt, K. M., 6089
 Berridge, M. V., 3356
 Bertino, J. R., 4244, 6909
 Bertolini, F., 3106
 Bérubé, G., 6625
 Besaratinia, A., 4331
 Beske, F., 1768
 Bessho, M., 1171
 Best, C. J. M., 5325
 Besterman, J. M., 4325
 Betel, D., 1284
 Betensky, R. A., 1790
 Bettaieb, A., 1815
 Beurdeley-Thomas, A., 1388
 Beyser, K., 3009
 Bhagwat, S. S., 1439
 Bhalla, K., 5761
 Bhalla, K. N., 466
 Bharara, S., 3347
 Bhatia, N., 5280
 Bhatia-Gaur, R., 2999
 Bhujwalla, Z. M., 6731
 Bianchini, A., 7050
 Biard, D. S. F., 5425
 Bias, C., 4854
 Biassoni, R., 6178
 Biciatti, S., 7143
 Bichler, K.-H., 5818
 Bicknell, R., 1326, 5912
 Bidart, J.-M., 1020
 Bieberich, C. J., 338
 Bieche, I., 5874
 Biegel, J. A., 323
 Bieszczad, C. K., 892
 Bieth, A., 3511
 Bigler, J., 3361
 Bigley, A. L., 4645
 Bignell, G. R., 6451
 Bickfalvi, A., 6884
 Bilhou-Nabera, C., 5408
 Billerey, C., 1815
 Bindra, R. S., 3014
 Bird, C. C., 3992
 Birebent, B., 5267
 Birkenkamp-Demtroder, K., 4352
 Birnstiel, M. L., 1477
 Birsner, A. E., 2300
 Bishop, J. S., 4023
 Bisi, J. E., 1171
 Bissell, M. J., 7102
 Bissonette, R., 6376
 Biswal, S., 5196
 Biunno, I., 567
 Black, K. L., 5657, 7170
 Blackwell, J. L., 4273
 Blackwood, M. A., 1481
 Blades, N. J., 819
 Blakey, D. C., 3711, 7247
 Blanco, C., 2660
 Blankenstein, T., 2856
 Blaschuk, O., 6688
 Blasco, M. A., 552
 Blaser, M. J., 2385
 Blaszyk, H., 6796
 Blecker, E. R., 1784, 2253, 6485
 Blood, E. A., 715
 Bloome, E., 5267
 Blumenstock, J. E., 4963
 Blumenthal, R. D., 2029
 Blyth, K., 7181
 Bobiak, M. L., 1797
 Bocchinfuso, W. P., 2798
 Bocci, G., 2731, 6938
 Bocker-Edmonston, T., 6796
 Boczkowski, D., 5041
 Bode, A. M., 1300, 1343
 Bode, W., 5543
 Bodmer, W., 53, 4562
 Boecker, W., 1020
 Boehrer, S., 1768, 7050
 Boerman, O. C., 6146
 Boffey, S. J., 4645
 Bogin, L., 1948
 Boheler, K. R., 3257
 Bohlen, P., 2567, 2731
 Bohr, V. A., 1349
 Bois-Joyeux, B., 1158
 Boissier, S., 6538
 Boisson, C., 848
 Boivin, G. P., 6362
 Bok, D., 1654
 Bokenmeyer, C., 2758
 Boklan, J., 2104
 Bol, D. K., 2516
 Boland, D., 4445
 Boldog, F. L., 3834
 Boidrini, R., 301
 Bolli, M., 3453
 Bolognesi, C., 5418
 Bomalaski, J. S., 5443
 Bonaccorsi, P., 4109
 Bondy, M. L., 4566
 Bonfils, C., 4325
 Bonham, M., 3920
 Bonney, P. L., 356
 Bonvini, P., 1559
 Bookstein, R., 5027, 6045
 Boon, E. M. J., 5126
 Boon, T., 5510
 Boone, C. W., 682, 5178, 6506
 Boonstra, H., 6146
 Boosalis, M., 4985
 Booth, K., 359
 Borden, E. C., 3453
 Bornmann, W. G., 4236, 4244
 Borrás, E., 2058
 Borrebaeck, C. A. K., 4398
 Bosinco, G. M., 4459
 Bosl, G. J., 6218
 Bosserhoff, A. K., 5962
 Bostick, R., 3361
 Bottema, K. M., 4854
 Bottinger, E. P., 6278
 Bouadjar, B., 7186
 Boucher, D. L., 6606
 Boudreau, R., 7102
 Bou-Hanna, C., 2169
 Bouker, K. B., 3428
 Boulares, A. H., 4439
 Bour, G., 6211
 Bouras, T., 1289
 Bourdon, V., 6218
 Bouscarel, B., 179
 Boustany, R.-M., 801
 Bouvet, M., 1534
 Bowden, G. T., 3044
 Bowen, W. C., 2064
 Bowen, W. D., 313
 Bowers, W. J., 6545
 Bowman, E. D., 3244
 Bowman, T., 6659
 Boyer, J., 2644
 Boyer, T. G., 3966
 Boykin, D. W., 7219
 Boynton, A., 2806
 Brabender, J., 371
 Brabletz, T., 3009
 Bracci, P. M., 4630
 Bracht, T., 542
 Bradstock, K. F., 283
 Brady, F., 5698, 5912
 Brady, H., 1439
 Brady, J. N., 3562
 Brammah, S., 1394
 Bramson, J., 5148
 Brand, K., 7139
 Brandenburg, S., 6442
 Brandt, B., 1020
 Brandt, G., 3626
 Brash, D. E., 1443
 Braun, K., 7018
 Bray, J., 7357
 Brechbiel, M. W., 560, 860, 5755

AUTHOR INDEX TO VOLUME

- Breistol, K., 3120
 Breikreutz, B.-J., 3005
 Bremnes, R., 3971
 Brennan, M. F., 135, 6909
 Brenner, M. K., 1123, 7195
 Brenton, J. D., 3466, 5076
 Bressac-de Paillerets, B., 764
 Breton, C., 4623
 Brewer, G. J., 4854
 Brewster, S. F., 2942
 Bridge, J. A., 135, 4711
 Bridger, G., 5930
 Briehl, M. M., 5089
 Brignell, G., 6997
 Brinckerhoff, C. E., 7200
 Brinkley, W. R., 4115
 Briollais, L., 4095
 Briones, J., 3195
 Bristow, R., 6194
 Britt, W. J., 3347
 Bröcker, E.-B., 2125, 5664
 Brodeur, G. M., 1802, 6462, 6481, 6651
 Brodin, B., 3861
 Brodt, P., 5393
 Broët, P., 4685
 Broggi, M., 2332
 Bröker, L. E., 4081
 Bronder, J. L., 5236
 Bronk, S., 1648
 Bronson, R. T., 2281
 Bronstein, J. M., 2287
 Brooks, J. S. J., 135
 Brooks, M. W., 6348
 Brose, M. S., 6997
 Brossart, P., 5065
 Broussard, S. R., 4746
 Brown, A. M. C., 5405
 Brown, E. B., 6831
 Brown, J., 4757
 Brown, J. M., 5248
 Brown, K. M., 2654
 Brown, L. F., 2004
 Brown, M., 89, 1045
 Brown, N. S., 1326
 Brown, P. H., 6376
 Brown, S., 4968
 Brown, S. L., 4202
 Brown, V. D., 967
 Browne, L. W., 2890
 Bruckheimer, E. M., 6712
 Brueckl, W. M., 3009
 Bruland, O. S., 3120
 Brünagel, G., 2437
 Brune, K. A., 3789
 Brunner, J., 6750
 Brünner, N., 3428
 Brusie, V., 213
 Bruyneel, E., 4879
 Bubendorf, L., 1256
 Bucala, R., 5881
 Bucana, C., 5720
 Buchczyk, D. P., 4922
 Buchdunger, E., 5476
 Buchmann, A., 5685
 Buchsbaum, D. J., 773
 Buck, A. K., 3331
 Buckle, T., 6158
 Budach, V., 6621
 Budman, D., 290
 Bueno, R., 4963
 Bueren, J. A., 5013
 Buerger, H., 1020
 Bueso-Ramos, C., 4945
 Buetow, K., 3340
 Buettner, R., 5962, 6659
 Buettner, T. L., 445
 Buffinton, G. D., 2092
 Buisine, M.-P., 848
 Bulavin, D. V., 7305
 Bult, C. J., 1235
 Bunch, D., 990
 Bundred, N. J., 122
 Bunn, P. A., 3971
 Bunz, F., 1129
 Burbee, D., 2715
 Burg, M. A., 977
 Burgart, L. J., 1531
 Burger, A. M., 3113
 Burger, R. A., 5001
 Buricchi, F., 6489
 Burke, J., 2806
 Burke, P. A., 4263
 Burke, W., 376
 Burlingame, S. M., 1123
 Burlini, A., 3106
 Burnette, P. K., 5761
 Burns, P. N., 6371
 Burton, E. C., 6205
 Burton, J., 2029
 Buscail, L., 6124
 Busch, T. M., 7273
 Büschenfelde, C. M., 2244
 Buschle, M., 1477
 Bushell, M., 2272
 Bussink, J., 7066
 Bussolati, B., 2406
 Bussolati, G., 2406
 Busson, P., 1920
 Buteau-Lozano, H., 4977
 Buterin, T., 4229
 Butler, M. P., 4089
 Buttitta, F., 2535
 Byeon, M. K., 5083
 Byers, S. W., 6688
 C
 Cabañas, M. E., 5672
 Cabon, F., 6538
 Cachafeiro, C., 990
 Cai, D., 5267
 Cai, S., 6475
 Cai, S.-L., 3766
 Cai, Y., 5399
 Cairncross, J. G., 1790
 Cajal, S. R., 3855
 Calaluze, R., 2890
 Caldwell, C. W., 3214
 Caligiuri, M., 1261
 Caligiuri, M. A., 6552
 Calise, D., 6124
 Calvisi, D. F., 4459
 Calvo, A., 3934, 5325
 Camafeita, E., 3167
 Camarero, G., 6297
 Cameron, E., 7175
 Cameron, E. R., 7181
 Cameron, J. L., 1868
 Camoratto, A. M., 6462
 Camp, R. L., 497
 Campbell, K., 7102
 Campbell, R., 4109
 Campbell, R. B., 6831
 Campisi, J., 547, 4736
 Campo, E., 619
 Campo, L., 1326
 Canbay, A. E., 6500
 Canessa, P. A., 5418
 Canitrot, Y., 3511
 Canning, C., 5517
 Canron, X., 6884
 Canto, M., 1868
 Cantor, A., 6659
 Cantor, H., 2281
 Cao, B., 589
 Cao, D., 2313
 Cao, L., 4843
 Cao, X., 2856
 Capella, G., 4519, 5902
 Capello, D., 4089
 Caputo, L., 5267
 Caragine, T. A., 1110
 Carcangiu, M.-L., 2778
 Cardenas, D. M., 2771
 Cardiff, R. D., 2999, 4812, 5096
 Cardinali, B., 1196
 Cardones, A. R., 7328
 Cardounel, A. J., 307
 Carducci, M., 2576, 5618
 Carey, D., 4273
 Carl, V. S., 4061
 Carles-Kinch, K., 2840
 Carlomagno, F., 1077, 7284
 Carlo-Stella, C., 6152
 Carlson, B. L., 7291
 Carlton, P. S., 4376
 Carmella, S. G., 129
 Carmen, J. C., 7280
 Carmichael, J., 1669
 Carnot, F., 1868
 Caron, A., 1388
 Carpten, J. D., 1784
 Carrabba, G., 6884
 Carrasquillo, J. A., 5755
 Carr-Locke, D. L., 682
 Carroll, J. S., 3126, 6916
 Carroll, V. A., 5912
 Carson, J. P., 18
 Carter, D., 6667
 Casaletto, J., 1196
 Casalini, P., 567
 Casanova, B., 3402
 Casanova, M. L., 3402
 Caspar, C. B., 5845
 Cassidy, J., 6857
 Cassetti, M. C., 5792
 Cassoni, P., 2406
 Castedo, M., 1388
 Castelli, F., 213
 Castiglioni, F., 1321
 Castiglioni, P., 1116
 Casto, B. C., 5295
 Castranova, V., 5689
 Castrillon, D. H., 2761
 Catley, L. P., 4996
 Cattaneo, M., 567
 Caullee, K., 6211
 Cavalli, L. R., 6990
 Cavenee, W. K., 6764
 Cayre, A., 617
 Cazares, L. H., 3609
 Cazaux, C., 3511
 Celestino, J., 6376
 Celestino, J. C., 5551
 Celikkaya, G., 6634
 Celis, E., 5807
 Cerignoli, F., 1196
 Cermak, L., 6278
 Cernaianu, G., 4034
 Cerottini, J.-C., 1743, 2058
 Cerrano, P. G., 5418
 Certa, U., 3453
 Cervek, M., 2771
 Ceryak, S., 179
 Cevario, S., 7175
 Chabay, P. A., 4876
 Chace, D. F., 3736
 Chacko, S., 3340
 Chada, S., 2239
 Chadwell, B. A., 6817
 Chaganti, R. S. K., 4089, 6218
 Chaganti, S., 4089
 Chakladar, A., 4307
 Chakravarti, A., 200, 4307
 Chambers, A. F., 887, 2162
 Chambers, W. H., 2583
 Chames, P., 3184
 Chamorro, M., 6674
 Champlin, R. E., 3603
 Chan, A. S., 6451
 Chan, D. C. F., 3063
 Chan, D. W., 1868
 Chan, F. L., 6039
 Chan, K. C., 122
 Chan, K. Y. K., 4151
 Chan, S., 2761
 Chan, T. L., 6451
 Chandler, D. S., 1952
 Chandra, D., 2976
 Chandramouli, V. R., 6246
 Chandrasekaran, R., 1939
 Chang, A. C., 1289
 Chang, B.-I., 1784, 2253, 6485
 Chang, C., 6039
 Chang, C.-C., 6178
 Chang, C.-F., 4346
 Chang, D. D., 5358
 Chang, J., 801
 Chang, J.-Y., 3716
 Chang, L., 4491
 Chang, L. M., 6779
 Chang, P., 4566
 Chang, P.-L., 5336
 Chang, Q., 6035
 Chang, Y.-S., 6952
 Chaplin, D. J., 7247
 Chapman, J. M., 5083
 Chapman, W., 3663, 4095
 Chapoval, A., 1884
 Chappuis, P. O., 6808
 Charboneau, L., 3244
 Charbonnier, F., 848
 Charrier, L., 2169
 Charytonowicz, E., 6973
 Chatterjee, P., 3562
 Chatterjee, S., 3175
 Chattopadhyay, S., 6434
 Chaturvedi, P., 1797
 Chaudhary, P. M., 5897
 Chaudhri, N., 2365
 Chauhan, D., 3876
 Chauvet, C., 1158
 Chayvialle, J.-A., 4829
 Cheadle, C., 2923
 Cheadle, J. P., 363
 Cheburkin, Y., 840
 Chedorge, M., 2169
 Chella, A., 2535
 Chen, A., 1036
 Chen, B., 4419
 Chen, C., 3636
 Chen, C.-F., 5134
 Chen, C.-L., 6952
 Chen, C.-M., 3214
 Chen, C.-S., 6928

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Chen, D., 967, 1178
 Chen, D. J., 2483
 Chen, D. Y.-S., 1613
 Chen, D. Z., 433
 Chen, D.-S., 4346
 Chen, E. J., 113
 Chen, F., 2468
 Chen, F.-A., 2611
 Chen, H., 338
 Chen, J., 589, 1305
 Chen, J. H., 3736
 Chen, J. Z., 6470
 Chen, J.-G., 1935
 Chen, L., 1761, 1884, 3459, 4413, 5517
 Chen, L.-C., 1330
 Chen, L.-T., 3716
 Chen, N., 1300, 1343
 Chen, P.-J., 4346
 Chen, P.-L., 2498, 3966, 5134
 Chen, S., 6740
 Chen, S.-Y., 1123, 2600
 Chen, T.-H., 7001
 Chen, W. R., 4295
 Chen, X., 1213, 1458, 1737, 2430, 4704
 Chen, Y., 391, 3743, 6246
 Chen, Y.-T., 4041
 Chen, Y.-W., 4346
 Chen, Z., 5049
 Chen, Z.-S., 3144, 6172
 Cheng, J., 4157
 Cheng, J. C., 2365
 Cheng, J. D., 4767
 Cheng, J. Q., 4575
 Cheng, L., 2232, 3904
 Cheng, S.-Y., 756
 Cheng, Y., 241
 Cheng, Y.-c., 459, 1624
 Cheng, Y.-F., 6952
 Cheng, Z.-J., 5223
 Cherrington, J. M., 1702
 Chesney, J., 5881
 Chester, R., 4645
 Cheung, A. L. M., 1662
 Cheung, A. M. Y., 6194
 Cheung, A. N. Y., 4151
 Cheung, N.-K., 2988
 Cheung, N.-K. V., 1761
 Cheung, S. T., 4704
 Chevallier, O., 4685
 Chevallier, P., 2861
 Cheville, J. C., 3308, 6796
 Chew, K. L., 3812
 Chia, M., 171
 Chiang, Y.-H., 756
 Chiao, J. W., 2
 Chiaradonna, F., 7050
 Chiarugi, P., 6489
 Chiba, N., 4222
 Chiba, T., 506
 Chieco-Bianchi, L., 6099
 Chien, J., 262
 Childs, A. C., 4592
 Childs, G., 1184, 6973
 Chillakuru, R. A., 3834
 Chin, K., 3636
 Chinnadurai, G., 3373
 Chinnaiyan, A. M., 2337, 4427
 Chinratanalab, W., 4132
 Chiodoni, C., 4390
 Chiorazzi, N., 290
 Chirnomas, R. B., 113
 Chiu, P. P. L., 5828
 Chiu, S. W., 4464
 Chlenski, A., 7357
 Cho, B., 3233
 Cho, K. R., 4722
 Cho, Y.-M., 1956
 Choi, I.-H., 1809
 Choi, Y., 1275
 Chong, J.-M., 233
 Chong, T. W., 6924
 Chopra, D., 2976
 Chou, T.-C., 6909
 Chow, K. U., 1768
 Chow, T. Y. K., 5888
 Chrastina, A., 4469
 Christa, L., 1868
 Christensen, L. L., 4352
 Christiansi, D. C., 1377, 2819
 Christie, N., 2141
 Christofori, G., 603
 Christopher, S. A., 6639
 Christov, K. T., 5178
 Chtarbova, S., 1718
 Chu, D., 1213
 Chu, P., 6667
 Chuang, L. S.-H., 1592
 Chuang, Y.-Y. E., 6246
 Chun, K.-H., 3530
 Chung, F.-L., 2
 Chung, L. P., 4464
 Chung, L. W. K., 3084
 Chung, M., 1275
 Chung, N. H. C., 7170
 Chung, Y.-L., 688
 Churchman, M., 4562
 Ciardiello, F., 7284
 Ciesielski, M., 3159
 Ciesielski, M. J., 6552
 Cifuentes, E., 2488
 Cin, P. D., 3980
 Ciolino, H. P., 3685
 Cirilli, A., 3654, 6381
 Cirri, P., 6489
 Civin, C. I., 2232, 3904
 Claesson-Welsh, L., 1944
 Clarijs, R., 7059
 Clark, B., 5049
 Clark, G. M., 6510
 Clark, J., 2798
 Clark, M. A., 5443
 Clarke, A. R., 6615
 Clarke, R., 3428
 Clarkson, B., 4236, 4244
 Claus, E. B., 6667
 Claypool, K., 5153
 Cleaveland, E. S., 892
 Cleaves, R., 2232, 3904
 Clemens, M. J., 2272
 Clements, M. A., 3609
 Clements, W. M., 3503
 Cleris, L., 6152
 Cleton-Jansen, A.-M., 48, 4599
 Cleveland, J. L., 2184
 Clevers, H., 5126
 Clézardin, P., 6538
 Clifford, R., 3340
 Clifford, S. C., 3803, 5906
 Cline, E. I., 7143
 Cobbs, C. G., 3347
 Cobbs, C. S., 3347
 Coderre, J. A., 3159
 Coffey, D. S., 647, 4029
 Coffin, D., 6246
 Cogen, P. H., 3794
 Cohen, B., 1330
 Cohen, C. J., 3184, 5835
 Cohen, H., 2660
 Cohen, M. B., 4812, 5096
 Cohen, P., 3530
 Cohn, S. L., 7357
 Coker, J. S., 4164
 Colau, D., 5510
 Colburn, N., 3044
 Colditz, G. A., 1045
 Cole, P. A., 2522, 6231
 Coleman, A. E., 1152
 Coleman, N., 6959
 Colgan, S. P., 3387
 Colgia, L., 4434
 Collard, J. G., 4484
 Collingridge, D. R., 5912
 Collins, C. C., 1939
 Collins, N. K., 990
 Collins, S. J., 48
 Collot, F., 2327
 Colombel, M., 6538
 Colombo, B., 941
 Colombo, M. P., 4390
 Colombo, T., 2332
 Colomer, D., 619
 Coman, W., 3759
 Combaret, L., 2771
 Combaret, V., 3646
 Comerford, K. M., 3387
 Commes, T., 3950
 Comoglio, P. M., 7025
 Compoin, A., 1609
 Conaway, C. C., 2
 Conaway, M. R., 6418
 Condeelis, J. S., 6278, 7166
 Connett, J. M., 445
 Connor, J. R., 165
 Conrad, S. E., 3985
 Constantiniu, O., 6901
 Contag, C. H., 5785
 Conte, R., 6178
 Conti, C. J., 3276, 3402
 Contreras, J. I., 5273
 Conway, K., 1987
 Conway, T. F., 2611
 Conway, T. F., Jr., 7254
 Cook, J. A., 6246
 Coomber, B. L., 1931
 Coon, C. I., 7200
 Cooney, M., 3408
 Cooper, C., 1832
 Cooper, C. S., 135
 Cooper, W. A., 1394
 Corao, D. A., 1014
 Corazzari, M., 5158
 Corbi, A. L., 3167
 Corbin, A. S., 7149
 Corbin, S., 3477
 Cordell, S., 1050
 Cordon-Cardo, C., 2988, 6973
 Cornelison, R., 1256
 Cornélisse, C., 4599
 Cornélisse, C. J., 48
 Corner, G. A., 4791
 Corstens, F. H., 6146
 Cortes, U., 6990
 Corti, A., 867, 941
 Corvalan, J. R. F., 2468
 Corveleyn, A., 5408
 Cosman, D., 6178
 Costa, M., 5689
 Cottam, H. B., 4007
 Couch, F. J., 3587
 Couch, V. L., 3587
 Couillard, M., 2210
 Coulie, P. G., 5510
 Coulombe, R. A., Jr., 105
 Couvé-Privat, S., 7186
 Coval, K., 213
 Cox, A. D., 4142
 Cox, C., 6451, 6997
 Cox, G., 1315
 Cox, G. J., 2493
 Cox, K., 5597
 Cozzi, G., 6489
 Cozzi, P., 2332
 Craddock, C. F., 4730
 Craig, B. A., 356
 Craig, R. W., 892
 Cramer, D. W., 3058
 Cramer, S. D., 6817
 Cranston, D., 2957
 Crawford, E. D., 5218
 Crawford, H. C., 5559
 Crawford, K. W., 313
 Crawford, S. E., 7357
 Creaney, J., 2766
 Cremesti, A., 2531
 Crémonin, C., 5425
 Cristiano, R. J., 3530
 Croce, C. M., 2258, 2398
 Croft, J., 6362
 Crook, T., 2072
 Crooks, H., 2744
 Crooks, L. A., 2370
 Cross, M., 1944
 Croucher, P. I., 1619
 Crowe, J., 5375
 Crowell, R. E., 2248, 2370
 Crum, C. P., 682
 Csizsar, K., 4478
 Cuezva, J. M., 6674
 Cui, H., 6442
 Cui, L., 603, 1987
 Cui, T.-G., 4123
 Cummings, J., 1876
 Cummins, A. B., 4169
 Cunha, G. R., 2999
 Curiel, D. T., 609, 1266, 1271, 4273, 4663, 5736
 Curley, S. A., 1952, 3620
 Curnis, F., 867, 941
 Curry, B., 4645
 Curry, B. J., 5749
 Curwen, J. O., 4645
 Cuthbert-Heavens, D., 2957
 Czerwinski, D. K., 5845
 Czyzyk-Krzeska, M. F., 1682

D

- Dafni, H., 6731
 D'Agati, V., 2210
 Dagenais, S. L., 5273
 Dahler, A. L., 3759
 Dahlstrom, J. E., 2092
 Dahm, P., 5041
 Dai, C., 5551
 Dai, D., 881
 Dai, T., 1961
 Dai, W., 2
 Dai, Y., 1961
 Dairkee, S. H., 1000, 1939, 5980
 Daley, G. Q., 535
 Dall, P., 1266
 Dalla-Favera, R., 4089
 Dallol, A., 5874
 D'Amato, R. J., 2300

AUTHOR INDEX TO VOLUME

- Dammann, R., 3698
 Dan, S., 1139
 Danan, J.-L., 1158
 Danenberg, K. D., 371
 Danenberg, P. V., 371
 Daneshvar, B., 4339
 Dang, J., 1222
 Dang, T. D., 3298, 6021
 Dangler, C. A., 696
 Daniel, J. J., 2092
 Daniel, L. W., 6817
 Danks, M. K., 5001
 Dannenberg, A. J., 2522, 5405
 Dannull, J., 5041
 Danska, J. S., 5828
 Dantzer, R., 4746
 Darling, G., 3005
 Darrah, D. M., 4722
 Dasari, R. R., 682, 5375
 Dasenbrock, C., 3448
 da Silva, N. F., 3803
 Dasnois, L., 2327
 Dassonneville, L., 7219
 Dauer, M., 2347
 Dauzonne, D., 6506
 Davalos, A. R., 2637
 Davidoff, A. M., 3077
 Davidson, M. T. M., 887
 Davie, J. R., 75
 Davies, D. R., 2942
 Davies, E., 4164
 Davies, F., 5019
 Davies, H., 6451, 6997
 Davies, L., 1724
 Davies, M., 5564
 Davies, R., 4256
 Davis, A., 6080
 Davis, A. L. G., 2141
 Davis, B. J., 990
 Davis, B. M., 3070
 Davis, E. M., 3477, 5523
 Davis, G., 5058
 Davis, J. W., 3609
 Davis, M. A., 5463
 Davis, N., 3428
 Davis, P. D., 7247
 Davis, S. L., 7154
 Davis, T. W., 5778, 6706
 Davison, T. L., 6667
 Dawson, M., 3842
 Day, K. V., 4637
 Day, N. E., 3052
 Daya-Grosjean, L., 7186
 Daynes, R. A., 6870
 Deacu, E., 6820
 Deaglio, S., 2406
 Dearnaley, D. P., 3369
 Debes, J. D., 5632
 Debiton, E., 2771
 Debruyne, P., 1718
 Debuire, B., 4685
 Debus, J., 7018
 De Carvalho, M., 4854
 Decaudin, D., 1388
 DeClue, J. E., 4507
 De Fabo, E. C., 6724
 de Felipe, C., 7343
 Degani, H., 1948, 1966
 Degen, J. L., 6966
 DeGortari, A. E., 356
 DeGraff, W., 6246
 DeGraffenried, L., 6141
 de Gruijl, F. R., 1338
 de Heredia, M. L., 6674
 Deininger, M. W., 7149
 Dejana, E., 2567
 Dejmek, J., 409
 de Jong, A., 472
 Dejourmet, R., 3782
 de Juan, C., 3855
 de Kok, J. B., 2695
 de la Chapelle, A., 4579
 Delahunt, B., 4554
 Delaney, M. A., 4307
 Delannoy, M. J., 6405
 De Latour, M., 1890
 DeLeo, A. B., 3521
 Delikatny, E. J., 1394
 Dell, J., 2516
 Dell'Agola, C., 3106
 Delorme, D., 4325
 Del Piero, F., 7273
 Delsol, G., 1489, 3511
 Del Valle, L., 7093
 Delzenne, N., 3555
 De Marzo, A. M., 2220, 6405
 De Matteo, E., 4876
 DeMatteo, R. P., 5260
 Demeure, R. J., 3555
 Demidem, A., 1890
 De Miglio, M. R., 4459
 Demirpence, E., 6519
 Demopoulos, R., 2778
 Demou, Z. N., 5301
 DeNardo, G. L., 4263
 DeNardo, S. J., 4263
 Deng, J., 346
 Deng, M., 535
 Denis, M., 2169
 Denkberg, G., 3184
 Denmeade, S. R., 986
 Denner, L., 6080
 Dennis, J. L., 5999
 Denny, W. A., 1425
 Dent, P., 188
 Deora, A., 5405
 De Pascalis, R., 5049
 DePeralta-Venturina, M., 4968
 DePinho, R. A., 2761, 6724
 De Pinieux, G., 1388
 DeRisi, J., 4525
 Deryugina, E. I., 580
 Desai, K., 1148, 3493
 Desai, N., 2999
 Desai, S., 1439
 de Sauvage, F. J., 5308
 Desbaillets, L., 2962
 De Schrijver, E., 642
 de Silva Rudland, S., 3417
 Detmar, M., 2004
 de Toledo, S. M., 5436
 Devaux, B., 2546
 Devereux, T. R., 6424
 de Vere White, R. W., 1496
 De Vivo, I., 2819
 DeVries, G. H., 7357
 de Waal, R. M. W., 341, 7059
 Dewald, G. W., 715
 DeWeese, T. L., 7230
 De Wever, I., 3980
 de Wilde, P. C. M., 7066
 Dhanabal, M., 2468, 3834
 Dhanalakshmi, S., 3063
 Dhawan, P., 7335
 Diamandis, E. P., 295
 Diaz, J., 6659
 Diaz, R., 4514
 Díaz-Rubio, E., 3855
 DiBello, C., 7143
 Dibello, F., 3654
 Di Bonito, P., 3654
 Dichgans, J., 1915
 Dick, R. D., 4854
 Dicker, A. J., 3759
 Dickerson, W. M., 789
 Dickinson, C., 5470
 Dickson, C., 4562
 Dictor, M., 4398
 Diegelman, P., 6639
 Dietmaier, W., 3009, 6796
 Dietrich, P.-Y., 1743
 Dietz, A., 6566
 Díez, J. L., 5013
 DiGiovanna, M. P., 6667
 DiGiovanni, J., 7207
 Dijkgraaf, I., 6146
 Dijkman, R., 5389
 Dilley, J., 3743
 Dimri, G. P., 4736
 Dimtchev, A., 6879
 D'Incalci, M., 2332
 Ding, Q., 5336
 Ding, W.-Q., 947, 5223
 Di Nicola, M., 6152
 Di Nicola, N., 1284
 Dinjens, W., 2758
 Dinjens, W. N. M., 1531
 Dinney, C. P., 5720
 Dinsdale, D., 4256
 DiRenzo, J., 89
 Dirks, A. J., 4592
 Dirven, C. M. F., 5736
 Divine, K. K., 2370
 Divoky, V., 5995
 Dixelius, J., 1944
 Dixon, K., 2766
 Dlugosz, A. A., 5308
 Dmitriev, I., 1266, 4273
 Dmitriev, I. P., 609
 Doerge, D. R., 1978, 2474
 Doetschman, T., 6362
 Dolan, J. P., 5069
 Dolmans, D. E. J. G. J., 2151, 4289
 Domann, F. E., 1205
 Dominici, C., 301
 Donà, M. G., 3654
 Donald, S., 4256
 Doñate, F., 5344, 5470
 Donfrancesco, A., 301
 Dong, B., 397
 Dong, D., 7207
 Dong, Y., 708
 Dong, Y. B., 1776
 Dong, Z., 1300, 1343
 Donnelly, E., 4671
 Donnelly, S., 5881
 Donnenberg, A. D., 3521
 Donnenberg, V. S., 3521
 Donoviel, D. B., 3221
 Doody, J. F., 2567
 Dorion-Bonnet, F., 48
 Dorsey, R., 2606
 Dougherty, G. J., 7247
 Dougherty, R. H., 3257
 Doughty, J. M., 4123
 Dowe, A., 3369
 Dowlati, A., 3408
 Downes, A., 6132
 Dracheva, T., 2744, 3340
 Dragsted, L. O., 4339
 Dralle, H., 3698
 Dranoff, G., 796, 5517
 Dreijerink, K., 3498
 Dressler, L., 1987
 Drevs, J., 4015
 Drijfhout, J. W., 472
 Dritschilo, A., 6879
 Drouin, S. S., 1987
 Druker, B. J., 7149
 Du, B., 5405
 Du, C., 18
 Dubeau, L., 7207
 DuBois, R. N., 3282
 Dubois, V., 2327
 Duchesne, M.-J., 6519
 Duckett, A., 967
 Duell, E. J., 4630
 Duensing, S., 7075
 Duesberg, P., 6345
 Dugas, M., 251
 Duguay, D., 5148
 Duh, F.-M., 3498
 Duivenvoorden, W. C. M., 1588
 Dukes, M., 4645
 du Manoir, S., 6211
 Dunbrack, R. L., Jr., 4767
 Duncan, A. M. V., 5457
 Dunn, T. A., 2220
 Dunning, A. M., 3052
 Dunson, D. B., 3395
 Durand, R. E., 6827
 Duray, P., 6724
 Duray, P. H., 3581
 Durham, W. F., 5778
 Dutoit, V., 1743, 2058
 Dutriaux, A., 1129
 Deutschman, G. E., 1624
 Duval, A., 1609, 2447
 Duvall, J., 3562
 Dwyer-Nield, L. D., 6850
 Dyck, P. A., 4419
 Dyson, N. J., 200

E

- Eads, C. A., 1296
 Easton, D. F., 3052, 3369
 Eaton, C. L., 1619
 Eberhard, D., 2546
 Eckard, J., 417
 Eckardt, K.-U., 3803
 Eckerdt, F., 4186
 Eddy, E. M., 990
 Edgington, T. S., 5470, 7118
 Edkins, S., 6451
 Edmiston, S. N., 1987
 Edmonston, T. B., 1014
 Edmund, N. A., 3868
 Edwards, D. R., 5543
 Edwards, D. S., 6146
 Edwards, E., 4671
 Edwards, E. M., 4478
 Edwards, R., 4256
 Edwards, S., 3369
 Edwards, S. W., 6500
 Eeles, R. A., 3369
 Eggert, A., 1802, 6462
 Egilmez, N. K., 2611, 7254
 Eguchi, S., 7213
 Egyed, A., 1477
 Ehemann, V., 5139
 Ehinger, M., 4398
 Ehninger, G., 4955
 Ehteshami, M., 5657, 7170
 Eiben, G. L., 5792
 Eichwald, E. J., 6870

AUTHOR INDEX TO VOLUME

- Eigler, A., 2347
 Eils, R., 2993
 Einhorn, E., 6997
 Eischen, C. M., 1222, 2184
 Eisenbach, L., 5835
 Ek, S., 4398
 El-Alfy, M., 721
 Elbaggari, A., 5536
 El-Deiry, W. S., 7316
 Elder, D. E., 3992
 El-Gamil, M., 3630
 El-Hizawi, S., 3264
 Elia, A., 6194
 Elkahloun, A., 6240
 Elkahloun, A. G., 1256
 Ellenson, L. H., 4722
 Elliott, J., 2766
 Elliott, M. J., 1776
 Ellis, D. L., 7335
 Ellis, L. M., 2034
 Ellison, D. W., 5906
 El-Naggar, A., 1952
 El-Naggar, A. K., 6414
 El-Rifai, W., 2625, 4061, 6823
 El-Sheikh, A., 5470, 7118
 Elstrodt, F., 1822
 El-Tanani, M., 3417
 Emanuele, M. J., 7273
 Emmell, E., 2824
 Emmert-Buck, M. R., 3498, 5325
 Enam, S., 7093
 Endres, S., 2347
 Enerbäck, C., 43
 Engbring, J. A., 3549
 Engle, S. J., 6362
 Engles, J., 371
 Engles, J. M., 3659
 Enholm, B. C., 1669
 Enjo, K., 636
 Ensor, C. M., 5443
 Entschladen, F., 6467
 Enzmann, T., 251
 Eppig, J. T., 1235
 Erban, J., 2741
 Erdos, M., 141
 Erff, M., 2583
 Eriksson, M., 5210
 Eriksson, S., 3100
 Ernst, M., 6779
 Errington, F., 5495
 Esche, H., 3598
 Eshhar, Z., 6803
 Eshleman, J. R., 7230
 Eshleman, J. S., 7291
 Espejo, A., 6475
 Espinosa, R., III, 3477, 5523
 Esposito, G., 6099
 Esser, N., 4015
 Esteban-Barragán, M. A., 2929
 Esteller, M., 1166, 3659, 4519, 5902
 Evangelista, A., 7357
 Evans, A. E., 1802, 6462
 Evans, M. K., 1349
 Evans, M. S., 4575
 Evans, P. R., 3369
 Evans, S. M., 3626
 Ewan, K. B., 5627
 Ewing, C. M., 2220

F
 Fages, C., 4805
 Fahrner, J. A., 7213
 Fairclough, R., 6659
 Faith, 6485
 Falcone, R., 6659
 Falini, B., 1559
 Falk, C. S., 480
 Fallavier, M., 4829
 Fallavollita, L., 5393
 Fan, A., 3221
 Fan, D., 5720
 Fan, H., 5611
 Fan, S., 141
 Fan, S. T., 4704
 Fang, B., 2715, 3620, 7264
 Fang, G., 3842
 Fang, H., 7328
 Fang, J., 3138, 4212
 Fang, J-L., 1978
 Fang, Y., 7157
 Farago, M., 5835
 Farber, R. A., 6061
 Farhana, L., 3842
 Farley, K. M., 5035
 Farrell, P. J., 2072
 Farrer, R., 7357
 Faul, M. M., 5597
 Faure, P., 6124
 Faustman, D. L., 24
 Fauth, C., 1129
 Favrot, M-C., 3646
 Fearon, E. R., 1613, 4722
 Fears, T. R., 3992
 Fedele, M., 2398
 Federoff, H. J., 6545
 Fedorov, L. M., 6297
 Fedrowitz, M., 1356
 Fei, P., 7316
 Feil, A., 781
 Feinberg, A. P., 48, 6442, 6784
 Feld, M. S., 682, 5375
 Feldman, A. L., 3934
 Feldman, M., 6997
 Feldman, M. D., 747, 1481
 Felix, D. H., 4757
 Feltes, C. M., 6688
 Feng, H., 1662
 Feng, W-h., 1920
 Feng, X., 2468, 5106
 Feng, Z., 3609
 Fenoglio-Preiser, C., 3503
 Fenstermaker, R. A., 3159, 6552
 Fenton, R. G., 450
 Feo, F., 4459
 Ferdinandusse, S., 2220
 Ferenczi, K., 528
 Ferguson, P. R., 2644
 Ferhle, W., 1256
 Fernald, A. A., 5523
 Fernandes Da Silva, N., 5874
 Fernandez, A-M., 2327
 Fernández, P. L., 619
 Fernández-Aceñero, M. J., 3402
 Fernández de Velasco, J., 5013
 Fernando, G. J. P., 6438
 Fernando, H. C., 2681
 Ferner, R. E., 1573
 Feron, O., 3555
 Ferrara, J. L. M., 796
 Ferrario, A., 3956
 Ferreira, C. G., 4081
 Ferrer, F., 2576
 Ferrer-Mirallès, N., 4514
 Ferrone, S., 6178
 Feuerstein, B. G., 6205
 Feunteun, J., 764, 3883
 Feuring-Buske, M., 1730
 Fey, G. H., 2848
 Fialkov, J. M., 3093
 Fiaschi, T., 6489
 Fidler, I. J., 1996, 3603, 5720
 Fiebig, H. H., 3113
 Fields, H. W., 5451
 Filiberti, R., 5418
 Filippova, G. N., 48
 Filleur, S., 6538
 Fillion, C., 721
 Filomenko, R., 1815
 Finan, D., 5076
 Finch, R. A., 3221
 Finelli, P., 2398
 Fingleton, B., 5559
 Finkelstein, S., 2141
 Finkelstein, S. D., 2681, 3521
 Finnerty, B., 2567
 Finney, G. L., 6916
 Firat-Geier, E., 6901
 Firoozbakht, F., 2749
 Fischer, P., 4820
 Fischer, S. M., 1178, 2516
 Fischetti, L., 867
 Fishbein, M. C., 3207
 Fishel, R., 1014, 5988, 6796
 Fisher, C., 135
 Fisher, D., 2098
 Fisher, P. W., 1797
 Fishman, D. A., 5358
 Fitzmaurice, M., 5375
 Flanagan, R. C., 5218
 Flavell, R. A., 1343
 Flavia Di Renzo, M., 7025
 Fleitmann, J-K., 1477
 Fleming, J., 4757
 Fleming, N., 363
 Fleshman, J. W., 445
 Fleshner, N. E., 2540
 Flesken-Nikitin, A., 2498, 5134
 Fletcher, C. D. M., 3980
 Fletcher, J. A., 6035
 Fletcher, L., 241
 Flies, D., 1884
 Flies, D. B., 4413
 Flora, R., 4730
 Flores, K. R., 4289
 Fluiter, K., 2024
 Foà, R., 5408
 Fodor, J., 4836
 Fodstad, O., 3120
 Foekens, J. A., 4617
 Foglieni, C., 941
 Fölsch, U. R., 910
 Fong, S. F. T., 4478
 Fonseca, R., 715
 Fontana, J. A., 3842
 Fontanini, G., 7284
 Ford, O. H., 2423
 Foreman, T. L., 2423
 Forman, S. J., 3175
 Formelli, F., 6152
 Formigli, L., 6489
 Fornace, A. J., Jr., 7305
 Forsyth, P., 6205
 Fosdick, L., 3361
 Fossà, S. D., 512, 2359
 Foster, C. J., 1952
 Foster, F. S., 6371
 Foster, P., 6462
 Foulkes, W. D., 6808
 Fournel, M., 4325
 Fournier, A., 721
 Fournier, P., 6538
 Fox, B. A., 3914
 Fox, E., 3485
 Fox, J. G., 696
 Fraga, M. F., 4519
 Fram, R., 789
 Francia, G., 2731
 Francisco, J. A., 3736
 Francisco, L. V., 3736
 Franco, S., 552
 Franconi, R., 3654
 Frankel, A. E., 1730
 Franken, K. L. M. C., 472, 6187
 Franklin, W. A., 3971
 Frantz, G., 2546
 Fränzel-Luiten, E., 7298
 Frati, L., 1196
 Frau, M., 4459
 Frazer, I. H., 6438
 Frazier, M., 1952
 Freiburg, T., 848
 Frechette, S., 4325
 Fredericksen, Z., 3587
 Frederiksen, C. M., 4352
 Freed, D. D., 3221
 Freeman, J., 2982
 Freeman, M. R., 1549, 2227
 Freeman, T., 6959
 Frei, E., 5678
 Freier, S., 219
 Frenkel, K., 417
 Freudenberg, M., 6901
 Freudenstein, J., 3448
 Freund, D., 4955
 Freund, G. G., 4746
 Frey, A. B., 1110
 Freytag, S. O., 4968
 Fricker, S., 5930
 Friebe-Hoffmann, U., 3521
 Friece, C. R., 7042
 Frieden, B. R., 3675
 Friedl, P., 2125
 Friedlander, D. R., 2660
 Friedlos, F., 1724
 Friedman, A. D., 2232, 3904
 Friedman, D., 3377
 Friedman, H. S., 3335
 Friedmann, P. S., 1757
 Friedrichs, W. E., 6141
 Frielink, C., 6146
 Friend, S., 3883
 Frierson, H., Jr., 2625
 Frierson, H. F., 6418
 Frierson, H. F., Jr., 4061, 6823
 Frieser, M., 3113
 Frilling, A., 3598
 Fritz, A., 3048
 Fritz, B., 2993
 Fritz, J., 1477
 Frödin, J-E., 1364
 Frohlich, V. C., 6278
 Fry, R. D., 1014
 Fu, K. K., 7350
 Fu, T., 7195
 Fu, X., 2306
 Fuchs, E., 5664
 Fueyo, J., 5736
 Fuggle, S., 2493
 Fuhrman, U., 3766
 Fujibayashi, Y., 445
 Fujii, H., 5813
 Fujii, T., 3340
 Fujita, M., 5651
 Fujita, N., 2971

AUTHOR INDEX TO VOLUME

- Fujiwara, H., 3751
 Fujiwara, M., 2236
 Fujiwara, O., 1956
 Fukai, Y., 7162
 Fukami, T., 5129
 Fukayama, M., 233
 Fuks, Z., 2531
 Fukuchi, M., 7162
 Fukuda, M., 4194
 Fukuda, M. N., 4194
 Fukuda, T., 5603
 Fukuda, Y., 2215
 Fukuhara, H., 5129
 Fukui, R., 1410
 Fukumura, D., 2151, 4289, 6831
 Fukushima, S., 3592
 Fulci, G., 2897
 Fuller, G. N., 5551
 Fulton, A. M., 2343, 2606
 Funahashi, Y., 6116
 Furge, K. A., 6598
 Furnari, F. B., 6764
 Fürstenberger, G., 4610
 Furukawa, M., 6337
 Furukawa, T., 2834
 Furukawa, Y., 518, 5651, 7012
 Furumai, R., 4916
 Furuta, T., 4899
 Fusco, A., 1077, 2398, 7284
 Futreal, P. A., 6451, 6997
 Fuxius, S., 4015
- G**
- Gaarde, W. A., 3257
 Gabari, I., 3167
 Gabrielli, B., 875
 Gabrielson, E., 3971
 Gaddy-Kurten, D., 5571
 Gadiseti, 6246
 Gadedicke, S., 6901
 Gage, W. R., 2220
 Gaidano, G., 4089
 Gaikwad, A., 3030
 Gail, M. H., 3992
 Galambos, P., 2347
 Galanis, E., 4656, 6070
 Galanos, C., 6901
 Galappathi, K., 661, 1847
 Galbraith, S. M., 7247
 Galipeau, J., 5148
 Gallez, B., 3555
 Gallie, B. L., 967
 Galliera, E., 2332
 Gallinger, S., 1284
 Gallo, E., 4390
 Gallo, J. M., 1382
 Galm, O., 5902
 Gama, P., 2778
 Gamba, A., 5853
 Gan, D.-D., 7093
 Gandhi, V., 3100
 Ganem, D., 4525
 Gannon, G., 603
 Gano, J., 2806
 Gansbacher, B., 5543
 Ganss, R., 1462
 Gant, T. W., 4256
 Ganther, H. E., 156, 708
 Gao, B., 734, 2715, 3971
 Gao, F. G., 6438
 Gao, P., 3751
 Gao, Q., 3315
 Garabedian, E. M., 1555
 Garattini, E., 2192
 Garber, J., 3485, 3925
 Garbow, J. R., 445
 Garcia, R., 4514, 6659
 García-Castro, J., 5013
 García-Pardo, A., 2929
 García-Sánchez, F., 5013
 Gardelle, O., 2962
 Gardiner, B. B., 226
 Gardner, A. E., 4599
 Garès, M., 3511
 Garmestani, K., 5755
 Garner, E. I. O., 3058
 Garrido, C., 1815
 Gärtner, S., 840
 Garvin, A. J., 6598
 Gasbarri, A., 3861
 Gasco, M., 2072
 Gascon, R., 5536
 Gascoyne, R. D., 4089
 Gasper, W. J., 5463
 Gassmann, M., 2962
 Gastaldi, T., 1559
 Gastineau, D., 1884
 Gastman, B. R., 4884
 Gatenby, R. A., 3675, 5218
 Gates, J., 5564
 Gatter, K., 2493
 Gatter, K. C., 1326, 2957
 Gatto, S., 5995
 Gattuso, P., 4876
 Gaudet, J., 43
 Gault, E., 7175
 Gauniz, F., 5685
 Gauny, S. S., 1279
 Gautam, S., 2488
 Gawlinski, E. T., 5218
 Gay, J., 4115
 Gaymes, T. J., 2791
 Gayo-Fung, L. M., 1439
 Gazdar, A., 3945
 Gazdar, A. F., 3382, 5897, 6820
 Gazit, A., 1077
 Gazit, G., 2468
 Gazzoli, I., 3925
 Ge, S., 6270
 Geacintov, N. E., 4229
 Gebhardt, R., 5685
 Gee, J. M., 122
 Gee, M. S., 747
 Geenen, V., 4623
 Geil, L., 3498
 Geissinger, E., 4820
 Gelmann, E. P., 2654
 Geluk, A., 472
 Geng, L., 4671
 Geng, Y., 4540
 Geoerger, B., 764, 5736
 Georgakoudi, I., 682
 Gera, J., 5027
 Geraci, M., 3971
 Geraci, M. W., 734
 Geradts, J., 1987
 Gerald, W. L., 1761, 2988, 4499
 Gerber, J. N., 4289
 Gerber, P. A., 4922
 Gerbin, C. S., 5358
 Gere, S., 4191
 Gerhard, B., 1730
 Gernert, K. M., 2897
 Geroni, C., 2332
 Guerrero, R., 6997
 Gerritsen, W. R., 5736, 6165
 Gerson, S. L., 3070
 Gescher, A. J., 4256
 Geschwind, J.-F. H., 3909
 Gesell, T. L., 734
 Gespach, C., 4879
 Gessain, A., 3562
 Getzenberg, R. H., 2437
 Gevrey, J.-C., 4829
 Ghali, L. R., 4773
 Ghidoni, R., 2455
 Ghilardi, J. R., 7343
 Ghirelli, C., 1321
 Gho, Y. S., 6312
 Ghosh, D., 4427
 Ghosh, P. M., 2630
 Giaccone, G., 4081
 Gianni, M., 2192
 Gianni, M. A., 6152
 Giannini, G., 1196
 Giannoni, E., 6489
 Giardina, C., 3667
 Giardino, D., 2398
 Gibbs, R., 3369
 Gibril, F., 3702
 Gibson, E. M., 488
 Gibson, J. J., 7200
 Gibson, K. H., 5749
 Gibson, S. B., 488
 Giese, N. A., 3729
 Gilbert, M. R., 4364
 Gilboa, E., 5041
 Gildea, J. J., 982, 6418, 6981
 Gildea, J. W., 6981
 Gillan, L., 5358
 Gillatt, D., 4123
 Gillespie, G. Y., 773, 2699, 3347
 Gillespie, J. W., 3498
 Gilliland, F. D., 2248, 2370
 Gillis, A. J. M., 1822, 2758
 Gilmour, S. K., 67
 Gayo-Fung, L. M., 1439
 Gimmi, C. D., 437
 Ginn, O., 3698
 Ginn, C. D., 437
 Ginn, D., 381
 Giodini, A., 2462
 Giordano, T. J., 4722
 Giorgi, C., 3654
 Giraudier, S., 4685
 Gisselsson, D., 2675, 5939
 Giuliano, R. E., 6545
 Giussani, C., 6884
 Gladson, C. L., 2699, 5336
 Gladu, J., 2390
 Glaser, M., 5912
 Glatstein, E., 7273
 Glatting, G., 3331
 Glazer, C. A., 3335
 Glazer, R. I., 3538
 Glickman, N. W., 356
 Glover, T. W., 5273
 Glusenkamp, K.-H., 1718
 Glynn, R., 1289
 Go, V. L. W., 741
 Gobbi, A., 3106
 Goebel, S. U., 3702
 Goepfert, T. M., 4115
 Goertz, D. E., 6371
 Goffin, J. R., 6808
 Gofman, I., 5536
 Goggins, M., 1868
 Goich, S., 5308
 Gokden, N., 6470
 Gold, L. I., 2778
 Goldberg, I. D., 141
 Goldberger, N., 1256
 Goldblum, J. R., 135
 Goldenberg, D. M., 2029
 Golding, M., 5698
 Goldman, I. D., 6434
 Goldschmidt, E., 4685
 Goldsmith, J. D., 135
 Goldstein, A. M., 4191
 Goldstein, L. A., 4884
 Goldstein, M., 6803
 Golembieski, W. A., 6270
 Gollnick, S. O., 1604
 Golob, M., 5962
 Golubeva, O., 4996
 Golpon, H. A., 734
 Gomer, C. J., 1458, 3956
 Gomez, D., 3365
 Gómez-Pineda, A., 5013
 Gonzales, F. A., 961, 2378, 6456
 Gonzales, M. I., 5505
 Gonzalez, A. M., 977
 Gonzalez, F. J., 3030
 González-Quevedo, R., 3855
 Goode, E. L., 3052
 Gooderham, N., 4605
 Gopalakrishnan, R., 4376
 Gorbsky, G. J., 2462
 Gordon, C. M., 4041
 Gordon, G. J., 4963
 Gordon, J. I., 1555
 Gordon, J. R., 2043
 Gore, S. D., 5618
 Gorelik, E., 5727
 Gores, G. J., 1648, 6500
 Gorfajn, B., 3377
 Gorn, I., 1477
 Gorospe, M., 3257
 Gosink, M., 2913
 Gotanda, T., 2834
 Goto, H., 3711, 5967
 Goto, M., 7004
 Gottenger, E., 5974
 Gotthard, S., 4955
 Gottlieb, D. J., 283
 Götz, R., 6297
 Gouble, A., 1489
 Gough, M., 5495
 Gough, M. J., 6566
 Gould, M. N., 1241
 Gould, V. E., 4876
 Goulding, E. H., 990
 Goulet, B., 6625
 Gouttefangeas, C., 5818
 Gozzetti, A., 5523
 Grachtchouk, M., 5308
 Graff, B. A., 661, 1847
 Graham, G., 359
 Graham, G. A., 4645
 Gramatzki, M., 2848
 Grammer, J. R., 2699, 5336
 Grana, T. M., 4142
 Grant, S., 188
 Grass, L., 295
 Graw, J., 3048
 Gray, J. W., 1000, 1939, 3636
 Gray, P., 6870
 Grazide, S., 1489
 Greaves, P., 4256
 Greco, M. A., 2660
 Green, J. E., 3934, 5325
 Green, L., 5106
 Green, S. J., 3691
 Green, S. K., 2731, 6891
 Greenberg, N. M., 7135
 Greene, G. F., 6470
 Greenwald, B. D., 3493

- Grégoire, M., 1050, 2861
 Grégoire, V., 3555
 Gregory, C. W., 2423
 Greil, J., 2848
 Greiner, J. W., 5049, 5058, 6944
 Greipp, P. R., 715
 Grenier, J., 721
 Gri, G., 4390
 Griffin, C., 3789
 Griffin, C. A., 647
 Griffin, C. S., 6263
 Griffin, J. D., 5019
 Griffin, R. J., 1702
 Griffith, T. S., 3093, 7170
 Griffiths, J. R., 688
 Grill, J., 764, 5736, 6165
 Grimes, M. J., 2370
 Grimwade, D., 4730
 Grinstein, S., 4876
 Groden, J., 2766, 3503
 Groom, A. C., 887, 2162
 Grossman, D. A., 3826
 Grossschmidt, K., 5317
 Grotzer, M. A., 1802
 Gruman, L. M., 665
 Grundy, P. E., 48
 Grünebach, F., 5065
 Grünwald, V., 6141
 Grupp, S. A., 4212
 Grushko, T. A., 1481
 Gryfe, R., 1284
 Gschwendt, B., 6698
 Gschwind, A., 6329
 Gu, J., 3620
 Gu, X., 3782
 Gu, Z., 3428
 Guadagni, F., 5049
 Guan, J., 1598
 Guan, X., 5344
 Guan, X. Y., 4704
 Guan, X.-Y., 7157
 Guan, Y., 6909
 Guba, M., 4034
 Gubish, C. T., 2141
 Gückel, B., 2052
 Guda, K., 3667
 Gudas, J. M., 113, 5106
 Gudas, L. J., 1196, 1654
 Guerry, D. P., IV, 3992
 Guglielmi, J., 6538
 Guha, S., 1632
 Guichard, S. M., 5001
 Guida, T., 1077, 7284
 Guillaume, P., 1743
 Guillaume, R., 2210
 Guillaume, T., 4985
 Guillemette, C., 1978
 Guillermin, C., 3562
 Guiot, M.-C., 2131
 Gulding, K. M., 982
 Gulino, A., 1196
 Gullans, S. R., 4963
 Gumbiner-Russo, L., 3782
 Gumin, G. J., 2318
 Gunawardena, R. W., 6587
 Gunn, R. N., 5698
 Gunning, W. T., 4199
 Gunz, D., 4229
 Guo, C., 6481, 6651
 Guo, H.-B., 6837
 Guo, M., 1166, 4023, 4637, 5902
 Guo, P., 756
 Guo, S., 652
 Guo, W.-X., 801
 Guo, X., 589, 1196, 1654
 Guo, Y., 4413
 Guo, Y. J., 4678
 Gupta, A., 4376
 Gupta, D., 4996, 5019
 Gupta, K., 4491
 Gupta, S. K., 4484
 Gure, A. O., 4041
 Gustafsson, J. A., 4849
 Gusterson, B., 2072
 Gutierrez, M. A. R., 7170
 Gutiérrez, M. D., 2929
 Gutkind, J. S., 1401
 Gutmann, D. H., 1573, 2085
 Guy, S. P., 5749
 Gwady, F. G., 1688
 Gwyn, K., 1676
- H**
- Ha, L., 179
 Ha, S., 1275
 Haaf, T., 219
 Haapasalo, H., 3798
 Habeler, W., 6099
 Haber, D. A., 2741
 Habib, S., 4376
 Haddad, B. R., 6990
 Haffty, B. G., 497
 Hagedorn, M., 6884
 Hagelstein, M.-T., 4623
 Hagemann, R., 4352
 Hagemeyer, A., 5408
 Hagihara, N., 1433
 Hagiwara, K., 63
 Haglund, C., 632
 Hagos, F. G., 1481
 Hahn, W. C., 6348
 Haiman, C. A., 1045
 Hainaut, P., 2897
 Hait, W. N., 6864
 Hajra, K. M., 1613
 Haka, A. S., 5375
 Hakem, R., 6194
 Half, E., 1676, 4903, 6323
 Halford, S., 53
 Hall, J. A., 58
 Hallahan, D. E., 4671
 Halloum, A., 397
 Halmos, B., 528
 Halmos, G., 781
 Halpern, A., 3992
 Halsor, E. F., 661
 Halter, G., 3331
 Halvorsen, O. J., 6808
 Ham, A.-J. L., 5189
 Hamada, K., 3939
 Hamaguchi, M., 2215, 2414, 3929, 3962
 Hamamoto, R., 5651
 Hamamoto, T., 5955
 Hamamoto, Y., 3939
 Hamaoka, S., 6116
 Hamaoka, T., 3751
 Hamburger, A. W., 1004
 Hamdy, F. C., 1619
 Hamel, E., 4007
 Hamelin, R., 1609, 2447
 Hamidi, H., 6108
 Hamilton, T. A., 2606
 Hammer, J., 2600
 Hämmerling, G. J., 1462
 Hammond, E. H., 7350
 Hampel, H., 4579
 Hampton, G. M., 6418
 Han, C., 2957
 Han, F.-Y., 5457
 Han, H., 2890, 4843
 Han, S. W., 3226
 Han, S.-J., 1809
 Han, X., 5336
 Han, Z.-B., 5168
 Hana, K., 2236
 Hanada, R., 333, 4571
 Hanagiri, T., 1751
 Hanahan, D., 2731
 Hanash, S. M., 4722, 5273
 Hanawalt, P. C., 5288
 Hande, M. P., 6194, 6990
 Haneda, T., 6116
 Haney, N., 488
 Hankinson, S. E., 1045
 Hann, B., 3812
 Hannay, J. A. F., 2034
 Hansbury, M. J., 4909
 Hansen, G. B., 2675, 5939
 Hansen, M., 4339
 Hansen-Petrik, M. B., 403
 Haq, R., 5076
 Haque, S. J., 1103
 Hara, A., 6367
 Hara, Y., 4445, 7241
 Harada, H., 2013
 Harada, K., 3382, 5897
 Harada, M., 1471
 Harada, N., 1971
 Harada, T., 835
 Haraguchi, M., 2834
 Harano, T., 271
 Harari, P. M., 4300
 Harbeck, N., 840, 4617
 Harbor, P. C., 1103
 Harden, S., 371
 Harders, C., 2856
 Harding, M. A., 982, 6418, 6981
 Häring, H.-U., 840
 Harkin, D. P., 2644
 Harkins, L., 3347
 Härkönen, P. L., 2708
 Harms, H. J., 2248, 2370
 Harousseau, J.-L., 2861
 Harpaz, N., 1148, 6820
 Harper, J., 6823
 Harper, S. J., 4123
 Harrell, C., 2798
 Harrington, D., 715
 Harrington, K. J., 5495, 6566
 Harris, A. L., 688, 1315, 1326, 2493, 2957, 5912, 6924
 Harris, C. C., 3244
 Harris, D. M., 741
 Harris, L. C., 5001
 Harrison, C., 4065
 Harrison, D. J., 6615
 Harrison, P. R., 4757
 Hart, A. A. M., 7110
 Hartge, P., 3992
 Hartmann, A., 809, 6796
 Hartmann, C., 4100
 Hartmann, L., 3587
 Hartmann, L. C., 4656
 Hasegawa, S., 7012
 Haseman, J., 990
 Hasemeier, B., 6634
 Haslam, K., 3861
 Hasmann, M., 1057
 Hassan, K. A., 6414
 Hastie, N. D., 6615
 Haston, C. K., 3782
 Hasumi, Y., 2019
 Hata, K., 6367
 Hatfield, M., 6070
 Hatsukami, D. K., 129
 Hattori, T., 4938
 Hauck, W. W., 4054, 5413
 Haukaas, S. A., 6808
 Hautaniemi, S., 6240
 Havaux, N., 2327
 Haviv, Y. S., 4273
 Havre, P. A., 1443
 Hawighorst, T., 2004
 Hawk, N., 386
 Hawkins, A. L., 647
 Hawkins, G. A., 1784, 2253, 6485
 Hawkins, N., 53
 Hay, R. J., 5897
 Hayakawa, M., 4176
 Hayakawa, T., 2203
 Hayashi, K., 6390
 Hayashi, N., 1567
 Hayashi, S., 2203
 Hayashi, S.-i., 4849
 Hayashi, T., 24, 3876
 Hayashi, Y., 33, 333, 4075, 4571, 4849
 Hayes, R. B., 2654
 Haynl, A., 3009
 Hayward, S. W., 2999
 Hazel-Martin, D., 6598
 He, H., 669
 He, M., 1987
 He, P., 3244
 He, Z., 5590
 Healey, C. S., 3052
 Healey, J. H., 135
 Heath, V., 2072
 Hebbel, R. P., 4491
 Heber, D., 741, 5204
 Heberer, M., 3453
 Hebert, F., 781
 Hecht, D., 5370
 Hecht, S. S., 129
 Hecker, T. P., 2699
 Heckford, S. E., 854
 Heckl, S., 7018
 Hedrick, N. M., 2085
 Heere-Ress, E., 2098
 Hegerfeldt, Y., 2125
 Heglans, T., 4034
 Heidt, M., 4610
 Heike, Y., 560, 860
 Hein, C., 1503
 Heise, C., 6070
 Heldin, C.-H., 5476
 Helén, P., 3798
 Helenius, H., 7364
 Helfrich, W. G., 2474
 Hellawell, G. O., 2942
 Helmbach, H., 6698
 Hellsby, N. A., 1425
 Hemenway, D., 4169
 Hemminki, A., 1266, 1271, 4273
 Hempen, P. M., 5351
 Henderson, B. W., 1604
 Henderson, K. J., 715
 Henderson, K. W., 5083
 Henderson, M. A., 1289
 Henderson, R., 1737
 Hendrick, J.-C., 4623
 Hendriks, J. A., 6187
 Hendrix, M. J. C., 665, 4478
 Heng, H., 2115

AUTHOR INDEX TO VOLUME

- Hennequin, L. F., 4645
Hennig, J., 4015
Hennighausen, L., 1030, 7166
Henriksen, G., 3120
Henry, F., 1050
Henry, M., 7102
Hensel, C. H., 2637
Hensen, K., 1510
Henshall-Powell, R. L., 5627
Henson, E. S., 488
Herbrand, U., 1718
Herbstritt, C. J., 3691
Herlyn, D., 5267
Herlyn, M., 226, 3200, 3581, 6997
Herman, J. G., 1166, 2157, 3659, 4519, 5902, 7213
Hermann, C., 2244
Hermanson, G., 5845
Hermeking, H., 6255
Herndier, B. G., 5536
Herrmann, J., 2468, 3834
Herter, P., 1718
Herva, R., 4554
Herzog, C. R., 6424
Heselmeyer-Haddad, K., 2365
Heslop, H. E., 7195
Hess, M. T., 4229
Hess, S. D., 2611
Hessels, D., 2695
Hetzl, M., 3331
Hewett, P. W., 1669
Hewitt, S. C., 2798
Hewson, Q. D. C., 5158
Heylen, N., 2327
Heyns, W., 642
Hicke, B. J., 4029
Hicklin, D. J., 2034, 2567, 2731
Hicks, J. L., 2220, 6405
Hicks, K. O., 1425
Hicks, M. J., 1123
Hickson, J. A., 6717
Hidalgo, M., 6141
Hideshima, T., 3876, 4996, 5019
Hiendlmeyer, E., 3009
Hietanen, S., 7364
Higashibata, Y., 3751
Higashiyama, S., 6289
Higgins, J., 5041
Higuchi, H., 1648, 6500
Hii, G., 6651
Hildesheim, J., 7305
Hill, A. E., 5867
Hill, H. C., 7254
Hill, J., 6376
Hill, J. S., 2151, 4289
Hill, S. A., 7247
Hillan, K., 2546
Hiller, L., 2072
Hilsenbeck, S. G., 6376
Hiltunen, E. L. J., 6410
Himmelsbach, J., 5230
Hinze, S. J., 4599
Hippo, Y., 233
Hiraga, A., 860
Hirai, K., 1641
Hiraiwa, Y., 3962
Hirakawa, M., 1450
Hirao, A., 6194
Hiraoka, M., 2013
Hirasawa, A., 4860
Hirasawa, K., 1696
Hirata, A., 2554
Hirata, K., 518
Hirata, M., 1025
Hirata, Y., 13
Hirohashi, S., 2971, 4860
Hirose, Y., 6367
Hirsch, F. R., 3971
Hirt, U. A., 7139
Hirte, H. W., 1588
Hisa, Y., 6289
Hisatomi, H., 13
Hisatsune, A., 6579
Hiscott, J., 5148
Hishiki, T., 6462
Hiti, A. L., 3826
Ho, C-P., 2516
Ho, H. T. B., 4890
Ho, J. W., 6451
Ho, R., 6462
Hoa, M., 7154
Hoang-Vu, C., 3698
Hobart, P., 5845
Hobbs, C. A., 67
Hockemeyer, J., 3113
Hodek, P., 5678
Hodge, J. W., 5058, 5770
Hodges, A. K., 363
Hoelzer, D., 1768, 7050
Hoey, T., 5420
Hofbauer, R., 5317
Hoffman, M. P., 3549, 5370
Hoffman, R. M., 1534, 4685
Hoffmann, J.-S., 3511
Hoffmann, N., 5835
Hoffmann, T. K., 3521
Hoffmeyer, S., 1503
Höfler, H., 840, 3048
Hofmann, J., 1087
Hofmann, M., 5317
Hofmann, U. B., 7059
Hofstaedter, F., 809, 6796
Hofstetter, A., 809
Hogan, V., 4484
Hogarty, M. D., 6481, 6651
Högerkorp, C.-M., 4398
Hogg, A., 1425
Hogge, D. E., 1730
Höglund, M., 2675, 5939
Hogue, C. W., 1284
Holbrook, N. J., 3257
Holcomb, I., 2546
Holder, A. L., 7247
Holen, I., 1619
Holland, E. C., 4364, 5551
Holland, J. F., 6080
Hollander, M. C., 7305
Hollenbach, S. J., 3729
Hollingsworth, M. A., 819
Holly, E. A., 3992, 4630
Holm, R., 512
Holmgren, L., 575
Holtsberg, F. W., 5443
Holzer, A., 6559
Hong, J., 7241
Hong, M.-H., 589
Hong, S.-I., 6318
Hong, W. K., 351, 2430, 2813, 3530, 4992, 5119, 6414
Hong, Y. J., 5365
Hongo, J. A., 2546
Honn, K. V., 2721
Hood, K. A., 3356
Hoogenboom, H. R., 3184, 5835
Hooper, J. D., 7083
Hooshdaran, M. Z., 1370
Höpfel, G., 2962
Hopkins, T. M., 2141
Hori, M., 1567
Horiguchi, S.-i., 4849
Horinouchi, S., 4916
Horsfall, D. J., 854
Hortobagyi, G., 5703
Horton, J., 5778
Horwitz, L. D., 6924
Horwitz, S. B., 1935
Hosaka, T., 5859
Hoshi, S., 3850
Hoshiga, M., 1410
Hoshikawa, Y., 734
Hosoda, M., 2203
Hostetter, G., 1256
Hotchkiss, K. A., 4791
Hou, W., 3702
Houghten, R., 2058
Houghton, P. J., 5001
Houle, C. D., 990
Houlston, R. S., 1166, 3803
Houseknecht, V., 6545
Howard, B., 424
Howard, M., 2332
Howarth, D. J. C., 295
Howe, C. L., 6667
Howe, L. R., 5405
Howell, S. B., 6559
Howell, W. M., 3369
Howitt, R., 3417
Hrobowski, Y., 6717
Hruban, R. H., 819, 1868, 3789
Hsiao, L.-L., 4963
Hsieh, C.-L., 3084, 6442
Hsu, H.-C., 4346
Hsu, J.-h., 5027
Hsu, L.-C., 6357
Hu, B., 1598
Hu, H.-M., 3914
Hu, L., 1087, 5027
Hu, N., 4191
Hu, Q., 7219
Hu, W., 6857
Hu, Y. J., 48
Hu, Z., 3377
Hua, L., 7230
Huang, C., 5689, 6857
Huang, C. C., 5867
Huang, C.-f., 3226
Huang, D., 171
Huang, H., 1008, 2043, 2592, 4157, 5470, 5632, 7118
Huang, H.-J. S., 6764
Huang, J., 4812, 6039
Huang, J. J., 3226
Huang, L., 6712
Huang, M., 5761
Huang, R., 2806
Huang, R.-P., 2806
Huang, S., 547, 5106
Huang, S. F., 5720
Huang, S.-M., 4300
Huang, T. H.-M., 3214
Huang, X., 3620, 5727
Huang, X. F., 2600
Huang, Y., 2913, 6857
Huang, Z., 466
Hubalek, M., 4535
Huber, C., 2856, 6750
Hudis, C., 5405
Huebner, K., 4054
Huerta, S., 741, 5204
Huet, T., 2318
Huettner, C. S., 528
Hufsky, H., 3113
Hug, B. A., 2906
Hugenschmidt, H., 4015
Hughes, G. D., 4645
Hui, C.-c., 5308
Hui, R., 6916
Huibregtse, J. M., 3315
Huisman, C., 4081
Huisman, M. T., 6158
Hukin, J., 2660
Hung, M.-C., 8, 346, 1311, 5703, 6712
Hungerhuber, E., 809
Hunt, D. F., 18
Hunt, K. K., 2239
Hunter, D. J., 1045
Hunter, D. S., 3766
Huo, D., 6717
Huo, K.-K., 7157
Hurlbert, M. S., 6385
Hurle, M. R., 1797
Husain, S. R., 3575
Hussenet, T., 6211
Hutchinson, O. C., 5912
Hüttelmaier, S., 6278
Huttunen, H. J., 4805
Hwang, S. T., 7328
Hwang, S.-L., 6952
Hwu, P., 5144
Hylander, B. L., 5800
Hyman, E., 6240
Hynes, N. E., 3151
Hytioglou, P., 6820
I
Iacobelli, S., 840, 2535
Iacobuzio-Donahue, C. A., 5351
Iacono, L., 3646
Iacopetta, B., 1609
Iavarone, A., 301
Ichigotani, Y., 2215, 3929, 3962
Ichihara, F., 5813
Ichikawa, T., 367
Ichimaru, N., 1410
Ichinose, M., 1433
Idezawa, T., 5611
Iglehart, J. D., 2267
Ihrig, M., 696
Iida, S., 4089
Iizumi, M., 1246
Iizuka, N., 3939
Ijzenberg, A., 6615
Ikawa, S., 636
Ikebuchi, Y., 6015
Ikeda, R., 2834
Ikegaki, N., 1802, 6462
Ikegami, T., 179
Ikezo, T., 5204
Ilagan, J., 2281
Ilango, G., 307
Iliakis, G., 1598, 2483, 6031
Illei, P., 2988
Illmer, T., 4955
Ilyas, M., 4562
Im, S.-Y., 1809
Imaida, K., 1956
Imamura, M., 4549, 5859
Imanishi, T., 3751
Imoto, I., 4860
Imyanitov, E., 840
Inaguma, S., 1956
Inazawa, J., 4860
Indraccolo, S., 6099
Indranie, C., 165

AUTHOR INDEX TO VOLUME

- Ingle, J. N., 3587
 Ings, S. J., 4730
 Iniesta, P., 3855
 Ino, K., 2753
 Inokuchi, J., 5668
 Inoue, H., 2937, 3819
 Inserra, A., 301
 Ioffe, O. B., 5463
 Ip, C., 708, 4383
 Ip, M. M., 4383
 Irani, J., 4854
 Irani, R., 3782
 Irby, R. B., 2669
 Irie, T., 1567
 Irwin, R. W., 741, 5204
 Isaacs, J. T., 986
 Isaacs, S. D., 1784, 2253, 6485
 Isaacs, W. B., 647, 1784, 2220, 2253, 6485
 Ishihara, T., 1410
 Ishii, A., 3850
 Ishii, N., 2897
 Ishikawa, S., 7124
 Ishikawa, T.-o., 506, 2261
 Ishimoto, O., 636
 Ismail, A., 5590
 Isohama, Y., 6579
 Isola, J., 632, 4554
 Israel, B., 1920
 Israel, M. A., 3729
 Israely, T., 6731
 Itahana, K., 4736
 Ito, A., 1025
 Ito, E., 33
 Ito, T., 4282
 Ito, Y., 1450
 Itoh, Y., 1410
 Ivakine, E., 5828
 Iwamoto, M., 3702
 Iwanaga, T., 560
 Iwanaga, Y., 2618
 Iwashita, T., 2414
 Izumi, Y., 6831
- J**
- Jäättelä, M., 7139
 Jabbour, H. N., 424
 Jablons, D. M., 3636
 Jablonski, S. A., 1797
 Jaboin, J., 6108, 6756
 Jackson, D. G., 1315, 6966
 Jackson, J. A., 4645
 Jackson, M. W., 854
 Jackson, S. C., 2294
 Jacob, L., 5267
 Jacobs, B., 3453
 Jacobs, J. J. L., 4736
 Jacobson, B. C., 682
 Jacquemin-Sablon, A., 4453
 Jaffe, R. B., 1087
 Jäger, D., 4041
 Jäger, E., 4041
 Jain, A. N., 957, 3636
 Jain, R. K., 2151, 4289, 6831
 Jaiswal, A. K., 3030
 Jalali, F., 6194
 Jallo, G. I., 2660
 Janek, K., 2875
 Jänicke, F., 4617
 Jänne, P. A., 5242
 Jansen, B., 2098
 Jansen, P. J., 801
 Janssen, H., 5408
 Janssen, M. L., 6146
 Jardine, L., 1876
 Jarry, A., 2169
 Järvinen, H., 1166, 4554
 Jasin, M., 1279
 Jass, J. R., 5988, 6011
 Jeang, K.-T., 2618
 Jeffers, M., 2468, 3834
 Jefferson, A. M., 1152
 Jeffrey, I. W., 2272
 Jeffy, B. D., 113
 Jen, J., 2744, 3340
 Jena, N., 535
 Jenkins, R. B., 3587, 4100, 6205
 Jenkins, W. T., 3626
 Jenne, J., 7018
 Jensen, E. R., 2287
 Jensen, J. A., 129
 Jensen, R. T., 3702
 Jensen, R. V., 4963
 Jensen-Pergakes, K., 977
 Jerónimo, C., 371
 Jesberger, J., 3408
 Jetten, A. M., 901
 Ji, L., 2715
 Jia, X.-C., 2468
 Jiang, B.-H., 5689
 Jiang, J.-D., 6080
 Jiang, P., 1534
 Jiang, W., 156, 1178, 5280
 Jiang, Y., 924, 1910
 Jiang, Z., 1624
 Jin, D.-Y., 1662
 Jin, X., 376, 1330
 Jing, D. D., 3226
 Jo, M., 5564
 Joel, S. P., 1876
 Joensuu, H., 632, 5210
 Joehn, L., 4100
 Johnson, A. C., 827
 Johnson, A. J., 4413
 Johnson, B. E., 5242, 6304
 Johnson, D. G., 3276
 Johnson, G., 3971
 Johnson, J. P., 5920
 Johnson, J. R., 6485
 Johnson, M., 3587
 Johnson, M. R., 5867
 Johnson, R. L., 5867
 Johnston, M., 3005
 Johnston, P. G., 2644
 Johnston, R., 4445
 Johnstone, C. N., 6779
 Jolicœur, P., 6625
 Jones, A., 2957
 Jones, J., 819, 5351, 7166
 Jones, J. L., 3289
 Jones, P. A., 961, 2378, 6456
 Jones, R. T., 3244
 Jones, T., 5698
 Jong, Y. S., 7254
 Jongen, J. L. M., 7343
 Jonkers, J., 1862
 Jönsson, M., 409
 Joos, S., 2993
 Jorcano, J. L., 3402
 Jorecyk, C., 5325
 Jordan, B. F., 3555
 Jordan, V. C., 4419
 Jorgenson, P., 3005
 Joseph, J., 6467
 Joseph, P., 703
 Joshi, H. C., 4109
 Josien, R., 1050
 Jost, B., 6211
 Jothy, S., 2731
 Jouault, H., 4685
 Jovanovic, B. D., 4419
 Jovanovic, V. P., 3438
 Jove, R., 5761, 6659
 Joyner, A. L., 6385
 Ju, Y. H., 2474
 Juang, S.-H., 3716
 Juarez, J. C., 5344
 Jucker, R., 3507
 Judah, D. J., 4256
 Juhola, M., 6410
 Jull, B., 403
 Jung, A., 3009
 Jung, D., 5370
 Jung, G., 2592
 Jung, M., 6879
 Jung, M. W., 4169
 Jungbluth, A. A., 4041
 Junker, K., 6796
 Jurisica, I., 3005
- K**
- Kaanders, J. H. A. M., 7066
 Kabos, P., 5657, 7170
 Kabosova, A., 5657
 Kadambi, A., 2151, 4289
 Kadlubar, F. F., 6470
 Kaganovsky, E., 1036
 Kagawa, S., 6598
 Kai, H., 6579
 Kaina, B., 1524
 Kaiser, S. A., 4419
 Kajiyama, H., 2753
 Kakiuchi, Y., 1567
 Kakkanaiah, V. N., 4007
 Kalat, M., 5489
 Kalita, A., 4325
 Kalli, K. R., 4656
 Kallio, M. J., 2462
 Kallioniemi, A., 2359, 2625, 6240
 Kallioniemi, O.-P., 1256, 2359, 6240
 Kalluri, R., 789
 Kalpana, G., 323
 Kaluz, S., 4469
 Kaluzová, M., 4469
 Kamar, M., 6837
 Kamata, J., 6116
 Kamberov, Y. G., 277
 Kamibayashi, C., 2715
 Kaminishi, M., 6645
 Kamphaus, G. D., 789
 Kandasamy, K., 4929
 Kandouz, M., 2721
 Kanduri, C., 4545
 Kanduri, M., 4545
 Kaneda, A., 6645
 Kanerva, A., 1266, 1271, 4273
 Kang, C., 6312
 Kang, H.-S., 6318
 Kang, J., 5325
 Kang, T., 675
 Kang, X., 5144
 Kannagi, R., 6289
 Kanno, H., 7004
 Kanno, J., 2236
 Kantarjian, H. M., 5995
 Kantoff, P., 5517
 Kantoff, P. W., 1045
 Kantor, J. A., 5049
 Kanugula, S., 3037
 Kanzaki, T., 2834
 Kao, C., 3084
 Kaplan, D. R., 2131, 6756
 Kaplan, L. S., 6966
 Kapp, L., 5536
 Karagas, M. R., 152
 Karaguni, I.-M., 1718
 Karashima, T., 5720
 Karaskova, J., 3466, 6194
 Kardias, S. L. R., 4722
 Karhausen, J., 3387
 Karhu, A., 4554
 Karlan, B. Y., 5358
 Karlsson, A., 2650
 Karlsson, M. C. L., 6891
 Karmand, A. J., 3549
 Karp, D. D., 528
 Karras, J., 6659
 Harrison, T., 6717
 Kas, K., 1510
 Kaser-Hotz, B., 2962
 Kashentseva, E. A., 609
 Kasperbauer, J. L., 1884
 Kasprzyński, A., 1718
 Kass, E. S., 5049
 Kast, W. M., 5792
 Kastan, M. B., 4588
 Kastner, B. D., 7291
 Kasumi, F., 560
 Katagiri, T., 518, 1139, 3244, 5859, 7012
 Katano, K., 6559
 Kataoka, Y., 5603
 Katayama, H., 5168
 Kates, R. E., 4617
 Katiyar, S., 1370
 Kato, H., 7162
 Kato, M., 2203, 2414, 5955
 Kato, T., 7012
 Katsuo, Y., 1410
 Kattan, M. W., 5974
 Katz, A. A., 424
 Katz, R., 7350
 Katz-Brull, R., 1966
 Kaufman, D. G., 79
 Kaufmann, D., 1503
 Kaufmann, M., 4186
 Kaufmann, S. H., 6500
 Kaul, S. C., 4434
 Kaur, B., 2478, 2897
 Kauraniemi, P., 6240
 Kavanagh, K. T., 652
 Kawa, K., 333
 Kawabata, M., 5955
 Kawagishi, R., 6015
 Kawaguchi, H., 333
 Kawahara, C., 636
 Kawai, A., 135
 Kawai, N., 1567
 Kawai, T., 4176
 Kawakami, K., 3575
 Kawakami, M., 3575
 Kawakami, T., 2690
 Kawakami, Y., 4836
 Kawakami-Kimura, N., 6289
 Kawamori, T., 28
 Kawamoto, S., 560, 860, 7004
 Kawamoto, Y., 2414
 Kawano, S., 1567
 Kawano, Y., 7124
 Kawata, R., 6289
 Kay, N. E., 715
 Kazim, L., 1737
 Kazuki, Y., 3322
 Ke, L. D., 1854

AUTHOR INDEX TO VOLUME

- Ke, Q., 5689
 Keblusek, P., 4736
 Keck-Waggoner, C. L., 4054
 Kedar, D., 5720
 Keilholz, U., 1743
 Keith, R. L., 734
 Keith, W. N., 5999
 Keller, E. T., 1832
 Keller, G. A., 2546
 Kelley, K. W., 4746
 Kelloff, G. J., 5178
 Kelsey, K. T., 152, 4630
 Kemming, D., 1020
 Kempkes, B., 2267
 Kendrew, J., 4645
 Kenerson, H. L., 5645
 Kennedy, R., 5495
 Kennel, M., 2824
 Kenner, O., 1503
 Kenney, S. C., 1920
 Kensler, T. W., 5196
 Kenter, G., 472
 Kerbel, R. S., 1838, 1931, 2731, 6371, 6891, 6938
 Kere, J., 3798
 Kerkvliet, N., 2162
 Kern, S. E., 819, 3789, 5351
 Keshavjee, S., 3005
 Keski-Oja, J., 5580
 Ketchen, A-M., 4065
 Keydar, I., 1093
 Keyes, K., 5597
 Keyser, C. P., 7343
 Khaletskiy, A., 1213
 Khalili, K., 7093
 Khammanivong, V., 6438
 Khammukhune, S., 1439
 Khanna, C., 6108
 Kharbanda, S., 789
 Khatib, A-M., 5393
 Khil, M., 4968
 Khodavirdi, A. C., 4812
 Khokha, R., 5543
 Khong, H. T., 3020
 Khoo, U-S., 4151
 Kiaris, H., 781
 Kickhoefer, V. A., 7298
 Kiechle, M., 4617
 Kiemeny, L. A., 2695
 Kiguchi, K., 2516
 Kijima, T., 6304
 Kikkawa, F., 2753
 Kikuchi, A., 4571
 Kikuchi, T., 3244
 Kilbey, A., 7181
 Killary, A. M. N., 1952
 Killion, J. J., 5720
 Kilpatrick, K. E., 2840
 Kim, B-C., 3649, 5365
 Kim, C. J., 6108, 6756
 Kim, C. W., 6312
 Kim, D. C., 747
 Kim, H., 6674
 Kim, H-T., 5365, 6376
 Kim, I. Y., 3649, 5365
 Kim, J., 1549, 5267
 Kim, J. H., 4202, 4968
 Kim, J. M., 4212
 Kim, J-H., 38, 7234
 Kim, J-S., 2744
 Kim, K., 1241
 Kim, K-M., 1166
 Kim, M. J., 2999
 Kim, M-S., 6318
 Kim, O. J., 3503
 Kim, R. B., 4955
 Kim, S-J., 3649, 5365, 5720, 7135
 Kim, S-T., 4588
 Kim, T-G., 7234
 Kim, T-Y., 7234
 Kimchi, A., 5618
 Kimos, M. C., 3493, 3641, 6820
 Kimura, A., 1567
 Kimura, J., 4282
 Kinch, M. S., 2840
 King, P. H., 3347
 King, W., 4132
 Kiniwa, Y., 4836
 Kinnula, V., 5210
 Kinsler, E. L., 2906
 Kinugawa, N., 4048
 Kinzler, K. W., 1129, 4579
 Kioschis, P., 6698
 Kirchner, T., 3009
 Kirkwood, J. M., 213
 Kirlappos, H., 1477
 Kirn, D., 6070
 Kirn, D. H., 764
 Kirschmann, D. A., 4478
 Kirschner, M. W., 3842
 Kisley, L. R., 6850
 Kitagawa, T., 4282
 Kitahara, O., 518, 1139
 Kitakata, H., 6682
 Kitamura, T., 28, 5955
 Kitamura, Y., 3751
 Kitange, G., 4100
 Kitazawa, J., 33
 Kiuru, M., 4554
 Kizaka-Kondoh, S., 2013
 Klamut, H., 171
 Klar, E., 1462
 Klausner, R. D., 3014
 Kleer, C. G., 4854
 Klein, P. S., 277
 Klein, R., 2516
 Kleiner, H., 7207
 Kleinman, H. K., 3549, 5370, 6312
 Klement, G., 1838
 Klenova, E. M., 48
 Klijn, J. G. M., 4617
 Kloetzel, P-M., 2875
 Kloosterboer, F., 346
 Klos, K., 5703
 Klotz, L. H., 2540
 Klotz, L-O., 4922
 Klotzbücher, M., 3766
 Klussman, K., 3736
 Knapp, D. W., 356
 Knayzev, P., 840
 Knee, D. A., 1904
 Knight, J., 3663
 Knobloch, T. J., 5295
 Knoepf, S. M., 5083
 Knowlton, M., 6740
 Knox, W. F., 122
 Knudsen, B. S., 1654
 Knudsen, E. S., 323, 6587
 Knuechel, R., 809, 6796
 Knuth, A., 4041
 Knuutila, S., 2625, 4061, 4554
 Knyazeva, T., 840
 Ko, B., 7207
 Ko, H., 7207
 Ko, H-M., 1809
 Ko, Y. H., 3909
 Kobashi, N., 4916
 Kobayashi, H., 560, 860, 4075
 Kobayashi, K., 28, 179
 Kobayashi, M., 28, 333
 Koc, H., 5183
 Koch, C., 3009
 Koch, C. J., 3626, 7273
 Koch, H. B., 6255
 Koch, Y., 1036
 Kocher, O., 528
 Kochetkova, M., 4599
 Kodama, T., 233
 Koeffler, H. P., 741, 5204
 Koeppen, H., 2546
 Koh, G. Y., 1809
 Kohn, K. W., 1688, 5743
 Kohno, T., 2019
 Kohonen-Corish, M. R. J., 2092
 Kohu, K., 3322
 Koike, L., 1025
 Koivisto, P., 1256
 Koivusalo, R., 7364
 Koki, A. T., 625
 Kokkola, A., 2625
 Kolb, E. A., 3377
 Kolesnick, R., 2531
 Koller, B., 901
 Köllermann, M. W., 251
 Kolodner, R. D., 3485, 3925
 Kolozsvary, A., 4202
 Komatsu, Y., 4916
 Komietani, T., 2554
 Komiya, A., 48
 Komiyama, S., 3351
 Komori, M., 1567
 Kondo, A., 6559
 Kondo, E., 6390
 Kondo, M., 2715, 4282
 Kondo, T., 6682
 Kondoh, S., 835
 Kondrat, N., 2115
 Kondziolka, D., 2583
 Konerding, M. A., 4015
 Konishi, F., 560
 Konishi, H., 271
 Konishi, J., 860
 Kono, K., 5813
 Kononen, J., 1256
 Koonce, L., 2798
 Kopitz, C., 5543
 Korach, K. S., 2798
 Koratkar, R., 5413
 Kore, M., 5611
 Korn, B., 6698
 Kornacker, M., 5785
 Kornaga, T., 2749
 Kornprobst, M., 4879
 Korsmeyer, S. J., 2184
 Kort, E. J., 589
 Korz, C., 2993
 Kosaka, T., 4176
 Kosari, F., 3308
 Koslowski, M., 6750
 Kosma, V-M., 6410
 Kossakowska, A., 1696
 Kosuge, D., 1669
 Kothari, N. H., 5611
 Kottke, T., 6566
 Kough, E. C., 3691
 Koul, S., 6218
 Kouprina, N., 367
 Koutalos, Y., 1420
 Kovacs, G., 957
 Kovar, H., 4583
 Kovats, S., 262
 Koyama, M., 6390
 Kraemer, K. H., 4899
 Kraggerud, S. M., 512
 Kragh, M., 1191
 Krajewska, M., 6674
 Krajewski, S., 6674
 Kral, S., 2875
 Krämer, A., 4186
 Kramer, P. M., 4199
 Krasna, M. J., 3493
 Krasnykh, V., 1266, 4273
 Krause, P., 6750
 Krausz, E., 7364
 Krawczak, M., 363
 Kreipe, H., 6634
 Kreisberg, J. L., 2630
 Krell, H-W., 5543
 Kremen, T. J., 2287
 Kresty, L. A., 5295
 Kriazhev, L., 5590
 Krieg, P., 4610
 Krishna, M. C., 307
 Kristjansen, P. E. G., 1191
 Kroemer, G., 1388
 Kronenberg, A., 1279
 Krouse, R. S., 3175
 Krüger, A., 4617, 5543
 Kruger, W. D., 6639
 Kruh, G. D., 3144, 6172
 Kruk, P. A., 4575
 Krupke, D. M., 1235
 Kruse, P., 1503
 Kruszewski, M., 2576
 Krutzsch, H., 6740
 Krutzsch, H. C., 1541
 Kruyt, F. A. E., 4081
 Krystal, G., 188
 Kshirsagar, S., 4491
 Kuang, J., 6870
 Kuang, X., 5153
 Kubin, M., 6178
 Kucherlapati, R., 2993
 Kucherlapati, R. S., 6218
 Kudo, A., 6688
 Kudoh, M., 1904
 Kufe, D., 789
 Kufer, P., 251
 Kugoh, H., 3766
 Kuick, R., 4722
 Kuja-Panula, J., 4805
 Kukoc-Zivoinov, N., 1768
 Kulesz-Martin, M., 3264
 Kulik, G., 18
 Kultti, A., 6410
 Kumamoto, K., 6289
 Kumar, A., 3315, 7219
 Kumar, M., 6997
 Kumar, R., 1251
 Kume, A., 2019
 Kundu, N., 2343, 2606
 Kundu, S. D., 7135
 Kung, H-f., 3226
 Kung, H-J., 1496, 6606
 Kuno, T., 2203, 6367
 Kuntz, S. M., 947, 5223
 Kuo, M. T., 4903, 6323
 Kuo, M-L., 1222
 Kuo, W-L., 1939, 3636
 Kuo, Y-M., 6559
 Küpcü, Z., 5489
 Küpers, H., 2848
 Kuppusamy, P., 307
 Kuramochi, M., 5129
 Kuramoto, T., 3592
 Kurata, M., 6224

AUTHOR INDEX TO VOLUME

- Kuratomi, Y., 3351
 Kurebayashi, S., 901
 Kurek, R., 5685, 5818, 6740
 Kurie, J. M., 3530, 3945
 Kuriyama, K., 5603
 Kuriyan, J., 4236, 4244
 Kurland, A. R., 6006
 Kuroki, T., 2258
 Kuronen, A. T., 6410
 Kurooka, M., 1261
 Kurzrock, R., 932
 Kusano, N., 835
 Kuschel, B., 3052
 Kushner, D., 397
 Kushner, P. J., 141
 Kuske, M. A., 5920
 Kussie, P., 2567
 Küsters, B., 341
 Kusugami, K., 2385
 Kusuzaki, K., 5859
 Kuwada, S. K., 6870
 Kuwajerwala, N., 2488
 Kuwano, H., 7162
 Kuwano, M., 2554, 2834, 3144, 4048
 Kuwano, T., 2554
 Kuzdzal, S., 1868
 Kuzmin, I., 3498
 Kwappenberg, K. M. C., 472
 Kwon, E., 7135
 Kyi, A. T., 7328
 Kyprianou, N., 597
- L**
- Laboisie, C. L., 2169
 Labrie, C., 721
 Labrie, Y., 721
 Lacroix-Triki, M., 3511
 Ladanyi, M., 135, 2988
 Ladner, R. D., 4909
 Ladu, S., 4459
 Laframboise, S., 3466
 Lagowski, J. P., 3264
 Lahermo, P., 1166, 3798
 Lahrech, H., 5672
 Lahrs, S., 5260
 Lahti-Domenici, J., 4540
 Lahusen, T., 1401
 Laiho, P., 1166, 4352, 5989
 Laird, A. D., 5727
 Laird, P. W., 1296
 Lake, R. A., 2353
 Lakkakorpi, P. T., 2708
 Lal, A., 3335
 Lam, C. L., 4464
 Lam, J. T., 1266
 Lam, W., 459, 1624
 Lam, W. K., 4464
 Lam, W. L., 6447
 Lambek, C. L., 4244
 Lamborn, K. R., 4263, 6205
 Lamfers, M. L. M., 5736
 Lamph, W. W., 6376
 Lamy, S., 381
 Lan, K-H., 5703
 Land, S., 213
 Landázuri, M. O., 2929
 Landen, J. W., 4109
 Landesman-Bollag, E., 6770
 Landini, E., 5418
 Lane, H. A., 3151
 Lang, F. F., 1069, 2318
 Lang, R., 4109
 Lang, S. H., 58
 Lange-Asschenfeldt, B., 2004
 Langenbach, R., 3395
 Längler, F., 6634
 Langland, G., 2766
 Lansdorp, P. M., 6990
 Lansiaux, A., 7219
 Lansita, J. A., 6791
 Lantry, L. E., 3024
 Lantvit, D. D., 5178
 Lapadat, R., 3971
 Lapointe, D. S., 3233
 Lapointe, R., 5144
 LaPushin, R., 7264
 Lara, C., 7093
 Larcher, F., 3402
 Lardeux, B., 4977
 Larionov, V., 367
 Larizza, L., 2398
 Laroocca, D., 977
 LaRochelle, W. J., 2468, 3834
 La Rose, J. H., 5743
 La Rosée, P., 7149
 Larsen, R. H., 3120
 Larsson, O., 135, 3861
 Larsson, R., 4206
 Lasarev, M., 1518
 Lasky, L. A., 2546
 Lasorella, A., 301
 La Starza, R., 5408
 Latham, D. E., 4307
 Latham, P., 179
 Latif, F., 3803, 5874, 5906
 Latif, T., 2644
 LaTulippe, E., 4499
 Lau, A., 4890
 Launonen, V., 1166, 4554
 Laurberg, S., 4352
 LaVallee, T. M., 3691
 Lavery, T. T., 6598
 Law, P-Y., 4491
 Lawlor, E. R., 4711
 Lawrence, T. S., 2337
 Lazar, M. A., 2906
 Lazaro, L. L., 4256
 Lazarus, P., 1978
 Le, J. L., 3812
 Le, K-a., 129
 Le, N. D., 6447
 Le, X-F., 7264
 Leach, F., 3649
 Leahy, K. M., 625
 Le Beau, M. M., 3477, 5523
 LeBlanc, R., 2131, 2300, 4996
 Le Bricon, T., 2771
 Lebrun, J-J., 4678
 Lebtahi, K., 2327
 Lechner, J. F., 2370
 Leder, P., 4781
 Leduy, L., 6625
 Lee, A. S., 1458, 7207
 Lee, A. T., 5720
 Lee, C., 7135
 Lee, C. A., 3395
 Lee, C. M., 4282
 Lee, C. S. L., 6916
 Lee, C-C., 589
 Lee, D. K., 3649, 5365
 Lee, H. M., 6312
 Lee, H-K., 1809
 Lee, H-Y., 3530, 3945
 Lee, I., 6837
 Lee, J., 262
 Lee, J. C., 747
 Lee, J. I., 6414
 Lee, J. J., 351, 1178, 2813
 Lee, J. S., 3893
 Lee, K., 3144
 Lee, K-H., 4916
 Lee, L. M. L., 665
 Lee, L-F., 6606
 Lee, M. P., 4191
 Lee, M. W., 466
 Lee, N. C., 4696
 Lee, P. W. K., 1696
 Lee, P-H., 4346
 Lee, R. J., 2077
 Lee, R. Y., 3428
 Lee, S., 1275, 5703
 Lee, S. P., 6952
 Lee, S. Y. D., 2906
 Lee, S-H., 6318
 Lee, T. H., 6312
 Lee, T-H., 6952
 Lee, W. M. F., 747
 Lee, W. S., 6385
 Lee, W-H., 2498, 3773, 3966, 5134
 Lee, Y., 6395
 Lee, Y-F., 6039
 Lee, Y-P., 5564
 Leek, R. D., 688, 1315, 1326, 2493, 2957
 Leenders, W. P. J., 341
 Leeuwenburgh, C., 4592
 Leffert, J. J., 2313
 Leggatt, G. R., 6438
 Leggett, B., 3641, 5988, 6820
 Leggett, B. A., 6011
 Legros, J-J., 4623
 Lehmann, U., 6634
 Lehr, H-A., 6750
 Lehtonen, R., 4554
 Lei, X., 4273
 Lei, Y-X., 703
 Leist, M., 7139
 Leistner, W., 1503
 Leit, S., 4325
 Leitch, A., 6615
 Leitner, W. W., 5144
 Leiva, I., 5325
 Lemke, N., 6270
 Leng, L., 5881
 Lengauer, C., 1129
 Lentzsch, S., 2300, 4996, 5019
 Leonard, S. S., 5689
 Leonessa, F., 3428
 Leoni, L., 4007
 Leppä, S., 5210
 Lerman, M. I., 2715, 3498, 4469
 Lerner, A., 5711
 LeRoith, D., 1030, 6529
 Leslie, K. K., 881
 Lessey, B. A., 79
 Leung, D. H., 135
 Leung, K. M., 4890
 Leung, S. Y., 6451
 Lev, A., 3184
 Levenson, A. S., 4419
 Levina, E., 5947
 Levine, B. D., 5778
 Levitt, R. J., 7372
 Levitzki, A., 1077
 Levsky, J. M., 6006
 Levy, D., 7102
 Levy, R., 3195, 5845
 Lew, Y. S., 4202
 Lewin, J. S., 3408
 Lewis, J. S., 445
 Leygue, E., 2736
 Leytin, A., 1148
 Lhoták, S., 1588
 Li, B. F-L., 1592
 Li, C., 5019
 Li, D., 4023, 4566, 4637
 Li, F., 1251, 2043, 5035
 Li, G., 1330, 4061
 Li, G. C., 2483, 6031
 Li, H., 307, 2029, 4507
 Li, J., 756, 2085, 3024, 4300, 5420, 5689, 6857
 Li, J-H., 171
 Li, J-J., 1213
 Li, J-N., 6080
 Li, K., 1330
 Li, M., 7012, 7124
 Li, R., 6345
 Li, R. J., 6447
 Li, S., 2337, 3722, 5019, 6712
 Li, W., 5027
 Li, W. W., 6909
 Li, X., 338, 417, 5867
 Li, Y., 1330, 1737, 2576, 2766, 3630, 3743, 6035, 6080
 Li, Y. F., 5144
 Li, Y-F., 2248
 Li, Z., 1000, 1939, 4325, 5980
 Li, Z-Y., 1063, 6089
 Liang, G., 961, 6430, 6456
 Liang, Y., 4867
 Liao, F., 2567
 Liao, L. M., 2287
 Liber, H. L., 6400
 Libutti, S. K., 3934
 Lichenstein, H. S., 2468, 3834
 Lichtenstein, A., 5027
 Lichter, P., 2993, 6698
 Lieber, A., 1063, 6089
 Lieberman, J. R., 5564
 Liénard, D., 1743
 Lieubeau, B., 1050
 Liew, F. Y., 4390
 Liewald, F., 3331
 Lillemo, K. D., 1868
 Lillie, J., 262
 Lillo, R., 5013
 Lim, J. T. E., 3997
 Lin, B., 2806, 5019
 Lin, C-L., 6952
 Lin, D., 6430
 Lin, E. Y., 7166
 Lin, H-J., 376
 Lin, J., 376, 1305, 2227, 3226
 Lin, J. C. Y., 6456
 Lin, K., 5308
 Lin, L., 5273
 Lin, M. C., 3226
 Lin, R., 5148
 Lin, S-Z., 756
 Lin, T., 3620
 Lin, W-J., 6039
 Lin, Y., 2806, 4029
 Linardakis, E., 5495, 6566
 Linch, D. C., 4730
 Lindblom, A., 48
 Lindner, G., 6724
 Lindsey, J. C., 5906
 Lindstrom, M. J., 1241
 Linehan, W. M., 3014, 3498
 Ling, X. B., 5420
 Ling, Y-H., 6080
 Lingnau, M. W., 7143
 Lingnau, K., 1477

AUTHOR INDEX TO VOLUME

- Linnebacher, M., 2052
 Liotta, L. A., 3244
 Liou, J.-Y., 1624
 Lipp, M., 1743
 Lippman, S. M., 1178, 2813, 5119
 Lips, J., 1524
 Liston, B. W., 4376
 Litman, E. S., 881
 Little, J. B., 2531, 5436
 Litwin, S., 3200
 Liu, A., 3428
 Liu, B., 3530
 Liu, C., 796, 4244, 5470, 7118
 Liu, C.-Y., 5134
 Liu, D., 6414
 Liu, D. D., 351
 Liu, E. T., 1688, 1987, 3581, 6246
 Liu, F.-F., 171
 Liu, G., 1377, 2819
 Liu, H., 4295
 Liu, J., 386
 Liu, J. R., 924
 Liu, J.-F., 3716
 Liu, J.-W., 2976
 Liu, K., 433
 Liu, L., 3037, 3070, 4545
 Liu, M., 5399
 Liu, M. Y., 6475
 Liu, N., 3005
 Liu, S., 4023, 4637, 7357
 Liu, T. C., 3493
 Liu, T.-J., 1069
 Liu, T.-W., 3716
 Liu, V. C., 7135
 Liu, W. J., 6438
 Liu, X., 6481
 Liu, X.-g., 1802
 Liu, X.-H., 1433
 Liu, Y., 3459, 6357
 Livingston, S., 6659
 Ljung, B.-M., 1000, 5980
 Ljungkvist, A. S. E., 7066
 Lloyd, D. R., 5288
 Lloyd, M., 5295
 Lo, H. S., 4191
 Lo, S. H., 4217
 Lo, T. B., 4217
 Lo, W.-F., 6952
 Lobanenkova, V. V., 48
 Lobl, T. J., 2327
 Lockman, J., 4579
 Lo Coco, F., 5618
 Loda, M., 89, 3485, 3925
 Loeb, L. A., 3511
 Loeffler, J. S., 200, 4307
 Loeppen, S., 5685
 Loeser, W., 5818
 Loft, S., 4339
 Loftin, C. D., 3395
 Lofton-Day, C., 3214
 Logan, T., 213
 Lohse, C. M., 6566
 Lokker, N. A., 3729
 Lomonosova, E., 3373
 Long, D. J., II, 3030
 Longley, D. B., 2644
 Longoni, P., 6152
 Looijenga, L. H. J., 1822, 2758
 Look, A. T., 6481
 Look, M. P., 4617
 Lopez-Barcons, L., 4514
 López-Casillas, F., 4690
 Lorenzato, A., 7025
 Losa, M., 2398
 Löscher, W., 1356
 Löser, R., 1057
 Lotan, R., 1178, 2430
 Lothe, R. A., 512, 2359
 Lott, S. T., 1952
 Loughran, T., 5761
 Louie, D. C., 4089
 Louis, D. N., 1790, 4100
 Louis, N. A., 3387
 Loukinov, D. I., 48
 Louro, I. D., 5867
 Louvet, C., 4879
 Lovat, P. E., 5158
 Lövborg, H., 4206
 Lovell, M., 1952
 Lowe, L., 5308
 Lowler, K. P., 796
 Lowry, D. T., 1152
 Lowy, A. M., 3503
 Lu, C., 3005
 Lu, H., 7241
 Lu, J., 1884, 3428, 5807
 Lu, M., 4968, 6973
 Lu, M. L., 2227
 Lu, N., 4191
 Lu, W., 1305
 Lu, Y., 1087
 Lubet, R. A., 3024, 5178
 Luboshits, G., 1093
 Lucas, T., 2098
 Lucchiari-Hartz, M., 6901
 Lucroy, M. D., 4295
 Lue, J., 4514
 Luger, N. M., 7343
 Luker, G. D., 2195
 Luketich, J. D., 2141, 2681
 Luna, M., 3956
 Luna, M. C., 1458
 Lundin, J., 632
 Lundin, M., 632
 Luo, J., 2220
 Luo, L.-Y., 295
 Luong, M. X., 3233
 Lupold, S. E., 4029
 Lusher, M. E., 5906
 Lushnikov, E. F., 7031
 Luthra, S. K., 5912
 Lutterbaugh, J., 1134
 Lutterbüse, R., 251
 Lutz, R. J., 2546
 Lyakhovich, A., 2115
 Lynch, M., 2644
 Lynch, T. J., 1377, 2819
 Lynn, W. S., 5153
 Lyons, S., 1862
 MacGowan, J., 3044
 Macgregor, P. F., 3466
 Mach, D. B., 7343
 Machida, K., 3929, 3962
 Machida, N., 233
 Machover, D., 4685
 Mack, D., 1134
 MacKenzie, K. L., 2104
 MacLeod, A. R., 4325
 Macris, M. H., 4711
 Madelmont, J. C., 1890
 Madelmont, J.-C., 2771
 Maeda, H., 3138
 Maeda, M., 5168
 Maemondo, M., 63
 Maesako, Y., 6224
 Magee, C., 3909
 Magaldo, T., 4685
 Magni, F., 1116
 Magni, M., 6152
 Magnusson, C. G. M., 1364
 Mahboobi, S., 3113
 Maher, E. R., 3803, 5874
 Mahieux, R., 3562
 Mai, K. H., 5196
 Mai, M., 6682
 Mai, W.-Y., 589
 Maillere, B., 213
 Maitland, N. J., 58
 Maitra, A., 5897
 Mak, T. W., 2281, 6194
 Makarla, P., 3382
 Maki, W., 7328
 Makita, T., 4812
 Makita, Z., 5881
 Makitaro, R., 5210
 Makkar, V., 3408
 Malapetsa, A., 5457
 Malik, S. N., 4690
 Malkinson, A. M., 734, 1152, 6850
 Mallery, S. R., 5295, 5451
 Mallett, R. W., 5755
 Malluck, C., 417
 Malphurs, J., 990
 Malumbres, M., 4514
 Mambo, E., 1349
 Man, S., 2731
 Manabe, R.-i., 5603
 Mancuso, P., 3106
 Manda, R., 7162
 Mandahl, N., 3861, 3980
 Mandal, M., 1251
 Mandriota, S. J., 603
 Manfioletti, G., 3766
 Mangues, R., 4514
 Manjili, M. H., 1737
 Mann, K. K., 3945
 Mann, L., 5597
 Männel, D. N., 4034
 Manning, B. M., 6870
 Manning, C. B., 4169
 Manning, P. T., 165
 Mantyh, P. W., 7343
 Mao, C., 7207
 Mao, L., 351, 4992, 6414
 Marais, R., 1724
 Marcelli, M., 6080
 Marcenaro, S., 6178
 March, G. E., 6405
 Marchenko, N. D., 7083
 Marchetti, A., 2535
 Marchini, S., 2332
 Marchion, D. C., 3132
 Marchisio, P. C., 2462
 Marconato, L., 7273
 Mareel, M., 1718, 4879
 Mariadason, J. M., 4791
 Marincola, F., 5267
 Marincola, F. M., 3581
 Marini, F. C., 3603
 Maris, J. M., 6481, 6651
 Markey, M. P., 6587
 Markowitz, S., 1134
 Marks, F., 4610
 Marmé, D., 4015
 Marques, M. M., 1978
 Marres, H. A. M., 7066
 Mars, W. M., 2064
 Martens, H., 4623
 Marth, C., 4535
 Martin, C., 848
 Martin, G. M., 367
 Martin, J., 1724
 Martin, J. M., 4599
 Martineau, D., 5148
 Martinek, V., 5678
 Martinelli, G., 3106
 Martinez, J.-L., 4736
 Martínez-Palacio, J., 3402
 Martin-Fontecha, A., 1116
 Martini, A., 5408
 Martinson, H. M., 3335
 Marusawa, H., 6674
 Maruta, H., 669
 Maruyama, T., 28, 5129
 Marynen, P., 5408
 Masferrer, J. L., 625, 5405, 5778, 6706
 Mashino, K., 2937
 Massé, D., 1050
 Massion, P. P., 3636
 Masso-Welch, P. A., 4383
 Massuger, L. F., 6146
 Mastrangelo, D., 5897
 Mastrangelo, M., 5267
 Masuda, A., 271
 Masuda, K., 1450
 Masuda, M., 3351, 3997, 5129
 Masuda, N., 7162
 Masuda, T.-a., 3819
 Matei, D., 5358
 Mathiesen, B., 661, 1847
 Mathiowitz, E., 7254
 Matraga, C. B., 1707
 Matrisian, L. M., 5559
 Matsubara, N., 3641, 5988
 Matsuda, H., 271, 4282
 Matsuda, K., 2004, 2883, 5611
 Matsuda, S., 2215, 3929, 3962
 Matsumori, Y., 3711
 Matsumoto, T., 1944
 Matsumoto, Y., 5813
 Matsushima, K., 3751
 Matsushita, S., 2834
 Matsuyama, A., 4916
 Matsuzaki, Y., 179
 Matta, H., 5897
 Mattern, K., 1057
 Mattern, M. R., 1797
 Mattfeldt, T., 3331
 Mattner, F., 1477
 Matusik, R. J., 5096
 Matzku, S., 4263
 Maublant, J., 617
 Maulik, G., 6304
 Maurici, D., 2897
 Maxwell, P. H., 2957
 Maxwell, P. J., 2644

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- May, C., 2104
 May, K. F., Jr., 3459
 Mayer, F., 2758
 Mayotte, J., 2468
 Mazar, A. P., 4678, 5344
 Mazurchuk, R., 2561
 Mazure, N. M., 1158
 Mazzola, L. M., 6831
 Mazzolini, G., 3167
 Mazzoni, I. E., 2131
 McAlhany, S. J., 3298, 6021
 McAllister, K. A., 990
 McBride, W. H., 5230
 McCadden, J., 2576
 McCarron, S. L., 3369
 McCarty, M., 5106
 McCauley, L. K., 1832
 McCormick, F., 3812
 McCormick, J. J., 1443
 McCrae, K. R., 3408, 5344
 McCue, P. A., 4054
 McCulloch, T., 1669
 McDermott, U., 2644
 McDonald, D. M., 5381
 McDonald, W. F., 3834
 McElhiney, J., 5223
 McEntee, M. F., 403
 McGarvey, K., 6740
 McGrath, M. S., 5536
 McGregor, F., 4757
 McIntire, L. V., 5301
 McJilton, M. A., 2423
 McKeenan, K., 1898
 McKeenan, W. L., 1898
 McKeithan, T. W., 3477
 McKenzie, O. L. D., 4599
 McKie, J. A., 1439
 McKie-Bell, P. R., 5867
 McKinnon, P. J., 6395
 McKinsty, R., 188
 McLean, K., 6740
 McLeod, R., 359
 McMahon, S. J., 4109
 McMasters, K. M., 1776
 McNiel, E. A., 3826
 McPherson, J. P., 6194
 McQueeney, K. D., 3834
 McSheehy, P. M. J., 688
 Mebel, E., 6712
 Mechttersheimer, G., 2993
 Mecklenburg, I., 251
 Mecklin, J-P., 1166
 Mecucci, C., 5408
 Medina, D., 4115
 Medrano, E. E., 6231
 Meeker, A. K., 6405
 Mehlh, K., 1050, 2861
 Meggetto, F., 1489
 Meier, F., 226
 Meijer, C. J. L. M., 618
 Meijer-van Gelder, M. E., 4617
 Melcher, A., 5495
 Melcher, A. A., 6566
 Melero, I., 3167
 Melief, C. J. M., 472, 6187
 Melikian, A. A., 1330
 Melillo, G., 4316
 Melino, G., 5158
 Mellinghoff, I. K., 5254
 Mellor, R., 7083
 Mellstedt, H., 1364
 Melnyk, N., 4711
 Melton, D. W., 4065
 Meltzer, S. J., 1148, 3382, 3493, 3641, 5637, 5988, 6011, 6820
 Ménard, S., 567, 1321
 Mendoza, N., 5485
 Mendoza, V., 4690
 Meng, Q., 141
 Meng, X., 7241
 Meng, Z. H., 1000, 1939, 5980
 Menke, A. L., 6615
 Menon, M., 2488, 4968
 Menssen, A., 6255
 Merajver, S. D., 4854
 Meram, A., 2721
 Mercier, F., 5148
 Mercier, P., 1489
 Mercurio, A. M., 7203
 Mergny, J-L., 3365
 Merino, M. J., 6740
 Merlano, M., 2072
 Merlino, G., 2951, 6724
 Merok, J. R., 6791
 Mertens, F., 3980
 Mertens, J. C., 497
 Mertz, J. E., 6510
 Mesri, E. A., 4854
 Messiaen, L., 1503
 Messing, E. M., 6039
 Mester, J., 4879
 Meterissian, S., 6625
 Metz, C., 5881
 Metzger, G., 4685
 Meyer, A. M., 6850
 Meyers, D. A., 1784, 2253, 6485
 Meyerson, M., 7001
 Mhashikar, A. M., 2239
 Mian, B., 5720
 Miao, L., 3084
 Miccoli, L., 5425
 Michaelsson, J., 1116
 Michailidis, G., 4722
 Michalickova, K., 1284
 Michalopoulos, G. K., 2064
 Miele, L., 665
 Miers, L. A., 4263
 Mihich, E., 3883
 Mikami, T., 2236
 Mikesch, J-H., 1020
 Mikhailova, M., 2630
 Mikheeva, G. V., 1266
 Miki, H., 669, 2503
 Miki, K., 5967
 Miki, T., 5967
 Miksicek, R. J., 2736
 Milan, G., 1116
 Milanese, M., 6152
 Milanini, J., 4977
 Milas, L., 7350
 Milbrandt, J., 1555
 Milhollen, M., 789
 Millán, J. L., 1822
 Millar, A., 3663, 4095
 Millar, R. P., 424
 Millard, P., 2493
 Miller, C. R., 773
 Miller, C. T., 5273
 Miller, D. P., 1377, 2819
 Miller, G., 5260
 Miller, G. J., 5096
 Miller, J. F., 2287
 Miller, J. H., 3356
 Miller, L. D., 1688, 3581
 Miller, L. J., 947, 5223
 Miller, W. H., Jr., 3893, 3945
 Miller, W. T., 4236
 Miller, Y. E., 734
 Millikan, R., 1987
 Mills, G. B., 1087
 Mills, L., 5106
 Millward, C., 5536
 Mipied, N., 2861
 Mimaki, Y., 1025
 Mimori, K., 2258
 Min, H-Q., 589
 Minamishima, Y. A., 995
 Mine, S., 3819
 Minna, J., 6997
 Minna, J. D., 2715, 3498, 5874
 Minskoff, S. A., 3834
 Mintum, J. E., 6462
 Mir, L., 4453
 Mirensky, T., 6651
 Misk, D. E., 4722, 5273
 Mishal, Z., 4685, 7219
 Mishima, K., 6764
 Mishima, M., 6559
 Mitchell, B. S., 3100
 Mitchell, J. B., 307, 6246
 Mitchell, R., 5881
 Mitelman, F., 2675, 3980, 5939
 Mitrou, P. S., 1768
 Mitsiades, C. S., 3876, 4996
 Mitsiades, N., 3876, 4996
 Mitsui, S., 295
 Miura, K., 3244
 Miura, M., 4860
 Miwa, N., 5651
 Mixson, A. J., 5463
 Miyahara, R., 7124
 Miyajima, A., 4176
 Miyajima, K., 3382, 5897
 Miyamoto, T., 3939
 Miyasaka, M., 4282
 Miyata, Y., 1025
 Miyazaki, J-i., 7166
 Miyazaki, K., 2203
 Miyazaki, T., 7162
 Miyazono, K., 5955
 Miyoshi, E., 1567
 Miyoshi, H., 1971, 2261, 4549
 Mizuguchi, H., 2203
 Mizukami, H., 2019, 3244
 Mizuno, K., 271
 Mizuno-Horikawa, Y., 5603
 Mizushima, T., 277
 Mizutani, K., 669
 Mizutani, S., 2753
 Mladek, A. C., 7291
 Mo, R., 5308
 Mocellin, S., 3581
 Mochida, Y., 4048
 Modugno, M., 1321
 Moerland, E. W., 48
 Mohammed, S. I., 356
 Mohandas, T. K., 892
 Mohr, J. L., 2423
 Mohsin, S. K., 6376
 Mok, S. C., 3058, 6218
 Mølk, A. M., 4339
 Molenkamp, G., 2131
 Mollenhauer, J., 6698
 Möller, P., 4339
 Molnar-Kimber, K., 3438
 Momoeda, M., 2019
 Monestiroli, S., 3106
 Mon-foote, T., 5571
 Monga, S. P. S., 2064
 Monia, B. P., 5393, 5888
 Monni, O., 2359, 2625, 6240
 Monno, A., 941
 Monos, D., 5267
 Montag, A., 251, 6598, 6717
 Montalto, M. C., 3387
 Montgomery, B., 3920
 Montgomery, C. A., 3030
 Montgomery, E., 4061
 Montgomery, K., 2993
 Montiel, J. L., 4690
 Moon, E-Y., 5711
 Moon, I-S., 7234
 Moon, R. C., 5178
 Moore, D. H., 957, 1000
 Moore, D. T., 3868
 Moore, J., 1315
 Moore, J. M., 48
 Moore, J. W., 2957, 6924
 Moore, M. A. S., 2104
 Moore, M. D., 734
 Moossa, A. R., 1534
 Moots, P. P., 2370
 Mora, J., 1761, 2988
 Mora, L. B., 6659
 Morán, A., 3855
 Moran, R. G., 5236
 Morello, D., 1489
 Moreno, V., 5902
 Moretta, A., 6178
 Moretta, L., 6178
 Morgan, W. T., 5344
 Morham, S. G., 3395
 Mori, H., 6367
 Mori, M., 2258, 2937, 3819
 Mori, N., 3939
 Mori, T., 1246
 Mori, Y., 1148, 3493, 3641, 5637, 6820
 Morilla, R., 4730
 Morimoto, J., 1410
 Morimura, K., 3592
 Morin, P. J., 2923
 Morineau, N., 2861
 Morinello, E. J., 5183, 5189
 Morishige, K-i., 6015
 Morita, A., 1471
 Morizet, J., 764
 Morley, S., 2272
 Mörry, T., 1718
 Morris, J., 122
 Morris, M. R., 3803
 Morris, V. L., 2162
 Morrison, L., 2365
 Morse, H. C., III, 48
 Morse, M. A., 4376, 5451
 Mortini, P., 2398
 Mortin-Toth, S., 5828
 Morton, C. C., 43
 Morton, C. L., 5001
 Morton, R. A., 3649, 5365
 Morvan, D., 1890
 Moskaluk, C., 2625
 Moskaluk, C. A., 4061, 6418, 6823
 Mosse, Y., 6651
 Mossink, M. H., 7298
 Mossman, B. T., 4169, 6065
 Mota, S. C. F., 6187
 Motoyama, A. B., 3151
 Mott, L. A., 152
 Motwani, M., 3950
 Moul, J. W., 6812
 Mousses, S., 1256, 2359, 6240
 Mu, R., 1330
 Mucilli, F., 2535
 Muerkoster, S., 910
 Mufti, G. J., 2791

AUTHOR INDEX TO VOLUME

- Muga, S., 2516
Mukai, T., 3751
Mukaída, N., 6682
Mukunyadzi, P., 6470
Mulé, K., 2064
Mullen, C. A., 208
Mullen, J. P., 3766
Mullenders, L. H., 4229
Müller, A., 1014, 3654, 6381
Muller, D., 6211
Müller, H. M., 4535
Muller, J., 6545
Müller, K., 4610
Müller, M. G., 682
Müller, O., 1718
Müller, P., 4034
Müller, S., 840
Muller, W. J., 5405
Müller-Driver, R., 4015
Müller-Holznier, E., 4535
Multani, A., 3030
Munaron, L., 2406
Munger, J. S., 2778
Münger, K., 7075
Muniappan, B. P., 3271
Munn, L. L., 6831
Munshi, N. C., 2982, 3876, 4996, 5019
Munson, P. J., 5370
Münster, P. N., 3132
Münstermann, E., 6698
Muntoni, A., 4757
Murai, M., 3751
Murai, N., 1971
Murai, T., 4282
Murakami, T., 7328
Murakami, Y., 5129
Murata, H., 1567, 7004
Murata, Y., 6015
Murrillas, R., 3402
Muro-Cacho, C., 6659
Muron, M. R., 4459
Muroso, S., 6337
Murphy, J., 3466
Murphy, K. M., 3789
Murphy, L. C., 2736
Murray, J. C., 1669
Murty, V. V. V. S., 6218
Muschel, R. J., 241, 1910
Muschler, J., 7102
Musgrove, E. A., 3126, 6916
Musgrove, H. L., 4645
Mutoh, M., 28
Mutsaers, A. J., 356
Mutti, L., 5418
Myal, Y., 2736
Myers, E. N., 3521
Myers, P., 2798
Myoung, H.-J., 7234
- N**
- Nabel, G. J., 1261
Nabors, L. B., 3347
Nacer-Chérif, H., 1158
Naderi, A., 3587
Nadkarni, K. V., 887, 2162
Naef, F., 6218
Naegeli, H., 4229
Näf, D., 1235
Nafziger, D., 4968
Nagane, M., 6764
Nagar, B., 4236, 4244
Nagarajan, R., 2085
Nagarajan, S., 2869
Nagasawa, H., 2531, 6400
Nagase, H., 675
Nagashima, Y., 7004
Nagayama, S., 5859
Nagi, P., 4273
Nagle, R. B., 2890
Nagorsen, D., 1743
Nagy, A., 781
Nahta, R., 2267
Naito, S., 2554, 4048, 4273, 5668
Naito, Y., 3962
Naka, T., 5800
Nakada, M. T., 2824
Nakagawa, H., 277, 4579
Nakagawa, T., 271, 2203
Nakagawara, A., 2203
Nakajima, H., 4916
Nakajima, M., 7162
Nakajima, Y., 2834
Nakamura, J., 5189
Nakamura, K., 2883
Nakamura, N., 89
Nakamura, T., 295, 3322, 5859
Nakamura, Y., 518, 1139, 1246, 2883, 3244, 5651, 5859, 7012
Nakanishi, K., 2971
Nakashima, I., 2414
Nakashima, T., 3351
Nakashima, Y., 5859
Nakatani, Y., 6390
Nakau, M., 2261, 4549
Nakayama, E., 1471
Nakayama, H., 3939
Nakayama, J., 4194
Nakayama, K., 995, 3819
Nakayama, K.-I., 995, 3819
Nakayama, T., 5859
Nallainathan, D., 3466
Nallasivam, P., 4089
Namba, H., 7031
Nambiar, P. R., 3667
Nandi, A. K., 338
Nanjangud, G., 2104
Nanus, D. M., 1654
Naoki, K., 7001
Napolitano, M., 1077
Nara, K., 6116
Nardin, S. R., 1534
Narita, Y., 6764
Narumiya, S., 28, 506
Nascimento, L., 6231
Nasi, S., 3507
Nassirpour, R., 1534
Natali, P. G., 6381
Nathwani, A. C., 3077
Nattel, S., 4843
Naumov, G. N., 2162
Naus, C. C. G., 3544
Nawrocky, M. M., 3159
Naylor, M. A., 7247
Naylor, S. L., 542, 2637
Nchekwube, E. J., 4007
Nederlof, P. M., 7110
Nedospasov, S. A., 4034
Neef, R., 5920
Neeman, M., 6731
Neff, J. R., 135
Negrin, R. S., 5785
Neil, J. C., 7175, 7181
Neill, G. W., 4773
Neilly, M. E., 3477
Neiman, P. E., 48
Nelson, H. H., 152
Nelson, J. L., 7280
Nelson, P. S., 3920
Nelson, W. G., 7230
Nemati, F., 1388
Nemenoff, R. A., 734
Nemoto-Sasaki, Y., 6682
Nepveu, A., 6625
Neri, M., 5418
Nervi, C., 7050
Nesbit, M., 3200
Nesland, J. M., 512
Nessling, M., 2993, 6698
Nestle, F. O., 6750, 7328
Nettelbeck, D. M., 1266, 1271, 4663
Neuberg, D., 4996
Neumaier, B., 3331
Neuman, T., 5657
Neumark, E., 1093
Newman, B., 1987
Ng, C. Y. C., 3077
Ng, I. O. L., 4704
Ng, R. W. M., 1662
Ngan, H. Y. S., 4151
Ngo, D., 171
Nguyen, C., 5974
Nguyen, C. T., 2378, 6456
Nguyen, K. C. Q., 5420
Ni, S., 1063, 6089
Nicholas, R. W., 5571
Nichols, P., 7207
Nicholson, A., 6997
Nicholson, R. I., 122
Nickel, A. E., 1296
Nickoloff, B. J., 665
Nicolaou, K. C., 6938
Nicolas, J.-C., 6519
Nicolò, G., 2455
Nicotra, M. R., 6381
Niculescu-Duvaz, I., 1724
Nieder, M., 2327
Niedermann, G., 6901
Nieva, D. R. C., 4478
Niewolna, M., 917
Niggemann, B., 6467
Nihei, N., 367
Nijman, H. W., 6187
Nikitakis, N. G., 1004
Nikitin, A. Y., 5134
Nilbert, M., 5939
Nilsen, K., 661, 1847
Nilsson, G., 3861
Nimmanapalli, R., 5761
Nimura, Y., 3929
Nishanian, T. G., 2744
Nishi, H., 827
Nishi, K. H., 827
Nishikawa, S. G., 1696
Nishikori, M., 6224
Nishino, N., 4916
Nishiyama, M., 4916
Nishizaki, M., 2715
Nißlein, T., 3448
Noessner, E., 480
Nolan, J., 7247
Nomoto, S., 3659
Nomura, S., 3751
Nomura, T., 518
Nonomura, N., 1410
Nooi, M., 2024
Noonan, F. P., 6724
Nordenskjöld, A., 6598
Nordquist, R. E., 4295
Norman, K. L., 1696
Northcote, P. T., 3356
Norton, J. A., 4696, 5069
Nosrati, A., 1134
Notario, V., 2690
Nowak, A. K., 2353
Nuchtern, J. G., 1123
Nukiwa, T., 63, 636, 3641
Numico, G., 2072
Nuñez, G., 924
Nunez, N. P., 6529
Nuovo, G. J., 1261
Nussbaum, A. K., 2875
Nyaga, S. G., 1349
Nyati, M. K., 2337
Nyhus, J. K., 7042
Nylander, K. D., 4867
Nylandsted, J., 7139
- O**
- Obata, Y., 1751
Oberley, L. W., 1205
Obermayr, F., 5818
Obika, S., 3751
Obinata, M., 636
Obrodovic, D., 7050
O'Brien, S. J., 7175
O'Bryan, E., 5761
O'Callaghan, N. J., 4599
Ochiya, T., 1641
Ochs, K., 1524
Odesa, S. K., 2287
O'Donnell, A. H., 4588
Offringa, R., 472, 6187
O'Flaherty, J. T., 6817
Ogama, Y., 6390
Ogawa, H., 3711, 5967
Ogawa, M., 5651
Ogawa, S.-i., 2554
Ogilvie, D. J., 4645
Ogilvie, L. M., 1724
Ogiso, Y., 5008
Oh, D. S., 6052
Oh, H.-K., 1592
Oh, J. J., 3207
O'Hara, J., 3555
Ohara, N., 6390
Ohgaki, H., 2592, 6990
Ohira, M., 2203
Ohki, M., 3592
Ohlsson, R., 4545
Ohnishi, Y., 518
Ohnmacht, G. A., 3581
Ohno, H., 6224
Ohta, M., 2937
Ohta, T., 3592
Ohtsuru, A., 7031
Ohuchida, S., 28
Ohwada, S., 3322
Ohyama, C., 3850, 4194
Oien, K. A., 5999
Oike, M., 1450
Ojo-Amaize, E. A., 4007
Oka, M., 3939, 4894
Oka, T., 6390
Okabe, T., 6116
Okada, H., 2583, 5955
Okada, N., 1110
Okada, T., 3939
Okamoto, M., 2834
Okamura, T., 333
Okan, N. A., 6231
Okayasu, I., 2236
Okayasu, R., 6400

AUTHOR INDEX TO VOLUME

- Oken, M. M., 715
Okita, K., 835
Okochi, E., 3592
Okogun, J. I., 4007
Okon, E., 1036
Okorokov, A. L., 1876
Okuda, K., 7004
Okui, A., 295
Okumura, K., 5668
Okuyama, A., 1410
Olaru, A., 3493, 3641, 5637, 6820
Old, L. J., 4041
O'Leary, E., 1439
Olesen, S. H., 4352
Oleynikov, Y., 6278
Oliaro, A., 7025
Oliva, J., 6519
Olive, P. L., 4469
Oliver, D. H., 7230
Oliverio, S., 5158
Olivero, M., 7025
Olivier, A., 2131
Olivier, K., 5495
Oliyai, C., 2327
Ollikainen, V., 3798
Olopade, O. I., 1481
Olschwang, S., 848
Olshen, A. B., 957, 3636
Olsson, P. G., 1822
O'Malley, B. W., Jr., 4023, 4637
O'Meally, R. N., 7230
Omoto, Y., 4849
on der Heide, M., 3331
Ong, T-m., 703
Onida, F., 5995
Onishko, H., 4671
Onkamo, P., 3798
Ono, M., 2554, 2834
Ono, R., 333, 4075
Ono, T., 1471
Onyango, P., 6442
Ooms, M. E., 6187
Oosterhuis, J. W., 1822, 2758
Opipari, A. W., 924
Oplanich, S., 1761
Opolon, P., 764
Oprysko, P. R., 3626
O'Reilly, S., 1443
Oren, M., 5947
Orlandi, R., 567
Orlowski, R. Z., 3868
Ormsby, I., 6362
Ornberg, R. L., 625, 6706
Orntoft, T. F., 961, 4352
Orrico, M., 4685
Orringer, M. B., 5273
Orr-Urtreger, A., 6803
Ortiz-Hidalgo, C., 7093
Osada, H., 271
Oshima, H., 506, 1971
Oshima, J., 367, 547
Oshima, K., 3929
Oshima, M., 506, 1971, 2261, 4549, 6846
Oshimura, M., 3322, 6784
Osman, S., 5698, 5912
Ossendorp, F., 6187
Östman, A., 5476
Ostrand-Rosenberg, S., 4406
O'Sullivan, M. J., 4065
Oswald, U., 3009
Ota, S., 1471
Ota, T., 5168
Otake, Y., 7124
Otava, A., 1477
Otsuki, Y., 1410
Otte, A. P., 618
Ottey, M., 4054
Ottmann, O. G., 7050
Ouchida, M., 6390
Outram, S. V., 4730
Ouwehand, M., 6158
Overall, C. M., 283
Overholser, J., 2567
Overmoyer, B., 3408
Owa, T., 6116
Owen, J. S., 6817
Oxford, G., 6418
Oyemade, O. A., 4007
Oyen, W. J., 6146
Ozaki, T., 2203
Ozawa, K., 2019
Ozawa, Y., 6116
Ozçelik, H., 4151
Ozog, M. A., 3544
- P**
- Packeisen, J., 1020
Packer, R. J., 323
Padigar, M., 3834
Padley, D., 1884
Padovan, E., 3453
Pae, C., 547
Páez, J. G., 2690
Pagano, J. S., 6337
Paielli, D., 4968
Paiement, J-P., 5888
Paik, C. H., 5755
Pajares, M. J., 5627
Pajonk, F., 5230
Pajovic, S., 967
Palazzo, J., 4054
Palazzo, J. P., 1014, 7093
Palmer, C., 4169
Palmisano, W. A., 2370
Pals, S. T., 5126
Palumbo, J. S., 6966
Pan, K., 6430
Pan, Q., 4854
Panacchia, L., 3507
Panasci, L., 5457
Panasci, L. C., 5888
Pandeya, N., 6011
Pang, J., 1987
Pant, A. C., 391
Pantel, K., 251
Panzarella, G., 7083
Pao, A. Y., 1311
Papadopoulos, T., 6297
Papon, J., 1890
Parada, L. F., 4507
Paranawithana, S. R., 466
Parekh, H. K., 2193
Parekh, T. V., 2778
Pariikh, D., 1069
Park, C. W., 5755
Park, H., 1702
Park, I-C., 6318
Park, J., 1284
Park, J. P., 892
Park, J-G., 38
Park, L., 5755
Park, M-J., 6318
Park, S. H., 6318
Park, S-Y., 459
Parker, A. R., 7230
Parkinson, E. K., 4757
Parmigiani, G., 819
Parr, T., 7207
Parrella, P., 3659
Parrish, R. S., 3722
Parry, G. C., 5344
Parvin, J. D., 4222
Pascale, R. M., 4459
Pascasio, L., 1439
Paschen, A., 2875
Pasqualini, R., 867
Passe, S., 6205
Passlick, B., 251
Pastan, I., 5755
Paster, W., 5489
Pastorek, J., 4469
Pastoreková, S., 4469
Pataer, A., 2239
Patak, P., 4922
Patanè, S., 7025
Patel, A., 5058
Patel, J., 5405
Patel, V., 1401
Pathak, S., 3030
Paul, B. A., 67
Paul, R., 6712
Paulding, W. R., 1682
Paulus, P., 5317
Paunu, N., 3798
Pavey, S., 875
Pawlowski, S., 6362
Paz, M. F., 4519
Peabody, J., 4968
Peale, F., 2546
Pearson, A. D. J., 5158, 5906
Pease, K. M., 4419
Pease, L. R., 4413
Peat, D., 4123
Pedersen, P. L., 3909
Pediaditakis, P., 2064
Peehl, D. M., 1654
Peek, R. M., Jr., 2385
Pegg, A. E., 3037
Pegg, J., 4968
Pehamberger, H., 2098
Pei, D., 675
Pei, L., 5420
Pei, P., 5451
Peinado, M. A., 4519, 5902
Peipp, M., 2848
Pelicci, P. G., 7050
Pellicena, P., 4236
Pellicer, A., 4157, 4514
Penault-Llorca, F., 617
Pende, D., 6178
Peng, A. C., 3244
Peng, H., 8, 3773
Peng, K-W., 4656
Peng, Y., 5420, 6400
Pennington, C., 5543
Pennisi, P. A., 6529
Penttinen, J., 6410
Pepper, M. S., 603
Péqueux, C., 4623
Pequignot, E., 4054, 5413
Pereira, M. A., 4199
Pérez, Y., 5672
Perez de Castro, I., 4514
Perez-Diez, A., 3581
Perez-Soler, R., 4514, 6080
Peric-Hupkes, D., 3233
Peritt, D., 5267
Perlman, E. J., 6981
Perrone, E., 5418
Perrot-Appianat, M., 4977
Perry, A., 2085
Perry, K., 3493, 3641, 5637
Persaud-Sawin, D-A., 801
Perucho, M., 1961
Peschel, C., 2244
Pestell, R. G., 141, 2077, 3997
Petermann, R., 4583
Peters, C. M., 7343
Peters, J. P. W., 341
Peters, K. B., 5248
Petersen, D., 3581
Petersen, G. M., 3789
Peterson, T., 6566
Petricoin, E. F., III, 6740
Petros, W. P., 3408
Petrulis, E., 4566
Pett, M., 6959
Pezo, R. C., 6006
Pezzella, F., 1326
Pezzuto, J. M., 5178
Pfeffer, K., 4034
Pfeifer, G. P., 3698, 4331
Pfeifer, S., 4545
Phan, V., 5495
Phaneuf, S. L., 4592
Pharoah, P. P. D., 3052
Phillips, G. L., 5485
Phillips, T., 4592
Philpott, M. P., 4773
Piacentini, M., 5158
Pianetti, S., 652
Pidgeon, G. P., 2721
Pien, C. S., 4996
Pienta, K. J., 1832
Pierantoni, G. M., 2398
Pierce, A. J., 1279
Pierce, M., 6837
Pieters, R., 2157
Pietras, K., 5476
Pili, R., 2455
Pillaire, M-J., 3511
Pillarisetty, V. G., 5260
Pilz, B., 2516
Pinedo, H. M., 5736, 6165
Pinilla, C., 2058
Pinkas, J., 4781
Pinkel, D., 3200, 3636
Pinski, J., 986
Pinthus, J. H., 6803
Pintilie, M., 3005
Piotrowska, K., 3048
Piovan, E., 6099
Pipkorn, R., 7018
Pise-Masison, C. A., 3562
Pistritto, G., 3200
Pitt, W. G., 7280
Pittman, B., 6424
Pitts, R. L., 43
Pizzey, A. R., 4730
Pizzorno, G., 2313
Platt-Higgins, A., 3417
Platz, E. A., 2220, 6405
Platzer, P., 1134
Player, A., 3340
Plon, S. E., 1123
Pluderi, M., 6884
Plunkett, M. L., 5344
Po, L. S., 4890
Podar, K., 5019
Poehlein, C. H., 3914
Poh, C., 6447
Poirier, M., 6625
Poirson-Bichat, F., 1815
Polikoff, D., 3636

AUTHOR INDEX TO VOLUME

- Pollack, I. F., 2583
 Pollak, M., 7372
 Pollan, M., 4519
 Pollard, J. W., 7166
 Pollegioni, L., 1321
 Pollock, R. E., 2034
 Polson, A. G., 4525
 Polyak, K., 43, 4540
 Pommier, Y., 1688, 4899, 5743
 Ponder, B. A. J., 3052
 Pongratz, H., 3113
 Ponomareva, O. N., 1518
 Pons, M., 6519
 Poon, R. Y. C., 4890
 Pop, L. A. M., 7066
 Popa, C., 3759
 Popescu, N., 6348
 Popescu, N. C., 4054
 Popović, S. V., 1588
 Porter, C. W., 6639
 Porter, D., 4540
 Porter, D. A., 43
 Poser, I., 5962
 Post, D. E., 2478
 Potapova, O., 3257
 Potoczek, M., 4054
 Potten, C. S., 122
 Potter, D., 3221
 Potter, J. D., 3361
 Potter, J. M., 6966
 Potter, P. M., 5001
 Pouch, M.-N., 2771
 Poullart, P., 1388
 Poulsen, H. E., 4339
 Poulosom, R., 2942
 Poupon, M.-F., 1388
 Poustka, A., 6698
 Pouvelle-Moratille, S., 213
 Powell, J. A., 4599
 Powell, J. I., 3581
 Powell, R. L., 3971
 Powell, S. M., 2625, 4061, 6823
 Powell, W. C., 4812, 5096
 Powers, S., 5420
 Powis, G., 5089
 Pow-Sang, J., 6659
 Prabhu, V. V., 5370
 Pradayrol, L., 6124
 Pradono, P., 63
 Prados, M., 6205
 Prang, N., 251
 Precht, D., 840
 Preciado, M. V., 4876
 Prendergast, G. C., 450
 Prenzel, N., 6329
 Prescott, M. S., 5273
 Presti, J. C., Jr., 957
 Pretlow, T. G., 6606
 Prevo, R., 1315
 Pribluda, V. S., 3691
 Price, P., 5698, 5912
 Priddy, R., 6447
 Prieto, J., 3167
 Prince, C. W., 5336
 Pringle, J. H., 3289
 Profitlich, S., 1524
 Proia, A. D., 801
 Pröls, E., 5920
 Protopenov, A., 3498
 Pruneri, G., 3106
 Prystowsky, M., 6973
 Prystowsky, M. B., 1184
 Puccetti, E., 1768, 7050
 Pugacheva, E. M., 48
 Puisieux, A., 848, 3646
 Pulaski, B. A., 4406
 Pullen, J. K., 5792
 Pullen, S. M., 1425
 Pumphrey, C. Y., 3722
 Puntoni, R., 5418
 Purdie, D., 6011
 Puri, R. K., 3575
 Pützer, B. M., 3598
 Q
 Qi, C.-F., 48
 Qi, H., 721
 Qi, M., 433
 Qian, C.-N., 589
 Qiang, W., 5153
 Qin, Z., 2856
 Qu, Q., 1330
 Qu, Y., 3609
 Qu, Z., 1555
 Qualman, S. J., 4711
 Quigley, J. P., 7083
 Quinn, A. G., 4773
 Quistorff, B., 1191
 R
 Ra, M. S., 1809
 Raab-Traub, N., 1920
 Raaphorst, F. M., 618
 Rabascio, C., 3106
 Rabbani, S. A., 2390, 4678, 5344
 Rabinowich, H., 4884
 Radcliffe, J. N., 1757
 Raderschall, E., 219
 Radonovich, M., 3562
 Radovanovic, I., 2592
 Radulovich, N., 3005
 Raffeld, M., 1256, 3702
 Raffo, A. J., 2175
 Rafie, N., 3408
 Raftogianis, R. B., 3144
 Ragg, E., 2332
 Raghow, S., 1370
 Rahaman, S. O., 1103
 Rahimpour, S., 1036
 Rahman, A., 6045
 Rahmani, M., 188
 Rahmatpanah, F., 3214
 Rainbow, A. J., 5528
 Raja, R., 3667
 Rajagopal, A., 391
 Rajapaksa, R., 5845
 Rajkumar, S. V., 715
 Rajopadhye, M., 6146
 Raju, U., 2318
 Rak, J., 1931
 Rak, J. W., 1838
 Raleigh, J. A., 6827, 7066
 Ramachandra, M., 6045
 Ramaswamy, S., 4963
 Ramesh, N., 3743
 Ramirez, M., 5013
 Ramirez, R. A., 4383
 Ramirez-Solis, R., 3221
 Rammensee, H.-G., 2592, 5818
 Ramos-Nino, M. E., 6065
 Ramponi, G., 6489
 Ran, S., 6132
 Ranalli, M., 5158
 Ranasinghe, A., 5183, 5189
 Randle, B., 6070
 Rando, R. R., 1654
 Rangell, L., 2546
 Rangnekar, V. M., 1768
 Ranicar, A. S., 5698
 Rantala, I., 3798
 Ranzani, G. N., 1609
 Rao, A., 6817
 Rao, C. V., 165, 6506
 Rao, P. H., 4089, 6218
 Rapisarda, A., 4316
 Rapp, U. R., 6297
 Rappaport, S. M., 1330
 Rasey, J., 1518
 Rasmussen, H., 1847
 Rasnick, D., 6345
 Raso, E., 2824
 Rassool, F. V., 2791
 Rastelli, L., 3834
 Rastert, R., 7018
 Ratcliffe, P. J., 2957
 Rattel, B., 1057
 Rauen, K. A., 3812
 Raugei, G., 6489
 Rauscher, F. J., III, 1, 3773
 Rauvala, H., 4805
 Ravani, S. A., 5627
 Ravetch, J. V., 6891
 Ravey, P., 977
 Ravi, R., 1583, 4180
 Ray, R. B., 6141
 Raynaud-Messina, B., 3511
 Raz, A., 4484
 Re, G. G., 6598
 Reali, E., 5058
 Rebbeck, T. R., 6651
 Rebel, H., 1338
 Recio, J. A., 2690, 6724
 Reddel, R. R., 1289, 4434
 Reddy, B. S., 165
 Reddy, J. L., 5897
 Reddy, R. K., 7207
 Redfern, C. P. F., 5158
 Redhead, N. J., 4065
 Redon, R., 6211
 Redston, M., 1284
 Ree, A. H., 4165
 Reed, H., 4722
 Reed, J. C., 1904, 6674
 Reed, K. A., 1382
 Reed, S. I., 4535
 Rehemtulla, A., 2337
 Rehg, J. E., 2184
 Reichardt, P., 251
 Reichert, J., 5065
 Reichert, U., 3842
 Reid, T., 6070
 Reimer, C. L., 789
 Reimers, J. M., 5641
 Reinders, M. J. T., 7110
 Reinhardt, J., 2
 Reinhold, W. C., 1688
 Reis, J., 5536
 Reiss, D. J., 497
 Reiss, M., 497, 2778
 Reissmann, T., 3113
 Reiter, Y., 3184, 5835
 Relloso, M., 3167
 Remaley, A. T., 3649
 Remick, S. C., 3408
 Rempel, S. A., 6270
 Rémy, C., 5672
 Ren, M., 2455
 Ren, Y., 6952
 Renner, R. J., 5451
 Repasky, E., 1737
 Repasky, E. A., 5800
 Reperant, M., 1609
 Resau, J. H., 589
 Reschke, D. K., 5641
 Reschner, A., 3453
 Reske, S. N., 3331
 Restifo, N. P., 3581, 5144
 Reuter, V., 4499, 6218
 Rey, O., 1632
 Reynolds, P. N., 1271
 Reynolds, S. H., 1152
 Rhee, C. H., 6318
 Rheingold, S., 4212
 Rhim, J. S., 1654, 3498, 6812
 Rhodes, D. R., 4427
 Riabowol, K., 4445
 Ricci, C., 5995
 Ricciardelli, C., 854
 Richards, F. M., 3803
 Richards, W. G., 4963, 7001
 Richardson, A., 4540
 Richardson, P., 3876
 Richardson, P. G., 4996, 5019
 Richmond, A., 7335
 Richmond, G. H. P., 4645
 Rickinson, A. B., 6952
 Ricordy, R., 3507
 Riddle, D., 6566
 Rideout, D. C., 1394
 Ridley, A. J., 4805
 Ried, T., 1134, 2365
 Riegman, P. H. J., 1531
 Rieker, R. J., 2993
 Riese, H. H., 552
 Riess, K., 5230
 Riethmüller, G., 251
 Riggins, G. J., 3335, 6823
 Riley, J., 4256
 Rimm, D. L., 497
 Rimmer, A., 2592
 Rimoldi, D., 1743
 Rinaldi, A. L., 5451
 Rinaldi, C., 1196
 Ringné, M., 6240
 Rinker-Schaeffer, C. W., 6717
 Rinkes, I. H. M. B., 4289
 Riou, J.-F., 3365
 Risdon, G., 3736
 Rishi, A. K., 3842
 Rishi, I., 6997
 Risinger, J. I., 3251
 Risom, L., 4339
 Ristimäki, A., 632
 Ritchey, J. W., 4295
 Ritter, C. A., 4132
 Ritter, G., 4041
 Rittman, B., 2468
 Ritz, J., 5517
 Rivat, C., 4879
 Rivenson-Segal, D., 1966
 Rivera, A. A., 4663
 Rivera, P., 6178
 Rivera-Gonzalez, R., 89
 Robbins, P. D., 5853
 Robbins, P. F., 3630, 5144
 Röbe, J., 2347
 Roberts, C. W. M., 323
 Roberts, D. D., 1541
 Roberts, J. S., 854
 Robertson, E. J., 4558
 Robertson, K., 3408
 Robey, R., 6108
 Robey, R. W., 5035
 Robins, D. M., 4854

AUTHOR INDEX TO VOLUME

- Robinson, B. C., 2151
 Robinson, B. W. S., 2353
 Robinson, S. P., 688
 Robles, A. I., 3244
 Roboz, J., 6080
 Rochdi, M., 6559
 Rodemann, H. P., 1915
 Rodeschini, O., 2398
 Rodolfo, C., 5158
 Rodrigo, K. A., 5451
 Rodrigues, S., 4879
 Rodriguez, C. O., Jr., 3100
 Rodriguez, J. A., 4081
 Rodriguez, M., 351, 4413
 Rodriguez, R., 2576
 Rodriguez-Calvillo, M., 3167
 Roeder, B. L., 7280
 Roelofs, R. W., 2695
 Roetger, A., 1020
 Roffler, S. R., 6089
 Rofstad, E. K., 661, 1847
 Rogan, E. G., 3395
 Rogan, P. K., 3251
 Rogatko, A., 4767
 Rogers, L. A. C., 6817
 Rogers, M. S., 2300
 Rogers, P. M., 3276
 Rogers, S. D., 7343
 Rogounovitch, T. I., 7031
 Rohde, M., 7139
 Rollins, B., 6304
 Roloff, F., 7280
 Romagnolo, D. F., 113
 Rome, L., 6070
 Romero, P., 1743, 2058
 Romieu-Mourez, R., 6770
 Ronchini, C., 567
 Ronson, B., 4023
 Rood, B. R., 3794
 Rook, S. L., 789
 Rooney, C. M., 7195
 Ropponen, K., 6410
 Rosai, J., 3980
 Rosato, A., 1116
 Rose, D. G., 1014
 Rose, J. A., 1518
 Rosemann, M., 3048
 Rosen, B., 3466
 Rosen, E. M., 141
 Rosen, N., 2982, 3132
 Rosenberg, D. W., 3667
 Rosenberg, S. A., 3020, 3581, 3630, 5144
 Rosenblatt, J. D., 6545
 Rosenblum, M. K., 5551
 Rosenthal, D., 6879
 Rosin, M. P., 6447
 Rosolen, A., 1559
 Ross, D., 1420
 Ross, S., 2546
 Ross, S. R., 747
 Rossant, J., 3005
 Rossi, D., 4089
 Rosso, E., 7025
 Rosty, C., 1868
 Rotaru, J. H., 3159
 Roth, J. A., 2239, 2715, 6997
 Roth, R. B., 656
 Rothas, D. A., 5451
 Rothenfusser, S., 2347
 Rothen-Rutishauser, B., 437
 Rothman, K., 376
 Rottapel, R., 5076
 Rouillard, D., 1388
 Roumiantsev, P. O., 7031
 Rounbehler, R. J., 3276
 Roussel, M. F., 1222
 Rouwé, B., 3356
 Rowan, A., 53
 Rowley, D. R., 3298, 6021
 Rowley, R. B., 2516
 Roy-Burman, P., 4812, 5096
 Rozenblum, E., 6240
 Rozengurt, E., 1632
 Rozovsky, U., 6803
 Rubin, H., 6350
 Rubin, J., 6070
 Rubin, K., 5476
 Rubin, M., 5420
 Rubin, M. A., 2546, 4427
 Rubinstein, D. B., 4985
 Rubio-Godoy, V., 1743, 2058
 Rucker, N., 1458
 Ruckert, S., 3009
 Rudin, C. M., 3515
 Rudland, P. S., 3417
 Rudy, W., 2052
 Rueschoff, J., 1014, 6796
 Rugarli, C., 1116
 Ruggiero, J., 6385
 Ruiter, D. J., 341, 7059
 Ruiz, A., 1654
 Ruotsalainen, P., 7364
 Ruppert, J. M., 5867
 Rusan, N. M., 4109
 Rüschhoff, J., 3009
 Rush, W. L., 6724
 Rushkin, E., 1966
 Russel, D., 6141
 Russell, J. S., 2318
 Russell, R. L., 2313
 Russell, S. J., 4656
 Russo, A., 6246
 Rustgi, A. K., 277
 Rustum, Y. M., 5800
 Rusyn, E. V., 4142
 Rutgers, J., 6717
 Ruthardt, M., 1768, 7050
 Rux, J. J., 3773
 Ryan, A. J., 7284
 Ryan, P. E., 6606
 Rydholm, A., 3980
 Rýdlová, H., 5678
 Rylova, S. N., 801
 Rynkiewicz, S. D., 2337
 Ryschich, E., 1462
 Ryu, B., 819
 Ryu, J-H., 7241
- S**
- Saad, S., 283
 Sabel, M. S., 7254
 Sabés, M., 5672
 Sabino, M. A. C., 7343
 Sacchi, A., 867
 Sacchi, N., 2455
 Sacco, R., 2535
 Sadanaga, N., 2937
 Sadelain, M., 2104
 Sadvakassova, G., 5590
 Saenko, V. A., 7031
 Saffaei, R., 6559
 Saffroy, R., 4685
 Saga, T., 860
 Sagebiel, R. W., 3992
 Sahin, A., 1676, 6740
 Sahin, A. A., 1251, 4566
 Sahin, U., 6750
 Saijo, Y., 63
 Saito, H., 271
 Saito, I., 1641
 Saito, M., 3850
 Saito, S., 3850
 Saji, S., 4849
 Sak, A., 6621
 Saka, A., 3663
 Sakamoto, H., 1641
 Sakamoto, M., 2971, 4860
 Sakaue, M., 901
 Salani, D., 6381
 Salazar, V. S., 5778
 Sales, K. J., 424
 Salgia, R., 5242, 6304
 Säll, T., 2675, 5939
 Salminen, T., 632
 Salomons, G. S., 2157
 Salovaara, R., 4554
 Salowsky, R., 6698
 Salvesen, H. B., 6808
 Salwen, H. R., 7357
 Samanta, M., 3347
 Samimi, G., 6559
 Sampsel, J. W., 7042
 Sampson, J. H., 3335
 Sampson, J. R., 363
 Samson, L. D., 656
 Samuels, S. E., 2771
 Sanchez-Carbayo, M., 6973
 Sanchez-Cespedes, M., 3659, 4519
 Sánchez-Madrid, F., 2929
 Sánchez-Pernaute, A., 3855
 Sanders, M. O., 1481
 Sanders, S., 2690
 Sanderson, R. D., 3722
 Sandler, A. D., 3093
 Sands, A. T., 3221
 Sangfelt, O., 4535
 Santamaría, G., 6674
 Santoro, M., 1077, 7284
 Santos, S., 5013
 Santucci, R., 5470
 Sanz, G., 4453
 Sapino, A., 2406
 Sapra, P., 7190
 Sarasin, A., 4899, 7186
 Sargent, L. M., 1152
 Sarkaria, J. N., 7291
 Sarnaik, A., 3503
 Sartor, C. I., 4142
 Sasaki, H., 1641, 1641, 1790, 5308
 Sasaki, K., 835, 4894
 Sasaki, T., 1944
 Sasaki, Y., 1567
 Sasatomi, E., 2681
 Sasazuki, T., 5668
 Sashida, Y., 1025
 Sasieni, P., 53
 Satagopan, J., 4499
 Sathasivam, N., 1394
 Sathyaranayana, U. G., 3382
 Sato, F., 1148, 3382, 3493, 3641, 5637, 6820
 Sato, K., 4894
 Sato, M., 5603
 Sato, N., 860
 Sato, T., 1025
 Satoh, M., 3850
 Satoh, S., 7012
 Sattler, M., 6304
 Satyamoothy, K., 226
 Sauk, J. J., 1004
 Saul, D., 2848
 Saunders, H. M., 747, 2962
 Saunders, N. A., 3759
 Saurin, J-C., 4829
 Sausville, E. A., 1401, 4316
 Sauter, E. R., 3200
 Sauter, G., 1256, 6240
 Sawa, T., 3138
 Sawada, K., 6015
 Sawiris, G. P., 2923
 Sawyers, C. L., 5254
 Sayeed, A., 5980
 Scaife, C. L., 6870
 Scanlan, M. J., 4041
 Scanlon, I., 1724
 Scappini, B., 5995
 Scardino, P., 4499
 Schadendorf, D., 1743, 2875, 6698
 Schaefer, T. S., 1069
 Schäfer, H., 910
 Schäfer, R., 5317
 Schäffer, E., 3048
 Schagdarsurengin, U., 3698
 Schaich, M., 4955
 Schaid, D., 3587
 Schäkel, U., 4955
 Schalken, J. A., 2695
 Schalkwijk, L., 7059
 Schally, A. V., 781
 Schartl, M., 4820
 Schattman, G. C., 665
 Scheffer, G. L., 7298
 Scheffold, C., 5785
 Scheffold, Y. C., 5785
 Scheibenbogen, C., 1743
 Schell, M., 3646
 Schellens, J. H. M., 6158
 Schellhammer, P. F., 3609
 Schemainda, I., 1057
 Schendel, D. J., 480
 Scheper, R. J., 7298
 Scher, H., 4499
 Scherf, U., 1688
 Schiavetti, F., 5510
 Schick, M., 6698
 Schier, K., 1020
 Schiestl, R. H., 547
 Schild, H., 2875
 Schindler, T., 4236, 4244
 Schinkel, A. H., 2294
 Schipper, H. M., 3893
 Schirle, M., 2875, 5818
 Schirmmeister, H., 3331
 Schlake, G., 809
 Schlegel, W., 2098
 Schlierf, B., 2848
 Schlom, J., 5049, 5058, 5770, 6944
 Schlossman, R. L., 5019
 Schmeits, J., 3485
 Schmid, J. A., 4583
 Schmidt, B., 2244
 Schmidt, E. V., 2267
 Schmidt, K. H., 5641
 Schmidt, L. J., 1008, 5632
 Schmidt, M., 3113
 Schmidt, W., 1477
 Schmidt, W. E., 910
 Schmits, R., 2281
 Schmitt, L. D., 3812
 Schmitt, M., 840, 4617
 Schmitz, J., 5058
 Schmitz, V., 3167
 Schneider, D., 5685
 Schneider, E., 5035

AUTHOR INDEX TO VOLUME

- Schnell, P. O., 1682
 Schnitt, S., 43
 Schnurr, M., 2347
 Schoen, R. E., 2437
 Schoester, M., 7298
 Scholz, C., 2347
 Schoor, O., 5818
 Schor, N. F., 4867
 Schouten, R., 1338
 Schow, P., 2546
 Schrama, D., 5664
 Schreiber, H., 5792
 Schroeder, G., 6621
 Schroers, R., 2600
 Schubert, F., 2993
 Schuler, U. S., 4955
 Schüller, S., 5489
 Schultz, C., 6270
 Schulz, J. B., 1915, 2592
 Schumm, P. L., 1481
 Schürkes, C., 99
 Schwab, M., 5139
 Schwaenen, C., 2993
 Schwall, R., 5485
 Schwaninger, R., 437
 Schwartz, D. R., 4722
 Schwartz, G. K., 3950
 Schwartz, P. S., 6928
 Schwartz, R., 4491
 Schwartz, S., 3070
 Schwarz, E. M., 5564
 Schwarz, M., 5685
 Schwarz, U. I., 4955
 Schwei, M. J., 7343
 Schweiger, S., 219
 Schweighoffer, T., 5489
 Schweinfest, C. W., 5083
 Sciort, R., 3980
 Scott, D. L., 3093
 Scott, J., 6205
 Scott, K., 5930
 Scott, L., 6959
 Scotto, K. W., 3377, 6909
 Scotton, C. J., 5930
 Serepanti, I., 1196
 Scudiero, D. A., 4316
 Secker, G. A., 4599
 Seddaiu, M. A., 4459
 Sedivy, J. M., 1129
 Seelig, S., 4132
 Seftor, E. A., 665, 4478
 Seftor, R. E. B., 665
 Segal, J. G., 4696
 Segall, J. E., 6278, 7166
 Seger, D., 1966
 Segura, I., 552
 Sehgal, C. M., 747
 Seiden, I., 3005
 Seidlitz, E., 1588
 Seigne, J., 6659
 Seitz, G., 6750
 Seki, N., 2203
 Seki, T., 609
 Seki, Y., 6579
 Sekido, M., 3159
 Sekiguchi, K., 5603
 Sekiya, T., 3322
 Selaru, F., 5637
 Selaru, F. M., 1148, 3493, 3641, 6820
 Selby, M., 4316
 Seldin, D. C., 6770
 Seldin, M. F., 2261, 4549
 Seliger, B., 2856
 Sellappan, S., 5703
 Sellers, T. A., 3587
 Sellers, W., 89
 Sellers, W. R., 6803
 Selvaraj, P., 2869
 Selzer, E., 2098
 Semba, T., 6116
 Senglali, A., 6519
 Semmes, O. J., 3609
 Sen, A., 262
 Senderowicz, A. M., 1401
 Senft, J. R., 1152
 Senga, T., 2414, 3962
 Senger, D. L., 2131
 Senitzer, D., 3175
 Seno, H., 506
 Seo, J.-M., 3365
 Seo, K. H., 1809
 Seong, D. H., 3649, 5365
 Seppälä, M., 79
 Seraj, M. J., 982, 6418
 Serewko, M. M., 3759
 Serrano, J., 3702
 Seruca, R., 1609
 Servant, M., 5148
 Seshadri, R., 4599
 Sessoms, A., 3395
 Seta, K., 4176
 Seth, P., 43, 4540
 Sette, A., 3630
 Sevignani, C., 4054
 Sgroi, D., 43
 Sgroi, D. C., 2741, 6740
 Shabram, P., 6045
 Shafer-Peltier, K. E., 5375
 Shah, A. B., 5260
 Shah, A. H., 7135
 Shah, J. H., 2300
 Shah, R., 417
 Shahbazian, D., 1093
 Shalaby, R., 5980
 Sham, J. S. T., 7157
 Shames, D., 2175
 Shammas, M. A., 2982
 Shan, J., 290
 Shao, J., 3282
 Shao, R., 1311
 Shapiro, E., 4157
 Shapiro, G. I., 1707
 Shariat, S. F., 5974
 Sharma, P., 1103
 Sharpless, N. E., 2761
 Shau, W.-Y., 4346
 Shaw, D. E., 5344
 Shaw, J. L., 208
 Shayakhmetov, D. M., 1063
 Shchhaveleva, I., 6172
 She, Q.-B., 1300, 1343
 She, Y., 3950
 Shedden, K. A., 4722
 Sheets, E. E., 682
 Shekhar, M. P. V., 2115
 Shen, B., 1213, 6026
 Shen, H., 4992
 Shen, J., 5153
 Shen, M. M., 2999
 Shen, W.-H., 4746
 Sheng, H., 3282, 5308
 Shenoy, S. M., 6006
 Shepherd, D., 5720
 Shepherd, F. A., 3005
 Sheppard, B. J., 696
 Sherif, Z. A., 4439
 Sheriff, D. D., 665
 Sherley, J. L., 6791
 Sherman-Baust, C. A., 2923
 Sherr, C. J., 1222
 Shi, G., 4637
 Shi, H., 403, 3214
 Shi, M., 3221
 Shi, Q., 2806
 Shi, W., 171
 Shi, X., 5689
 Shi, X.-B., 1496
 Shi, Y., 5027
 Shi, Y. Y., 3868
 Shi, Y.-X., 1854
 Shibata, D., 1148, 1166, 3493, 3641, 6820
 Shibata, D. M., 5637
 Shibata, K., 2753
 Shibuta, K., 2937
 Shibuya, M., 2019, 5129
 Shibuya, N., 33, 4571
 Shichiri, M., 13
 Shide, K. L., 7291
 Shields, J. D., 4123
 Shiff, B., 2660
 Shih, C., 5597
 Shimada, H., 2987
 Shimizu, C., 4849
 Shimizu, K., 6390
 Shimizu-Yoshida, Y., 7031
 Shimkets, R. A., 3834
 Shimokawa, T., 5651
 Shin, J.-H., 38
 Shin, K.-H., 38
 Shina, S., 1093
 Shipley, J., 135
 Shipulina, N. V., 5344
 Shirafuji, N., 3929
 Shiraga, M., 5967
 Shirai, T., 1956
 Shiraishi, K., 835
 Shiraishi, T., 2258
 Shirakawa, K., 560, 860
 Shirasawa, S., 5668
 Shivapurkar, N., 3382, 5897
 Shochat, D., 2327
 Shoemaker, R. H., 4316
 Shoemaker, S., 4383
 Shohet, J. M., 1123
 Shoji, Y., 28
 Shono, T., 1069
 Shore, R., 1330
 Shridhar, V., 262
 Shtutman, M., 5947
 Shu, H., 6740
 Shukla, S., 3159, 6552
 Shuman, A. L., 3626
 Shureiqi, I., 1178
 Shusterman, S., 6651
 Shustova, V., 3493
 Shuto, T., 6579
 Sicinska, E., 535
 Sicinski, P., 535
 Sidney, J., 3630
 Sidransky, D., 371, 3659
 Siebert, M., 4610
 Siegal, C. B., 3736
 Siegfried, J. M., 2141
 Siersema, P. D., 1531
 Sies, H., 4922
 Signoretti, S., 89
 Sijts, A. J. A. M., 2875
 Siligan, C., 4583
 Silva, J., 5485
 Silver, D. P., 2761
 Silverman, R. H., 397
 Simari, R., 6566
 Simeone, P., 3654, 6381
 Simi, B., 165
 Simile, M. M., 4459
 Simms, L. A., 6011
 Simola, K. O. J., 3798
 Simon, R., 2058, 3244, 3581
 Simon, S. M., 391
 Simonassi, C., 5418
 Simons, J., 2576
 Simons, J. W., 2478
 Simons, L. A., 4419
 Sims, P. J., 397
 Sin, J.-L., 7234
 Sinclair, C. S., 3587
 Singer, J., 3893
 Singer, R. H., 6006, 6278
 Singh, A. B., 7335
 Singh, B., 1184, 2744
 Singh, G., 1588, 5528, 5845
 Singh, L., 3315
 Singh, R. P., 3063
 Singh, S. V., 3615
 Singletary, S. E., 4566
 Singleton, B. K., 6263
 Sinicrope, F., 4903
 Sinicrope, F. A., 1676, 6323
 Sinn, B., 6621
 Siracusa, L. D., 5413
 Sircchia, S. M., 2455
 Sironi, E., 2455
 Sirotiak, F. M., 3950
 Sistonon, P., 1166
 Siu, W. Y., 4890
 Sivula, A., 632
 Sjöberg, J., 4554
 Sjöblom, T., 5476
 Sjöquist, M., 5476
 Skaar, T. C., 3428
 Skinner, R. A., 5571
 Skinnider, B., 6194
 Skorecki, K. L., 3184
 Skotheim, R. L., 2359
 Skytting, B., 135, 3861
 Slamon, D. J., 3207
 Slawin, K. M., 5974
 Slebos, R. J. C., 6052
 Slezak, J., 3587
 Small, G. W., 3868
 Smart, R. C., 3395
 Smit, D. J., 226
 Smith, A., 4499
 Smith, A. G., 4256
 Smith, D. I., 262
 Smith, L., 3759
 Smith, L. H., 1688
 Smith, L. R., 5792
 Smith, M., 323
 Smith, M. F., Jr., 4061
 Smith, P., 2072
 Smith, R., 1184
 Smith, T. M., 2370
 Smits, D., 341
 Smulson, M., 6879
 Smulson, M. E., 4439
 Smyth, M. J., 4406
 Sniecinski, I., 3175
 Snipes, G. J., 2131
 Snyder, P. W., 356
 So, S., 4704
 So, T., 1751
 Sobue, G., 2414
 Succi, N., 1184

AUTHOR INDEX TO VOLUME

- Socci, N. D., 6973
 Soderberg, C. L., 3587
 Söderhäll, S., 6598
 Söderkvist, P., 2650
 Soeters, R. P., 424
 Sohara, Y., 3962
 Sohda, M., 7162
 Soiffer, R. J., 5517
 Solary, E., 1815
 Soldatenkov, V., 6879
 Sollenberger, J. E., 3789
 Solomon, E., 4730
 Solomon, K. R., 2227
 Solorzano, C. C., 1996
 Somasundaram, R., 5267
 Somasundaram, S., 3868
 Somenzi, G., 2455
 Somers, R., 5408
 Somerville, M. J., 359
 Sommer, A., 5230
 Sommer, P., 4478
 Sone, S., 3711, 5967
 Sonenshein, G. E., 652, 6770
 Song, C. W., 1702
 Song, H., 5267, 5295
 Song, M., 2875
 Song, S.-K., 1555
 Song, W., 5974
 Song, Z., 5096
 Sonneveld, P., 7298
 Sonoda, H., 3819
 Sonoshita, M., 6846
 Sonveaux, P., 3555
 Soosaipillai, A., 295
 Sorcinelli, M. D., 4109
 Sordat, B., 4829
 Sørensen, F. B., 4352
 Sorensen, P. H. B., 4711
 Soria, J.-C., 351
 Soroceanu, L., 580
 Soucek, L., 3507
 Soung, M. C., 2287
 South, L. S., 5867
 Southey, M. C., 1289
 Southgate, C., 3369
 Sowter, H. M., 6924
 Spagnoli, G. C., 3453
 Spahn, L., 4583
 Spalding, J., 3395
 Spanjaard, R. A., 7154
 Specht, K., 840
 Speicher, M. R., 1129
 Spencer, D. M., 5974
 Spencer, S. D., 2546
 Spendlove, H. E., 4599
 Spetz, A.-L., 575
 Spiegelman, D., 1045
 Spisek, R., 2861
 Spitz, D. R., 5436
 Spitz, M. R., 2813, 4992
 Spooner, R. A., 1724
 Sporchia, B., 1321
 Spraggon, L., 6615
 Spring, H., 7018
 Spring, K., 5637
 Springer, C. J., 1724
 Spruck, C. H., 4535
 Spurbeck, W. W., 3077
 Squire, J., 6194
 Squire, J. A., 967, 3466
 Sreedharan, S., 4637
 Sreekumar, A., 2337
 Srikantan, V., 6812
 Srinivasan, S., 3315
 Srisuma, S., 5196
 Srivastava, R. K., 4929
 Srivastava, S., 6812
 Stabile, L. P., 2141
 Stafford, L. J., 5399
 Stagg, J., 5148
 Stahl, J., 854
 Stallmach, T., 2962
 Stambler, B., 3408
 Stamp, G., 5930
 Stampfer, M. J., 2654
 Stampf, J., 43
 Stanbridge, E. J., 4469
 Stanley, E. R., 5317
 Stanley, M. A., 6959
 Stannard, B., 6529
 Starink, T. M., 5389
 Stass, S. A., 5463
 Staub, J., 262
 Steadman, D. J., 2654
 Stearman, R., 3014
 Steckley, J. L., 359
 Steeg, P. S., 6740
 Steel, C., 5698
 Steele, V. E., 4199, 5178, 6506
 Steeves, R. M., 2546
 Stein, B., 1439
 Stein, C. A., 2175
 Stein, G. S., 2510, 3233
 Stein, J. L., 2510, 3233
 Stein, R., 2029
 Steinbach, J. P., 2592
 Steinbauer, M., 4034
 Steiner, M. S., 1370
 Steinwaerder, D. S., 6089
 Stenwig, A. E., 512
 Stepanova, L., 1222
 Stephen, A. E., 2004
 Stephen, D., 6385
 Stephens, C. E., 7219
 Stephens, L. C., 3620
 Stephens, P., 6451, 6997
 Stern, D. F., 6667
 Stevanovic, S., 2875, 5818
 Stevenson, F. K., 1757
 Stewart, A. L., 2239
 Stewart, C., 708
 Stewart, J., Jr., 2699, 5336
 Stewart, J. C., 2840
 Stewart, M., 7181
 Stiborová, M., 5678
 Stidley, C. A., 2370
 Stievano, L., 6099
 Stiewe, T., 3598
 Stine, O. C., 3641
 Stockert, E., 4041
 Stoehr, R., 6796
 Stoelcker, B., 4034
 Stoffregen, E. P., 7149
 Stokes, E. E., 3058
 Stokes, E. S. E., 4645
 Stokoe, D., 3636
 Stoltzfus, P., 2365
 Stoner, G. D., 4376, 6857
 Stoop, H., 1822
 Stopfer, P., 4034
 Stoppacciaro, A., 4390
 Storkus, W. J., 5853
 Stortchevoi, A., 4985
 Story, M. D., 6414
 Stout, K., 219
 Stower, M., 58
 Strain, C. M., 5001
 Strand, K., 2654
 Stratford, I. J., 688, 2962
 Stratford, M., 3408
 Stratford, M. R. L., 7247
 Strathee, C. A., 171
 Stratton, M. R., 6451, 6997
 Straub, J., 4562
 Straubinger, R. M., 2561
 Straume, O., 6808
 Strausberg, R. L., 3340
 Strebhardt, K., 4186
 Streit, M., 2004
 Strelkov, I. S., 75
 Stribbling, S. M., 1724
 Stricker, H., 4968
 Striet, J. B., 1682
 Strife, A., 4244
 Strigård, K., 1364
 Strobeck, M. W., 6587
 Strohmaier, H., 4535
 Strömberg, U., 3980
 Strome, S., 6566
 Strome, S. E., 1884
 Strong, L. C., 1952
 Strongin, A. Y., 580
 Strutton, G. M., 3759
 Strzelecki, D. M., 4711
 Stuart, S., 1123
 Stubbs, M., 688
 Stucchi, C., 6152
 Studeny, M., 3603
 Stumm, S., 2052
 Sturm, R. A., 226
 Stuschke, M., 6621
 Su, H., 4191
 Su, L., 1377, 2819
 Su, L.-K., 1311
 Su, W., 4282
 Su, Z., 5041
 Subbaramaiah, K., 2522, 5405
 Subjeck, J. R., 1737
 Suckow, V., 219
 Sucov, H. M., 4812
 Sudakin, V., 1797
 Sudilovsky, D., 3812
 Sugai, H., 5813
 Sugamura, K., 5800
 Sugarbaker, D. J., 4963, 7001
 Sugaya, M., 1751
 Sugi, N. H., 6116
 Sugie, S., 6367
 Sugihara, H., 4938
 Sugihara, K., 13
 Sugihara, K.-i., 6846
 Sugimoto, Y., 28
 Sugimura, T., 28, 3592, 6645
 Sugio, K., 1751
 Sugiono, M., 4123
 Sugita, M., 3971
 Suh, Y.-A., 3945
 Suico, M. A., 6579
 Sullivan, A., 2072
 Sullivan, C. M., 3729, 4478
 Sumizawa, T., 2834
 Sun, B., 781
 Sun, H., 2606
 Sun, J.-Y., 3175
 Sun, L.-Z., 4690
 Sun, N., 6857
 Sun, S.-Y., 2430
 Sun, T., 386
 Sun, T.-T., 4157
 Sun, X., 6026
 Sun, Y., 2875, 2913, 6323
 Sun, Y. J., 4903
 Sundberg, J. P., 1235
 Sures, I., 840
 Susini, C., 6124
 Sutherland, M. K., 1439
 Sutherland, R. L., 3126, 6916
 Suttmüller, R. P. M., 6187
 Suto, S., 5168
 Sutton, J. N., 18
 Suva, L. J., 5571
 Suzui, M., 3351, 3997
 Suzuki, A., 4194, 6194
 Suzuki, F., 5168
 Suzuki, H., 48
 Suzuki, I., 1961
 Suzuki, K., 1266, 1961
 Suzuki, M., 4194
 Suzuki, S., 1410
 Suzuki, T., 2753
 Svoboda, K. M., 4419
 Swalsky, P. A., 2681
 Swarbrick, A., 3126
 Sweeney, P., 5720
 Swenberg, J. A., 5183, 5189
 Swerdel, M., 2516
 Swinkels, D. W., 2695
 Swinnen, J. V., 642
 Swisher, S. G., 2239
 Swoboda, R., 5267
 Swope, S., 2654
 Sy, T., 1401
 Sykes, S. N., 2287
 Symons, M., 2462
 Syngal, S., 3485, 3925
 Sze, D., 6070
 Szeles, A., 575
 Szepeshazi, K., 781

T

- Taatjes, D. J., 4169
 Tabayoyong, W. B., 7135
 Tada, Y., 4048
 Taddei, M. L., 6489
 Taffaro, M. L., 5242
 Tagliabue, E., 1321
 Tago, K.-i., 3322
 Taguchi, K.-i., 4048
 Taguchi, O., 6289
 Tahara, M., 6015
 Tai, L. S., 4704
 Tai, Y.-T., 3876, 5019
 Taichman, N. S., 1832
 Taichman, R. S., 1832
 Taidi, B., 5845
 Taillandier, D., 2771
 Taira, K., 4434
 Tajima, N., 7004
 Takada, S., 6390
 Takaha, N., 647
 Takahara, S., 1410
 Takahashi, A., 5813
 Takahashi, K., 6116, 6390
 Takahashi, M., 28, 2203, 2414, 5076, 5651, 6598
 Takahashi, N., 6909
 Takahashi, S., 1956
 Takahashi, T., 271, 3850
 Takahashi, Y., 6682
 Takaku, K., 506, 4558, 6846
 Takamura, M., 2971
 Takayama, H., 6724
 Takayama, S., 1904
 Takeda, K., 2414
 Takemoto, N., 3939

AUTHOR INDEX TO VOLUME

- Takemura, H., 5743
 Takenawa, T., 669, 2503
 Takenoyama, M., 1751
 Takeshita, F., 1641
 Taketani, T., 33, 333, 4075, 4571
 Taketani, Y., 2019
 Taketo, M. M., 506, 1971, 2261, 4549, 4558, 6846
 Takeuchi, K., 2019
 Taki, T., 33, 333, 4075, 4571
 Takita, H., 2611
 Talbot, I., 53
 Talini, D., 6489
 Talks, K. L., 1326
 Tallini, G., 3980
 Talmage, K., 6966
 Talpaz, M., 932
 Tam, P. K. H., 6952
 Tamada, K., 1884, 4413
 Tamai, Y., 1971
 Tamaoki, N., 518
 Tamesa, T., 3939
 Tammam, J. G., 789
 Tammi, M., 6410
 Tammi, R., 6410
 Tamura, G., 3641
 Tan, C., 1083, 2546
 Tan, D.-J., 972
 Tan, E. H.-H., 1592
 Tan, J., 4671
 Tan, L., 924
 Tan, M., 2913
 Tan, W., 6430
 Tan, Y., 4685
 Tanaka, A., 4916
 Tanaka, F., 2937, 7124
 Tanaka, M., 63
 Tanaka, T., 4282, 6367, 6390
 Tang, D. G., 2976
 Tang, H., 376, 924
 Tang, M.-s., 6857
 Tang, S.-H., 2976
 Tang, T. C.-M., 7157
 Tang, X., 4903
 Tang, X. M., 1676, 6323
 Tangen, C. M., 5218
 Tangoku, A., 3939
 Tanguy, M.-L., 4685
 Tani, K., 28
 Tani, T., 4938
 Taniguchi, H., 233
 Taniguchi, N., 6289
 Tanimoto, M., 6390
 Tanino, M., 5168
 Tanius, F., 7219
 Taniwaki, M., 333, 4075
 Tanji, N., 2210
 Tannenbaum, C. S., 2606
 Tanwar, M. K., 4364
 Tasaka, K., 6015
 Tatò, F., 3507
 Tatsuka, M., 5168
 Tatum, T., 5853
 Tavassoli, M., 2072
 Taya, Y., 2883
 Taylor, A., 3408
 Taylor, C. F., 2957
 Taylor, J. A., 3251, 6052
 Taylor, J. M. G., 4722
 Taylor, M., 1326
 Taylor, P. R., 4191
 Tazawa, R., 63
 Teh, B. T., 589, 6598
 Teh, M.-T., 4773
 Tei, K., 6289
 Teichberg, D., 2923
 Teichberg, S., 290
 Teicher, B. A., 5597
 Tellez, C., 5106
 Tellez, C. S., 2370
 Temparis, S., 2771
 Templeton, N. S., 1541
 Tenan, M., 1191
 ten Asbroek, A. L. M. A., 2024
 Tenen, D. G., 528
 TenEyck, C. J., 4656
 Tensen, C. P., 5389
 te Poele, R. H., 1876
 Tepper, C. G., 6606
 Tepperberg, J., 5761
 Terada, M., 560, 1641
 Terada, Y., 5168
 Terao, M., 2192
 te Riele, H., 2092
 Terleth, C., 1338
 Terracciano, L., 3453
 Terrian, D. M., 2423
 Terrier-Lacombe, M.-J., 764
 Terry, A., 7175
 Terui, K., 33
 Teshima, T., 796
 Thacker, J., 6263
 Thakur, N., 4545
 Thaler, H. T., 5405
 Thant, A. A., 3962
 Theodorakis, P., 3373
 Theodore, L. J., 5755
 Theodorescu, D., 982, 6418, 6981
 Theus, A. M., 3722
 Thiede, C., 4955
 Thiel, E., 1743
 Thiele, C. J., 323, 1196, 6108, 6756
 Thilly, W. G., 3271
 Thimmlappa, R. K., 5196
 Thirdborough, S. M., 1757
 Thomas, A. P., 4645
 Thomas, G., 3485
 Thomas, M., 2813
 Thomas, M. W., 363
 Thompson, D. C., 6850
 Thompson, E. J., 3044
 Thompson, H. J., 156, 5280
 Thompson, J. D., 3736
 Thompson, T. E., 3251
 Thonnard, J., 5510
 Thorpe, P. E., 6132
 thor Straten, P., 5664
 Thurston, S. W., 1377
 Thykjaer, T., 961
 Tiano, H. F., 3395
 Tibaldi, E. V., 6304
 Tichansky, D. S., 3200
 Tilanus, H. W., 1531
 Tilignac, T., 2771
 Tilleray, V. J., 2272
 Tilley, W. D., 854
 Timar, J., 2824
 Timblin, C. R., 4169, 6065
 Timmerman, J., 3195
 Timmerman, J. M., 5845
 Timmons, C. F., 5897
 Timper, A., 3048
 Timpl, R., 1944
 Tin, R. T., 5096
 Tinari, N., 2535
 Tindall, D. J., 1008, 5632
 Tinkenberg, B. A., 4909
 Tiraby, G., 6124
 Tirapu, I., 3167
 Tisato, V., 6099
 Tjarks, W., 3159, 6552
 Tobin, P., 2546
 Toda, K., 6289
 Todo, S., 2203, 2971
 Tofilon, P. J., 1069, 2318
 Togashi, K., 860
 Tognin, S., 2462
 Toguchida, J., 5859
 Toi, M., 4849
 Tokita, H., 2203
 Tokugawa, T., 4938
 Tolba, K. A., 6545
 Toma, S., 2455
 Tomajer, V., 1116
 Tomida, A., 5008
 Tomita, K., 3351
 Tomlinson, G. E., 5897
 Tomlinson, L., 53, 4562
 Tomlinson, S., 1110
 Tonetti, C., 4685
 Tong, W.-M., 6990
 Tong, Z., 5528
 Topalian, S. L., 5505
 Toquet, C., 2169
 Torbenson, M. S., 3909
 Torchilin, V. P., 6831
 Toriyama-Baba, H., 1641
 Török, N. J., 1648
 Torres, A., 3855
 Torrisi, A., 2406
 Tortora, G., 7284
 Tosello, V., 6099
 Touloukian, C. E., 5144
 Toyama, T., 4445
 Toyooka, K. O., 3382
 Toyooka, S., 3382, 5897, 6820
 Tozer, G. M., 7247
 Tozer, R. G., 1588
 Trachy-Bourget, M.-C., 4325
 Tran, C., 5254
 Trapasso, F., 2258
 Travis, E. L., 3782
 Travis, W. D., 3340
 Treadway, P., 5597
 Trent, J. M., 1784, 2220
 Treseler, P. A., 3636
 Treston, A. M., 2300
 Tretiakova, M., 6598
 Triche, T. J., 4711
 Trifan, O. C., 5778
 Trikha, M., 2824, 5336
 Trink, B., 3659
 Trivedi, C., 3842
 Trofimova, I., 6879
 Troglio, F., 567
 Trouet, A., 2327
 Trowbridge, D. B., 6870
 Troy, H., 688
 Troyer, D. A., 2077
 Trudel, M., 2210
 True, L. D., 5645
 Tsai, E.-M., 8
 Tsai, M.-H., 6246
 Tsai, Y. C., 2378
 Tsang, F. C., 4890
 Tsang, K. Y., 5049
 Tsao, M. S., 3005
 Tsao, M.-S., 6194
 Tsao, S. W., 1662
 Tschumi, A. I., 2385
 Tse, C., 542, 2637
 Tse, C.-K., 1987
 Tsong, J., 4514
 Tsuboyama, T., 5859
 Tsuchiyama, J., 6390
 Tsuda, H., 4860
 Tsui, J., 1458
 Tsui, W. W., 6451
 Tsuji, S., 1567
 Tsujii, M., 1567
 Tsukahara-Tamai, N., 6116
 Tsukuda, K., 3438
 Tsuneyoshi, M., 4048
 Tsung, K., 4696, 5069
 Tsung, Y. L., 4696, 5069
 Tsunoda, T., 518, 1139, 5668, 5859, 7012
 Tsuruo, T., 2019, 2971, 5008
 Tsuruoka, A., 6116
 Tsutsumi, S., 233, 4484
 Tsyb, A. F., 7031
 Tu, X., 7350
 Tucker, M. A., 3992
 Tudan, C., 2131
 Tukada, K., 7162
 Tunheim, S. H., 661
 Tunstead, J. R., 6791
 Turaga, V., 5041
 Türeci, O., 6750
 Turker, M. S., 1518
 Turley, H., 1326, 2493
 Turnbull, D. H., 6385
 Turner, A., 1784, 2253, 6485
 Turner, B. C., 4054
 Turner, G. D. H., 2942
 Turner, K. J., 2957
 Turner, R. E., 6304
 Tusch, M., 2125
 Tuxhorn, J. A., 3298, 6021
 Tyagi, A. K., 3063
 Tyers, M., 3005
 Tyrsin, O. Y., 6297
 Tyson, F. L., 1152
 Tzukerman, M., 3184

U

- Uberla, K., 6099
 Uchimiya, H., 2834
 Uchimura, S., 3939
 Uchiyama, T., 6224
 Ueda, C., 6224
 Ueda, E., 901
 Ueda, N., 6116
 Ueda, T., 4899
 Uekusa, Y., 3751
 Uenaka, A., 1471
 Ueno, N. T., 6712
 Ueyama, Y., 518
 Uhrborn, L., 5551
 Ullenhag, G. J., 1364
 Ullrich, A., 840, 2535, 3402, 6329
 Ulmer, J. E., 48
 Ulrich, C. M., 3361
 Ulusakarya, A., 4685
 Umbach, D. M., 6052
 Unfried, K., 99
 Unger, C., 4015
 Untergasser, G., 6255
 Upender, M. B., 1134
 Uprichard, M., 6070
 Upton, P. B., 5189
 Urabe, M., 2019
 Uranchimeg, B., 4316
 Urba, W. J., 3914
 Urbanek, M., 6651

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

Usadel, H., 371
 Ushijima, T., 3592, 6645
 Uskokovic, M. R., 741
 Usui, K., 63
 Uto, A., 6579
 Uzgare, A. R., 986

V

Väänänen, H. K., 2708
 Vacanti, J. P., 2004
 Vacek, P., 4169
 Vaidya, B., 226
 Vaillancourt, M., 6045
 Vaillant, F., 7181
 Vakkari, M.-L., 2625
 Valent, P., 2098
 Valentine, P. J., 4645
 Valianou, M., 4767
 Valladares, M., 6812
 Vallette, G., 2169
 Valmori, D., 1743, 2058
 Valtorta, E., 2398
 van Beethoven, A., 5845
 van Beusechem, V. W., 5736, 6165
 van Bezouw, S., 2157
 Van Boexlaer, S., 4879
 Van Buren, E., 3842
 Van Dam, J., 682
 van Dekken, H., 1531
 van den Berg, J., 5736
 Van den Berghe, H., 3980
 van den Doel, P. B., 6165
 van den Hoogen, F. J. A., 7066
 van der Burg, S. H., 472, 6187
 Vander Griend, D. J., 6717
 Vander Heiden, M. G., 3515
 van der Hulst, J. M., 472
 van der Kogel, A. J., 341, 7066
 van der Meijden, C. M., 2510
 van der Meijden, C. M. J., 3233
 van der Neut, R., 5126
 Vandertop, W. P., 5736
 Van de Sande, T., 642
 Van de Ven, W. J. M., 1510
 van de Wetering, M., 5126
 Vande Woude, G. F., 589
 van Doorn, L.-J., 2385
 van Doorn, R., 5389
 Van Echo, D. A., 4023
 Vanegas, S., 2468
 van Eyndhoven, W. G., 5420
 van Golen, K. L., 4854
 van Groenigen, M., 2024
 van Gurp, R. J. H. L. M., 1822
 Vanhoefer, U., 3113
 Vanhulle, V. P., 3555
 Vanin, E. F., 3077
 van Lohuizen, M., 619, 4736
 van Meijgaarden, K. E., 472
 Van Meir, E. G., 1191, 2478, 2897
 Van Ness, B., 715
 Vanni, R., 3980
 van Noesel, M. M., 2157
 Van Parijs, L., 7135
 van Steeg, H., 1338
 van Tellingen, O., 6158
 van Trappen, P., 1315
 van't Veer, L. J., 7110
 Van Valckenborgh, I. C. C., 1510
 Van Vleet, T. R., 105
 Van Waes, C., 5049
 van Welssem, T., 7110
 Van Wier, S. A., 715

van Wijnen, A. J., 2510, 3233
 van Zon, A., 7298
 Vardantan, L., 7305
 Varghese, H. J., 887
 Vargo-Gogola, T., 5559
 Varis, A., 2625
 Varma, H., 3985
 Varner, J. A., 4007
 Varticovski, L., 188
 Vasmatazis, G., 3308
 Vass, J. K., 5999
 Vass, W. C., 4507
 Vassal, G., 764, 5736
 Vasselli, J. R., 3014
 Vassileva, V., 4095
 Vaughan, L., 1604
 Vaughan, M. M., 4383
 Veach, D. R., 4236, 4244
 Vecchio, G., 1077, 7284
 Veer Reddy, G. P., 2488
 Velasco-Miguel, S., 4507
 Velcich, A., 6006
 Velders, M. P., 5792
 Velicescu, M., 2378, 6456
 Veltman, J. A., 957
 Venkateswaran, V., 2540
 Venter, D. J., 1289
 Venuti, A., 3654, 6381
 Verdier-Pinard, P., 4007
 Verhaegh, G. W., 2695
 Verhoeven, G., 642
 Vermeer, M. H., 5389
 Vermeij, P., 472
 Vernejoul, F., 6124
 Verrijp, K., 341
 Verschöyle, R. D., 4256
 Versteeg, R., 2157
 Verstovsek, S., 5995
 Vessella, R., 5470
 Viacava, P., 5874
 Viars, C., 6981
 Vicario, J. L., 5013
 Vickroy, J. D., 2468
 Vierboom, M. P. M., 6187
 Vietmeier, B. N., 2437
 Vieweg, J., 5041
 Vieyra, D., 4445
 Vile, R., 1884, 5495
 Vile, R. G., 6566
 Vilenchik, M., 2175
 Villa, L., 2583
 Villanueva, C., 3402
 Villanueva, J., 488
 Viridis, P., 4459
 Virmani, A., 3945
 Virshup, D. M., 6357
 Virtanen, S. S., 2708
 Visakorpi, T., 4554
 Visscher, D. W., 2115
 Vitagliano, D., 1077, 7284
 Vocke, C. D., 3498
 Voeller, H. J., 2654
 Vogel, U., 4339
 Vogel, W., 1503
 Vogelbaum, M. A., 1103
 Vogelstein, B., 1129, 4579
 Vogelzang, N. J., 6598
 Voisine, C., 1050
 Volante, M., 2406
 Volk, E. L., 5035
 Volpe, P., 6997
 Volpert, O. V., 7357
 von der Lieth, C. W., 7018
 Von Hoff, D. D., 2890

von Montfort, C., 4922
 von Stemm, A., 3200
 von Tiehl, K., 3956
 Voo, K. S., 7195
 Vooijs, M., 1862
 Vorburger, S. A., 2239
 Vorndamm, J., 910
 Voss, S., 1884
 Voûte, P. A., 2157
 Voz, M. L., 1510
 Vrana, J. A., 892

W

Waas, J., 3408
 Wacheck, V., 2098
 Wada, H., 7124
 Wada, M., 4048
 Wada-Takahashi, Y., 6909
 Wadhwa, R., 4434
 Wadsworth, P., 4109
 Wadsworth, P. F., 4645
 Wadum, L., 3587
 Waelti, E., 437
 Wagner, L. M., 5001
 Wagner, R., 6099
 Wagner, U., 1256
 Wahl, A. F., 3736
 Wahlberg, S. S., 3485
 Waidyanatha, S., 1330
 Wain, J. C., 1377, 2819
 Wakabayashi, K., 28
 Wakabayashi, T., 6116
 Wakasugi, H., 560, 860
 Wakefield, S. J., 3356
 Wakefield, T. L., 1884
 Wakeham, A., 6194
 Wakeling, A. E., 5749
 Wakisaka, N., 6337
 Walch, A., 3048
 Walcott, F. L., 4566
 Waldeck, W., 7018
 Waldman, F. M., 957
 Waldman, T., 2744
 Waldmann, T. A., 1083, 5755
 Walker, C., 2736
 Walker, C. L., 3766, 6475
 Walker, J. P., 2151, 4289
 Walker, R. A., 3289
 Wall, N. R., 2462, 3093
 Wallace, T. J., 3387
 Wallin, H., 4339
 Wallwiener, D., 2052, 6740
 Walsh, M. D., 6011
 Walsh, P. C., 1784, 2253, 6485
 Walter, S., 5818
 Walther, S., 3144
 Wancewicz, E. V., 5393
 Wanders, R. J., 2220
 Wang, A., 5308
 Wang, C., 141
 Wang, C. C., 2806
 Wang, C-X., 2
 Wang, C-y., 3221
 Wang, D., 4525
 Wang, E., 3581, 4464
 Wang, F., 1898
 Wang, G-Q., 4884
 Wang, H., 840, 2483, 4413, 4843
 Wang, H-G., 466
 Wang, J., 208, 1534, 1956, 3503, 4843
 Wang, J. D., 1410
 Wang, J. Y., 2982
 Wang, J-A., 141
 Wang, K., 3308
 Wang, K. K., 1531
 Wang, K. K. W., 2913
 Wang, L., 4992, 7264
 Wang, L-G., 6080
 Wang, L-M., 589
 Wang, M., 4273
 Wang, Q., 848
 Wang, R-f., 3630, 5505, 7195
 Wang, R-Y., 7264
 Wang, S., 1148, 3493, 3641, 5637, 6820
 Wang, S-C., 8, 1311
 Wang, T. C., 696
 Wang, W., 2232, 6278, 7166
 Wang, X., 18, 1598, 1662, 2064, 2483, 5505, 6031
 Wang, X-Y., 1737
 Wang, Y., 386, 625, 917, 1598, 2483, 2999, 3024, 3428, 6031, 6080, 6434, 7166
 Wang, Z., 4843
 Wang, Z-Q., 6990
 Wani, M. C., 7377
 Ward, M. D., 48, 3609
 Ward, R., 53
 Ward, T., 990
 Ward, Y., 5505
 Warner, M., 4849
 Warren, W. H., 4876
 Warters, R., 5627
 Wasan, H., 53
 Washburn, B., 7050
 Waskewich, C., 2029
 Wassenaar, T. M., 2385
 Wasserman, R., 4212
 Watanabe, I., 860
 Watanabe, K., 28
 Watanabe, K-i., 2203
 Watanabe, N., 3592
 Watanabe, R., 3850
 Watanabe, T., 4849, 7012
 Waters, C. A., 2151
 Wathen, K., 1676
 Watkins, S., 2583, 5727
 Watson, K. L. M., 5543
 Watson, M. A., 2085
 Watson, P., 6625
 Watson, P. H., 2736
 Waxman, D. J., 6928
 Waxman, S., 3893, 5618
 Wazer, D. E., 3315, 4736
 Webb, P., 141
 Weber, B. L., 1481, 6997
 Weber, G. F., 2281
 Weber, K., 3048
 Weber, M. J., 18
 Weckermann, D., 251
 Wedge, S. R., 4645
 Weeraratna, A., 986
 Weghorst, C. M., 5295
 Wegmann, N., 437
 Wei, Q., 4992
 Wei, Q. V., 2813
 Weidmann, E., 1768
 Weidner, M., 5962
 Weil, M., 1093, 3782
 Weibaecher, K. N., 2098
 Wein, L. M., 6070
 Weinberg, R. A., 6348
 Weinberg, V., 3812
 Weiner, H. L., 6385
 Weiner, L. M., 4767

AUTHOR INDEX TO VOLUME

- Weinmeister, P. M., 2162
 Weinschenk, T., 5818
 Weinstein, I. B., 3351, 3997
 Weinstein, J. N., 1688
 Weinstein, M. D., 5536
 Weisberg, E., 5019
 Weisenberger, D. J., 2378, 6456
 Weiss, E. H., 480
 Weiss, M. J., 6651
 Weisser, C., 4820
 Weissman, B., 323
 Weitman, D. M., 3794
 Weizer, A. Z., 5041
 Welch, J. N., 3428
 Welch, M. J., 445
 Wellbrock, C., 4820
 Weller, E., 5019
 Weller, M., 1915, 2592, 7139
 Wells, P., 5698
 Welsh, S. J., 5089
 Welt, S., 4041
 Wen, X., 2778
 Wen, Y., 8
 Wendt, M. A., 7203
 Wenger, R. H., 2962
 Wenig, B., 1184
 Weremowicz, S., 43
 Wergin, M., 2962
 Werneburg, N. W., 6500
 Wernet, D., 5818
 Wescott, G. G., 2423
 Wesierska-Gadek, J., 4206
 Wesseling, P., 341
 Wessels, L. F. A., 7110
 Wessendorf, S., 2993
 West, A. R., 3207
 West, C. R., 3417
 West, L. M., 3356
 Westermann, J., 1356
 Westra, W. H., 3659
 Wetterwald, A., 437
 Wettstein, P., 1884
 Whary, M. T., 696
 Wheeler, T. M., 5974
 Whelan, J., 403
 White, J. D., 1669
 White, J. G., 6278
 White, M. F., 6035
 White, M. J., 881
 White, P. S., 6481, 6651
 White, R. L., 6357
 Whiteford, C., 3562
 Whitehall, V. L. J., 5988, 6011
 Whiteside, D., 359
 Whiteside, T. L., 3521
 Whong, W-Z., 703
 Whysner, J., 2
 Wick, A., 1915
 Wick, W., 1915, 7139
 Wickramasinghe, D., 5485
 Wickström, S. A., 5580
 Widmer, M. B., 5800
 Widmer, W. R., 356
 Widschwendter, M., 4535
 Wieckowski, E., 4884
 Wiedmer, T., 397
 Wiehle, S. A., 3530
 Wieland, W., 6796
 Wiemer, E. A. C., 7298
 Wiencke, J. K., 4630
 Wiener, D., 1978
 Wiese, C., 1279
 Wiesener, M. S., 3803
 Wiewrodt, R., 3438
 Wigle, D. A., 3005
 Wigler, N., 1093
 Wijdenes, J., 1388
 Wijffels, K. I. E. M., 7066
 Wilbanks, G. D., 5930
 Wilber, K., 2365
 Wilcox, R., 1884
 Wilcox, R. A., 4413
 Wild, J., 6108
 Wild, R., 1702
 Wilder, E. L., 277
 Wilding, G., 6039
 Wilding, J., 4562
 Wildner, G., 3048
 Wiley, K. E., 1784, 2253, 6485
 Wileyto, E. P., 7273
 Wilhelm, M., 957
 Will, R. D., 6698
 Willard, M. T., 2478
 Willemze, R., 5389
 Willén, H., 3980
 Willett, W. C., 1045
 Willhite, D., 1289
 Willi, N., 1256
 Williams, B. O., 6598
 Williams, B. W., 1702
 Williams, C. R., 773
 Williams, E., 213
 Williams, K. J., 688, 2962
 Williams, P. J., 917
 Williams, R. D., 3093
 Williams, S. L., 6587
 Williamson, K. A., 6615
 Willink, R., 2248
 Willis, J., 1134
 Wills, J. C., 6870
 Wills, K., 6045
 Willson, J. K. V., 1134
 Wilson, A. J., 6006
 Wilson, D. R., 2318
 Wilson, J. L., 5930
 Wilson, K., 1134
 Wilson, S. M., 887, 2162
 Wilson, W. D., 7219
 Wilson, W. R., 1425
 Wilting, J., 6884
 Winde, G., 1718
 Windle, J. J., 2077
 Wingefeld, C., 437
 Wink-Godschalk, J. C. J., 1531
 Winkler, M., 4123
 Winkler, R., 4623
 Winski, S. L., 1420
 Winstanley, J. H. R., 3417
 Winter, C. L., 6481
 Winters, S. A., 2370
 Winton, T., 3005
 Wirths, S., 5065
 Wischhusen, J., 2592
 Wiseman, R. W., 990, 3024
 Wisniewski, D., 4244
 Wit, E. C., 5999
 Witham, T. F., 2583
 Wittig, C., 4015
 Wittig, R., 6698
 Wittmann, B., 1477
 Wojciechowski, J., 4206
 Wolf, D. M., 881
 Wolf, G., 6621
 Wolf, M., 2625, 6240
 Wolf, S. F., 5727
 Wolford, C. C., 7042
 Wong, B. C. Y., 3226
 Wong, J., 3945
 Wong, J. Y. C., 1213
 Wong, K. J., 5755
 Wong, K. K., Jr., 3175
 Wong, L.-J. C., 972
 Wong, M. K., 5727
 Wong, M. P., 4464
 Wong, P. K. Y., 5153
 Wong, S., 1458, 3956
 Wong, S. Y., 4704
 Wong, S.-T., 4773
 Wong, Y. C., 1662
 Woo, S.-H., 4325
 Wood, J., 4015, 5019
 Woodburn, J. R., 5749
 Woodgett, J., 3005
 Woodruff, J. M., 135
 Woods, J. D., 2681
 Wooster, R., 6451, 6997
 Working, P., 3743
 Wosikowski, K., 1057
 Wotton, S., 7181
 Wrana, J. L., 4558
 Wrba, F., 2098
 Wright, B. E., 5641
 Wright, G. L., Jr., 3609
 Wright, M., 3511
 Wrobel, G., 2993
 Wu, C. J., 5517
 Wu, D., 2423
 Wu, F., 2468, 3834
 Wu, J., 4812, 5564
 Wu, K., 6376
 Wu, M., 2098
 Wu, Q.-L., 7157
 Wu, R., 4722, 5273
 Wu, X., 2813, 5096
 Wu, X.-R., 4157
 Wu, Y., 386, 1030, 2567, 4100, 5035, 6442
 Wulfskuhle, J. D., 6740
 Wurm, R., 6621
 Wyatt, C. A., 7200
 Wyckoff, J., 7166
 Wyckoff, J. B., 6278
 Wynter, C. V. A., 6011
- X**
- Xia, C., 5399
 Xia, L., 1213, 1496, 6606
 Xia, W., 346, 6712
 Xiang, J., 2043
 Xiang, R. H., 542, 2637
 Xiao, D., 3615
 Xiao, N., 5325
 Xiao, Q., 290
 Xiao, S., 6035
 Xiao, X., 756
 Xie, D., 7157
 Xie, R.-L., 2510
 Xie, S., 386
 Xie, W., 497
 Xie, Y., 3861
 Xing, D., 6430
 Xiong, Y., 1171
 Xu, B., 1330, 3226, 4588
 Xu, H., 3538
 Xu, H.-p., 290
 Xu, J., 1784, 2253, 6485
 Xu, K., 2715
 Xu, L. L., 1377
 Xu, X., 1178
 Xu, X.-C., 6376
 Xu, Y., 1148, 3493, 3641, 4637, 5637, 6820
 Xu, Z.-Y., 5457
 Xu-Welliver, M., 3037
- Y**
- Yageta, M., 5129
 Yaguchi, T., 4434
 Yakar, S., 1030
 Yakes, F. M., 4132
 Yakovlev, A. G., 4439
 Yamada, K., 307
 Yamada, N. A., 6061
 Yamada, S. D., 6717
 Yamada, Y., 6367
 Yamada-Okabe, H., 3939
 Yamaguchi, H., 466, 2503, 2937
 Yamaguchi, K., 4894
 Yamaguchi, N., 295, 3751
 Yamamoto, A., 5967
 Yamamoto, H., 1641
 Yamamoto, I., 7004
 Yamamoto, M., 2414, 5196
 Yamamoto, Y., 6116
 Yamaoka, Y., 7012
 Yamashita, K., 1961
 Yamashita, S., 3592, 7031
 Yamazaki, K., 1139
 Yamori, T., 1139
 Yan, C., 4867
 Yan, H., 1330, 4579, 6246
 Yan, M., 5153
 Yan, P. S., 3214
 Yan, P. T., 4325
 Yan, Y., 5457
 Yanagawa, R., 518, 1139
 Yanagihara, K., 4894, 6645, 7124
 Yancey, D., 5041
 Yang, B., 4843
 Yang, C. S., 7241
 Yang, F., 6021
 Yang, H., 3084, 4575
 Yang, H. L., 1776
 Yang, J., 4690
 Yang, J.-M., 6864
 Yang, L., 3084
 Yang, M., 1534, 3834
 Yang, Q., 2606, 7357
 Yang, S., 371
 Yang, T., 2583
 Yang, W., 3159, 4791, 5703, 6552
 Yang, X. J., 6598
 Yang, X.-D., 2468
 Yang, X.-F., 5517
 Yang, Y., 2232, 3498, 3904, 5420
 Yang, Y.-M., 2
 Yang, Z., 1251
 Yano, M., 1025
 Yano, S., 3711, 5967
 Yao, M., 7004
 Yao, Z., 5755
 Yarbrough, W. G., 1171
 Yaron, Y., 6803
 Yarranton, G. T., 2327
 Yasuda, J., 2971
 Yasuda, M., 1751
 Yasui, N., 5603
 Yasui, Y., 3609
 Yasumaru, M., 1567
 Yasumatu, R., 3351
 Yasumoto, K., 1751
 Yau, E. K., 5755
 Ye, M., 129
 Ye, Y., 3826

AUTHOR INDEX TO VOLUME

- Yeatman, T. J., 2669
 Yee, D., 4369, 4491
 Yee, J., 5273
 Yeh, G. C., 3685
 Yeh, S-H., 4346
 Yen, N., 2715
 Yen, T. J., 1797
 Yeo, C. J., 1868
 Yeo, U-C., 3200
 Yeung, F., 3084
 Yeung, R. S., 5645
 Yi, B., 917
 Yi, H., 5727
 Yin, J., 1148, 3382, 3493, 3641, 5637, 6820
 Yin, S., 1330
 Yliskoski, M., 6410
 Yo, G. H., 6712
 Yoder, B. K., 5867
 Yokota, Y., 301
 Yokozaki, S., 2215
 Yonaga, M., 6116
 Yoneda, T., 917
 Yoo, H., 6318
 Yoon, J-H., 6500
 Yoshida, C., 6823
 Yoshida, K., 2883
 Yoshida, M., 4916
 Yoshida, N., 5603
 Yoshida, T., 1641, 2236
 Yoshikawa, H., 2019
 Yoshikawa, Y., 3819
 Yoshimatsu, K., 6116
 Yoshimi, N., 6367
 Yoshinaga, K., 13
 Yoshino, T., 6390
 Yoshizaki, T., 6337
 You, M., 3024, 6424
 You, X. J., 5611
 Youle, R. J., 1433
 Young, J., 3641, 5637, 5988, 6011, 6820
 Young, M. A., 4244
 Young, M. R., 3044
 Yousem, S. A., 2681
 You-Ten, A., 6194
 Yu, C., 188, 1898, 6430
 Yu, D., 1020, 2034, 5703
 Yu, D-C., 3743
 Yu, H., 910
 Yu, J. L., 1838, 1931, 6371
 Yu, J. S., 5657, 7170
 Yu, Q., 5743
 Yu, S., 4637
 Yu, W-G., 3751
 Yu, Y., 2951, 7264
 Yuan, J., 4186, 7264
 Yuan, L., 290
 Yuan, R-Q., 141
 Yue, P., 2430
 Yuen, S. T., 6451
 Yulug, I., 2072
 Yung, W. K. A., 1854
 Yvon, A-M., 4109

Z
 Zaak, D., 809
 Zabarovsky, E., 3498
 Zaenker, K. S., 6467
 Zafarana, G., 1822
 Zagzag, D., 2660, 6385
 Zahurak, M., 2232, 3904
 Zahurak, M. L., 1868
 Zalusky, D., 5489
 Zambrowicz, B. P., 3221
 Zanardo, L., 6796
 Zanation, A., 1171
 Zangani, D., 4383
 Zanke, B., 3466, 5076
 Zapata, J. M., 6674
 Zarnegar, R., 2064
 Zarour, H. M., 213
 Zatyka, M., 3803
 Zauner, W., 1477
 Zavadil, J., 6278
 Zegarra-Moro, O. L., 1008
 Zehetner, M., 5489
 Zelent, A., 5618
 Zembutsu, H., 518, 1139
 Zemel, M. B., 403
 Zeng, G., 3630
 Zeng, H., 3144, 6172
 Zeng, T., 6447
 Zeng, X., 3538
 Zenger, E., 5536
 Zeytin, H., 6944
 Zha, S., 2220
 Zhai, J., 2798
 Zhai, Y., 4722
 Zhan, X. H., 3691
 Zhang, B., 450
 Zhang, D., 2313
 Zhang, H., 3711, 3794, 5743, 5967
 Zhang, H. J., 1205
 Zhang, H-Z., 7350
 Zhang, J., 2600, 2906, 3743, 4194
 Zhang, J-C., 5344
 Zhang, L., 2034, 3620, 5463, 6430, 6447
 Zhang, M., 2337, 5755
 Zhang, N., 3221
 Zhang, Q., 6400
 Zhang, S., 1311
 Zhang, W., 4566
 Zhang, X., 1330, 2306, 4369, 5564
 Zhang, Y., 924, 1205, 3842, 3962, 4843, 6376
 Zhang, Z., 3024
 Zhang, Z-T., 4157
 Zhao, J., 397
 Zhao, L., 1030
 Zhao, R., 6434
 Zhao, S., 6246
 Zhao, W., 1205
 Zhao, Y., 2058, 3581, 6740
 Zhou, H. E., 3084
 Zheng, L., 2498, 3773, 6026
 Zheng, P., 3459
 Zheng, S. L., 1784, 2253, 6485
 Zhong, H., 2478
 Zhong, L., 4115
 Zhong, Q., 3966
 Zhong, X-S., 5689
 Zhou, A., 397
 Zhou, B., 8
 Zhou, B-B. S., 1797
 Zhou, H., 4142
 Zhou, J., 3077
 Zhou, J-H., 4746
 Zhou, L., 1541
 Zhou, Q., 397
 Zhou, R., 2561, 3515
 Zhou, W., 1377
 Zhou, X., 3782
 Zhou, X-J., 2637
 Zhou, X-Y., 1598, 2483
 Zhou, Y., 1688
 Zhou, Z., 2824
 Zhu, H., 4605
 Zhu, J., 4566
 Zhu, W., 3200
 Zhu, Y., 1797, 2813, 3428
 Zhu, Z., 156, 5280
 Zhuang, L., 2227
 Zhuang, S-M., 2650
 Zhurinsky, J., 5947
 Ziegler, U., 2962
 Zijlstra, A., 7083
 Zilberberg, L., 6884
 Zimmerman, C. L., 129
 Zimmermann, S., 3598
 Zimonjic, D. B., 4054, 6348
 Zippelius, A., 251
 Zittoun, J., 4685
 Zitzmann, S., 5139
 Zoltoski, A. J., 4439
 Zompetta, C., 3603
 Zou, A., 6045
 Zou, T. T., 3493
 Zou, T-T., 1148, 3641
 Zou, Y., 8
 Zou-Yang, H., 2239
 Zunino, S. J., 2848
 Zwaveling, S., 6187
 Zweier, J. L., 307
 Zweifel, B. S., 625, 5778, 6706
 Zysman, M., 3663

SUBJECT INDEX

Volume 62

A

- A1 protein**
mIngh interactions, 1275
- A6**
combined with tamoxifen, breast cancer, 4678
- Aag**
-null mice
bone marrow alkylation resistance, 656
- 17-AAG: See 17-Allylamino-17-demethoxygeldanamycin**
- ABCC6: See Multidrug resistance protein 6**
- Abl**
imatinib-resistant Abl mutants
PD180970 activity against, 7149
- N-Acetylglucosaminyltransferase V**
and β_1 integrin glycosylation, 6837
- N-Acetyl-L-cysteine**
benzyl and phenethyl conjugates, dietary
B(a)P-induced lung tumorigenesis inhibition, A/J mice, 2
- Acinar differentiation**
promotion by metallothionein, 5370
- β -Actin**
 β -actin/AUF1 transgenic mice
sarcoma, 1489
- Acyclic retinoid**
growth inhibition, hepatoma, 3997
- Adeno-associated virus**
-encoded angiostatin
tumor growth inhibition, glioma, 756
rAAV-mediated tsFlk-1 expression
growth inhibition, renal tumors, 3077
Rb protein protection, 2982
recombinant rAAV
dendritic cell-targeted candidate vaccine,
chronic myelogenous leukemia, 3175
- Adenocarcinoma**
colon
EGCG stability, uptake, metabolism and efflux, 7241
endometrial
Ishikawa
stromal regulation, 79
esophageal
HNF3 α (*FOXA1*) amplification and overexpression, 5273
gastric
HPP1 and *hMLH1* hypermethylation, 5637
inhibition by *semaphorin 3B*, 542
lung
allelic imbalance, nonsmokers, 4464
BRAF mutations, 7001
expression analysis, 3244
HNF3 α (*FOXA1*) amplification and overexpression, 5273
LKB1/STK11 inactivation, 3659
pulmonary metastases
ZD6126 effects, 3711
molecular markers, 5999
pancreatic
peptidomic marker peptide discovery, 4894
risk
XRCC1 Arg399Gln polymorphism and, 4630
pancreatic ductal
HIP/PAP-I, 1868
- Adenoma**
colorectal
CDH13 promoter region methylation, 3382

- TS* polymorphisms and, 3361
- pituitary
HMG2A overexpression, 2398
- Adenomatous polyposis coli (APC) gene**
APCDD1
upregulation, colon cancer, 5651
Apc^{Δ716} knockout mice
malignant intestinal polyp progression
Smad2 null mutation and, 4558
Apc^{min} mice
CEA-based vaccine antitumor activity, 6944
tumor load reduction by vitamin D₃ compounds, 741
Apc^{Min/+} mice
microadenomatous lesions, colon, 6367
PGE₂ modulation of NSAID effects, 403
Apc^{Min/+}, *CASTB6F1 Mom1^{S/S}* mice
polyp multiplicity, 5413
Apc^{Min/+} *Dnmt1*-hypomorphic mice
polyp inhibition, 1296
Apc/Smad2 compound mutant mice
invasive tumors, 5955
methylation
lung cancer, 371
MSI+ endometrial cancers, 3663
mutations
growth advantages, colorectal tumors, 363
polymerase β and, colon tumors, 3271
- Adenosine triphosphate**
 β -F1-ATPase inhibition, carcinoma, 6674
- Adenovirus**
c-erbB-2 oncoprotein-targeting, 609
combined with enzyme-activated prodrug therapy, 6089
conditionally replicative Ad Δ 24-p53
oncolytic potency, 6165
dendritic cell activation, 5260
double suicide gene therapy, locally recurrent prostate cancer, 4968
DT-A gene transfer, 2576
E2F-1 gene transfer
combined with chemotherapy, melanoma, 1776
replication-selective, 3438
endostatin
growth inhibition, mammary tumors, 3934
liver metastasis-specific, 1063
mda-7, mechanism of action, 2239
oncolytic *d11520*
hepatic arterial administration, 6070
p53 gene transfer
phosphorylation, glioma, 1069
purging, autologous PBSC transplantation, 5013
RB94 treatment, head and neck squamous cell carcinoma, 4637
renal cell carcinoma gene therapy, 4273
replication enhancement by vitamin D₃, 3084
type 5
conditionally replicative Ad5- Δ 24RGD
combined with radiotherapy, glioma, 5736
ovarian cancer treatment, 1266
type 5 E1A
oncolytic mutations, melanoma-targeted, 4663
systemic gene therapy, 6712
tumor inhibition mechanisms, 346
- ADI: See Arginine deiminase**
- Aflatoxins B₁**
metabolism and cytotoxicity, bronchial cells, 105

Age

- ING1 properties and, 4445
- Aggressiveness**
associated genomic alterations, bladder cancer, 6981
- AIM-1/aurora-B**
overexpression
and cancer, 5168
- Akt**
Akt/PKB tumor progression, melanoma, 7335
cholesterol and, prostate cancer, 2227
 Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
herceptin-induced inhibition, 4132
phosphorylation sites
14-3-3 and tuberin interactions, 6475
- Albumin**
adducts
and benzene metabolism, 1330
- Alendronate**
lysophosphatidic acid-induced migration inhibition, ovarian cancer, 6015
- O⁶-Alkylguanine DNA alkyltransferase**
Lys-165 mutations
chemotherapy-induced, colon cancer, 3070
NO-induced inactivation and degradation, 3037
- Alleles**
separation
and splicing alterations, 4579
-specific tumor growth inhibition, 2024
- Allelic deletions: See Deletions**
- Allelic imbalance**
lung adenocarcinoma, nonsmokers, 4464
- Allelotype**
neuroblastoma, 1761
- 17-Allylamino-17-demethoxygeldanamycin**
and HER2 status, 3132
NPM-ALK expression downregulation, anaplastic large cell lymphoma, 1559
- α -particle-irradiation**
bystander effects
oxidative metabolism and, fibroblasts, 5436
radionuclide ²²³Ra antitumor effects, skeletal metastases, 3120
- Alternate reading frame**
ARF^{-/-}Bax^{-/-} mice
tumor spectrum, 2184
ARF-p53 pathway, colon tumors, 3667
Ink4a/Arf gene deficiency
gliomagenesis, mouse, 5551
and UV-induced melanomagenesis, 6724
p53-independent S-phase delay, 1171
- Alveolar rhabdomyosarcoma**
fusion-negative, 4704
- American Association for Cancer Research (AACR)**
Special Conference on Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications *In Vivo*, meeting report, 2195
special meeting "Colon Cancer: Genetics to Prevention," 6779
- γ -Aminobutyric acid**
cell migration inhibition, SW 480 colon cancer cells, 6467
- S-3-Amino-phthalimido-glutarimide**
angiogenesis and tumor growth inhibition, mice, 2300
- AML: See Leukemia, acute myeloid**
- AML1-ETO**
cooperative domains, bone marrow cell ex-

- pansion, 2906
- Amphotericin**
RAGE-binding motif
metastasis blockade, 4805
- AN-238**
and colon cancer, 781
- Analytical tools**
meeting report, 3883
- Androgen-induced bZIP**
expression and regulation, prostate cancer, 721
- Androgen receptor**
AR mutations
prostate cancer, 1496
relapsed CWR22 prostate cancer cell growth, 6606
CAG repeat
HBV-related female hepatocarcinogenesis, 4346
polymorphism
and breast cancer risk, 1045
cell proliferation, androgen-refractory prostate cancer, 1008
transactivation by IL-6
mediation by p300, 5632
- Aneuploidy**
DNA polymerase β and, 3511
- Angioarrestin**
tumor-inhibiting properties, 3834
- Angiogenesis**
EGFR-dependent, skin carcinogenesis, 3402
GPIIb/IIIa and $\alpha v\beta 3$ integrins and, 2824
HIF-2 α breast tumor macrophage expression and, 1326
induction
lymphotoxin- β receptor, 4034
morphine, 4491
inhibition
angioarrestin, 3834
bisphosphonates, prostate, 6538
celecoxib, mechanism, 625
combination urokinase-derived A6 and tamoxifen, breast cancer, 4678
conjugated linoleic acid, 4383
and EGFR-targeting, 2554
IL-12, mammary carcinoma, 747
modified PF-4 peptides, 6884
S-3APG, mice, 2300
SPARC, neuroblastoma, 7357
tetrathiomolybdate, 4854
thrombospondin 2, cell-based antiangiogenic gene therapy, 2004
TrkA, neuroblastoma, 1802
mouse intestinal tumor models, 506
platelet-activating factor-induced nuclear factor κB , 1809
selectin and integrin roles, nude rats, 6289
short-telomere mice, 552
TGF- β and, prostate cancer-reactive stroma, 6021
tumor cell extracellular membrane vesicle activity, 6312
tumor growth dependence, review, 1931
tumor-infiltrating macrophages and, 7042
ZD1839 effects, 4300
- Angiogenic factors**
expression after chemotherapy, 5597
- Angiopietins**
expression, non-small cell lung cancer, 7124
- Angiostatin**
AAV-encoded
tumor growth inhibition, glioma, 756
- Angiotensin II**
type I
antagonist
pulmonary metastasis prevention, renal cell carcinoma, 4176
- Anionic phospholipids**
exposure, tumor blood vessels, 6132
- Anoikis**
induction by Smad4, 6045
- Anti-angiogenic compounds**
synergistic activity
prediction by gene expression profiling, 7143
- Antibodies: See also Monoclonal antibodies**
anti-adhesive
and antibody-dependent cellular cytotoxicity, 6891
colon cancer antigen recognition, 4041
EphA2 targeting
malignant cell inhibition, 2840
human anti-MUC18
growth and metastasis inhibition, melanoma, 5106
human TCR-like MUC1-specific recombinant, 5835
internalizing
antibody-targeted liposomal drug targeting, 7190
recombinant
TCR-like telomerase-specific, 3184
vascular endothelial-cadherin E4G10
tumor growth inhibition, 2567
- Antibody-dependent cellular cytotoxicity**
anti-adhesive antibody and, 6891
- Anticancer agents**
apoptosis-induced delivery, 1382
ErbB-targeted
and EGF-related ligands, 3151
sensitivity
expression profiles, 518
- Antiestrogen**
sensitivity
cyclin D1 overexpression and, breast cancer, 6916
- Antifolate**
toxicity
uracil misincorporation, 4909
- Antigen**
cancer/testis
gene expression, lung cancer, 3971
carcinoembryonic
anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
-based vaccine
antitumor activity, MIN mice, 6944
head and neck cancer immunotherapy target, 5049
colon cancer
antibody recognition, 4041
HLA-DP3
-restricted EBNA1 peptides, T helper, 7195
HLA-DR7
-restricted epitopes
and hTRT, 2600
melanoma
isolation by SEREX, 4836
retroviral, CTL-recognized, 5510
presentation
transporter for antigen presentation (TAP) I-deficient tumors, 2856
prostate stem cell
therapy target, 2546
"self"
tumor expression
and CD4⁺ T-cell function, 5144
serological analysis
new SEREX approach, lung cancer, 1751
sialyl Lewis
COX-2 and, colon cancer, 1567
sialyl Lewis X
-dependent lung colonization, melanoma, 4194
- tumor-associated
melanoma with vitiligo
isolation by SEREX, 4836
-primed dendritic cells, cancer vaccines, 1884
SOX10, 3020
T-cell response, poly-L-arginine vaccination, 1477
- Antigen-presenting cells**
CD8⁺ T cell interactions, 5065
- Antimicrotubule drugs**
stathmin and, breast cancer, 6864
- Antioxidants**
thiol
apoptosis induction, tumor cells, 1443
- Antisense**
colony-stimulating factor I
growth inhibition, solid tumors, 5317
oligodeoxynucleotides
DNA-PKcs inactivation, 6621
oligonucleotides
c-myc
growth inhibition, MCF-7 breast cancer cells, 3126
C-raf
colorectal cancer liver metastasis inhibition, 5393
Ku86
effects, malignant glioma, 5888
RNA
bcl-xL expression downregulation, 2175
- Antivascular therapy**
monitoring, high-frequency Doppler ultrasound, 6371
- AP-1**
asbestos-induced, mesothelioma, 6065
BPDE-induced transactivation
inhibition by berry extracts, 6857
- Apo-2 ligand**
apoptosis
sensitization by casein kinase II inhibition, 4180
TRAIL/Apo2L-induced apoptosis, colorectal cancer, 1583
- Apoptosis: See also Anoikis**
adhesion-dependent
NF- κB inhibitors, colon cancer, 6870
 β -pol deficiency and, 1524
calpain-dependent
induction by ARHI, ovarian and breast cancer, 7264
chemotherapy-induced
BDNF-TrkB-PI3K pathway protection, neuroblastoma, 6756
inhibition by curcumin, breast cancer, 3868
c-myc-induced, polycystic kidney disease, 2210
discodermolide and epothilone B, non-small cell lung cancer, 4081
drug delivery, 1382
epithelial cells
BAX, 3373
fenretinide-induced, neuroblastoma, 5158
flavopiridol-induced, S-phase, 1707
induction
Ad-mda-7, lung cancer, 2239
Bad (S112D S136A)-DTTR protein, 1433
Bcr/Abl-expressing leukemia, 188
CD437, lung cancer, 2430
endothelial irradiation-induced NO, 1450
glioma-associated hyaluronan, dendritic cells, 2583
HDAC5, 2913
2-methoxyestradiol, ER α / β -independent, 3691
neoglycans, 3722

- neural stem cell-mediated TRAIL therapy, glioblastoma, 7170
 quinazolines, prostate cancer, 597
 Rac inhibition, glioma, 2131
 raloxifene
 androgen-independent prostate cancer, 5365
 prostate cancer LNCaP cells, 3649
 saquinavir, 5230
 sigma-2 receptor agonists, 313
 thiol antioxidants, tumor cells, 1443
 WK175, leukemia, 1057
 inhibition by nitric oxide, 1648
in vivo doxorubicin-induced, cardiomyocytes, 4592
 modulation by inhibitor of caspase-3-activated DNase, colon cancer, 2169
 Myc-induced
 Omomyc and, 3507
 PEITC-induced
 ERKs, prostate cancer, 3615
 protein synthesis
 inhibition, 2272
 regulation
 HERG K⁺ channel, 4843
 p53AIP1, 2884
 resistance
 COX-2 expression, colon cancer, 6323
 matrilysin selection, mammary cells, 5559
 reversal by mPBR ligands, 1388
 RhoA-dependent, prostate cancer, 2630
 Smac, prostate cancer LNCaP cells, 18
 steroid-induced, pre-B cells, 4212
 T-cell activation, pancreatic cancer, 2347
 TRAIL/Apo2L-induced
 colorectal cancer, 1583
 COX-2 and, colon cancer, 4903
 PI3K/PTEN/Akt kinase pathway, non-small cell lung cancer, 4929
 renal cell carcinoma, 3093
 sensitization by casein kinase II inhibition, 4180
Apoptosome
 activation, ovarian cancer, 924
Apoptotic factors
 and P450 gene therapy, 6928
Aptamers
 prostate-specific RNA, 4029
9-β-d-Arabinosylguanine
 phosphorylation by dCK and dGK, 3100
Arginine deiminase
 melanoma and hepatocellular carcinoma inhibition, 5443
Arginine-glycine-aspartic acid (Arg-Gly-Asp) (RGD) peptides
 radiolabeled, tumor targeting, 6146
 tumor cell binding, 5139
ARH1 gene
 calpain-dependent apoptosis induction, ovarian and breast cancer, 7264
2-Aroylindoles
 small molecule tubulin inhibitors, 3113
Arsenic trioxide
 mechanism of action, review, 3893
 and tumor radiation response, 4202
Artificial neural networks
 esophageal lesions, 3493
Asbestos
 -induced AP-1 and Fra-1, mesothelioma, 6065
 -induced proliferation
 inhibition by mutant EGFR, lung epithelium, 4169
Ascites
 carcinomatous
 inhibition by sFlt-1, 2019
Astrocytoma
 anaplastic
 focal adhesion kinase signaling *in vivo*, 2699
 cell migration promotion by brain osteopontin, 5336
 pilocytic
 gene expression analysis, 2085
 progression
 p53 functional loss, 2897
Ataxia and Rad3-related/CHK1 pathway
 S checkpoint
 Ku and, 2483
Ataxia telangiectasia mutated
 Atm^{-/-} mice
 thymic lymphoma prevention by dexamethasone, 5153
AUF1/heterogeneous nuclear ribonucleoprotein D (hnRNP)
 β-actin/AUF1 transgenic mice, sarcoma, 1489
 overexpression, mice tumorigenesis, 1489
Aurora A
 mammary tumorigenesis, rat, 4115
Aurora B: See AIM-1
Autocrine motility factor
 Rho-like GTPase changes, 4484
5-Aza-2'-deoxycytidine
 gene induction, fibroblasts, 961
Azotemia
 postoperative
 and metastatic renal cell carcinoma, 5218
- B**
- B7.2**
 B7.2-IgG fusion protein
 combined with SU6668, breast tumor therapy, 5727
Bad
 diphtheria toxin transport domain fusion protein Bad (S112D S136A)-DTTR
 apoptosis induction, 1433
Bag1 proteins
 growth regulation, breast cancer, 1904
Barrett's esophagus
 artificial neural networks and cDNA microarrays, 3493
 7q132.3-q36.1 loss, 1531
Basal cell carcinoma
 FOXM1 expression, 4773
 xeroderma pigmentosum
 smoothened mutations, 7186
Bax
 ARF^{-/-}*Bax*^{-/-} mice
 tumor spectrum, 2184
 conformational change by BMS-247550, breast cancer, 466
 epithelial cell apoptosis, 3373
Bcl-2
 homology 3 (BH3)-only proteins
 Bim splice variant Bimγ, identification and characterization, 2976
 oncogenesis, rat, 6297
BCL-6 gene
 alternative breakpoint region, B-cell non-Hodgkin's lymphoma, 4089
 H4/BCL6 fusion gene, B-cell non-Hodgkin's lymphoma, 6224
bcl-xL
 downregulation by antisense RNA, 2175
Bcr-Abl
 cyclin D2 induction, 535
 inhibition by Bcr
 Ser 354 requirement, 386
 inhibitors, characterization, 4244
 leukemia
 apoptosis induction, 188
 leukemia, acute
 STI-571 and, 5761
- 7418
- mutations, leukemia, 5995
BCRP: See Breast cancer resistance protein
Benzene
 albumin adducts
 and metabolism, 1330
Benzo(a)pyrene
 lung tumorigenesis
 inhibition by dietary BITC-NAC and PEITC-NAC, A/J mice, 2
 neoplastic transformation, lung fibroblasts, 4605
Benzo(a)pyrene diol-epoxide
 -induced AP-1 and NFκB
 inhibition by berry extracts, 6857
Benzo(a)pyrene-trans-7,8-dihydrodiol
 glucuronidation, characterization, 1978
Benzodiazepine receptor
 peripheral
 ligands
 apoptosis resistance reversal, 1388
Benzo(g)chrysene-DNA adducts
 global nucleotide excision repair
 regulation by p53, fibroblasts, 5288
Benzylamide sulindac analogues
 effects, chronic lymphocytic leukemia, 5711
Berry extracts
 effects on BPDE-induced AP-1 and NFκB, 6857
β-cell carcinogenesis
 VEGF and tumor progression, 603
Betaglycan
 recombinant soluble sBG
 antitumor activity, breast cancer, 4690
BH3 (Bcl-2 homology 3)-only proteins
 Bim splice variant Bimγ, identification and characterization, 2976
bik gene
 systemic tumor inhibition, 8
Bile acids
 Mcl-1 protein degradation inhibition, 6500
Bimγ
 BH3-only Bim splice variant, 2976
Biotin
 ⁹⁰Y-labeled DOTA-biotin
 pretargeted
 radioimmunotherapy, mice, 5755
Bisphosphonates
 angiogenesis inhibition, prostate, 6538
Black raspberry extracts
 effects on BPDE-induced AP-1 and NFκB, 6857
Bladder cancer
 aggressiveness
 associated genomic alterations, 6981
 de novo methylation
 cell division requirements, 2378
 DNA polymerase β splice variants, 3251
 G_{M3} antitumor effects, 3850
 invasive
 piroxicam effects, canine model, 356
 molecular profiling, 6973
 recurrence
 DAPK hypermethylation and, 4048
Bladder tumorigenesis
 epidermal growth factor receptor and, 4157
Bleomycin
 resistance
 SRPK1 inhibition and, 4453
BLM helicase
 DNA double-strand break repair, 2766
Blood, peripheral
 lymphocytes
 micronuclei
 and pleural malignant mesothelioma susceptibility, 5418
 progenitor cells
 mobilization by combination defibrotide

- and rhG-CSF, mice, 6152
- stem cells
- transplantation, autologous
- adenoviral purging, 5013
- Blood flow**
- antivascular therapy and
- monitoring, high-frequency Doppler ultrasound, 6371
- Blood vessels**
- leakiness, meeting report, 5381
- patterning
- VEGF isoforms and, melanoma, 1838
- tumor
- anionic phospholipid exposure, 6132
- phosphatidylserine marker, 6132
- B lymphocytes**
- leukemia, acute lymphoblastic
- early
- steroid-induced apoptosis, 4212
- lymphoma
- candidate tumor suppressor gene, chromosome 15q15, 7175
- CD40L-transduced tumor cell vaccine, 3195
- DNA vaccination, 5845
- lymphoma, non-Hodgkin's
- BCL-6* alternative breakpoint region, 4089
- cryptic *IGH* rearrangements, novel, 5523
- H4/BCL6* fusion gene, 6224
- translocation t(3;6)(q27 a1) breakpoints, 6224
- neoplasia
- growth inhibition by S-3APG, mice, 2300
- Bmi-1 gene**
- amplification and overexpression, hematological malignancies, 618
- mammary epithelial cell immortalization, 4736
- BMS-247550**
- Bax conformational change induction, breast cancer, 466
- Bombesin**
- invasion stimulation, colon cancer, 4829
- Bone**
- breast cancer metastasis
- IL-8 expression and, 5571
- osteosclerotic
- PDGF-BB and, 917
- tumor burden reduction by doxycycline, 1588
- prostate cancer metastasis
- stromal cell-derived factor-1/CXCR4, 1832
- Bone cancer pain**
- blockade by COX-2 inhibitors, 7343
- Bone marrow**
- alkylation
- resistance, *Aag* null mice, 656
- expansion
- AML1-ETO cooperative domains, 2906
- mesenchymal stem cells
- IFN- β tumor delivery, 3603
- neuroblastoma purging
- virus-directed enzyme prodrug therapy, 5001
- TGF- β signaling
- blockade, cancer gene therapy, 7135
- transplantation, allogeneic
- relapse, hematological malignancy, 208
- Bone morphogenetic protein 4**
- expression
- β -catenin and, cancer, 2744
- BRAF gene**
- mutations
- colorectal tumors, 6451
- lung adenocarcinoma, 7001
- lung cancer and melanoma, 6997
- Brain**
- malignant melanoma metastasis
- VEGF-A₁₆₅ vascularity effects, 341
- osteopontin
- astrocytoma cell migration promotion, 5336
- vinyl chloride-induced adducts, rat, 5183
- Brain-derived neurotrophic factor**
- BDNF-TrkB-PI3K pathway
- protection against chemotherapy, neuroblastoma, 6756
- Brain tumors**
- antivascular liposomal doxorubicin effects, rat model, 2561
- BRCA1 gene**
- associated breast cancer
- HER-2/neu*, 1481
- TBX2* amplification, 3587
- associated RING domain protein BARD1
- EWS-FLI1* interactions, 4583
- and RNA polymerase II holoenzyme, 4222
- epigenetic factors and, ovarian cancer, 4151
- estrogen receptor inhibition
- modulation by p300, 141
- mutation carriers
- breast cancer, 2741
- tumor gene profiling, 7110
- null fibroblasts
- nonhomologous end-joining activity, 3966
- protein phosphatase 1 α interactions, 6357
- and RNA polymerase II holoenzyme, 4222
- S-phase checkpoint requirements, 4588
- transcriptional inhibition, 113
- BRCA2 gene**
- cancer cell growth inhibition, 1311
- epigenetic factors and, ovarian cancer, 4151
- mutation carriers
- breast cancer, 2741
- mutations
- familial pancreatic cancer, 3789
- genomic instability, 6194
- homozygous
- cancer susceptibility, mice, 990
- related breast tumors
- TBX2* amplification, 3587
- Breast**
- epithelial cell proliferation
- EGFR tyrosine kinase inhibition effects, 122
- estrogen targets, 4540
- microcalcifications, Raman spectroscopy, 5375
- ribosomal phosphoproteins
- downregulation by GnRH, 1036
- Breast cancer**
- antiestrogen sensitivity
- cyclin D1 overexpression and, 6916
- antimicrotubule drug sensitivity
- stathmin and, 6959
- autologous PBSC transplantation
- adenoviral purging, 5013
- Bax conformational change induction by BMS-247550, 466
- BRCA1-associated
- HER-2/neu*, 1481
- BRCA1-BRCA2 mutation carrier, 2741
- BRCA1 mutation carriers
- genetic profiling, 7110
- calpain-dependent apoptosis
- induction by *ARHI*, 7264
- cell motility inhibition by IGFBP-1, 4369
- chemoprevention by selenium, mechanisms, 108
- chemotherapy-induced apoptosis inhibition by curcumin, 3868
- choline, 1966
- combination cilengitide and radioimmunotherapy, 4263
- combination ET-743 and paclitaxel, 6909
- COX-2 expression, 1676
- DAPK* gene methylation, 6634
- diagnosis, genetic
- fine-needle aspiration, 2365
- early stage
- TRB1* inactivation, 1939
- E-cadherin inhibition by *SLUG*, 1613
- estrogen receptor α -positive
- β cx protein, 4849
- estrogen-related receptors, 6510
- G3BP induction by heregulin, 1251
- gene expression patterns
- DNA amplification and, 6240
- genistein and tamoxifen interactions, 2474
- growth enhancement by complement inhibitor, rat model, 1110
- growth inhibition
- c-myc antisense oligonucleotides, MCF-7 cells, 3126
- combination urokinase-derived $\bar{A}6$ and tamoxifen, 4678
- growth prevention by FTY720, mouse, 1410
- growth regulation by Bag1 proteins, 1904
- hereditary nonpolyposis colorectal cancer
- tumor exclusion, 1014
- HER-2/neu*-induced
- inhibition by EGCG, 652
- reduction by celecoxib, 5405
- hormonal VEGF regulation, 1948
- IGF-IR signaling
- blockade by proinflammatory cytokines, 4746
- and metastatic phenotype, 6529
- infiltrating
- desmoplastic response, 5351
- inflammatory
- herceptin rapid accumulation and internalization, 860
- vasculogenic mimicry hemodynamics, 560
- invasive
- cadherin-11 and, 6688
- lysyl oxidase, 4478
- promotion by VEGF CXCR4 regulation, 7203
- Wnt-5a loss of expression, 409
- karyotypes, multivariate analysis, 2675
- metastasis
- blockade by COX-1 or COX-2 inhibitors, murine, 2343
- com1 expression, 4164
- and IGF-IRs, 6529
- prevention by FTY720, mouse, 1410
- metastasis to bone
- IL-8 expression and, 5571
- osteosclerotic
- PDGF-BB and, 917
- tumor burden reduction by doxycycline, 1588
- metastasis to liver
- specific adenovirus vector, 1063
- MTAP tumor suppressor activity, 6639
- NF- κ B activation promotion by protein kinase CK2, 6770
- 8-oxoG repair defects, 1349
- p53* mutations and smoking, 1987
- predictive uPA/PAI-1 impact, 4617
- prognosis
- COX-2 expression and, 632
- osteopontin and, 3417
- putative tumor suppressor gene *CBFA2T3*, 4599
- RANTES promalignant activity, 1093
- RAR β 2 reactivation, 2455
- recurrent

- early molecular marker, 1000
risk
androgen receptor CAG repeat polymorphism and, 1045
carcinogen exposure and, 4566
sBG antitumor activity, 4690
SERM-ER complexes
gene expression profiles, 4419
Smad signaling alterations, 497
somatic mtDNA mutations, 972
SP500263 effects against, 1439
stanniocalcin 2 expression, 1289
STAT3 activity modulation by p53, 376
superchemosensitization by Herceptin pretreatment, 5703
survival
genotype and, 3052
tenascin-C isoform expression, 3289
TSP50 activation, 290
tumor xenograft eradication by Hsp70 depletion, 7139
VEGF regulation by estrogen, 4977
- Breast cancer resistance protein**
Bcrp1 (Abcg2)
mutation hot spot
and doxorubicin resistance, 2294
wild-type
and methotrexate resistance, 5035
- Breast carcinogenesis**
early events, new *in vitro* model, 5980
- Breast ductal carcinoma *in situ***
COX-2 expression, 1676
proteomics, 6740
- Breast tumors**
BRCA1- and *BRCA2*-related
TBX2 amplification, 3587
cell aggressiveness
SEL1L expression and, 567
combination SU6668 and B7.2-IgG therapy, 5727
epithelial polarization by dystroglycan, 7102
fractionated photodynamic therapy, 4289
macrophage HIF-2 α expression
and angiogenesis, 1326
SBEM biomarker, 2736
- 3-Bromopyruvate**
intraarterial, liver cancer therapy, 3909
- Bronchial cells**
aflatoxin B₁ metabolism and cytotoxicity, 105
- Bronchial epithelium**
hypermethylation, smokers, 2370
- Bronchioloalveolar lung carcinoma**
feline, comparative studies, 3826
- Brostallicin**
anticancer activity
glutathione and, 2332
- Budding uninhibited by benzimidazole**
human *hBUB1* and *hBUBR1*
inactivation, 13
- Burkitt lymphoma**
MCL1-overexpressing
response to death stimuli, 892
- Bystander effects**
 α -particle-irradiation
oxidative metabolism and, fibroblasts, 5436
radiation
membrane signaling, 2531
3D cell cultures, 1425
- C
- CACB1 gene**
isolation, 1246
- c-Abl**
kinase domain crystal structures, 4236
- Cadherin**
vascular endothelial-cadherin antibody
- E4G10
tumor growth inhibition, 2567
- Cadherin-11**
and breast cancer invasion, 6688
- Cadmium**
-responsive proto-oncogene, novel, 703
- Café-au-lait spots**
hMSH2 germ-line mutations, 359
- Calcium binding proteins**
S100A
overexpression, gastric cancer, 6823
- Calpain**
-dependent apoptosis
induction by *ARH1*, ovarian and breast cancer, 7264
- Camptothecin**
gene expression changes, 1688
resistance
XRCC1, 459
- Cancer: See also specific cells, sites, types**
advanced
combrestatin A-4 phosphate, phase I trial, 3408
analytical tools, meeting report, 3883
CD40-expressing
T-cell activation inhibition, 2052
cell tracking
fully automated, collagen gels, 5301
diagnosis
gene ratios, 4963
H19 imprinting control region
de novo methylation, 4545
prognosis
glomeruloid microvascular proliferations and, 6808
progression
FGFR4 Arg³⁸⁸ allele and, 840
susceptibility
homozygous mutant *Brca2* mice, 990
- Cancer-inducible transgenes**
expression by Grp94 promoter, 7207
- Cancer prevention: See also Chemoprevention**
science and practice, perspectives, 5119
- Cancer Research**
future directions, 1
- Cancer/testis antigen**
gene expression, lung cancer, 3971
- Candidate of metastasis-1**
expression, breast cancer cells with metastatic potential, 4164
- Carbamate**
lung tumors
chemoprevention, mice, 4199
- Carbohydrate**
-dependent melanoma, melanoma, 4194
- Carbonic anhydrase IX**
activation by PI3K
oxygen levels, 4469
- Carboxypeptidase G2**
suicide gene therapy
prodrugs, 1724
- Carcinoembryonic antigen**
anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
-based vaccine
antitumor activity, MIN mice, 6944
head and neck cancer immunotherapy target, 5049
promoter
yeast cytosine deaminase expression, 2337
- Carcinogen**
adducts
nonrepairable, 4229
exposure
and breast cancer risk, 4566
loss of heterozygosity, lung tumorigenesis, 7420
- 6424
oral mucosa bioactivation
inhibition by curcumin, 5451
- Carcinogen-activating enzymes**
inhibition by fluasterone, 3685
- Carcinogenesis**
information degradation and, 3675
ultraviolet
inhibition by DFMO, *Xpa*^{-/-} mice, 1338
- Carcinoma *in situ***
ductal
active HER-2/*neu* signaling, 6667
breast
COX-2 expression, 1676
proteomics, 6740
- Carcinomatous ascites**
inhibition by sFlt-1, 2019
- Cardiomyocytes**
in vivo doxorubicin-induced apoptosis, 4592
- Carnosol**
COX-2 induction inhibition, 2522
- Casein kinase II**
inhibition
TRAIL/Apo2L-induced apoptosis sensitization, 4180
- Caspase 3**
inhibitor of caspase-3-activated DNase and colon cancer, 2169
TAT-ODD-Casp3^{WT} fusion protein
antitumor effects, 2013
- Caspase 8**
expression, pediatric tumors, 5897
- Caspase 9**
nitrosylation, 1648
- Caspase 10**
expression, pediatric tumors, 5897
- Caspases**
translation regulation, 2272
- Catecholamines**
regulation pVHL, PC12 cells, 1682
- Catechol-O-methyltransferase**
COMT gene polymorphisms
and ovarian cancer risk, 3058
- β -Catenin**
and bone morphogenetic protein 4 expression, cancer, 2744
low-molecular-weight protein tyrosine phosphatase interactions, cell-cell adhesion, 6489
mutations
gastric cancer, 3503
stable, mouse liver, 1971
nuclear translocation induction by HGF, 2064
PML induction, 5947
transcription regulation by Wnt-1, esophageal cancer, 277
tumor suppression, 5947
- Caveolin-1**
endostatin association, endothelial cells, 5580
- CBFA2T3 (*MTG16*) gene**
putative tumor suppressor, breast cancer, 4599
- CBF β -SMMHC: See Core binding factor β -smooth muscle myosin heavy chain**
- CCAAT-displacement protein/cut homeobox CDP/Cux p75**
characterization, 6625
- CCAAT/enhancer binding protein α**
downregulation, lung cancer, 528
- C6 cells**
mobile lipid compartment dimensions, 5672
- CC1-779**
efficacy, multiple myeloma, 5027
- CD2**
regulation, acute promyelocytic leukemia,

- 4730
- CD4**
T cells
EBNA1 peptide helpers, 7195
indirect tumor killing mediation, 2611
"self-" antigen tumor expression and, 5144
wtp53-specific, antitumor efficacy, 6187
- CD7**
CD7-exotoxin, scFv immunotoxin, 2848
- CD8**
T cells
antigen-presenting cell interactions, 5065
memory
activation, 6438
tumor killing
IFN- γ and, mice, 5058
tumor targeting, 5785
- CD13**
isoforms
differential expression, 860
- CD40**
ligand
combined SLC/CD40L-mediated immunotherapy, antitumor activity, 6545
-transduced lymphoma cell vaccine, 3195
T-cell activation inhibition, carcinoma, 2052
- CD44**
metastasis effects, sarcoma, 2281
standard form CD44s
HA-CD44s
and MMP-2 secretion, lung cancer, 3962
- CD45**
CD45RA⁺CCR7⁺ cytotoxic T lymphocytes, melanoma, 1743
- CD70**
immune escape pathway, glioblastoma, 2592
- CD95**
inhibition by Ras
reversal¹ by farnesyltransferase inhibitors, 450
ligand
monocyte expression, tumors, 1261
- CD102**
anti-ICAM-2 mAb, ICAM-2⁺ colon cancer, 3167
- CD137**
antitumor effects
IFN- γ , 4413
- CD437**
apoptosis induction, lung cancer, 2430
cross-resistance, paclitaxel-resistant ovarian carcinoma, 2192
E2F-1 and cyclin B modulation, prostate cancer, 3842
- cdc2**
regulation, radiation-induced G₂ delay, 241
- CDC4**
human *hCDC4* mutations, endometrial cancer, 4535
- CDH13 (H-cadherin)**
promoter region methylation, colorectal tumors, 3382
- C/EBP α : See CCAAT/enhancer binding protein α**
- Celecoxib**
angiogenesis inhibition, mechanism, 625
combined with CPT-11, anticancer/antiarrhythmia effects, 5778
combined with iNOS inhibitor, chemopreventive effects, 165
growth inhibition, cancer cells, 2029
HER-2/*neu*-induced breast cancer reduction, 5405
- Cell adhesion**
anti-adhesive antibody
and antibody-dependent cellular cytotoxicity, 6891
 β -catenin and low-molecular-weight protein tyrosine phosphatase interactions, 6489
-dependent apoptosis
NF- κ B inhibitors, colon cancer, 6870
fibrillar
formation by β 1-integrin
VHL role, 2929
homotypic
disruption by Src activity, colon cancer, 2669
regulation by CXCR4 and c-Kit, 6304
regulation by endostatin, 1944
- Cell aggressiveness**
SEL1L expression and, breast tumors, 567
- Cell cycle**
arrest
methylseleninic acid, mechanisms, 156
perifosine, squamous cell carcinoma, 1401
G₂ checkpoint
defect, small cell lung cancer, 271
Ku effects, ionizing radiation, 6031
G₁ phase
acceleration
cooperation with CBF β -SMMHC, leukemogenesis, 2232
G₂ phase
radiation-induced delay
cdc2 regulation, 241
G₁-S transition and M phase blockade by 3-IAABE, 6080
progression
gene profiling, 3233
S checkpoint
Ataxia and Rad3-related/CHK1-dependent
Ku and, 2483
Brcal requirements, 4588
S phase
ATM-independent checkpoint pathway, 1598
flavopiridol-induced apoptosis, 1707
p53-independent delay by ARF, 1171
resveratrol and prostate cancer cells, 2488
- Cell death: See also Apoptosis**
discodermolide and epothilone B, non-small cell lung cancer, 4081
- Cell differentiation**
blockade by leukemia-associated fusion proteins, 7050
induction
acute promyelocytic leukemia treatment, meeting report, 5618
neuroendocrine
activation by ERK, 1549
regulation
metallothionein, 5370
- Cell growth: See also Tumor growth**
anchorage-independent
PI3K/Akt pathway, hepatocellular carcinoma, 2971
deregulation
interferon regulatory factor 2-dependent, 2510
EDB-containing fibronectin-absent mice, 5603
Her-2-induced
inhibition by EGCG, breast cancer, 652
inhibition
acyclic retinoid, hepatoma, 3997
BRCA2, 1311
celecoxib, cancer cells, 2029
ciliary neurotrophic factor, C6 glioma cells, 3544
c-myc antisense oligonucleotides, MCF-7 breast cancer cells, 3126
connexin 43, glioblastoma, 2806
CuZnSOD, glioma, 1205
DRA-induced, 5083
endothelin A receptor blockade, cervical cancer, 6381
HDAC5, 2913
HEPSIN, prostate cancer, 6812
Icat gene, colon cancer, 3322
ICI 182,780
and IGF-I signaling, 3985
IGFBP-3, non-small cell lung cancer, 3530
phospholipid scramblase 1, ovarian cancer, 397
PKI-166, prostate cancer, 5254
progesterone, endometrial cancer, 881
silibinin, prostate cancer, 3063
modulation by selenium, prostate cancer, 2540
promotion by K-ras, head and neck squamous cell carcinoma, 7154
regulation
Bag1 proteins, breast cancer, 1904
Ras, micrometastasis, 887
relapse
AR mutations, CWR22 cells, 6606
- Cell immortalization**
Bmi-1, mammary epithelial cells, 4736
E6/E7
combination HPV-16 E7 and CpG-ODN immune therapy, 7234
immortal DNA strand co-segregation, 6791
mammary epithelial, characterization, 89
- Cell killing**
viral fusogenic membrane glycoproteins, solid tumors, 6566
- Cell lineage**
and *Msh2*^{-/-}*Rb*^{+/+} mice, 5134
- Cell migration: See also Invasion**
collective melanoma
plasticity, 2125
inhibition by GABA, SW 480 colon cancer cells, 6467
inhibition by NESH, 2215
lysophosphatidic acid-induced
inhibition by alendronate, ovarian cancer, 6015
microvascular
promotion by tenascin-C, 2660
promotion by brain osteopontin, astrocytoma, 5336
promotion by periostin, epithelial ovarian carcinoma, 5358
regulation by CXCR4 and c-Kit, 6304
stimulation by bombesin, colon cancer, 4829
T cell to tumor masses
CCR5, 3751
- Cell motility**
EGF receptor-regulated
Ral A, 982
inhibition by IGFBP-1, breast cancer, 4369
67-kDa laminin receptor and, 1321
- Cell proliferation: See also Cell growth**
androgen receptor, androgen-refractory prostate cancer, 1008
asbestos-induced
inhibition by mutant EGFR, lung epithelium, 4169
endothelial
metronomic chemotherapy and, 6938
epithelial
EGFR tyrosine kinase inhibition effects, breast, 122
glomeruloid microvascular, prognostic value, 6808
hsMAD1 and, 2618
inhibition
COX-2 inhibitors

- IGF-I and, pancreatic cancer, 7372
Mdm2 isoforms, 1222
2-methoxyestradiol, ER α /ER β -independent, 3691
neoglycans, 3722
polo-like kinase 1, cancer, 4186
magnetic field-induced, rat mammary gland, 1356
RhoA-dependent, prostate cancer, 2630
- Cell transformation**
HER-2
cyclin D1 rate-limiting effects, 2267
K-Ras
modulation by PPARs, intestinal epithelial cells, 3282
malignant
 Δ TA-p73, 3598
mediation by MEK1 signaling, Eph4 mammary epithelial cells, 4781
neoplastic
benzo(a)pyrene-induced, lung fibroblasts, 4605
neuroblastoma to neuronal cells
VHL protein, 7004
PDK1, mammary epithelial cells, 3538
Ras-induced
reversal by IND 12, 1718
RET
inhibition by PP1, 1077
- Cellular cytotoxicity**
antibody-dependent
anti-adhesive antibody and, 6891
- Cellular phones**
electromagnetic near field
lacI mutations, mice, 1956
- Cellular retinol-binding protein 1 gene**
hypermethylation-associated inactivation, cancer, 5902
- Cellular stress response**
PCPH oncogene and, 2690
- Central nervous system**
tumor immunity
induction by *L. monocytogenes* vaccine, 2287
- CENU: See Chloroethylnitrosourea**
- c-erbB-2**
adenovirus targeting, 609
early placenta insulin-like growth factor and, 1020
- Cervical cancer**
chemoradiation response
p53 and, 7364
cIAP1 expression, 4860
COX-1 upregulation, 424
growth inhibition by endothelin A receptor blockade, 6381
- Checkpoint kinase**
CHK1
ATM-independent S-phase checkpoint pathway, 1598
-dependent G₂ checkpoint
Ku effects, ionizing radiation, 6031
-dependent S checkpoint
Ku and, 2483
Chk2
inhibition by UCN-01, 5743
- Chemical carcinogenesis**
germ-line p53 mutations and, mice, 3024
- Chemokines**
receptor CCR5
T-cell migration to tumor masses, 3751
receptor CCR7
CD45RA⁺CCR7⁺ cytotoxic T lymphocytes, melanoma, 1743
lymph node metastasis, gastric cancer, 2937
receptor CXCR4
- and B16 lung metastases, murine, 7328
cell migration and adhesion regulation, small cell lung cancer, 6304
neutralization, non-Hodgkin's lymphoma, 3106
prostate cancer metastasis to bone, 1832
regulation by VEGF
invasion promotion, breast cancer, 7203
- Chemoprevention**
carbamate-induced lung tumors, mice, 4199
9-*cis*-retinoic acid, prostate carcinogenesis, 5178
combination iNOS and COX-2 inhibitors, colon cancer, 165
COX-2 induction inhibition, 2522
Nrf2-regulated genes, 5196
prostaglandin I₂ synthase overexpression, murine lung cancer, 734
selenium, breast cancer, 708
toremifene, prostate cancer, 1370
- Chemoradiation**
response
p53 and, cervical cancer, 7364
- Chemoresistance**
IL-1 β and, pancreatic cancer, 910
mediation by EGFR, glioblastoma, 4307
mediation by TrkB, neuroblastoma, 6462
modulation by rapamycin, prostate cancer, 6141
- Chemosensitivity**
and gene expression, cancer cells, 1139
modulation by Drg1, 3950
superchemosensitization
Herceptin pretreatment, breast cancer, 5703
- Chemotherapy**
angiogenic factor expression, 5597
apoptosis
inhibition by curcumin, breast cancer, 3868
BDNF-TrkB-PI3K pathway protection, neuroblastoma, 6756
combined with Ad-E2F-1 gene transfer, melanoma, 1776
combined with enzyme-activated prodrug therapy, 6089
combined with ganciclovir, EBV⁺ tumors, 1920
combined with NM-3, antineoplastic effects, 789
combined with TRAIL, colon tumors, 5800
enhancement by PDGF receptor antagonists, 5476
Lys-165 alkyltransferase mutations, colon cancer, 3070
metronomic
selectivity for endothelial cells, 6938
skeletal muscle ubiquitin-proteasome-dependent proteolysis inhibition, 2771
transcription-targeted agent ET-743, 3377
ultrasonically activated delivery, rat model, 7280
- Chfr**
ubiquitin ligase activity, 1797
- Childhood tumors**
atypical teratoid/rhabdoid tumors, workshop meeting report, 323
caspase 8 and *caspase 10* expression, 5897
solid tumors
MS-27-275 antitumor activity, 6108
- Chimeric idiotype**
DNA vaccination, B-cell lymphoma, 5845
- Chloroethylnitrosourea**
adaptive phospholipid metabolism changes, melanoma, 1890
- 1,3-bis(2-Chloroethyl)-1-nitrosourea**
combined with radiation
- resistance
mediation EGFR, glioblastoma, 4307
- Cholecystokinin B**
missplicing, pancreatic cancer, 947
- Cholesterol**
and Akt signaling, prostate cancer, 2227
- Choline**
breast cancer, 1966
- Chondroitin sulfate**
-binding cationic liposomes, novel liver metastasis inhibition, 4282
- Chromogranin A**
and tumor growth, mouse models, 941
- Chromosome 1p36.3**
imprinting absence, neuroblastoma, 6481
- Chromosome 3p14.2**
genetically unstable sequences, 3477
- Chromosome 3p21.3**
H37 lung cancer tumor suppressor gene, 3207
homozygous deletion region
tumor suppressor genes, 2715
- Chromosome 7q132.3-q36.1**
loss, Barrett's esophagus, 1531
- Chromosome 8p**
metastasis suppressor gene, rat prostate cancer, 367
- Chromosome 9**
alterations, flat urothelial neoplasia, 809
- Chromosome 12p11-p12**
EST array analysis, 6218
- Chromosome 13**
abnormalities, multiple myeloma, 715
- Chromosome 15q15**
B-cell lymphoma candidate tumor suppressor gene, 7175
- Chromosome 16p12-13**
familial neuroblastoma mapping, 6651
- Chromosome 17q**
gastric cancer, 2625
- Chromosome 20q13**
genes
and prostate tumorigenesis, 6803
- Chromosome 19q13.1**
candidate cervical cancer oncogene *SEI-1*, identification, 7157
- Chromosome 19q13.3**
D19S112-D19S246 transcript map, 4100
- Chromosomes**
alterations
colorectal cancer, 6350
HMG1(Y) and, prostate cancer, 647
lung adenocarcinoma, 1152
prognostic value, soft tissue sarcoma, 3980
amplification silence, colon cancer, 1134
immortal DNA strand co-segregation, 6791
instability
AIM-1 overexpression and, 5168
DNA polymerase β and, 3511
HPV-16 and, 7075
induction by Rad6 overexpression, 2115
lymphocytes
and oral premalignant lesions, 2813
translocation t(2;11)-acute myeloid leukemia *NUP98-HOXD11* fusion gene, 28
translocation t(11;12)(p15;q13)-acute myeloid leukemia
NUP98-HOXC11 fusion gene, 4571
translocation t(3;6)(q27 a11)-B-cell non-Hodgkin's lymphoma, 6224
translocation t(X;11)(q24;q23)-acute myeloid leukemia, infant
MLL-SEPTIN6 fusion gene, 333
- CHS 828**
sensitivity, PARP-1 fibroblasts, 4206
- Cilengitide**
combined with radioimmunotherapy, breast

- cancer, 4263
- Ciliary neurotrophic factor**
growth inhibition, C6 glioma cells, 3544
- Cimicifuga racemosa extract**
estrogen-dependent mammary tumor effects, 3448
- Cisplatin**
combined with IL-2 gene therapy, head and neck squamous cell carcinoma, 4023
resistance
copper homeostasis and, 6559
regulation by *XPB*, 5457
sensitivity
transcription-coupled nucleotide excision repair and, 4899
- CIZ/NMP4**
EWSR1 and *TAF15* fusions, acute leukemia, 5408
- c-jun**
dominant negative TAM-67
okadaic acid-induced tumor promotion blockade, 3044
- c-Jun NH₂-terminal kinase**
telomerase regulation, ovarian surface epithelial cells, 4575
- c-Jun NH₂-terminal kinase 1**
skin tumor development, mice, 1343
- c-Jun NH₂-terminal kinase 2**
gene expression regulation, 3257
- c-Kit receptor tyrosine kinase**
cell migration and adhesion regulation, small cell lung cancer, 6304
characterization, 4244
- CLN3 gene**
novel molecular cancer target, 801
- Clonality delineation**
metastasis-associated genes, hepatocellular carcinoma, 4711
- c-Met**
signaling, nonautocrine
metastasis promotion, 2951
- CML28**
overexpression, tumor cells, 5517
- c-myc**
antisense oligonucleotides
growth inhibition, MCF-7 breast cancer cells, 3126
apoptosis, polycystic kidney disease, 2210
transcription sites
novel detection, colon cancer, 6006
- Colitis-associated tumors**
HPPI aberrant methylation, 6820
Msh2-deficient mice, 2092
p14^{ARF} hypermethylation, 1148
- Collagen**
epithelial precancer fluorescent biomarker, 682
- Collagen gels**
fully automated cancer cell tracking, 5301
type 1
prostate cell interactions, 58
- Colon**
Apc^{Min/+} mice
microadenomatous lesions, 6367
maturation
gene expression profile, 4791
mutated crypts
ulcerative colitis, 2236
sucrose-rich diet-induced mutations, rat, 4339
- Colon adenocarcinoma**
EGCG stability, uptake, metabolism and efflux, 7241
- Colon cancer**
adhesion-dependent apoptosis
NF- κ B inhibitors, 6870
AN-238 and, 781
- antigen
antibody recognition, 4041
- apoptosis resistance
COX-2 expression, 6323
- cell migration inhibition by GABA, SW 480 cells, 6467
- chemotherapy
Lys-165 alkyltransferase mutations, 3070
chromosomal amplification silence, 1134
c-myc transcription sites, novel detection, 6006
COX-2 and sialyl Lewis antigens, 1567
elimination, germ-free TGF- β 1-deficient mice, 6362
growth inhibition
Icat, 3322
PC-SPES, 5204
growth regulation by IGF-I, 1030
homotypic adhesion disruption by Src activity, 2669
human papillomavirus JCV and, 7093
ICAM-2
anti-ICAM-2 mAb therapy, 3167
inhibitor of caspase-3-activated DNase and, 2169
invasion stimulation by bombesin, 4829
metastasis regulation by IGF-I, 1030
nuclear matrix protein alterations, 2437
prevention
combination iNOS and COX-2 inhibitors, 165
electron-donating ability and, 6506
genetics, meeting report, 6779
prostaglandin I₂ synthase gene transfer, 63
reovirus therapy, 1696
thromboxane A₂ synthase gene transfer, 63
TRAIL-induced apoptosis
COX-2 and, 4903
tumor xenograft eradication by Hsp70 depletion, 7139
- Colon cancer, hereditary nonpolyposis**
germ-line *MSH2* and *MLH1* mutations, prediction, 3485
- Colon carcinogenesis**
prostaglandin E receptor EP₄, 28
- Colon tumors**
APC mutations
polymerase β and, 3271
ARF-p53 pathway, mouse, 3667
combination TRAIL and chemotherapy, SCID mice, 5800
- Colony-stimulating factor 1**
antisense
growth inhibition, solid tumors, 5317
- Colorectal adenomas**
CDH13 promoter region methylation, 3382
TS polymorphisms and, 3361
- Colorectal cancer**
anti-rhCEA IgG subclass response, immunized patients, 1364
apoptosis
TRAIL/Apo2L-induced, 1583
CDH13 promoter region methylation, 3382
cytotoxic T cell inhibition by regulatory T cells, 5267
defective 8-oxo-G repair, 7230
early onset
hMSH2 and *hMLH1* promoter region
germ-line mutations, 38
gene expression, 4352
intrachromosomal genomic instability, 6350
karyotypic patterns, multivariate analysis, 5939
loss of imprinting, 6442
low-level microsatellite instability, 53, 1166, 5988
metastasis to liver
- inhibition by C-rac antisense oligonucleotides, 5393
- Met expression regulation by Wnt signaling, 5126
- microsatellite instability-high
frameshift TCF-4 mutations, 3009
MMP-3 promoter mutations, 3855
- MMR-deficient
mutation profiling, 1284
- non-microsatellite instability-high
heterogeneity, 6011
- NSAIDs and GATA-6, 1178
- prognosis
VEGF-D expression and, 1669
STI571 therapy, 4879
ulcerative colitis-associated
HPPI aberrant methylation, 6820
p14^{ARF} hypermethylation, 1148
- Colorectal cancer, hereditary nonpolyposis**
breast cancer tumor exclusion, 1014
hExo1 mutation alterations, 6026
hMSH2 and *hMLH1* promoter region germ-line mutations, 38
MLH1 hypermethylation, 3925
MSH2 inactivation, 848
- Colorectal carcinogenesis**
APCDD1 upregulation, 5651
- Colorectal tumors**
BRAF and *KRAS* mutations, 6451
growth
APC mutations and, 363
- Combrestatin A-4 phosphate**
phase I trial, advanced cancer, 3408
- Comparative genomic hybridization**
array-based
non-small cell lung cancer analysis, 3636
renal cell carcinoma diagnosis, 957
BRCA1 breast cancer tumor profiling, 7110
glioblastoma analysis
and survival, 6205
interglandular heterogeneity, pancreatic cancer, 835
sporadic ovarian cancer analysis, 3466
- Complementary DNA**
microarrays
epithelial ovarian cancer, 2923
esophageal lesions, 3493
head and neck squamous cell carcinoma, 1184
molecular profiling, bladder cancer, 6973
pancreatic cancer, 2890
serological identification of tumor antigens
by cDNA expression cloning
melanoma antigen isolation, 4836
- Complement inhibitor**
tumor growth enhancement, breast cancer, 1110
- Conjugated linoleic acid**
angiogenesis inhibition, 4383
- Connexin43**
growth inhibition, glioblastoma, 2806
increase by ciliary neurotrophic factor, C6 glioma cells, 3544
- Convection-enhanced delivery**
boronated epidermal growth factor, glioma, 6552
- COOH-terminal binding protein**
MIA downregulation, malignant melanoma, 5962
- Copper**
homeostasis
and cisplatin resistance, 6559
- Copper-64-pyruvaldehyde-bis(N⁴-methylthiosemicarbazone)**
tumor growth inhibition, 445
- Copper zinc superoxide dismutase**
growth inhibition, glioma, 1205

- Core binding factor β -smooth muscle myosin heavy chain**
cooperation with G₁ acceleration, leukemogenesis, 2232
- Corticosterone**
and energy restriction, 5280
- Coxsackie adenovirus receptor**
expression, prostate cancer, 3812
- CpG islands**
expressed sequence Tags, 3214
- CpG-oligodeoxynucleotide**
combined with HPV-16 E7, immune therapy, 7234
- CPI-0004Na**
toxicity, activity, and tissue distribution, 2327
- CPT-11: See Irinotecan**
- C-raf**
antisense oligonucleotides
colorectal cancer liver metastasis inhibition, 5393
- Crocidolite asbestos**
mutagenicity, 99
- CTCF**
functional change, cancer, 48
- Cten**
downregulation, prostate cancer, 4217
- Curcumin**
chemotherapy-induced apoptosis inhibition, breast cancer, 3868
oral mucosa carcinogen bioactivation inhibition, 5451
- Cutaneous melanoma**
cyclin D1 candidate oncogene, 3200
progression
VEGFR-3 marker, 7059
- Cutaneous T-cell lymphoma**
Fas splice variant, 5389
- CWR22 cells**
relapsed growth
AR mutations, 6606
- CXC chemokine receptor CXCR-4**
and B16 lung metastases, murine, 7328
cell migration and adhesion regulation, small cell lung cancer, 6304
neutralization, non-Hodgkin's lymphoma, 3106
prostate cancer metastasis to bone, 1832
regulation by VEGF
invasion promotion, breast cancer, 7203
- CXCL12**
ovarian cancer role, 5930
- Cyclic AMP response element binding protein**
and faslodex resistance, 3428
- Cyclic AMP response element binding protein-binding protein**
downregulation
and melanocyte senescence, 6231
- Cyclin B**
modulation by CD437, prostate cancer, 3842
- Cyclin B1**
and radiotherapy resistance, head and neck squamous cell carcinoma, 6414
- Cyclin D1**
and antiestrogen sensitivity, breast cancer, 6916
candidate oncogene, cutaneous melanoma, 3200
intestinal tumorigenesis, Min mice, 4562
modifier, VHL disease, 3803
rate-limiting effects, HER-2 transformation, 2268
regulation by hypoxia
VHL-mediated, renal cell carcinoma, 3014
skin carcinogenesis enhancement, 1641
SYT-SSX and, synovial sarcoma, 3861
- Cyclin D2**
induction by BCR/ABL, 535
- Cyclin E**
and antiestrogen sensitivity, breast cancer, 6916
- Cyclin L**
candidate head and neck cancer oncogene, 6211
- Cyclooxygenase 1**
deficiency
skin tumorigenesis reduction, 3395
inhibitors
metastasis blockade, murine breast cancer, 2343
upregulation, cervical cancer, 424
- Cyclooxygenase 2**
deficiency
skin tumorigenesis reduction, 3395
-derived PGE₂
tumor growth promotion, head and neck cancer, 6706
expression
apoptosis resistance, colon cancer, 6323
breast cancer, 1676
intestinal polyps, 6846
prognostic value, breast cancer, 632
inhibitors
bone cancer pain blockade, 7343
combined with iNOS inhibitor, chemopreventive effects, 165
combined with photodynamic therapy, 3956
IGF-I and, pancreatic cancer, 7372
metastasis blockade, murine breast cancer, 2343
retinoids and carnosol, 2522
and sialyl Lewis antigens, colon cancer, 1567
and TRAIL-induced apoptosis, colon cancer, 4903
tumorigenesis inhibition, skin, 2516
- Cyclophosphamide**
low-dose
antitumor effects, mice, 2731
- Cysteine**
secreted protein acidic and rich in cysteine (SPARC)
glioma invasion promotion, 6270
- Cysteamine**
adaptive phospholipid metabolism changes, melanoma, 1890
- Cytochrome c**
TRAIL-mediated release
blockade by epidermal growth factor, 488
- Cytochrome P450**
1A1
inhibition by fluasterone, 3685
Sudan I metabolism, 5678
1B1
inhibition by fluasterone, 3685
CYP17 polymorphisms
and ovarian cancer risk, 3058
gene therapy
apoptotic factors and, 6928
- Cytokines**
combined with vector-based vaccines, 5770
-encapsulated microspheres
tumor immunotherapy, 7254
gene polymorphisms
and prostate cancer, 3369
proinflammatory
IGF-IR blockade, 4746
telomerase activity modulation, multiple myeloma, 3876
- Cytomegalovirus**
human
infection and expression, malignant glioma, 3347
- Cytosine deaminase**
CD/5-FC gene therapy, glioma, 773
yeast
expression under CEA promoter, 2337
- Cytotoxicity**
aflatoxin B₁, bronchial cells, 105
antibody-dependent cellular
anti-adhesive antibody and, 6891
discodermolide and epothilone B, non-small cell lung cancer, 4081
DT₃₈₈IL3, acute myeloid leukemia stem cells, 1730
glycinamide ribonucleotide formyltransferase inhibitors, 5236
- Cytotoxic T lymphocytes**
CD45RA⁺CCR7⁺, melanoma, 1743
epitope
presentation rescue by PA28, melanoma, 2875
inhibition by regulatory T cells, colorectal cancer, 5267
memory
activation, 6438
prostate cancer-reactive, 5807
retroviral melanoma antigen recognition, 5510
tyrosinase-specific
PS-SCL recognition, 2058
- D**
- DAL-1**
TSLC1 association, lung cancer, 5129
- D-amino acid oxidase**
pegylated
tumor-targeted H₂O₂ generation, 3138
- DAO: See D-amino acid oxidase**
- DARPP-32 (dopamine and cAMP-regulated phosphoprotein of M_r32,000)**
overexpression, gastric cancer, 4061
truncated tDARPP
overexpression, gastric cancer, 4061
- DDATHF: See (6R)-Dideazatetrahydrofolate**
- DDC^{PCa} gene**
prostate tumor marker, 2695
- Death-associated protein kinase (DAPK) gene**
hypermethylation, bladder cancer, 4048
methylation
breast cancer, 6634
former smokers, 351
- Death stimuli**
MCL1-overexpressing Burkitt lymphoma response, 892
- Decoy adducts**
nonrepairable, 4229
- Defender against apoptotic cell death (DAD-R) gene**
and testicular germ cell tumors, 1822
- Defibrotide**
combined with rhG-CSF
stem cell mobilization, mice, 6152
- Deleted in malignant brain tumors 1 (DMBT1) gene**
peptidomic marker peptide discovery, pancreatic adenocarcinoma, 4894
polymorphisms, malignant glioma, 1790
- Deletions**
14-3-3 ϵ , small cell lung cancer, 271
mtDNA, thyroid tumors, 7031
plasmid-based assay, Werner syndrome fibroblasts, 547
stage II non-small cell lung cancer, 2681
Znf141/Ikaros gene, murine lymphoma, 2650
- Dendritic cells**
activation by adenovirus, 5260
EBV peptide-pulsed
immunotherapy, nasopharyngeal carcinoma, 6952

- iNOS induction by glioma-associated hyaluronan, 2583
- phenotype
interferon stimulated gene 15 and, melanoma, 3453
- pulsed
leukemic blast cross-presentation, 2861
- rAAV-targeted candidate vaccine, chronic myelogenous leukemia, 3175
- telomerase RNA-transfected, 5041
- tumor-primed
cancer vaccine, 1884
- vaccines
IL-18 gene-transduced, immunotherapy, 5853
- Dendritic-like cells**
silica-induced, 1050
- Deoxycytidine analogue monophosphates**
l-form
phosphorylation, 1624
- Deoxycytidine kinase**
ara-G phosphorylation, 3100
- 2-Deoxy-d-ribose**
2-deoxy-l-ribose functional effects, 2834
- 3-Deoxy-3-[¹⁸F]fluorothymidine-positron emission tomography**
lung nodules, 3331
- Deoxyguanosine kinase**
ara-G phosphorylation, 3100
- 2-Deoxy-l-ribose**
thymidine phosphorylation and dRib functional effects, 2834
- Depsipeptide: See FK228**
- Desferri-exochelin**
HIF, VEGF and NIP3 induction, 6924
- Desmoplasia**
gene expression, 5351
- Development**
Id2 and, 301
- Dexamethasone**
apoptosis, pre-B cells, 4212
thymic lymphoma prevention, *Atm*^{-/-} mice, 5153
- Diabetes**
lymphoid neoplasia, immunodeficient nonobese diabetic mice, 5828
- Diarrhea**
celecoxib and CPT-11 effects, 5778
CPT-11-induced prevention, 179
- (6R)-Dideazatetrahydrofolate**
cytotoxicity, 5236
- Diet**
sucrose-rich
mutations, rat colon, 4339
- Difluoromethylornithine**
UV carcinogenesis inhibition, *Xpa*^{-/-} mice, 1338
- 7,12-Dimethylbenz(a)anthracene**
IL-1 α induction, 417
mammary carcinogenesis
inhibition by resveratrol, rats, 4945
- 1,2-Dimethylhydrazine**
uterine sarcoma, p53 transgenic mice, 3024
- Dipeptidyl peptidase IV**
overexpression
and survival, ovarian cancer, 2753
- Diphtheria toxin**
A chain
adenoviral gene transfer, 2576
DT₃₈₈IL3 fusion protein
acute myeloid leukemia stem cell cytotoxicity, 1730
transport domain
Bad fusion protein Bad (S112D S136A)-DTTR
apoptosis induction, 1433
- Discodermolide**
cytotoxicity, non-small cell lung cancer, 4081
- Disease**
epigenetic mechanisms, meeting report, 6784
- d11520**
hepatic arterial administration, 6070
- DMBA: See 7,12-Dimethylbenz(a)anthracene**
- DNA**
amplification
and gene expression patterns, breast cancer, 6240
complementary
microarrays
epithelial ovarian cancer, 2923
esophageal lesions, 3493
head and neck squamous cell carcinoma, 1184
molecular profiling, bladder cancer, 6973
pancreatic cancer, 2890
serological identification of tumor antigens by cDNA expression cloning
melanoma antigen isolation, 4836
- CpG islands**
expressed sequence Tags, 3214
electrovaccination, melanoma, 5489
hypermethylation, histone modifications and gene expression dependent on, 7213
hypomethylation by methioninase, 4685
immortal strand co-segregation, 6791
methylation *de novo*
cell division requirements, bladder cancer, 2378
mitochondrial
deletions, thyroid tumors, 7031
mutations, prostate cancer, 6470
somatic mutations, breast cancer, 972
replication inhibition by Kin17, 5425
secondary structures
p53 hypermutable base positions, 5641
SZF1 binding, 3773
vaccination, B-cell lymphoma, 5845
vaccines, T-cell lymphoma, 1757
- DNA adducts**
benzo(g)chrysene
global nucleotide excision repair
regulation by p53, fibroblasts, 5288
nonrepairable, 4229
- DNA-binding protein B**
expression, vascular endothelial growth factor, 4985
- DNA damage**
clustered
complex rearrangements, 6263
double-strand breaks
aberrant repair, myeloid leukemia, 2791
homology-directed repair, 1279
repair
BLM helicase, 2766
metabolic inhibition response, 3515
p53 response mediation by TGF- β 1, 5627
senescence induction, tumor cells, 1876
tetranucleotide repeat mutations, 6052
VP-16-induced fragmentation
DNASIL3, osteosarcoma, 4439
- DNA-dependent protein kinase**
catalytic subunit *DNA-PKcs*
inactivation with antisense oligodeoxynucleotides, 6621
silencing by siRNAs, 6400
- DNA ligase I gene**
point mutation, mice, 4065
- DNA ligase IV**
medulloblastoma inhibition, 6395
- DNA-methyltransferase**
Apc^{Min/+} *Dnmt1*-hypomorphic mice
polyp inhibition, 1296
DNMT1 protein
depletion by methylating agents, 1592
- DNA-methyltransferase-3B promoter**
polymorphism
and lung cancer risk, 4992
- DNA polymerase β**
and aneuploidy and tumorigenesis, 3511
deficiency
and apoptosis, 1524
and low-level microsatellite instability, 6061
replication error spectrum, *APC* mutations, 3271
splice variants, bladder cancer, 3251
- DNA repair**
deficiency
FHIT/FRA3B locus and, 4054
double-strand break
aberrant, myeloid leukemia, 2791
BLM helicase, 2766
- genes**
mutations, MSI+ endometrial cancer, 4095
homology-directed, 1279
mismatch
deficiency
mutations, colorectal cancer, 1284
mutations, review, 2447
target gene mutation profiles, 1609
target genes for instability, review, 2447
gene rearrangements, hereditary nonpolyposis colorectal cancer, 848
nucleotide excision
global
regulation by p53, fibroblasts, 5288
transcription-coupled
and cisplatin sensitivity, 4899
8-oxo-G
defective, colorectal cancer, 7230
- DNASIL3**
VP-16-induced fragmentation, osteosarcoma, 4439
- DNAzymes**
VEGFR2, 5463
- Δ Np73**
oncogenic potential, 636
- Docetaxel**
combined with pegylated IFN- α 2b
prostate cancer inhibition, nude mice, 5720
systemic exposure
ritonavir-boosted, mice, 6158
- Dodecafluoropentane**
hypoxic tumor cell radiosensitization, 3626
- Donor leukocyte infusion**
immunized
tumor vaccine enhancement, 796
- Doppler ultrasound**
high-frequency
antivascular therapy monitoring, 6371
- Dormancy**
tumor
solitary cells and, 2162
- DOTA: See 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid**
- Down-regulated in adenoma (DRA) gene**
growth inhibition, 5083
- Doxorubicin**
combined with anti-flk-1 mAb, soft tissue sarcoma, 2034
in vivo
apoptosis, cardiomyocytes, 4592
liposomal
antivascular effects, rat brain tumor model, 2561
resistance
Bcrp1 mutation hot spot and, 2294
modulation by rapamycin, prostate cancer, 6141

Doxycycline
bone metastasis tumor burden reduction,
breast cancer, 1588

Drg1
chemosensitivity modulation, 3950

dRib: See 2-Deoxy-d-ribose

Drug delivery
apoptosis-induced, 1382
ultrasonically activated, rat model, 7280

Drug resistance
melanoma, 6698
multidrug resistance protein 6 properties,
6172
murine major vault protein MVP/LRP and,
7298
nuclear proteasome and, 5008

Drug transport
multidrug resistance protein 6 properties,
6172

ΔTA-p73
malignant transformation, 3598

Ductal carcinoma in situ
active HER-2/*neu* signaling, 6667
breast
COX-2 expression, 1676
proteomics, 6740

Dysplasia
oral
molecular analysis, 4757
oral epithelial, severe
p16^{INK4a} and *p14^{ARF}* alterations, 5295

Dystroglycan
epithelial polarization, breast tumor cells,
7102

E

E7820
integrin $\alpha 2$ inhibition, endothelium, 6116

E1A
oncolytic mutations, melanoma-targeted,
4663
systemic gene therapy, 6712
tumor inhibition mechanisms, 346

E6AP ubiquitin ligase
EG-induced E6TPI degradation mediation,
3315

Early growth response-1 gene
EGFR gene expression induction, hypoxia,
827

Early placenta insulin-like growth factor
and c-erbB-2-positive cells, 1020

E-cadherin
inhibition by *SLUG*, breast cancer, 1613

Ecteinascidin-743
combined with paclitaxel, breast cancer,
6909
hepatotoxicity, female rat, 4256
transcription-targeted chemotherapy agent,
3377

EDB-containing fibronectin
mice lacking, 5603

E2F-1
Ad-E2F-1 gene transfer
combined with chemotherapy, melanoma,
1776
modulation by CD437, prostate cancer, 3842
Myc-induced tumorigenesis inhibition, 3276
-targeted replication-selective adenovirus,
3438

E4G10
tumor growth inhibition, 2567

Electromagnetic near field
lacI mutations, mice, 1956

Electron-donating ability
and colon cancer prevention, 6506

Electronic expression profiling
prostate cancer, 3308

Electrovaccination
DNA
melanoma, 5489

ELF4: See MEF

Endocrine neoplasia, multiple
function-impaired RET-MEN2A
repair, 2414

Endometrial adenocarcinoma
Ishikawa
stromal regulation, 79

Endometrial cancer
early TGF- β signaling loss, 2778
growth inhibition by progesterone, 881
hCDC4 mutations, 4535
microsatellite instability
APC methylation, 3663
DNA repair gene mutations, 4095

Endometrial tumors
mismatch repair-deficient
target gene mutation profiles, 1609

Endostatin
adenoviral
growth inhibition, mammary tumors, 3934
cell adhesion regulation, 1944
extracellular matrix interactions, endothelial
cells, 5580

Endothelial cells
adhesion
regulation by endostatin, 1944
COX-2 expression, intestinal polyps, 6846
extracellular matrix
endostatin interactions, 5580
metronomic chemotherapy selectivity, 6938
tumor
placental growth factor survival factor,
2749

Endothelin A
receptor
blockade
growth inhibition, cervical cancer, 6381

Endothelium
integrin $\alpha 2$ inhibition by E7820, 6116
irradiated
PI3K/Akt signaling response, 4671
irradiation-induced NO
apoptosis induction, 1450
tumor
heparin-binding VEGF substructure bind-
ing, 7118

Energy restriction
mechanisms, 5280

Enzyme-activated prodrug therapy
combined adenoviral and cytostatic therapy,
6089
P450 gene-directed
apoptotic factors and, 6928

EphA2
antibody targeting
malignant cell inhibition, 2840

Epidermal growth factor
boronated
convection-enhanced delivery, glioma,
6552
receptor
anti-EGFR therapy resistance
mediation by IGFR-1, glioblastoma,
200
and bladder tumorigenesis, 4157
 Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
-dependent angiogenesis, skin carcinogen-
esis, 3402
expression
head and neck squamous cell carci-
noma, 7350
induction by *Egr-1*, hypoxia, 827
inhibition

antiangiogenic effects, 2554
effects, breast epithelial proliferation,
122
malignant pleural mesothelioma, 5242
metastatic pancreatic cancer, 1996
molecular targeting, neutron capture ther-
apy, 3159
mutations
asbestos-induced proliferation inhibi-
tion, lung epithelium, 4169
radiation and BCNU resistance mediation,
glioblastoma, 4307
-regulated cell motility
Ral A, 982
signaling
inhibition by ZD1839, 5749
Nf1:p53 mouse tumor cells, 4507
signal transactivation, head and neck
squamous cell carcinoma, 6329
truncated tREGFR
mitogenic blockade, pancreatic cancer,
5611
receptor 2
human: *See HER-2/neu*
receptor VIII
invasion gene activation, 3335
-related ligands
ErbB-targeted anticancer agents and, 3151
TRAIL-mediated cytochrome *c* release
blockade, 488

Epigallocatechin-3 gallate
Her-2-induced cell growth inhibition, breast
cancer, 652
stability, uptake, metabolism and efflux, co-
lon adenocarcinoma, 7241

Epigenetics
disease mechanisms, meeting report, 6784

Epithelial cancer
apoptosis
BAX, 3373
ovarian
cDNA array and, 2923
cell migration promotion by periostin,
5358
malignant
hyaluronan levels, 6410
risk
CYP17 and *COMT* polymorphisms and,
3058

Epithelial cells
breast
proliferation
EGFR tyrosine kinase inhibition effects,
122
intestinal
K-Ras transformation
modulation by PPARs, 3282
mammary
immortalization by *Bmi-1*, 4736
ING1 target gene detection by cDNA mi-
croarrays, mouse, 2203
MEK1 signaling and, Eph4 cells, 4781
psoriasis expression, 43
transformation by PDK1, 3538
ovarian surface
telomerase regulation by JNK, 4575
polarization by dystroglycan, breast tumors,
7102
prostate
senescence characterization by SAGE,
6255
RK3E
GLI-regulated transcripts, 5867

Epithelial cell tumors
Epstein-Barr virus-positive
combination chemotherapy and ganciclo-
vir, 1920

- Epithelial dysplasia**
oral
severe
p16^{INK4a} and *p14^{ARF}* alterations, 5295
- Epithelial neoplasia**
stromal regulation, 79
- Epithelial precancer**
NAD(P)H/collagen fluorescent biomarkers, 682
- Epithelial tumors**
ovarian
malignant
hyaluronidase activity, 6410
- Epithelium**
bronchial
hypermethylation, smokers, 2370
lung
asbestos-induced proliferation
inhibition by mutant EGFR, 4169
prostate
FGF8b overexpression, mouse, 5096
RXRα allele inactivation, prostatic intra-epithelial neoplasia, 4812
- Epothilone B**
cytotoxicity, non-small cell lung cancer, 4081
- Epothilone B analogue BMS-247550**
Bax conformational change induction, breast cancer, 466
- Epstein-Barr virus**
carcinoma, 4876
-encoded nuclear antigen 1 (EBNA1)
T helper peptides, 7195
epithelial cell tumors
combination chemotherapy and ganciclovir, 1920
latent membrane protein 1
FGF-2 induction and release, 6337
peptide-pulsed dendritic cell immunotherapy, nasopharyngeal carcinoma, 6952
- ErbB**
-targeted anticancer agents
and EGF-related ligands, 3151
- erbB-2: See HER-2/neu**
- ERCC2 gene**
polymorphisms
and smoking, lung cancer, 1377
- Esophageal adenocarcinoma**
HNF3α (FOXA1) amplification and overexpression, 5273
- Esophageal cancer**
artificial neural networks and cDNA microarrays, 3493
squamous cell
p16 silencing modes, 4938
RNF6 mutations, 4191
Smurf2 expression, 7162
WWOX alterations, 2258
T cell factor transcription regulation by Wnt-1, 277
- Esophageal tumorigenesis**
piroxicam effects, rat, 4376
- Esophagus, Barrett's**
artificial neural networks and cDNA microarrays, 3493
7q132.3-q36.1 loss, 1531
- Estradiol**
VEGF regulation, breast cancer, 4977
- Estrogen**
estrogen-responsive element-targeted histone deacetylase antiestrogen activity, 6519
lung cancer, 2141
mammary tumors
Cimicifuga extract effects, 3448
receptor
βcx protein, ERα-positive breast cancer, 4849
inhibition by BRCA1
modulation by p300, 141
SERM-ER complexes, breast cancer, 4419
receptor α
absent, mammary tumor onset delay, 2798
breast cancer
βcx protein, 4849
lung cancer, 2141
receptor β, lung cancer, 2141
targets, breast tissue, 4540
VEGF regulation, breast cancer, 4977
- Estrogen-related receptor α**
breast cancer, 6510
- Estrogen-related receptor γ**
breast cancer, 6510
- Estrogen-responsive element**
-targeted histone deacetylase
antiestrogen activity, 6519
- N²,3-Ethenoguanine**
vinyl chloride-induced
molecular dosimetry and repair, rats, 5189
rat brain and liver, 5183
- Etoposide**
-induced fragmentation
DNASIL3, osteosarcoma, 4439
- E6TPI**
EG-induced degradation
mediation by E6AP ubiquitin ligase, 3315
- Ewing's sarcoma**
EWS and *EWS-FLI1* fusion gene
BARD1 interactions, 4583
EWSR1-CIZ fusion gene, acute leukemia, 5408
- Exonuclease 1**
human *hExo1*
mutations, hereditary nonpolyposis colorectal cancer, 6026
- Exotoxins**
CD7-exotoxin, acute leukemia, 2848
- Expressed sequence tag (EST) arrays**
12p11-p12 amplicon analysis, 6218
- Extracellular matrix**
endostatin interactions, endothelial cells, 5580
- Extracellular membrane vesicles**
tumor cell
angiogenic activity, 6312
- Extracellular signal-regulated kinase**
inhibitors
apoptosis induction, Bcr/Abl-expressing leukemia, 188
neuroendocrine differentiation activation, 1549
PEITC-induced apoptosis, prostate cancer, 3615
and photodynamic therapy sensitivity, 5528
- F**
- Familial glioma**
linkage analysis, 3798
- Familial neuroblastoma**
chromosome 16p12-13 mapping, 6651
- Familial pancreatic cancer**
BRCA2 mutations, 3789
- Farnesyltransferase inhibitors**
Ras CD95 expression inhibition reversal, 450
- Fas gene**
splice variant, cutaneous T-cell lymphoma, 5389
- Fas ligand**
monocyte expression, tumors, 1261
- Faslodex (ICI 182,780)**
growth inhibition
and IGF-I signaling, 3985
resistance
molecular analysis, 3428
- Fatty acid synthase**
PI3k/PTEN/Akt kinase and, LNCaP prostate cancer cells, 642
- Feline immunodeficiency virus**
and chromosome 15q15 candidate tumor suppressor gene, B-cell lymphoma, 7175
- Fenretinide**
apoptosis, neuroblastoma, 5158
GADD153 and 12-LOX induction, 5158
- Fetal liver kinase 1**
anti-flk-1 mAb
combined with doxorubicin, soft tissue sarcoma, 2034
truncated soluble tsFlk-1
rAAV-mediated expression
growth inhibition, renal tumors, 3077
- α-Fetoprotein**
afp gene expression downregulation by hypoxia, 1158
- Fibrillar-type adhesions**
formation by β1-integrin
VHL role, 2929
- Fibrinogen**
deficiency
lymphatic metastasis, mice, 6966
- Fibroblast activation protein**
tumor growth promotion, 4767
- Fibroblast growth factor**
basic bFGF
prognostic value, lung cancer, 5210
receptor
FGFR4 Arg³⁸⁸ allele
and tumor progression, 840
receptor 1
phosphotyrosine 766, prostate tumor progression, 1898
- Fibroblast growth factor 2**
induction and release by EBV LMP1, 6337
- Fibroblast growth factor 8b**
overexpression, prostate epithelium, 5096
- Fibroblasts**
α-particle irradiation bystander effects
oxidative metabolism and, fibroblasts, 5436
Brca1-null
nonhomologous end-joining activity, 3966
COX-2 expression, intestinal polyps, 6846
gene induction by methylation inhibitors, 961
global nucleotide excision repair regulation by p53, 5288
histone H3 phosphorylation, mouse, 75
immortal
telomerase inhibition, 2104
Jnk1- and *Jnk2*-deficient
gene expression profile, murine cells, 1300
MMP-2 release, malignant cell contact, 283
PARP-1
CHS 828 sensitivity, 4206
plasmid-based deletion assay, Werner syndrome, 547
- Fibronectin**
EDB-containing, mice lacking, 5603
matrix assembly, EDB segment-absent mice, 5603
- Fibrosarcoma**
invasion inhibition by nobiletin, 1025
- Fibrosis**
pulmonary
radiation-induced, murine, 3782
- Fine-needle aspiration**
breast cancer diagnosis, genetic, 2365
- FK228 (depsipeptide)**
HDAC inhibition, mechanism, 4916
- Flavopiridol**
apoptosis induction, S-phase, 1707

- FLI1 gene**
EWS-FLI1 fusion gene
 BARD1 interactions, 4583
- Flt-1**
 promoter
 transcriptional targeting, teratocarcinoma, 1271
 soluble sFlt-1
 carcinomatous ascites inhibition, 2019
- Fluasterone: See 16 α -Fluoro-5-androsten-17-one**
- Fluorescence imaging**
 tumor growth and metastasis, pancreatic cancer, 1534
- 16 α -Fluoro-5-androsten-17-one**
 carcinogen-activating enzyme inhibition, 3685
- 5-Fluorocytosine**
 cytosine deaminase/5-FC gene therapy, glioma, 773
- Focal adhesion kinase**
 tumor signaling *in vivo*, 2699
- Folate**
 transport by MRP4, 3144
- Forkhead box FOXM1**
 expression, basal cell carcinoma, 4773
- 4-1BB**
 anti-4-1BB mAb
 and large tumor immunotherapy, 3459
- 14-3-3**
 tuberin interactions, 6475
- 14-3-3 ϵ**
 deletion, small cell lung cancer, 271
- 14-3-3 σ**
 methylation, oral carcinoma, 2072
- Fra-1**
 asbestos-induced, mesothelioma, 6065
- Fragile histidine triad (FHIT) gene**
FHIT/FRA3B locus
 genetically unstable sequences, 3477
 and repair-deficient cancers, 4054
 testicular germ cell tumorigenesis, 512
- Fructose-2,6-bisphosphatase**
 inducible
 expression, cancer, 5881
- FTY720**
 tumor growth and metastasis prevention, mouse breast cancer, 1410
- Fumarate hydratase (fumarase, FH) gene**
 mutations, hereditary leiomyomatosis and renal cell cancer, 4554
- Furamide analogues**
 cellular distribution, 7219
- Furin**
 proMT3-MMP processing, Madin-Darby canine kidney cells, 675
- Fusion genes**
EWS-FLI1 fusion gene
 BARD1 interactions, 4583
EWSR1-CIZ, acute leukemia, 5408
H4/BCL6 fusion gene, B-cell non-Hodgkin's lymphoma, 6224
MLL-LCX, acute myeloid leukemia with trilineage dysplasia, 4075
MLL-SEPTIN6, infant t(X;11)(q24;q23) acute myeloid leukemia, 333
NUP98-HOXC11, t(11;12) acute myeloid leukemia, 4571
NUP98-HOXD11, t(2;11)-acute myeloid leukemia, 33
SYT-SSX
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
TAF15-CIZ, acute leukemia, 5408
- Fusion proteins**
 Bad (S112D S136A)-DTTR
 apoptosis induction, 1433
 B7.2-IgG
 combined with SU6668, breast tumor therapy, 5727
 DT₃₈₈IL3 fusion protein
 acute myeloid leukemia stem cell cytotoxicity, 1730
 green fluorescent protein/TRAIL
 targeted expression, hepatocytes, 3620
 leukemia-associated
 differentiation blockade, 7050
 TAT-ODD, antitumor effects, 2013
- Fusion vaccines**
 melanoma, 5495
- Fusogenic membrane glycoproteins**
 viral
 solid tumor cell killing, 6566
- Fv antibody fragment**
 single-chain
 anti-Ras
 radiation-induced NF- κ B activation inhibition, 2318
 CD7-exotoxin, acute leukemia, 2848
- G**
- GABA: See γ -Aminobutyric acid**
- Gadd45a**
 -dependent stress MAPK and p53 activation, 7305
- GADD153**
 induction by fenretinide, 5158
- Ganciclovir**
 combined with chemotherapy, EBV⁺ tumors, 1920
- Ganglioside G_{M3}**
 antitumor effects, bladder cancer, 3850
- Gap junctional intercellular communication**
 menadiene and, 4922
- GART: See Glycinamide ribonucleotide formyltransferase**
- Gastric adenocarcinoma**
HPPI and *hMLH1* hypermethylation, 5637
- Gastric cancer**
 β -catenin mutations, 3503
 chromosome 17q characterization, 2625
 DARPP-32 and tDARPP overexpression, 4061
 gene expression analysis by oligonucleotide microarrays, 233
 gene silencing, 6645
Helicobacter-induced
 inhibition by p53-targeted disruption, 696
 hereceptin, 5813
hrgA and, Asians, 2385
 instabilotyping, 3641
 intestinal-type
 gene expression profiles, 7012
 metastasis to lymph nodes
 CCR7 expression, 2937
 S100A calcium binding protein overexpression, 6823
 serial analysis of gene expression, 6823
 Skp2 expression, 3819
- Gastrin**
 CCK-B/gastrin receptor missplicing, pancreatic cancer, 947
- Gastrinoma**
HER-2/neu expression, 3702
- Gastrointestinal cancer**
 length polymorphisms, short mononucleotide tract, 1961
 mismatch repair-deficient
 target gene mutation profiles, 1609
- Gastrointestinal hamartoma**
Lkb1 knockout mice, 2261
- GATA-6**
 NSAIDs and, colorectal cancer, 1178
- G3BP**
 induction by heregulin, breast cancer, 1251
- Gelatinase**
 MMP inhibitor specificity/efficacy correlation, T-cell lymphoma, 5543
- Geldanamycin**
 HIF-1 α inhibition, prostate cancer, 2478
- Gemcitabine**
 effects on humoral immune response, 2353
- Gene amplification**
 induction by mutant p53, 3264
- Gene-directed enzyme prodrug therapy**
 P450 gene
 apoptotic factors and, 6928
- Gene expression**
 analysis
 sensitivity to anticancer drugs, 518
 cDNA microarrays
 artificial neural networks and, esophageal lesions, 3493
 pancreatic cancer, 2890
 chemosensitivity and, cancer cells, 1139
 colorectal cancer, 4352
 comprehensive analysis, prostate cancer, 4499
 CPT-induced changes, 1688
 desmoplasia, 5351
 electronic profiling, prostate cancer, 3308
 EST arrays
 12p11-p12 amplicon, 6218
 genome-wide analysis, synovial sarcoma, 5859
 histone modification and, dependence on DNA hypermethylation, 7213
 HPV16 integration and
 cervical keratinocytes, 6959
 JNK2-regulated, 3257
 modulation by Kaposi's sarcoma-associated herpesvirus viral G protein-coupled receptor, 4525
 oligonucleotide microarrays, gastric cancer, 233
 patterns
 DNA amplification and, breast cancer, 6240
 single cell behavior correlation, metastatic mammary cancer, 6278
 pilocytic astrocytoma, 2085
 profiles
 anti-angiogenic therapy and, 7143
 bladder cancer, 6973
BRCA1 breast cancer tumors, 7110
 cell cycle progression, 3233
 colon cell maturation, 4791
 etiology-specific, mammary cancer, 3592
 favorable histology Wilms' tumor, 6598
 head and neck squamous cell carcinoma, 1184
 HTLV-1 infection, 3562
 intestinal-type gastric cancer, 7012
Jnk1- and *Jnk2*-deficient murine fibroblasts, 1300
 liposarcoma, 2993
 lung adenocarcinoma, 3244
 MHC I ligand analysis and, 5818
 ovarian cancer, 4722
 oxidative stress, breast cancer, 6246
 prostate cancer, meta-analysis, 4427
 prostate cancer progression, 5325
 SERM-ER complexes, breast cancer, 4419
 testicular germ cell tumorigenesis, 2359
 ratios, cancer diagnosis, 4963
 serial analysis
 epithelial senescence characterization, prostate, 6255
 gastric cancer, 6823
 pancreatic cancer, 819

- squamous cell carcinoma progression, 3759
- stromal cells
 - MMP-1 2G single nucleotide polymorphism and, 7200
- virus type linkage, hepatocellular carcinoma, 3939
- Gene polymorphisms**
 - AR CAG repeat
 - and breast cancer risk, 1045
 - cytokine
 - and prostate cancer, 3369
 - DMBT1*, malignant glioma, 1790
 - ERCC2*
 - and smoking, lung cancer, 1377
 - germ-line
 - and sputum promoter methylation, 2248
 - glutathione *S*-transferase P1
 - and sputum promoter methylation, 2248
 - NAD(P)H:quinone oxidoreductase
 - and sputum promoter methylation, 2248
 - NKX-3.1* C154T, 2654
 - short mononucleotide tract length, gastrointestinal cancer, 1961
 - single nucleotide
 - 2G
 - MMP-1 promoter, and gene expression, 7200
 - hOGG1*
 - and prostate cancer, 2253
 - MDR1*, acute myeloid leukemia, 4955
 - MMP2*
 - and lung cancer risk, 6430
 - thymidylate synthase* promoter
 - and colorectal adenomas, 3361
- Genes**
 - alterations, complex
 - clustered DNA damage, 6263
 - chromosome 20q13
 - and prostate tumorigenesis, 6803
 - colon cancer prevention, meeting report, 6779
 - cutaneous melanoma candidates
 - cyclin D1, 3200
 - head and neck cancer candidates
 - cyclin L*, 6211
 - induction by methylation inhibitors, fibroblasts, 961
 - invasion
 - activation by EGFRvIII, 3335
 - invasion suppressor
 - RhoGDI2, 6418
 - metastasis-associated
 - hepatocellular carcinoma, clonality delineation, 4711
 - metastasis suppressor
 - rat prostate cancer, 367
 - RhoGDI2, 6418
 - methyl-group metabolism
 - germ-line variants, 4519
 - Nrf2-regulated
 - cancer chemoprevention, 5196
 - ovarian cancer oncogene candidate *SEI-1*, identification, 7157
 - p53-regulated
 - modulation by thymidylate synthase, 2644
 - silencing, gastric cancer, 6645
 - tumor suppressor
 - chromosome 3p21.3 homozygous deletion region, 2715
 - tumor suppressor candidates
 - chromosome 15q15, B-cell lymphoma, 7175
- Gene therapy**
 - adenoviral, renal cell carcinoma, 4273
 - adenoviral double suicide, locally recurrent prostate cancer, 4968
 - cell-based antiangiogenic, 2004
 - cytosine deaminase/5-FC, glioma, 773
 - IL-2
 - combined with cisplatin, head and neck squamous cell carcinoma, 4023
 - P450
 - apoptotic factors and, 6928
 - PARP-based, prostate cancer, 6879
 - retroviral
 - bone marrow TGF- β signaling blockade, 7135
 - suicide
 - carboxypeptidase G2
 - prodrugs, 1724
 - inducible
 - combined with photodynamic therapy, 1458
 - nitroreductase
 - bystander effects, 3D cell cultures, 1425
 - systemic *bik*, 8
 - systemic *E1A*, 6712
 - tumor-targeted, nasopharyngeal carcinoma, 171
 - Genetic stability**
 - p53 and, 1129
 - Rb* gene and, mouse, 2498
 - Gene transfer**
 - adenoviral DT-A, 2576
 - adenoviral E2F-1
 - combined with chemotherapy, melanoma, 1776
 - adenoviral p53
 - phosphorylation, glioma, 1069
 - horizontal, 575
 - lymphocyte transgene *Lptn*
 - combined with adoptive T-cells, 2043
 - phagemid, carcinoma, 977
 - prostaglandin I₂ synthase, colon cancer, 63
 - retroviral vs lentiviral vectors, ovarian cancer, 6099
 - ssr2*
 - antitumor effects, pancreatic cancer, 6124
 - thromboxane A₂ synthase, colon cancer, 63
 - Genistein**
 - tamoxifen interactions, breast cancer, 2474
 - Genome-wide allelotyping**
 - early breast carcinogenesis events, new *in vitro* model, 5980
 - Genome-wide analysis**
 - gene expression, synovial sarcoma, 5859
 - Genomic alterations**
 - allele separation and, 4579
 - associated with aggressiveness, bladder cancer, 6981
 - Genomic expression**
 - EST arrays
 - 12p11-p12 amplicon, 6218
 - profiling, liposarcoma, 2993
 - Genomic instability**
 - BrcA2* and *p53* mutations, 6194
 - intrachromosomal, colorectal cancer, 6350
 - null human tumor cells, 6345
 - Genotype**
 - and breast cancer survival, 3052
 - Germ cell tumorigenesis**
 - testicular
 - gene expression profiling, 2359
 - Germ cell tumors**
 - refractory
 - microsatellite instability, 2758
 - testicular
 - DAD-R* and, 1822
 - FHIT*, 512
 - Gleevec: See Imatinib**
 - GLI**
 - regulated transcripts
 - RK3E epithelial cells, 5867
 - GLI2**
 - NH₂-terminal fragment
 - and skin tumor phenotype, 5308
 - Glioblastoma**
 - anti-EGFR therapy resistance
 - mediation by IGFR-1, 200
 - apoptosis induction
 - neural stem cell-mediated TRAIL therapy, 7170
 - combination radiation and chemotherapy resistance
 - mediation by EGFR, 4307
 - Δ EGFR/PI3-K/Akt/p27 signaling, 6764
 - growth inhibition by connexin 43, 2806
 - IL-4 signaling inhibition by IL-13R α 2, 1103
 - invasion
 - inhibition by PTEN, 6318
 - malignant
 - CD70 immune escape pathway, 2592
 - PDGF autocrine signaling, 3729
 - radiosensitization by rapamycin, U87 xenografts, 7291
 - survival
 - genetic alterations and, 6205
 - tumor vascularity reduction by TSP-1 overexpression, 1191
 - tumor xenograft eradication by Hsp70 depletion, 7139
 - Glioma**
 - boronated EGF delivery, convection-enhanced, 6552
 - CD/5-FC gene therapy, 773
 - combination radiotherapy and Ad5- Δ 24RGD, 5736
 - familial
 - linkage analysis, 3798
 - growth inhibition
 - AAV-encoded angiostatin, 756
 - ciliary neurotrophic factor, C6 cells, 3544
 - CuZnSOD, 1205
 - SPARC, 6270
 - IL-12 neural stem cell therapy, 5657
 - invasion
 - promotion by SPARC, 6270
 - reduction by temozolomide, 1915
 - malignant
 - DMBT1* gene polymorphisms, 1790
 - HCMV infection and expression, 3347
 - ONYX-015, xenografts, 764
 - YKL-40 serum marker, 4364
 - neural stem cell-mediated TRAIL therapy, 7170
 - neutron capture therapy
 - molecular EGFR targeting, 3159
 - survival
 - regulation by Rac, 2131
 - tumorigenicity
 - VEGF and, 1854
 - VEGF regulation by MT1-MMP, 580
 - Glioma-associated hyaluronan**
 - iNOS induction, dendritic cells, 2583
 - Gliomagenesis**
 - Ink4a-Arf* loss, mouse, 5551
 - Glomeruloid microvascular proliferations**
 - prognostic value, cancer, 6808
 - Glucose**
 - uptake and metabolism alterations
 - genotoxic exposure and, 3515
 - Glucose-regulated protein Grp94 promoter**
 - cancer-inducible transgene expression, 7207
 - Glutamine synthetase**
 - hepatocarcinogenesis promotion, mouse, 5685
 - Glutathione**
 - and brostallicin anticancer activity, 2332
 - tissue levels
 - and tumor redox status, 307

- Glutathione S-transferase μ**
GSTM1
and lung cancer risk, 2819
- Glutathione S-transferase π**
GSTP1
and lung cancer risk, 2819
methylation, former smokers, 351
polymorphisms
and sputum promoter methylation, 2248
- Glycinamide ribonucleotide formyltransferase inhibitors**
cytotoxicity, 5236
- Glycolipid-anchored GPI-IL-12**
antitumor immune response, 2869
- Glycoprotein**
fusogenic membrane
viral
solid tumor cell killing, 6566
histidine-profile-rich
antiangiogenic activity, 5344
- Glycoprotein IIb/IIIa**
tumor growth, angiogenesis, and metastasis, 2824
- Glycosaminoglycans**
heparin-binding VEGF substructure binding, 7118
- GnT-V: See N-Acetylglucosaminyltransferase V**
- Gonadotropin-releasing hormone**
breast ribosomal phosphoprotein downregulation, 1036
- G protein-coupled receptors**
KISS1, identification and characterization, 5399
viral
Kaposi's sarcoma-associated herpesvirus
gene expression modulation, 4525
- G-quadruplex ligands**
-related telomerase inhibitors
TRAP assay, 3365
- Granulocyte colony-stimulating factor**
recombinant human rhG-CSF
combined with defibrotide
stem cell mobilization, mice, 6152
- Granulocyte-macrophage colony-stimulating factor**
-encapsulated microspheres, tumor immunotherapy, 7254
- Granzyme B**
-mediated TCR ζ chain degradation, 4884
- Green fluorescent protein**
GFP/TRAIL fusion protein
targeted expression, hepatocytes, 3620
mammary tumor labeling, transgenic mice, 7166
- Green tea catechins**
VEGF receptor phosphorylation inhibition, 381
- GTPase**
Rho-like
autocrine motility factor-induced changes, 4484
- GTPase-activating protein SH3 domain-binding protein G3BP**
induction by heregulin, breast cancer, 1251
- H**
- H19**
de novo methylation, cancer, 4545
hypomethylation, colorectal cancer, 6442
- H37**
lung cancer tumor suppressor gene, 3207
- Hamartoma**
gastrointestinal
Lkb1 knockout mice, 2261
- H-cadherin: See CDH13**
- Head and neck cancer**
candidate oncogene *cyclin L*, 6211
immunotherapy
carcinoembryonic antigen target, 5049
- Head and neck squamous cell carcinoma**
combination IL-2 gene therapy and cisplatin, 4023
EGFR expression, 7350
EGFR signal transactivation, 6329
gene expression profiling, 1184
growth promotion by COX-2-derived PGE₂, 6706
growth promotion by K-ras, 7154
hypoxia-inducible factors, 2493
lymphangiogenesis, 1315
p53₂₆₄₋₂₇₂-specific T cells, 3521
radiotherapy resistance
cyclin B1 and, 6414
retinoblastoma 94 treatment, 4637
Stat3, 3351
treatment outcome
pimonidazole binding and tumor vascularity and, 7066
- Heat shock protein 60**
 $\alpha\beta 1$ integrin activation, 1541
- Heat shock protein 70**
depletion
tumor xenograft eradication, 7139
- Heat shock protein 110**
recombinant HSP110-HER-2/*neu* vaccine, 1737
- HeLa cells**
telomere dysfunction by hTERT COOH-terminal fragment polypeptide, 3226
- Helicobacter-induced gastric cancer**
inhibition by p53-targeted disruption, 696
- Helicobacter pylori restriction endonuclease-replacing gene *hrgA***
and gastric cancer, Asians, 2385
- Helper T lymphocytes**
CD4+
EBNA1 peptides, 7195
wtp53-specific, antitumor efficacy, 6187
HPV16 E2-specific responses, 472
NY-ESO-1 119-143 epitope, 213
- Hematological malignancy**
BMI-1 amplification and overexpression, 618
hMSH2 germ-line mutations, 359
relapse after allogeneic bone marrow transplantation, 208
- Hemostatic factors**
and metastasis, fibrinogen-deficient mice, 6966
- Heparin**
-binding VEGF substructure
glycosaminoglycans binding and tumor endothelium localization, 7118
- Hepatocytomy**
partial
recovery, Skp2-deficient mice, 995
- Hepatic arterial infusion**
oncolytic adenovirus *dl1520*, 6070
- Hepatitis B virus**
gene expression and, hepatocellular carcinoma, 3939
-related female hepatocarcinogenesis
androgen receptor CAG repeat, 4346
- Hepatitis C virus**
gene expression and, hepatocellular carcinoma, 3939
- Hepatocarcinogenesis**
genetic control, rat, 4459
HBV-related female
androgen receptor CAG repeat, 4346
promotion
glutamine synthetase, mouse, 5685
- Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein 1**
pancreatic ductal adenocarcinoma, 1868
- Hepatocellular carcinoma**
gene expression patterns
virus type linkage, 3939
growth
anchorage-independent
PI3K/Akt pathway, 2971
inhibition by arginine deiminase, 5443
Ku80 heterozygosity and, PARP-1^{-/-} mice, 6990
Lkb1 knockout mice, 4549
metastasis
hematogenous
PI3K/Akt pathway, 2971
metastasis-associated genes, clonality delineation, 4711
therapy
intraarterial ATP production inhibitor, 3909
- Hepatocyte growth factor**
 β -catenin nuclear translocation induction, 2064
tubulogenesis
N-WASP, 2503
- Hepatocyte nuclear factor 3 α gene (*HNF3 α*) (*FOXA1*)**
amplification and overexpression, esophageal and lung adenocarcinoma, 5273
- Hepatocytes**
targeted GFP/TRAIL expression, 3620
- Hepatoma**
growth inhibition by acyclic retinoid, 3997
HIF-1 β -deficient tumors, magnetic resonance studies, 688
- Hepatotoxicity**
ET-743, female rat, 4256
- HEPSIN gene**
functions, prostate cancer, 6812
- HER-2/*neu***
17-AAG and, 3132
active signaling, ductal carcinoma *in situ*, 6667
androgen-independent prostate cancer, 5485
anti-HER2 trastuzumab
synergy with T cells, 2244
antirat neu virosomes, cancer therapy, 437
BRCA1-associated breast cancer, 1481
cell growth
inhibition by EGCG, breast cancer, 652
expression, gastrinoma, 3702
induced breast cancer
reduction by celecoxib, 5405
recombinant HSP110-HER-2/*neu* protein, 1737
transformation
cyclin D1 rate-limiting effects, 2267
- Herceptin: See Trastuzumab**
- Hereditary leiomyomatosis**
FH mutations, 4554
- Hereditary nonpolyposis colorectal cancer**
breast cancer tumor exclusion, 1014
hExo1 mutation alterations, 6026
hMSH2 and *hMLH1* promoter region germ-line mutations, 38
MLH1 hypermethylation, 3925
MSH2 inactivation, 848
- Heregulin**
G3BP induction, breast cancer, 1251
- Herpes simplex virus**
amplicon
-mediated combined SLC/CD40L-mediated immunotherapy, antitumor activity, 6545
oncolytic, antitumor effects, 2306
- Herpesvirus**
Kaposi's sarcoma-associated
viral G protein-coupled receptor
gene expression modulation, 4525

- 5-HETE**
PC-3 cell stimulation, 6817
- High mobility group A2**
expression
and TSC2 loss, uterine leiomyoma, 3766
overexpression, pituitary adenomas, 2398
- High mobility group I(Y)**
and chromosomal rearrangements, prostate cancer, 647
- Histidine-profile-rich glycoprotein**
antiangiogenic activity, 5344
- Histone acetyltransferase**
p300/CBP
downregulation
and melanocyte senescence, 6231
regulation by polyamines, murine skin and tumors, 67
- Histone deacetylase**
class I
inhibition by FK228, mechanism, 4916
estrogen-responsive element-targeted antiestrogen activity, 6519
regulation by polyamines, murine skin and tumors, 67
- Histone deacetylase 5**
growth inhibition and apoptosis induction, 2913
- Histone H3**
phosphorylation, mouse fibroblasts, 75
- Histone H4**
H4/BCL6 fusion gene, B-cell non-Hodgkin's lymphoma, 6224
- Histone H3-lysine 9**
methylation, cancer, 6456
- Histone modifications**
Dependence on DNA hypermethylation, 7213
- Hodgkin's disease**
SGN-30 antitumor activity, 3736
- Homeobox gene *HOXC11***
NUP98-HOXC11 fusion gene, t(11;12) acute myeloid leukemia, 4571
- Homeobox gene *HOXD11***
NUP98-HOXD11 fusion gene, t(2;11)-acute myeloid leukemia, 33
- Homology-directed repair**, 1279
- Hormones**
VEGF regulation, breast cancer, 1948
- Host-derived matrix metalloproteinase**
expression, multiple-organ metastasis, 5967
- HPPI gene**
aberrant methylation, ulcerative colitis-associated colorectal cancer, 6820
hypermethylation, gastric adenocarcinoma, 5637
- Human endogenous retrovirus**
CTL-recognized retroviral melanoma antigen, 5510
- Human ether-a-go-go related gene (*HERG*) potassium channel**
tumor cell apoptosis and growth regulation, 4843
- Human kallikrein hK2**
preoperative RT-PCR-hK2 status
and prostate cancer progression, 5974
- Human kallikrein hK11**
prostate and ovarian carcinoma biomarker, 295
- Human lymphocyte antigen**
class I
LAK-T cell activity inhibition, 480
- Human lymphocyte antigen-A*0201**
HPV16 tumor model, 5792
- Human lymphocyte antigen DP3**
-restricted EBNA1 peptides, T helper, 7195
- Human lymphocyte antigen DR7**
-restricted epitopes
and hTERT, 2600
- Human papillomavirus 16**
and chromosome instability, 7075
- E6**
E6TP1 degradation
mediation by E6AP ubiquitin ligase, 3315
-immortalized tumor cells
combination HPV-16 E7 and CpG-ODN immune therapy, 7234
- E7**
combined with CpG-oligodeoxynucleotide, immune therapy, 7234
-immortalized tumor cells
combination HPV-16 E7 and CpG-ODN immune therapy, 7234
plant-derived
tumor protection, 3654
E2-specific Th responses, 472
gene expression changes, cervical keratinocytes, 6959
HLA-A*0201 HPV16 tumor model, 5792
PUFAs and skin cancer, transgenic mice, 433
- Human papillomavirus JC**
and colon cancer, 7093
- Human T-cell leukemia virus type 1**
infection
gene expression profiles, 3562
- Humoral immune response**
gemcitabine and, 2353
- Hyaluronan**
glioma-associated
iNOS induction, dendritic cells, 2583
HA-CD44s
and MMP-2 secretion, lung cancer, 3962
levels, malignant epithelial ovarian tumors, 6410
- Hyaluronic acid**
-induced invasion
inhibition by PTEN, glioblastoma, 6318
- Hyaluronidase**
activity, malignant epithelial ovarian tumors, 6410
- Hydrogen-ATP synthase**
 β -catalytic subunit β -F1-ATPase
inhibition, carcinoma, 6674
- Hydrogen peroxide**
tumor-targeted generation with pegylated DAO, 3138
- N-Hydroxy-4-acetylaminobiphenyl**
mutations, 4325
- Hydroxylutamide**
MAP kinase activation, prostate cancer, 6039
- 8-Hydroxyguanine**
human *hOGG1* variants
and prostate cancer, 2253
repair defects, breast cancer, 1349
- 8-Hydroxyguanosine**
defective repair, colorectal cancer, 7230
- 7-Hydroxystaurosporine**
Chk2 activity inhibition, 5743
- 3 β -Hydroxysteroid dehydrogenase *HSD3B* genes**
and prostate cancer susceptibility, 1784
- Hypermethylated in cancer (*HIC-1*) gene**
hypermethylation, medulloblastoma, 3794
- Hypermethylation**
-associated *CRBP1* gene inactivation, cancer, 5902
bronchial epithelium and sputum, smokers, 2370
DAPK, bladder cancer, 4048
HIC-1, medulloblastoma, 3794
hMLH1, gastric adenocarcinoma, 5637
HPPI, gastric adenocarcinoma, 5637
MLH1, hereditary nonpolyposis colorectal cancer, 3925
p14^{ARF}, colitis-associated tumors, 1148
TRAIL decoy receptors DcR1 and DcR2, tumors, 2157
- Hyperplasia**
myelogenous
NQO1 disruption, mice, 3030
- Hypoestoxide**
mechanism of action, 4007
- Hypomethylation**
methioninase, 4685
- Hypoxia**
afp gene expression downregulation, 1158
cyclin D1 regulation
VHL-mediated, renal cell carcinoma, 3014
EGFR gene expression induction by *Egr-1*, 827
and lymph node metastasis, melanoma, 1847
MDR1 induction, 3387
tumor cell radiosensitization by dodecafluoropentane, 3626
- Hypoxia-inducible factor**
expression, renal cell carcinoma, 2957
- Hypoxia-inducible factor 1**
induction by desferri-exochelin, 6924
inhibitors, identification, 4316
MDR1 regulation, 3387
- Hypoxia-inducible factor 1 α**
head and neck squamous cell carcinoma, 2493
increase by thioredoxin-1, 5089
inhibition by geldanamycin, prostate cancer, 2478
tumorigenesis, 2962
- Hypoxia-inducible factor 1 β**
-deficient tumors, magnetic resonance studies, 688
- Hypoxia-inducible factor 2**
induction by desferri-exochelin, 6924
- Hypoxia-inducible factor 2 α**
expression, breast tumor macrophages and angiogenesis, 1326
head and neck squamous cell carcinoma, 2493
- I**
- 3-IAABE: See 3-Iodoacetamido benzoyl ethyl ester**
- Icat gene**
growth inhibition, colon cancer, 3322
- ICI 182,780: See Faslodex**
- Id2**
development and neuroblastoma prognosis, 301
- Idiotypic**
chimeric
DNA vaccination, B-cell lymphoma, 5845
- IGH gene**
rearrangements, B-cell non-Hodgkin's lymphoma, 5523
- Imatinib (STI-571, Gleevec)**
apoptosis induction, Bcr/Abl-expressing leukemia, 188
and Bcr-Abl-positive acute leukemia, 5761
c-Abl complex
kinase domain crystal structures, 4236
colorectal cancer therapy, 4879
-resistant Abl mutants
PD180970 activity against, 7149
- Immortalization**
Bmi-1, mammary epithelial cells, 4736
E6/E7
combination HPV-16 E7 and CpG-ODN immune therapy, 7234
immortal DNA strand co-segregation, 6791
mammary epithelial cells, characterization, 89

Immune responses

- antitumor
 - augmentation, lymphopenic hosts, 3914
- GPI-IL-12, 2869
- humoral
 - gemcitabine and, 2353
- Immunodeficiency**
 - immunodeficient nonobese diabetic mice
 - lymphoid neoplasia, 5828
- Immunoglobulin G**
 - anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
 - B7.2-IgG fusion protein
 - combined with SU6668, breast tumor therapy, 5727
- Immunotherapy**
 - antirat neu virosomes, 437
 - carcinoembryonic antigen target, head and neck cancer, 5049
 - combination HPV-16 E7 and CpG-ODN, 7234
 - combined secondary lymphoid tissue chemokine/CD40L-mediated, antitumor activity, 6545
 - cytokine-encapsulated microspheres, 7254
 - EBV peptide-pulsed dendritic cell, nasopharyngeal carcinoma, 6952
 - IL-10
 - mediation by Mig and IP-10, 2606
 - IL-18 gene-transduced dendritic cell-based vaccines, 5853
 - large tumor
 - anti-4-1BB mAb and, 3459
 - laser
 - metastatic tumor treatment components, 4295
- Immunotoxins**
 - scFv
 - CD7-exotoxin, acute leukemia, 2848
- IND 12**
 - Ras-induced cell transformation reversal, 1718
- Inducible protein 10**
 - IL-10 tumor inhibition mediation, 2606
- Infant leukemia, acute myeloid**
 - t(X;11)(q24;q23)
 - MLL-SEPTIN6 fusion, 333
- Infection**
 - tumor
 - selective, 5470
- Infection**
 - HTLV-1
 - gene expression profiles, 3562
 - human cytomegalovirus, malignant glioma, 3347
- Infiltrating breast cancer**
 - desmoplastic response, 5351
- Inflammation**
 - microenvironment
 - tumor therapy and, 1462
- Inflammatory breast cancer**
 - hereceptin rapid accumulation and internalization, 860
 - vasculogenic mimicry hemodynamics, 560
- Information degradation**
 - and carcinogenesis, 3675
- ING1**
 - age-dependent properties, 4445
 - detection by cDNA microarray, mouse mammary epithelial cells, 2203
 - mouse homologue mINGh
 - A1 interactions, 1275
- ING1b**
 - p53 regulation, 4890
- Inhibitor of apoptosis IAP1**
 - cIAP1
 - expression, cervical cancer, 4860

IN11 gene

- rhabdoid tumors, meeting report, 323
- Ink4a/Arf gene**
 - deficiency
 - and UV-induced melanomagenesis, 6724
 - loss, mouse gliomagenesis, 5551
- Instability**
 - gastric cancer, 3641
- Insulin**
 - radiation response modulation, 3555
- Insulin-like growth factor**
 - binding protein 1
 - cell motility inhibition, breast cancer, 4369
 - binding protein 3
 - growth inhibition, non-small cell lung cancer, 3530
 - receptor 1
 - anti-EGFR therapy resistance mediation, glioblastoma, 200
 - expression, prostate cancer, 2942
 - signaling blockade by proinflammatory cytokines, breast cancer, 4746
- Insulin-like growth factor I**
 - and COX-2 inhibitor anti-proliferative effects, pancreatic cancer, 7372
 - growth and metastasis regulation, colon cancer, 1030
- receptors
 - metastatic phenotype and, breast cancer, 6529
 - signaling
 - ICI 182,780 growth inhibition and, 3985
- Insulin-like growth factor II**
 - IGF2 hypomethylation
 - loss of imprinting and, colorectal cancer, 6442
- Insulin receptor substrate 1**
 - activation, tumors, 6035
- Integrin**
 - tumor angiogenesis, nude rats, 6289
- $\alpha_3\beta_1$ Integrin**
 - activation by heat shock protein 60, 1541
- $\alpha_5\beta_1$ Integrin**
 - endostatin association, endothelial cells, 5580
- $\alpha_v\beta_3$ Integrin**
 - binding peptides
 - radiolabeled, tumor targeting, 6146
 - tumor growth, angiogenesis, and metastasis, 2824
- $\alpha 2$ Integrin**
 - inhibition by E7820, endothelium, 6116
- β_1 Integrin**
 - fibrillar adhesion formation
 - VHL role, 2929
 - glycosylation
 - GnT-V and, 6837
- β_3 Integrin**
 - osteonection induction, melanoma, 226
- Intercellular adhesion molecule-2**
 - anti-ICAM-2 mAb, ICAM-2⁺ colon cancer, 3167
- Interferon α -2b**
 - pegylated
 - combined with docetaxel
 - prostate cancer inhibition, nude mice, 5720
- Interferon β**
 - tumor delivery
 - mesenchymal stem cells, 3603
- Interferon γ**
 - CD137 mAb-mediated antitumor effects, 4413
 - and CD8⁺ T-cell-mediated tumor killing, mice, 5058
 - dependent phagocytic cells
 - 7432

- tumor growth regulation, metastatic mammary carcinoma, 4406
- IL-12-mediated tumor rejection, 4696
- monokine induced by (Mig)
 - IL-10 tumor inhibition mediation, 2606
- Interferon regulatory factor 1**
 - and faslindox resistance, 3428
- Interferon regulatory factor 2**
 - cell growth deregulation, 2510
- Interferon regulatory factor 3**
 - tumor suppressor activity, B16 melanoma, 5148
- Interferon stimulated gene 15**
 - and dendritic cell phenotype, melanoma, 3453
- Interleukin 1 α**
 - induction by DMBA, 417
- Interleukin 1 β**
 - and chemoresistance, pancreatic cancer, 910
- Interleukin 2**
 - gene therapy
 - combined with cisplatin, head and neck squamous cell carcinoma, 4023
- Interleukin 3**
 - DT₃₈₈ IL3 fusion protein
 - acute myeloid leukemia stem cell cytotoxicity, 1730
- Interleukin 4**
 - inhibition by IL-13R α 2, glioblastoma, 1103
- receptors
 - pancreatic cancer therapy, 3575
- Interleukin 6**
 - androgen receptor transactivation
 - mediation by p300, 5632
 - production, renal cell carcinoma, 932
- Interleukin 8**
 - and bone metastasis, breast cancer, 5571
- Interleukin 10**
 - tumor inhibition
 - mediation by Mig and IP-10, 2606
- Interleukin 12**
 - antitumor effects absent IFN- γ , 4390
 - encapsulated microspheres, tumor immunotherapy, 7254
 - glycolipid-anchored GPI-IL-12
 - antitumor immune response, 2869
 - neural stem cells, glioma therapy, 5657
 - tumor growth and angiogenesis inhibition, mammary carcinoma, 747
 - tumor rejection
 - effector mechanism, 5069
 - IFN- γ , 4696
- Interleukin 13**
 - receptor $\alpha 2$
 - IL-4 signaling inhibition, glioblastoma, 1103
- Interleukin 18**
 - gene transfer
 - dendritic cell-based vaccine, immunotherapy, 5853
- International consensus statement**
 - malignant peripheral nerve sheath tumors, neurofibromatosis 1, 1573
- Interstitial fluid pressure**
 - and metastasis, melanoma, 661
- Intestinal epithelial cells**
 - K-Ras transformation
 - modulation by PPARs, 3282
- Intestinal neoplasia, multiple**
 - Apc^{min} mice
 - tumor load reduction by vitamin D₃ compounds, 741
 - Apc^{Min/+} mice
 - microadenomatous lesions, colon, 6367
 - PGE₂ modulation of NSAID effects, 403
 - Apc^{Min/+}, CASTB6F1 *Mom1*^{S/S} mice
 - polyp multiplicity, 5413

Apc^{Min/+} *Dnmt1*-hypomorphic mice
 polyp inhibition, 1296
 Min mice
 CEA-based vaccine antitumor activity,
 6944
 cyclin D1, 4562
Intestinal polyps
 COX-2 expression, 6846
 malignant progression
Smad2 null mutation and, *Apc*^{Δ716}
 knockout mice, 4558
Intestinal tumorigenesis
 cyclin D1, Min mice, 4562
Intestinal tumors
 angiogenesis, mouse models, 506
 invasive, *Apc/Smad2* compound mutant
 mice, 5955
Intestinal-type gastric cancer
 gene expression profiles, 7012
Intra-abdominal malignancy
 advanced
 proliferation assessment by PET, 5698
Intraepithelial neoplasia, prostatic
 FGF8b mouse model, 5096
 inhibition by 9-*cis*-retinoic acid, rats, 5178
RXRα allele inactivation, prostate epithe-
 lium, 4812
Invasion: See also Cell migration
Apc/Smad2 compound mutant mice, 5955
 cadherin-11 and, breast cancer, 6688
 genes
 activation by EGFRvIII, 3335
 hyaluronic acid-induced
 inhibition by PTEN, glioblastoma, 6318
 inhibition
 alendronate, prostate cancer, 2708
HEPSIN, prostate cancer, 6812
 nobletin, fibrosarcoma, 1025
 temozolomide, glioma, 1915
 lysyl oxidase, breast cancer, 4478
 promotion
 bombesin, colon cancer, 4829
 SPARC, glioma, 6270
 VEGF CXCR4 regulation, breast cancer,
 7203
 suppressor gene RhoGDI2, 6418
Invasive bladder cancer
 piroxicam effects, canine model, 356
Invasive breast cancer
 Wnt-5a loss of expression, 409
3-Iodoacetamido benzoyl ethyl ester
 new cancericidal tubulin ligand, 6080
Ionizing radiation: See also Radiation
 α-particle
 bystander effects
 oxidative metabolism and, fibroblasts,
 5436
 endothelium response
 PI3K/Akt signaling, 4671
 -induced NO, endothelial
 apoptosis induction, 1450
 Ku G₂ checkpoint effects, 6031
 mutagenesis, solid tissue, 1518
 sensitivity
 modulation by insulin, 3555
 S-phase checkpoint
 Brcal requirements, 4588
Irinotecan
 combined with celecoxib
 anticancer/antidiarrhea effects, 5778
 diarrhea
 prevention, 179
Ishikawa endometrial adenocarcinoma
 stromal regulation, 79

J

JCV
 and colon cancer, 7093

Jnk1
 deficiency
 gene expression profile, murine fibro-
 blasts, 1300
Jnk2
 deficiency
 gene expression profile, murine fibro-
 blasts, 1300

K

Kallikrein
 human hK2
 preoperative RT-PCR-hK2 status
 and prostate cancer progression, 5974
 human hK11, prostate and ovarian carci-
 noma, 295
Kaposi's sarcoma
 -associated herpesvirus viral G protein-cou-
 pled receptor
 gene expression modulation, 4525
 oxytocin growth factor, 2406
Karyotypes
 breast cancer, multivariate analysis, 2675
 multivariate analysis, colorectal cancer, 5939
Keratinocytes
 TP53-inactive
 NF-κB activation in, 1213
Kidney disease
 polycystic
 c-myc-induced apoptosis, 2210
Kin17
 T antigen interactions and replication inhibi-
 tion, 5425
KISS1
 G protein-coupled receptor, identification
 and characterization, 5399
 identification and characterization, 5399
K-ras
 expression, head and neck squamous cell
 carcinoma, 7154
 mutations, colorectal tumors, 6451
 transformation
 modulation by PPARs, intestinal epithelial
 cells, 3282
Ku
 and Ataxia and Rad3-related/CHK1-depend-
 ent S checkpoint, 2483
 G₂ checkpoint effects, ionizing radiation,
 6031
Ku80
 heterozygosity
 and hepatocellular carcinoma, PARP-1^{-/-}
 mice, 6990
Ku86
 antisense effects, malignant glioma, 5888
KU-MEL-1
 identification, 4836

L

LacI
 mutations
 electromagnetic near field, mice, 1956
Lactate dehydrogenase C
 splice variants, cancer, 6750
 tumor-specific transcripts, 6750
Laminin
 metastasis, 3549
 receptor
 67-kDa
 and cell motility, 1321
Laminin-1
 -induced acinar differentiation
 promotion by metallothionein, 5370
Large cell lymphoma
 anaplastic
 NPM-ALK expression downregulation by
 17-AAG, 1559

Laser capture microdissection
 mtDNA mutations, prostate cancer, 6470
Laser immunotherapy
 metastatic tumor treatment components,
 4295
**LCX (leukemia-associated protein with
 CXXC domain)**
MLL-LCX fusion, acute myeloid leukemia
 with trilineage dysplasia, 4075
Lecithin:retinol acyltransferase
 reduction, prostate cancer, 1654
Leiomyoma
 uterine
 HMGA2 expression and TSC2 loss, 3766
Leiomyomatosis
 hereditary
FH mutations, 4554
Lentivirus
 gene transfer, ovarian cancer, 6099
Letters to the editor
 re: A. H. Ree *et al.*, 59: 4675-4680, 4164
 re: A. Kumar *et al.*, 61: 7552-7555, 2192
 re: C-H. Kao *et al.*, 61: 1412-1414, 617
 re: D. Zimonjic *et al.*, 61: 8838-8844, 6345
 re: G. Anderson *et al.*, 61: 8274-8283,
 6350
 re: J. Mora *et al.*, 61: 6892-6898, 2986
 re: P. Laiho *et al.*, 62: 1166-1170, 5988
 re: S. Beá *et al.*, 61: 2409-2412, 618
 re: Y. Kuniwa *et al.*, 61: 7900-7907, 4836
Leukemia
 acute
 Bcr-Abl-positive
 STI-571 and, 5761
 CD7-exotoxin effects, 2848
EWSR1-CIZ fusion, 5408
 induction by TEL-AML1, mice, 3904
TAF15-CIZ fusion, 5408
 apoptosis induction by WK175, 1057
 Bcr/Abl-expressing
 apoptosis induction, 188
 BCR/ABL mutations, 5995
 blast cross-presentation by pulsed dendritic
 cells, 2861
 myeloid
 aberrant double-strand break repair, 2791
SHPI aberrant methylation, 6390
 T-cell
 adult
 PS-341 therapy, murine model, 1083
Leukemia, acute lymphoblastic
 B-cell
 early
 steroid-induced apoptosis, 4212
Leukemia, acute myeloid
 -associated fusion proteins
 differentiation blockade, 7050
MDR1 polymorphisms, 4955
Runx1/AML-1 gene
 T-cell lymphoma role, 7181
 stem cells
 DT₃₈₈IL3 cytotoxicity, 1730
 t(2;11)
NUP98-HOXD11 fusion gene, 28
 t(11;12)(p15;q13)
NUP98-HOXC11 fusion gene, 4571
 trilineage dysplasia
MLL-LCX fusion gene, 4075
 t(X;1)(q24;q23)
 infant
MLL-SEPTIN6 fusion, 333
Leukemia, acute promyelocytic
CD2 gene expression regulation, 4730
 differentiation induction treatment, meeting
 report, 5618
Leukemia, chronic lymphocytic
 benzylamide sulindac analogue effects, 5711

- Leukemia, chronic myelogenous**
 candidate vaccine, rAAV dendritic cell-targeted, 3175
- Leukemogenesis**
 core binding factor β -smooth muscle myosin heavy chain and G_1 acceleration, mice, 2232
- Leukocytes**
 immunized donor leukocyte infusion tumor vaccine enhancement, 796
- Leukotriene pathway inhibitors**
 carbamate-induced lung tumor chemoprevention, mice, 4199
- LGDI069**
 ER-negative mammary tumor development prevention, mice, 6376
- Lipids**
 mobile compartment dimensions, C6 cells, 5672
 NMR-visible accumulation, 1394
- Liposarcoma**
 genomic and expression profiling, 2993
- Liposomes**
 antibody-targeted drugs
 targeting to internalizing antibodies, 7190
 cationic, novel
 liver metastasis inhibition, 4282
 doxorubicin
 antivasular effects, rat brain tumor model, 2561
 EIA gene, systemic therapy, 6712
 tumor distribution, 6831
- Lipoxygenase**
 carbamate-induced lung tumor chemoprevention, mice, 4199
- 12-Lipoxygenase**
 induction by fenretinide, 5158
 inhibition, prostate cancer, 2721
- 12S-Lipoxygenase**
 epidermis-type $e12S$ -LOX, mouse skin tumorigenesis, 4610
- 15-Lipoxygenase-1**
 upregulation by NSAIDs, colorectal cancer, 1178
- Listeria monocytogenes vaccines**
 CNS tumor immunity induction, 2287
- Liver**
 breast cancer metastasis
 -specific adenovirus vector, 1063
 β -catenin mutation, stable, 1971
 colorectal cancer metastasis
 inhibition by C-raf antisense oligonucleotides, 5393
 metastasis
 inhibition by novel cationic liposomes, 4282
 -specific adenovirus vector, 1063
 TNF-Rp55 knockout mice, 6682
 vinyl chloride-induced adducts, rat, 5183
- Lkb1 gene**
 inactivation, lung adenocarcinoma, 3659
 knockout mice
 gastrointestinal hamartoma, 2261
 hepatocellular carcinoma, 4549
- LMP: See Low molecular mass polypeptide**
- LNCAp cells**
 apoptosis
 Smac, 18
 apoptosis induction by raloxifene, 3649
 PI3K/PTEN/Akt kinase and fatty acid synthase, 642
- Lometrexol: See (6R)-Dideazetetrahydrofolate**
- Loss of heterozygosity: See also Deletions**
 BRCA1-BRCA2 mutation carrier breast cancer, 2741
- carcinogen-induced, lung tumorigenesis, 6424
 and second oral malignancy, oral cancer, 6447
 stage II non-small cell lung cancer, 2681
 VHL-associated pancreatic islet cell tumors, 1952
- Loss of imprinting**
 colorectal cancer, 6442
- Low molecular mass polypeptide**
 knockout mice
 uterine tumors, 24
- IRib: See 2-Deoxy-1-ribose**
- Lung**
 epithelium
 asbestos-induced proliferation
 inhibition by mutant EGFR, 4169
 nodules
 FLT-PET, 3331
 sialyl Lewis X antigen-dependent colonization, melanoma, 4194
- Lung adenocarcinoma**
 allelic imbalance, nonsmokers, 4464
 BRAF mutations, 7001
 chromosomal alterations, mouse, 1152
 expression analysis, 3244
 HNF3 α (FOXA1) amplification and overexpression, 5273
 LKB1/STK11 inactivation, 3659
 metastases
 pulmonary
 ZD6126 effects, 3711
- Lung cancer**
 APC promoter methylation, 371
 apoptosis induction by Ad-mda-7, 2239
 apoptosis induction by CD437, 2430
 BRAF and RAS mutations, 6997
 bronchioloalveolar
 feline, comparative studies, 3826
 cancer/testis antigen gene expression, 3971
 C/EBP α downregulation, 528
 chemoprevention by prostaglandin I_2 synthase overexpression, murine, 734
 diagnosis
 gene ratios, 4963
 ERCC2 polymorphisms and smoking and, 1377
 HA-CD44s and MMP-2 secretion, QG90 cells, 3962
 metastasis
 multiple-organ
 host-derived MMP expression, 5967
 prognosis
 syndecan-1 and bFGF and, 5210
 RAR β loss, 3945
 risk
 DNA-methyltransferase-3B promoter polymorphism and, 4992
 GSTP1, and GSTM1, and p53 combinations and, 2819
 MMP2 single nucleotide polymorphism and, 6430
 SEREX approach, new, 1751
 susceptibility
 bcl-2 and, rat, 6297
 TSLC1 and DAL-1 association, 5129
 tumor suppressor gene H37, 3207
- Lung cancer, non-small cell**
 angiopoietin expression, clinical significance, 7124
 array-based comparative genomic hybridization, 3636
 cell death by discodermolide and epothilone B, 4081
 estrogens, 2141
 growth inhibition by IGFBP-3, 3530
 molecular classification, 3005
- 90K (Mac-2 binding protein), 2535
 stage II
 allele loss, 2681
 TRAIL-induced apoptosis
 PI3K/PTEN/Akt kinase pathway, 4929
 transcriptome map, 3340
- Lung cancer, small cell**
 cell migration and adhesion
 regulation by CXCR4 and c-Kit, 6304
 14-3-3 ϵ deletion and G_2 checkpoint defects, 271
 oxytocin functional signaling, 4623
- Lung tumorigenesis**
 B(a)P-induced
 inhibition by dietary BITC-NAC and PEITC-NAC, A/J mice, 2
 carcinogen-induced loss of heterozygosity, mouse, 6424
 reduction by iNOS deficiency, mouse, 6850
- Lymph nodes**
 carbamate-induced
 chemoprevention, mice, 4199
- Lymphangiogenesis**
 head and neck squamous cell carcinoma, 1315
- Lymphatic drain**
 peritumor
 VEGF-induced, MR mapping, 6731
- Lymphatic metastasis**
 fibrinogen-deficient mice, 6966
- Lymph nodes**
 gastric cancer metastasis
 CCR7 expression, 2937
 metastasis
 hypoxia and, melanoma, 1847
- Lymphocytes**
 chromosome instability
 and oral premalignant lesions, 2813
 peripheral blood
 micronuclei
 and pleural malignant mesothelioma susceptibility, 5418
- Lymphocyte transgene Lptn**
 gene transfer
 combined with adoptive T-cells, 2043
- Lymphoid neoplasia**
 immunodeficient nonobese diabetic mice, 5828
- Lymphokine-activated killer-derived T cells**
 inhibition by HLA class I molecules, 480
- Lymphoma**
 anaplastic large cell
 NPM-ALK expression downregulation by 17-AAG, 1559
 B-cell
 candidate tumor suppressor gene, chromosome 15q15, 7175
 CD40L-transduced tumor cell vaccine, 3195
 DNA vaccination, 5845
- Burkitt
 MCL1-overexpressing
 response to death stimuli, 892
- mantle cell
 BMI-1 amplification and overexpression, 618
 SHP1 aberrant methylation, 6390
- T-cell
 cutaneous
 Fas splice variant, 5389
 DNA vaccines against, 1757
 epitope hierarchy subversion, 1116
 MMP inhibitor specificity/efficacy correlation, 5543
 ROR γ -deficient mice, 901
 Runx1/AML-1 role, 7181
- thymic

prevention by dexamethasone, *Atm*^{-/-} mice, 5153
Znfn1a1/Ikaros alterations, murine, 2650
Lymphoma, non-Hodgkin's
 B-cell
BCL-6 alternative breakpoint region, 4089
 cryptic *IGH* rearrangements, novel, 5523
H4/BCL6 fusion gene, 6224
 translocation t(3;6)(q27 aJ1) breakpoints, 6224
 CXCR4 neutralization, 3106
Lymphomagenesis
 murine model, 5536
Lymphopenic hosts
 antitumor immunity augmentation, 3914
Lymphotoxin- β receptor
 angiogenesis induction, 4034
Lysine 9
 methylation, cancer, 6456
Lysophosphatidic acid
 cell migration
 inhibition by alendronate, ovarian cancer, 6015
Lysyl oxidase
 breast cancer invasion, 4478

M

Mac-2 binding protein
 non-small cell lung cancer, 2535
Macrophages
HIF-2 α expression
 and angiogenesis, breast tumor, 1326
 placental growth factor survival factor, 2749
 tumor-infiltrating
 and tumor angiogenesis, 7042
Madin-Darby canine kidney cells
 proMT3-MMP processing by furin, 675
MAGE-A genes
 expression, disseminated tumor cells, 251
Magnetic field exposure
 cell proliferation, rat mammary gland, 1356
Magnetic resonance imaging
HIF-1 β -deficient tumor studies, 688
 mapping
 VEGF-induced peritumor lymphatic drain, 6731
 pancreatic cancer, transgenic mouse model, 1555
Major histocompatibility complex
 class I
 ligand analysis and gene expression profiling, 5818
 -related chain A recognition by NKG2D, tumors, 6178
 class I and class II dual-specific peptides, 3630
 class II-restricted mutated neo-PAP recognition, 5495
Major vault protein MVP/LRP
 and drug resistance, murine, 7298
Malignancy
 astrocytoma
 cell migration promotion by brain osteopontin, 5336
 conversion, VHL tumorigenesis, 1952
 epithelial ovarian cancer
 hyaluronan levels, 6410
 hyaluronidase activity, 6410
 glioblastoma
 CD70 immune escape pathway, 2592
 glioma
DMBT1 gene polymorphisms, 1790
 HCMV infection and expression, 3347
 ONYX-015, xenografts, 764
 YKL-40 serum marker, 4364
 hematological
BMI-1 amplification and overexpression, 618

hMSH2 germ-line mutations, 359
 relapse after allogeneic bone marrow transplantation, 208
 inhibition by EphA2 antibody targeting, 2840
 intestinal polyp progression
Smad2 null mutation and, *Apc* ^{Δ 716} knockout mice, 4558
 intra-abdominal
 advanced
 proliferation assessment by PET, 5698
 melanoma
 metastasis to brain
*VEGF-A*₁₆₅ vascularity effects, 341
 MIA downregulation by COOH-terminal binding protein, 5962
 MMP-2 release from fibroblasts, 283
 peripheral nerve sheath tumors
 neurofibromatosis 1
 international consensus statement, 1573
 pleural mesothelioma
 EGFR inhibition, 5242
 susceptibility
 peripheral blood lymphocyte micronuclei and, 5418
 prostate tumor progression
 FGFR1 phosphotyrosine 766, 1898
 second oral
 loss of heterozygosity and, 6447
 transformation
ΔTA-p73, 3598
Mammary carcinogenesis
 inhibition by resveratrol, rats, 4945
Mammary carcinoma: See also Breast cancer
 gene expression profiles
 etiology-specific, rat, 3592
 growth and angiogenesis inhibition by IL-12, 747
 metastatic
 growth regulation by IFN- γ -dependent phagocytic cells, 4406
 single cell behavior correlation with gene expression patterns, 6278
 Ras organ specificity, 1241
 solitary
 and dormancy, 2162
Mammary epithelial cells
 immortalization by *Bmi-1*, 4736
 immortalized, characterization, 89
ING1 target gene detection by cDNA microarrays, mouse, 2203
 MEK1 signaling and, Eph4 cells, 4781
 psoriasis expression, 43
 transformation by PDK1, 3538
Mammary gland
 cell proliferation
 magnetic field-induced, rat, 1356
 matrilysin selection for apoptosis resistance, 5559
Mammary tumorigenesis
 aurora A, rat, 4115
Mammary tumors
 estrogen-dependent
Cimicifuga extract effects, 3448
 estrogen receptor-negative
 development prevention by LGD1069, mice, 6376
 green fluorescent protein labeling, transgenic mice, 7166
 growth inhibition
 adenoviral endostatin delivery, transgenic mice, 3934
 onset delay by ER α removal, 2798
 p21^{WAF1/CIP1} deficiency, mouse, 2077
 photodynamic therapy
 antivascular effects, 2151

7435

Mantle cell lymphoma
BMI-1 amplification and overexpression, 618
 transcriptional profiling, 4398
Mapping
 magnetic resonance
 VEGF-induced peritumor lymphatic drain, 6731
 redox
 RIF-1 tumor tissue, 307
 transcriptome, non-small cell lung cancer, 3340
Matrilysin
 apoptosis resistance selection, mammary cells, 5559
Matrix metalloproteinase
 host-derived, multiple-organ metastasis, 5967
 inhibitors
 specificity/efficacy correlation, T-cell lymphoma, 5543
 membrane-type 1
 VEGF regulation, glioma, 580
Matrix metalloproteinase 1
 2G single nucleotide polymorphism, 7200
Matrix metalloproteinase 2
 release from fibroblasts on malignant cell contact, 283
 secretion
 HA-CD44s and, lung cancer, 3962
 single nucleotide polymorphism
 and lung cancer risk, 6430
Matrix metalloproteinase 7: See Matrilysin
Matrix metalloproteinase 9
 regulation by translational efficiency, murine prostate cancer, 1910
MCAM/MUC18
 human anti-MUC18
 growth and metastasis inhibition, melanoma, 5106
Mcl-1
 degradation
 inhibition by bile acids, 6500
 overexpression
 response to death stimuli, 892
mdmx (mdm4)
 p53 regulation, 3221
Measles virus
 ovarian cancer therapy, 4656
Medulloblastoma
 epigenetic *RASSF1A* gene inactivation, 5906
HIC-1 hypermethylation, 3794
 induction by Shh, mice, 6385
 inhibition by DNA ligase IV, 6395
Meeting reports
 AACR Special Conference on Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications *In Vivo*, 2195
 AACR special meeting "Colon Cancer: Genetics to Prevention," 6779
 blood vessel leakiness in cancer, 5381
 epigenetic disease mechanisms, 6784
 international consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1, 1573
 Joint International Conference on Acute Promyelocytic Leukemia and Differentiation Therapy, 5618
 Thirteenth Annual Pezcoller Symposium, 3883
 workshop on childhood atypical teratoid/rhabdoid tumors, 323
MEF
 X chromosome tumor suppressor gene, 6579
MEK1
 and Eph4 mammary epithelial cells, 4781

- Melanocytes**
 senescence
 p300 downregulation and, 6231
 survival
 osteopontin, 4820
- α -Melanocyte-stimulating hormone**
 p16 expression and, 875
- Melanoma**
 adaptive phospholipid metabolism changes
 to CENU, 1890
 antigen
 retroviral, CTL-recognized, 5510
 BRAF and RAS mutations, 6997
 CD45RA⁺CCR7⁺ CTLs, 1743
 cell migration, collective
 plasticity, 2125
 combination Ad-E2F-1 gene transfer and
 chemotherapy, 1776
 cutaneous
 cyclin D1 candidate oncogene, 3200
 progression
 VEGFR-3 marker, 7059
 DNA electrovaccination, 5489
 drug resistance, 6698
 fusion tumor cell vaccines, 5495
 IFN-stimulated gene 15 and dendritic cell
 phenotype, 3453
 inhibition
 arginine deiminase, 5443
 human anti-MUC18, 5106
 IRF-3 tumor suppressor activity, B16 tu-
 mors, 5148
 lymph node metastasis
 hypoxia and, 1847
 malignant
 metastasis to brain
 VEGF-A₁₆₅ vascularity effects, 341
 MIA downregulation by COOH-terminal
 binding protein, 5962
 metastasis
 carbohydrate-dependent, 4194
 immune responsiveness, 3581
 inhibition
 human anti-MUC18, 5106
 interstitial fluid pressure and, 661
 PHLDA1/TDAG51 function, 5920
 T-cell receptor transcripts, 5664
 transendothelial function, 665
 metastasis to lung
 CXCR4 expression and, murine B16 cells,
 7328
 sialyl Lewis X antigen-dependent coloni-
 zation, 4194
 noscapine treatment, murine, 4109
 oncolytic adenoviruses, 4663
 osteonectin induction by β_3 integrin, 226
 phenotype
 microphthalmia transcription factor and,
 2098
 risk
 UVB flux and time outdoors and, 3992
 tumor epitope presentation rescue by PA28,
 2875
 tumor progression
 Akt, 7335
 tumor vessel patterning
 VEGF isoforms and, 1838
- Melanoma-associated antigen**
 isolation by SEREX, 4836
- Melanoma differentiation-associated gene 7**
 (*mda7*)
 Ad-mda-7, mechanism of action, 2239
- Melanomagenesis**
 UV-induced
 Ink4a/Arf deficiency and, 6724
- Membrane signaling**
 radiation bystander effects, 2531
- Membrane-type 1 matrix metalloproteinase**
 VEGF regulation, glioma, 580
- Membrane-type matrix metalloproteinase 3**
 proMT3-MMP
 processing by furin, Madin-Darby canine
 kidney cells, 675
- Memoriam**
 Monroe E. Wall, 7377
- Memory cytotoxic T lymphocytes**
 activation, 6438
- Menadione: See Vitamin K₃**
- Menopause**
Cimicifuga extract treatment
 estrogen-dependent mammary tumor ef-
 fects, 3448
- Mesenchymal stem cells**
 IFN- β tumor delivery, 3603
- Mesothelioma**
 asbestos-induced AP-1 and Fra-1, 6065
 diagnosis
 gene ratios, 4963
 pemetrexed transporter, novel, 6434
 pleural malignant
 EGFR inhibition, 5242
 susceptibility, peripheral blood lympho-
 cyte micronuclei and, 5418
- Met**
 expression
 late-stage nasopharyngeal carcinoma, 589
 regulation by Wnt signaling, colorectal
 cancer, 5126
- Metabolism**
 inhibition response to DNA damage, 3515
- Metallothionein**
 tumor differentiation regulation, 5370
- Metastasis**
 bone
 IL-8 expression and, breast cancer, 5571
 tumor burden reduction by doxycycline,
 breast cancer, 1588
 breast cancer to liver
 -specific adenovirus vector, 1063
 candidate of (com1)
 expression, breast cancer cells with meta-
 static potential, 4164
 carbohydrate-dependent, melanoma, 4194
 CD44 gene effects, sarcoma, 2281
 fluorescence imaging, pancreatic cancer,
 1534
 GPIIb/IIIa and $\alpha v\beta 3$ integrins and, 2824
 hematogenous
 PI3K/Akt pathway, hepatocellular carci-
 noma, 2971
 immune responsiveness, melanoma, 3581
 inhibition
 amphotericin RAGE-binding motif, 4805
 bone marrow TGF- β signaling blockade,
 gene therapy, 7135
 combination pegylated IFN- α 2b and do-
 cetaxel, prostate cancer, 5720
 combination urokinase-derived $\Delta 6$ and
 tamoxifen, breast cancer, 4678
 COX-1 or COX-2 inhibitors, murine
 breast cancer, 2343
 human anti-MUC18, melanoma, 5106
 MKK4 activity, ovarian cancer, 6717
 NESH, 2215
 tetrathiomolybdate, 4854
 interstitial fluid pressure and, melanoma,
 661
 laminin peptide, 3549
 laser immunotherapy components, rats, 4295
 liver
 inhibition by C-raf antisense oligonucleo-
 tides, colorectal cancer, 5393
 inhibition by novel cationic liposomes,
 4282
- specific adenovirus vector, 1063
 TNF-Rp55 knockout mice, 6682
 lymphatic, fibrinogen-deficient mice, 6966
 lymph node
 CCR7 expression, gastric cancer, 2937
 hypoxia and, melanoma, 1847
 malignant melanoma to brain
 VEGF-A₁₆₅ vascularity effects, 341
 mediation by MEK1 signaling, EpH4 mam-
 mary epithelial cells, 4781
 MET somatic mutations, 7025
 micrometastasis
 growth regulation by Ras, 887
 MAGE-based diagnosis, 251
 multiple-organ
 host-derived MMP expression, lung can-
 cer, 5967
 osteosclerotic
 breast cancer to bone
 PDGF-BB and, 917
 phenotype
 and IGF-IRs, breast cancer, 6529
 PHLDA1/TDAG51 function melanoma, 5920
 postoperative azotemia and, renal cell carci-
 noma, 5218
 potential
 com1 expression, breast cancer, 4164
 prevention
 FTY720, mouse breast cancer, 1410
 promotion by nonautocrine c-Met signaling,
 2951
 prostate cancer to bone
 stromal cell-derived factor-1/CXCR4,
 1832
 pulmonary
 CXCR4 expression and, murine B16 mel-
 anoma cells, 7328
 prevention by angiotensin II type I antagon-
 ist, renal cell carcinoma, 4176
 ZD6126 effects, lung adenocarcinoma,
 3711
 rate-limiting steps, real-time PCR analysis,
 7083
 regulation
 IFN- γ -dependent phagocytic cells, mam-
 mary cancer, 4406
 IGF-I, colon cancer, 1030
 single cell behavior correlation with gene
 expression patterns, mammary cancer,
 6278
 skeletal
 ²²³Ra antitumor effects, 3120
 T-cell receptor transcripts, melanoma, 5664
 transendothelial function, melanoma, 665
 urokinase and, *in vivo*, 2390
 VEGF-R and EGF-R, pancreatic cancer,
 1996
- Metastasis-associated genes**
 hepatocellular carcinoma, clonality deline-
 ation, 4711
- Metastasis suppressor genes**
 RhoGDI2, 6418
- Methioninase**
 DNA hypomethylation, 4685
- Methotrexate**
 resistance
 BCRP and, 5035
 transport by MRP4, 3144
- 2-Methoxyestradiol**
 ER α / β -independent mechanism of action,
 3691
- Methoxyisobutylisonitrile**
 Tc-MIB1 scintimammography
 Pgp/MRP expression and, 617
- α -Methylacyl-CoA racemase**
 AMACR sequence variants
 and prostate cancer risk, 6485

- prostate cancer, 2220
- Methylating agents**
DNMT1 protein depletion, 1592
- Methylation: See also Hypermethylation**
aberrant
 HPPI gene, colitis-associated tumors, 6820
 SHPI gene, leukemias/lymphomas, 6390
- APC gene**
lung cancer, 371
MSI+ endometrial cancers, 3663
- CDH13** promoter region, colorectal adenoma, 3382
- DAPK gene**
breast cancer, 6634
former smokers, 351
- de novo*
cell division requirements, bladder cancer, 2378
 H19 imprinting control region, 4545
 14-3-3 σ , oral carcinoma, 2072
 GSTP1 gene, former smokers, 351
hypomethylation
 methioninase, 4685
- MGMT** promoter
sputum
 germ-line polymorphisms and, 2248
- p16*, former smokers, 351
- p16^{INK4a}* promoter
sputum
 germ-line polymorphisms and, 2248
- RASSF1A** gene, prostate cancer, 3498
- Methylation inhibitors**
gene induction, fibroblasts, 961
- Methyl-group metabolism genes**
germ-line variants, 4519
- O⁶-Methylguanine DNA methyltransferase**
promoter methylation
sputum
 germ-line polymorphisms and, 2248
- 2-Methyl-1,4-naphthoquinone: See Vitamin K₃**
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone**
metabolites, smokeless cessation, 129
- Methylseleninic acid**
cell cycle arrest mechanisms, 156
- Methylthioadenosine phosphorylase gene (MTAP)**
tumor suppressor activity, breast cancer, 6639
- MET oncogene**
somatic mutations, carcinoma metastases, 7025
- Mevalonate**
alendronate invasion inhibition and, prostate cancer, 2708
- MIA**
downregulation by COOH-terminal binding protein, malignant melanoma, 5962
- Microadenomatous lesions**
colon, *Apc^{Min/+}* mice, 6367
- Microarrays**
cDNA
 differential gene expression, pancreatic cancer, 2890
 epithelial ovarian cancer, 2923
 esophageal lesions, 3493
 gene expression profiling, head and neck squamous cell carcinoma, 1184
 ING1 target gene detection, mouse mammary epithelial cells, 2203
 molecular profiling, bladder cancer, 6973
 gene expression ratios, cancer diagnosis, 4963
 oligonucleotide
 gene expression analysis, gastric cancer, 233
- prostate cancer analysis, meta-analysis, 4427
- sporadic ovarian cancer analysis, 3466
- Tag**
expressed CpG island sequence, 3214
- Microcalcifications**
breast, Raman spectroscopy, 5375
- Microenvironment**
and tumor therapy, 1462
- Micrometastasis**
growth regulation by Ras, 887
MAGE-based diagnosis, 251
- Micronuclei**
peripheral blood lymphocyte
 and pleural malignant mesothelioma susceptibility, 5418
- Microphthalmia transcription factor**
and melanoma phenotype, 2098
- Microsatellite instability**
APC methylation, endometrial cancers, 3663
DNA repair gene mutations, endometrial cancer, 4095
high-level, colorectal cancer
 frameshift TCF-4 mutations, 3009
 MMP-3 promoter mutations, 3855
low-level
 colorectal cancer, 53
 DNA polymerase β and, 6061
 low-level, colorectal cancer, 1166, 5988
 refractory germ cell tumors, 2758
 upper urinary tract cancer, 6796
- Microsatellite mutator phenotype**
short mononucleotide tract length polymorphisms, gastrointestinal cancer, 1961
- Microspheres**
cytokine-encapsulated
 tumor immunotherapy, 7254
- Microtubule agents**
mitotic responses, differential, 1935
- Microtubule inhibitors**
2-aryloindoles, 3113
- Microtubules**
stability
 regulation by survivin, 2462
 -stabilizing agent peloruside A, 3356
- Microvascular endothelium**
tumor
 heparin-binding VEGF substructure binding, 7118
- Microvascular proliferations**
glomeruloid, prognostic value, 6808
- Mig-6**
NF- κ B activation, 5668
- Minichromosome maintenance protein**
MCM7
transactivation by MYCN, neuroblastoma, 1123
- Mismatch repair**
deficiency
 mutations
 colorectal cancer, 1284
 review, 2447
 target gene mutation profiles, 1609
 target genes for instability, review, 2447
 gene rearrangements, hereditary nonpolyposis colorectal cancer, 848
- Mitochondrial DNA**
deletions, thyroid tumors, 7031
mutations
 prostate cancer, 6470
 somatic, breast cancer, 972
- Mitogen-activated protein kinase**
activation
 Gadd45a-dependent, 7305
 hydroxylutamide, prostate cancer, 6039
 ERK pathway
 neuroendocrine differentiation activation, 1549
- inhibitors
 apoptosis induction, Bcr/Abl-expressing leukemia, 188
 p38^{HOG}
 senescence role, 5076
- Mitogen-activated protein kinase kinase 4**
metastasis suppressor activity, ovarian cancer, 6717
- Mitogenesis**
blockade by tREGFR, pancreatic cancer, 5611
- Mitosis**
checkpoint control, ovarian cancer, 1662
microtubule agent responses, 1935
regulation by survivin, 2462
- Mitotic arrest deficiency protein 1**
human hSMAD1
 and cell proliferation, 2618
- Mitotic arrest deficiency protein 2**
MAD2 expression, ovarian cancer, 1662
- MKT-077**
and telomerase activity, 4434
- MLL-LCX fusion gene**
acute myeloid leukemia with trilineage dysplasia, 4075
- MLL-SEPTIN6 fusion gene**
infant t(X;11)(q24;q23) acute myeloid leukemia, 333
- MN/carbonyl anhydrase IX**
activation by PI3K
 oxygen levels, 4469
- Modifier of Min 1 (Momi^{1R}) gene**
CASTB6F1 *Momi^{1R/S}*, *Apc^{Min/+}* mice
 polyp multiplicity, 5413
- Molecular imaging**
meeting report, 2195
- Molecular profiling**
bladder cancer, 6973
non-small cell lung cancer, 3005
- Monoclonal antibodies**
anti-4-1BB mAb
 and large tumor immunotherapy, 3459
anti-flk-1
 combined with doxorubicin, soft tissue sarcoma, 2034
anti-HER2 trastuzumab
 synergy with T cells, 2244
anti-ICAM-2 mAb, ICAM-2⁺ colon cancer, 3167
CD137
 -mediated antitumor effects
 IFN- γ , 4413
- Monocytes**
CD95L expression, tumors, 1261
- Monokine induced by IFN- γ**
IL-10 tumor inhibition mediation, 2606
- Morphine**
angiogenesis and tumor growth promotion, 4491
- Mouse double minute 2**
isoforms
 cell proliferation inhibition, 1222
- Mouse double minute 4**
p53 regulation, 3221
- Mouse Tumor Biology Database (MTB)**, 1235
- MRP6: See Multidrug resistance protein 6**
- MS-27-275**
antitumor activity, pediatric solid tumors, 6108
- MSI: See Microsatellite instability**
- MTG16 gene: See CBFA2T3 gene**
- Mucins**
MUC1
 human TCR-like MUC1-specific recombinant antibodies, 5835
MUC18

- human anti-MUC18
growth and metastasis inhibition, melanoma, 5106
- Mucosa**
oral
carcinogen bioactivation inhibition by curcumin, 5451
- Multidrug resistance 1 gene *MDR1***
polymorphisms, acute myeloid leukemia, 4955
regulation
HIF-1-dependent, 3387
- Multidrug resistance protein**
expression
and Tc-MIBI scintimammography, 617
- Multidrug resistance protein 1**
activity
in vivo analysis, 391
- Multidrug resistance protein 4**
methotrexate and folate transport, 3144
- Multidrug resistance protein 6**
drug resistance and transport properties, 6172
- Multiple antigen peptide**
cellular processing, 1471
- Multiple endocrine neoplasia**
function-impaired RET-MEN2A
repair, 2414
recessive syndrome, rat, 3048
- Multiple intestinal neoplasia**
Apc^{min} mice
tumor load reduction by vitamin D₃ compounds, 741
Apc^{Min/+} mice
microadenomatous lesions, colon, 6367
PGE₂ modulation of NSAID effects, 403
Apc^{Min/+}, *CASTB6F1 Mom1^{S/S}* mice
polyp multiplicity, 5413
Apc^{Min/+} Dnmt1-hypomorphic mice
polyp inhibition, 1296
Min mice
CEA-based vaccine antitumor activity, 6944
cyclin D1, 4562
- Multiple myeloma**
CCI-779 efficacy, 5027
chromosome 13 abnormalities, 715
PTK787/ZK222584 activity, 5019
telomerase activity modulation by cytokines, 3876
- Mutagenesis**
ionizing radiation, solid tissue, 1518
- Mutagenicity**
crocidolite asbestos, 99
- Mutations: See also Deletions**
androgen receptor
prostate cancer, 1496
APC
growth advantages, colorectal tumors, 363
polymerase β and, colon tumors, 3271
AR gene
relapsed CWR22 prostate cancer cell growth, 6606
BCR/ABL, leukemia, 5995
Bcrp1 hot spot
and doxorubicin resistance, 2294
BRAF
colorectal tumors, 6451
lung adenocarcinoma, 7001
BRCA1
carriers
tumor gene profiling, 7110
BrcA2
cancer susceptibility, mice, 990
genomic instability, 6194
BRCA1-BRCA2 mutation carrier
breast cancer, 2741
- β -catenin
gastric cancer, 3503
colonic mutated crypts, ulcerative colitis, 2236
compound *Apc* and *Smad2*
tumors, mice, 4558
DNA repair genes, MSI+ endometrial cancer, 4095
EGFR
asbestos-induced proliferation inhibition, lung epithelium, 4169
FH, hereditary leiomyomatosis and renal cell cancer, 4554
frameshift TCF-4, MSI-high colorectal cancer, 3009
germ-line
and breast cancer survival, 3052
hMSH2 and *hMLH1* promoter region, colorectal cancer, 38
hMSH2 hematological malignancy and café-au-lait spots, 359
MSH2 and *MLH1* mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
p53
and chemical carcinogenesis, mice, 3024
hCDC4, endometrial cancer, 4535
hExo1
alterations, hereditary nonpolyposis colorectal cancer, 6026
N-hydroxy-4-acetylaminobiphenyl, 4325
KRAS gene
colorectal tumors, 6451
lacI
electromagnetic near field, mice, 1956
MMP-3 promoter, MSI-H colorectal cancer, 3855
MMR-deficient colorectal cancer, 1284
MMR-deficient tumors, review, 2447
mtDNA, prostate cancer, 6470
neo-poly(A) polymerase
MHC class II-restricted recognition, 5495
Nkx3.1
prostate cancer initiation, mice, 2999
oncogenic
and tumor growth angiogenesis dependence, review, 1931
p53
gene amplification induction, 3264
genomic instability, 6194
hsMAD1 and, 2618
and smoking, breast cancer, 1987
point
DNA ligase I, mice, 4065
Znfn1a1/Ikaros gene, murine lymphoma, 2650
short mononucleotide tract length polymorphisms, gastrointestinal cancer, 1961
somatic
MET oncogene, carcinoma metastases, 7025
mtDNA, breast cancer, 972
RNF6, esophageal squamous cell carcinoma, 4191
stable
 β -catenin, mouse liver, 1971
sucrose-rich diet, rat colon, 4339
target gene, MSI-H cancer, 1609
topoisomerase I, novel, 3716
- MutL homologue**
human *hMLH1*
hypermethylation
HPPI hypermethylation and, gastric adenocarcinoma, 5637
promoter region germ-line mutations, colorectal cancer, 38
- MLH1*
germ-line mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
hypermethylation, hereditary nonpolyposis colorectal cancer, 3925
- MutS homologue**
human *hMSH2*
germ-line mutations
hematological malignancy and café-au-lait spots, 359
promoter region germ-line mutations, colorectal cancer, 38
- MSH2*
germ-line mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
inactivation, hereditary nonpolyposis colorectal cancer, 848
Msh2-deficient mice
colitis-associated tumors, 2092
Msh2^{-/-}Rb^{+/+} mice
cell lineage effects, 5134
- MV6401**
combined with photodynamic therapy
microvasculature effects, mammary tumors, 2151
- Myc**
-induced apoptosis
Omomyc and, 3507
tumorigenesis
inhibition by *E2f1*, 3276
- MYCN**
circulating DNA, neuroblastoma, 3646
MCM7 transactivation, neuroblastoma, 1123
- Myelogenous hyperplasia**
NQO1 disruption, mice, 3030
- Myeloma**
growth inhibition by PS-341, 4996
multiple
CCI-779 efficacy, 5027
chromosome 13 abnormalities, 715
PTK787/ZK222584 activity, 5019
telomerase activity modulation by cytokines, 3876
- N
- NAD(P)H**
epithelial precancer fluorescent biomarker, 682
- NAD(P)H:quinone oxidoreductase (NQO1/DIA4)**
NQO1 gene disruption, myelogenous hyperplasia, 3030
nuclear localization, cancer, 1420
polymorphisms
and sputum promoter methylation, 2248
- Nasopharyngeal carcinoma**
EBV peptide-pulsed dendritic cell immunotherapy, 6952
late-stage
Met expression, 589
tumor-targeted gene therapy, 171
- National Cancer Institute (NCI)**
workshop on childhood atypical teratoid/rhabdoid tumors, meeting report, 323
- Natural killer T cells**
CD8+
tumor targeting, 5785
- Neoglycans**
anticancer agents, 3722
- Neoplasia**
B-cell
growth inhibition by S-3APG, mice, 2300
benzo(a)pyrene-induced transformation, lung fibroblasts, 4605
epithelial
stromal regulation, 79

- lymphoid
immunodeficient nonobese diabetic mice, 5828
multiple endocrine
function-impaired RET-MEN2A
repair, 2414
- Neo-poly(A) polymerase**
mutations
MHC class II-restricted recognition, 5495
- NESH**
cell migration and metastasis inhibition, 2215
- Neural stem cells**
IL-12, glioma therapy, 5657
-mediated TRAIL delivery, glioma therapy, 7170
- Neuroblastic cells**
neuroblastoma, 2986
- Neuroblastoma**
allelotype, 1761
angiogenesis inhibition by SPARC, 7357
angiogenesis inhibition by TrkA, 1802
chemotherapy
BDNF-TrkB-PI3K pathway protection, 6756
chemotherapy resistance
mediation by TrkB, 6462
chromosome 1p36.3 imprinting absence, 6481
circulating *MYCN* DNA, 3646
familial
chromosome 16p12-13 mapping, 6651
fenretinide-induced apoptosis, 5158
MCM7 transactivation by *MYCN*, 1123
neuroblastic cells, 2986
prognosis
Id2 and, 301
purging
virus-directed enzyme prodrug therapy, 5001
retSDR1 and retinol metabolism, 1196
Schwannian stromal cells, 2986
transformation to neuronal cells by VHL protein, 7004
- Neuroendocrine differentiation**
activation by ERK, 1549
- Neurofibromatosis**
type 1
-associated pilocytic astrocytoma
gene expression analysis, 2085
malignant peripheral nerve sheath tumors
international consensus statement, 1573
NF1 gene
aberrant splicing, tumors, 1503
Nf1:p53 mouse tumor cells
EGFR signaling, 4507
type 2
NF2 gene
aberrant splicing, tumors, 1503
- Neuronal cells**
neuroblastoma transformation by VHL protein, 7004
- Neurotensin**
protein kinase D activation, pancreatic cancer, 1632
- Neutron capture therapy**
molecular EGFR targeting, glioma, 3159
- NIH 3T3 cells**
telomerase inhibition, 2104
- 90K (Mac-2 binding protein)**
non-small cell lung cancer, 2535
- NIP3**
induction by desferri-exochelin, 6924
- Nitric oxide**
alkyltransferase inactivation and degradation, 3037
apoptosis inhibition, 1648
irradiation-induced, endothelial
apoptosis induction, 1450
- Nitric oxide synthase**
inducible
deficiency
lung tumorigenesis reduction, mouse, 6850
induction by glioma-associated hyaluronan, dendritic cells, 2583
inhibitor
combined with COX-2 inhibitor, chemopreventive effects, colon cancer, 165
- 3-Nitroflavones**
electron-donating ability
and colon cancer prevention, 6506
- Nitroreductase**
suicide gene therapy
bystander effects, 3D cell cultures, 1425
- NKG2D**
MHC class I-related chain A and UL16-binding protein recognition, tumors, 6178
- Nkx-3.1 gene**
C154T polymorphism, 2654
mutations, prostate cancer initiation, 2999
prostate-derived Ets factor interactions, 338
- NM-3**
combined with chemotherapy, antineoplastic effects, 789
- Nobiletin**
tumor invasion inhibition, fibrosarcoma, 1025
- Nonsteroidal anti-inflammatory drugs**
effects
modulation by PGE₂, *APC*^{Min/+} mice, 403
and GATA-6, colorectal cancer, 1178
15-lipoxygenase-1 upregulation, colorectal cancer, 1178
- Noscapine**
melanoma treatment, murine, 4109
- N-ras gene**
tumor suppressor activity, 4514
- Nuclear factor E2 p45-related factor 2 (Nrf2)**
-regulated genes
cancer chemoprevention, 5196
- Nuclear factor κB**
activation
Mig-6-induced, 5668
PAF, 1809
promotion by protein kinase CK2, breast cancer, 6770
TP53-inactive keratinocytes, 1213
BPDE-induced transactivation
inhibition by berry extracts, 6857
and faslodex resistance, 3428
inhibitors
adhesion-dependent colon cancer apoptosis, 6870
platelet-activating factor-induced angiogenesis, 1809
radiation-induced
inhibition by anti-Ras scFv, 2318
upregulation by Akt/protein kinase B activation, melanoma, 7335
- Nuclear magnetic resonance**
lipid accumulation, 1394
mobile lipid compartment dimensions, C6 cells, 5672
- Nuclear matrix protein**
alterations, colon cancer, 2437
- Nucleophosmin**
and faslodex resistance, 3428
- Nucleophosmin-anaplastic lymphoma kinase**
expression downregulation by 17-AAG, anaplastic large cell lymphoma, 1559
- Nucleoporin gene NUP98**
NUP98-HOXC11 fusion gene, t(11;12)-acute 7439
myeloid leukemia, 4571
NUP98-HOXC11 fusion gene, t(2;11)-acute myeloid leukemia, 33
- Nucleotide excision repair**
global
regulation by p53, fibroblasts, 5288
transcription-coupled
and cisplatin sensitivity, 4899
- NY-ESO-1 119-143**
T-helper epitope, 213
- O**
- Okadaic acid**
tumor promotion
blockade by TAM-67, 3044
- Oligodeoxynucleotides**
antisense
DNA-PKcs inactivation, 6621
CpG-ODN
combined with HPV-16 E7, immune therapy, 7234
- Oligonucleotides**
c-myc antisense
growth inhibition, MCF-7 breast cancer cells, 3126
C-raf antisense
colorectal cancer liver metastasis inhibition, 5393
Ku86 antisense
effects, malignant glioma, 5888
microarrays
gene expression analysis, gastric cancer, 233
- Omomyc**
and Myc-induced apoptosis, 3507
- Oncogenesis**
bcl-2, rat, 6297
- ONYX-015**
malignant glioma xenografts, 764
- Oral carcinoma**
14-3-3σ methylation, 2072
second malignancy
loss of heterozygosity and, 6447
squamous cell
inhibition by curcumin, 5451
Stat3 downregulation by sulindac, 1004
- Oral dysplasia**
epithelial, severe
p16^{INK4a} and *p14^{ARF}* alterations, 5295
molecular analysis, 4757
- Oral mucosa**
carcinogen bioactivation inhibition by curcumin, 5451
- Oral premalignant lesions**
lymphocyte chromosome instability and, 2813
- Osteoblastic lesions**
zoledronate treatment, SCID mouse model, 5564
- Osteoblasts**
inhibition by Trk receptor, 986
- Osteolytic lesions**
zoledronate treatment, SCID mouse model, 5564
- Osteonectin**
induction by β₃ integrin, melanoma, 226
- Osteopontin**
brain
astrocytoma cell migration promotion, 5336
and breast cancer, 3417
melanocyte survival, 4820
- Osteoprotegerin**
survival factor, prostate cancer, 1619
- Osteosarcoma**
VP-16-induced fragmentation
DNASIL3, 4439

Outdoors time

and melanoma risk, 3992

Ovarian cancer

Ad5-Δ24RGD treatment, 1266

apoptosome activation, dysfunctional, 924

calpain-dependent apoptosis

induction by *ARHI*, 7264

candidate oncogene *SEI-1*, identification, 7157

CXCL12 role, 5930

epigenetic factors and *BRCA* genes, 4151

epithelial

cDNA array and, 2923

cell migration promotion by periostin, 5358

malignant

hyaluronan levels, 6410

risk

CYP17 and *COMT* polymorphisms and, 3058

gene transfer

retroviral vs lentiviral vectors, 6099

growth inhibition by phospholipid scramblase 1, 397

hK11 biomarker, 295

lysophosphatidic acid-induced migration inhibition by alendronate, 6015

MAD2 expression, 1662

measles virus therapy, 4656

mitotic checkpoint control, 1662

MKK4 metastasis suppressor activity, 6717

molecular profiling, 4722

paclitaxel resistance and RAR-γ, 2192

PI3k inhibition and paclitaxel, 1087

reovirus therapy, 1696

sporadic

parallel analysis by SKY, CGH, and microarray analysis, 3466

suppression subtraction hybridization libraries, 262

survival

dipeptidyl peptidase IV overexpression and, 2753

Ovarian surface epithelial cells

telomerase regulation by JNK, 4575

Ovarian tumors

epithelial

malignant

hyaluronidase activity, 6410

Oxidative metabolism

and α-particle irradiation bystander effects, fibroblasts, 5436

Oxidative stress

expression profiles, breast cancer, 6246

Oxygen

carbonic anhydrase IX expression activation by PI3K, 4469

intra-tumoral distribution, photodynamic therapy, 7273

Oxygen-dependent degradation

TAT-ODD fusion protein

antitumor effects, 2013

Oxytocin

functional signaling, small cell lung cancer, 4623

Kaposi's sarcoma growth factor, 2406

P

p14^{ARF}

alterations, severe oral epithelial dysplasia, 5295

expression

and p53 resistance, 1305

hypermethylation, ulcerative colitis-associated colorectal cancer, 1148

p16

expression

α-MSH and, 875

methylation, former smokers, 351

silencing modes, esophageal squamous cell carcinoma, 4938

p16^{INK4a}

alterations, severe oral epithelial dysplasia, 5295

and p53 deficiency, murine tumorigenesis, 2761

promoter methylation

sputum

germ-line polymorphisms and, 2248

p21^{Cip1/Waf1}

deficiency, mouse mammary tumors, 2077

and horizontal gene transfer, 575

p27

ΔEGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764

p38^{HOG}

senescence role, 5076

p53

activation

Gadd45a-dependent, 7305

AdΔ24-p53, oncolytic potency, 6165

adenoviral gene transfer

phosphorylation, glioma, 1069

alterations, flat urothelial neoplasia, 809

and chemoradiation response, cervical cancer, 7364

damage response

mediation by TGF-β1, 5627

deficiency

p16^{INK4a} and, murine tumorigenesis, 2761

functional loss, tumor progression, 2897

GART inhibitor cytotoxicity independence, 5236

and genetic stability, 1129

global excision repair regulation, fibroblasts, 5288

hypermutable bases

secondary structure positions, 5641

IL-6 production, renal cell carcinoma, 932

and lung cancer risk, 2819

mutations

gene amplification induction, 3264

genomic instability, 6194

germ-line

and chemical carcinogenesis, mice, 3024

hsMAD1 and, 2618

and smoking, breast cancer, 1987

p53-targeted disruption

Helicobacter-induced gastric cancer inhibition, 696

radiation response targets

tissue-specific induction, 7316

-regulated genes

modulation by thymidylate synthase, 2644

regulation

ING1b, 4890

mdmx, 3221

resistance

p14ARF expression and, 1305

STAT3 activity modulation, breast cancer, 376

wild-type

-specific CD4⁺ T-helper cells, antitumor efficacy, 6187

WT1 gene interactions, 6615

p53²⁶⁴⁻²⁷²

-specific T cells, head and neck squamous cell carcinoma, 3521

p53AIP1

apoptosis regulation, 2884

p70^{S6k}

UV-induced phosphorylation, signal pathways, 5689

p73

ΔNp73, oncogenic potential, 636

7440

p185^{HER2}; See HER-2/neu

p300

AR transactivation by IL-6, 5632

BRCA1 inhibition modulation, 141

downregulation

and melanocyte senescence, 6231

Paclitaxel

combined with ET-743, breast cancer, 6909

PI3k inhibition and, ovarian cancer, 1087

resistance

and RAR-γ, ovarian carcinoma, 2192

Pain

bone cancer

blockade by COX-2 inhibitors, 7343

Pancreatic adenocarcinoma

peptidomic marker peptide discovery, 4894

risk

XRCC1 Arg399Gln polymorphism and, 4630

Pancreatic cancer

apoptosis

T-cell activation, 2347

CCK-B receptor missplicing, 947

chemoresistance

IL-1β and, 910

differential gene expression, cDNA microarray, 2890

familial

BRCA2 mutations, 3789

growth, fluorescence imaging, 1534

growth inhibition by COX-2 inhibitors

IGF-I and, BxPC-3 cells, 7372

IL-4R-targeted therapy, 3575

interglandular heterogeneity, 835

magnetic resonance imaging, transgenic mouse model, 1555

metastasis

fluorescence imaging, 1534

VEGF-R and EGF-R, 1996

mitogenic blockade by trEGFR, 5611

protein kinase D activation

neurotensin-induced, 1632

secretin receptor, 5223

serial analysis of gene expression, 819

ssr2 gene transfer, antitumor effects, 6124

Pancreatic ductal adenocarcinoma

HIP/PAP-I, 1868

Pancreatic islet cell tumors

VHL-associated

loss of heterozygosity, 1952

Par-4

function, neoplastic T lymphocytes, 1768

PC-cell-derived growth factor/acroganin:

See **Progranulin**

PC-3 cells

5-HETE stimulation, 6817

PC12 cells

catecholamine regulation pVHL, 1682

PCPH oncogene

and cellular stress response, 2690

PC-SPES

growth inhibition, colon cancer, 5204

molecular effects, 3920

PD173955

c-Abl complex

kinase domain crystal structures, 4236

PD180970

activity against imatinib-resistant Abl mutants, 7149

Pediatric tumors

atypical teratoid/rhabdoid tumors, meeting report, 323

caspase 8 and *caspase 10* expression, 5897

solid tumors

MS-27-275 antitumor activity, 6108

Pegylated arginine deiminase (ADI-SS

PEG_{20,000})

melanoma and hepatocellular carcinoma in-

- hibition, 5443
- Pegylated interferon α -2b**
combined with docetaxel
prostate cancer inhibition, nude mice, 5720
- Peloruside A**
microtubule-stabilizing activity, 3356
- Pemetrexed**
transporter, mesothelioma, 6434
- Peptides**
arginine-glycine-aspartic acid (Arg-Gly-Asp) (RGD)
radiolabeled, tumor targeting, 6146
tumor cell binding, 5139
EBNA1 peptide helpers, CD4⁺ T cells, 7195
EBV peptide-pulsed dendritic cell immunotherapy, nasopharyngeal carcinoma, 6952
laminin, metastasis, 3549
MHC class I and class II dual-specific, 3630
modified PF-4
angiogenesis inhibition, 6884
multiple antigen
cellular processing, 1471
RGD binding, tumor cells, 5139
synthetic combinatorial libraries
positional scanning format
recognition by tyrosinase-specific CTLs, 2058
- Peptidomimics**
marker peptide discovery, pancreatic adenocarcinoma, 4894
- Perifosine**
cell cycle arrest, SCC, 1401
- Periostin**
cell migration promotion, epithelial ovarian carcinoma, 5358
- Peripheral blood**
lymphocytes
micronuclei
and pleural malignant mesothelioma susceptibility, 5418
progenitor cells
mobilization by combination defibrotide and rhG-CSF, mice, 6152
stem cells
transplantation, autologous
adenoviral purging, 5013
- Peripheral nerve sheath tumors**
malignant
neurofibromatosis 1
international consensus statement, 1573
- Peroxisome proliferator-activated receptors**
K-Ras transformation modulation, intestinal epithelial cells, 3282
- P-glycoprotein**
expression
and Tc-MIBI scintimammography, 617
- Phagemid gene transfer**
carcinoma, 977
- Phagocytic cells**
IFN- γ -dependent
tumor growth regulation, metastatic mammary carcinoma, 4406
- Phenethyl isothiocyanate**
apoptosis
ERKs, prostate cancer, 3615
- Phenotype**
dendritic cell
interferon stimulated gene 15 and, melanoma, 3453
Gli2 NH₂-terminal fragment and, skin tumor, 5308
metastatic
and IGF-IRs, breast cancer, 6529
microphthalmia transcription factor and, melanoma, 2098
- 1-Phenylazo-2-hydroxynaphthol: See Sudan I**
- PHLDA1/TDAG51 gene**
function, metastatic melanoma, 5920
- Phosphatidylinositol 3-kinase**
BDNF-TrkB-PI3K pathway
protection against chemotherapy, neuroblastoma, 6756
carbonic anhydrase IX expression activation oxygen levels, 4469
 Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
inhibition
herceptin-induced, 4132
and paclitaxel, ovarian cancer, 1087
PI3K/Akt pathway
anchorage-independent growth and hematogenous metastasis, liver cancer, 2971
irradiated endothelium, 4671
PI3K/PTEN/Akt pathway
and fatty acid synthase, LNCaP prostate cancer cells, 642
TRAIL-induced apoptosis, non-small cell lung cancer, 4929
- Phosphatidylserine**
tumor vessel marker, 6132
- 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase**
inducible
expression, cancer, 5881
- 3-Phosphoinositide-dependent protein kinase 1**
mammary epithelial cell transformation, 3538
- Phospholipids**
anionic
exposure, tumor blood vessels, 6132
metabolism
adaptive changes to chloroethylnitrosourea, melanoma, 1890
- Phospholipid scramblase 1**
growth inhibition, ovarian cancer, 397
- Phosphoproteins**
ribosomal
breast
downregulation by GnRH, 1036
- Photodynamic therapy**
antitumor vaccines, 1604
antivascular effects, mammary tumors, 2151
combined with COX-2 inhibition, 3956
combined with inducible suicide gene therapy, 1458
fractionated
vascular and tumor cell targeting, breast tumors, 4289
intra-tumoral oxygen distribution, 7273
sensitivity
extracellular signal-regulated kinase and, 5528
- Pilocytic astrocytoma**
gene expression analysis, 2085
- Pimodidazole**
binding
and treatment outcome, head and neck cancer, 7066
oral, 6827
- Piroxicam**
effects, canine invasive bladder cancer, 356
esophageal tumorigenesis effects, rat, 4376
- Pituitary adenomas**
HMG2 overexpression, 2398
- PKI-166**
growth inhibition, prostate cancer, 5254
- Placental growth factor**
survival factor, tumor endothelial cells and macrophages, 2749
- 7441
- Plant-derived HPV16 E7**
tumor protection, 3654
- Plasmid-based deletion assay**
Werner syndrome fibroblasts, 547
- Plasminogen activator inhibitor type 1**
predictive impact, breast cancer, 4617
- Plasticity**
collective melanoma cell migration, 2125
- Platelet-activating factor**
angiogenesis
nuclear factor κ B, 1809
- Platelet-derived growth factor**
autocrine signaling, glioblastoma, 3729
receptor
antagonists
chemotherapy enhancement, 5476
- Platelet-derived growth factor BB**
and osteosclerotic bone metastasis, breast cancer, 917
- Platelet-derived growth factor D**
expression, cancer, 2468
- Platelet factor 4**
modified peptides
angiogenesis inhibition, 6884
- Pleomorphic adenoma gene (PLAG) proteins**
tumorigenic characteristics, 1510
- Pleural mesothelioma**
malignant
EGFR inhibition, 5242
susceptibility
peripheral blood lymphocyte micronuclei and, 5418
- PML gene**
induction by β -catenin, 5947
- Podosomes**
formation
N-WASP, 669
- Polo-like kinase 1**
and cancer cell proliferation inhibition, 4186
- Poly(ADP-ribose) polymerase**
CHS 828 sensitivity, mouse fibroblasts, 4206
gene therapy, prostate cancer, 6879
PARP-1^{-/-} mice
Ku80 heterozygosity and hepatocellular carcinoma, 6990
- Polyamines**
histone acetyltransferase and histone deacetylase regulation, murine skin and tumors, 67
- Polycystic kidney disease**
c-myc-induced apoptosis, 2210
- Polyethylene glycol**
-conjugated d-amino acid oxidase
tumor-targeted H₂O₂ generation, 3138
pegylated arginine deiminase (ADI-SS PEG^{20,000} mw)
melanoma and hepatocellular carcinoma inhibition, 5443
pegylated IFN- α -2b
combined with docetaxel
prostate cancer inhibition, nude mice, 5720
- Poly-l-arginine**
vaccination, 1477
- Polymerase chain reaction**
real-time
metastatic cascade rate-limiting steps, 7083
reverse transcriptase
preoperative RT-PCR-hK2 status
and prostate cancer progression, 5974
- Polyps**
inhibition, *Apc*^{Min/+} *Dnmt1*-hypomorphic mice, 1296
intestinal
angiogenesis, mouse models, 506
COX-2 expression, 6846

- multiplicity, CASTB6F1 *Mom1^{S/S}*, *Apc^{Min/+}* mice, 5413
- Polyunsaturated fatty acids**
and skin cancer, HPV-16 transgenic mice, 433
- Positron emission tomography**
FLT-PET, lung nodules, 3331
in vivo VEGF imaging, 5912
proliferation assessment, advanced intra-abdominal malignancy, 5698
- Potassium channels**
HERG
tumor cell apoptosis and growth regulation, 4843
- PP1**
RET-transforming activity inhibition, 1077
- Precancer**
epithelial
NAD(P)H/collagen fluorescent biomarkers, 682
oral premalignant lesions
lymphocyte chromosome instability and, 2813
- pRL1a**
cellular processing, 1471
- Prodrugs**
carboxypeptidase G2 suicide gene therapy, 1724
enzyme-activated prodrug therapy
combined adenoviral and cytostatic therapy, 6089
P450 gene-directed
apoptotic factors and, 6928
virus-directed enzyme prodrug therapy
neuroblastoma purging, 5001
- Progesterone**
growth inhibition, endometrial cancer, 881
- Progranulin**
tumor progression, 5590
- Prolactinoma**
HMGA2 overexpression, 2398
- Prostacyclin: See Prostaglandin I₂**
- Prostaglandin E**
receptor EP₄
colon carcinogenesis, 28
- Prostaglandin E₂**
COX-2-derived
tumor growth promotion, head and neck cancer, 6706
NSAID effects modulation, *APC^{Min/+}* mice, 403
- Prostaglandin I₂ synthase**
gene transfer, colon cancer, 63
overexpression
chemoprevention, murine lung cancer, 734
- Prostate**
angiogenesis inhibition by bisphosphonates, rats, 6538
cellular interactions, type I collagen gels, 58
epithelial cell senescence
characterization by SAGE, 6255
epithelium
FGF8b overexpression, mouse, 5096
RXRα allele inactivation, prostatic intraepithelial neoplasia, 4812
- Prostate cancer**
AlbZIP expression and regulation, 721
androgen receptor mutations, 1496
androgen-refractory
cell proliferation
androgen receptor, 1008
apoptosis
induction by quinazolines, 597
induction by raloxifene, 5365
induction by raloxifene, LNCaP cells, 3649
RhoA-dependent, 2630
Smac, LNCaP cells, 18
- autocrine regulation by VEGF, 854
candidate gene targets
clinical validation, tissue microarrays, 1256
chemoresistance modulation by rapamycin, 6141
cholesterol and Akt signaling, 2227
coxsackie adenovirus receptor expression, 3812
Cten downregulation, 4217
cytokine gene polymorphisms and, 3369
detection by proteomic profiling, 3609
E2F-1 and cyclin B modulation by CD437, 3842
gene expression analysis
comprehensive, 4499
electronic expression profiling, 3308
meta-analysis, 4427
growth inhibition
combination pegylated IFN- α -2b and docetaxel, nude mice, 5720
HEPSIN, 6812
PKI-166, xenografts, 5254
silibinin, 3063
growth modulation by selenium, 2540
HEPSIN functions, 6812
HER2, 5485
HIF-1 α inhibition by geldanamycin, 2478
hK11 biomarker, 295
HMG1(Y) and chromosomal rearrangements, 647
hOGG1 variants and, 2253
IGF1R expression, 2942
initiation, *Nkx3.1* mutant mice, 2999
invasion
inhibition by alendronate, 2708
inhibition by *HEPSIN*, 6812
lecithin:retinol acyltransferase levels, 1654
12-lipoxygenase inhibition, 2721
MAP kinase activation by hydroxyflutamide, 6039
metastasis
inhibition by combination pegylated IFN- α -2b and docetaxel, nude mice, 5720
8p suppressor gene, rat, 367
metastasis to bone
stromal cell-derived factor-1/CXCR4, 1832
 α -methylacyl-CoA racemase, 2220
MMP-9 regulation by translational efficiency, murine, 1910
mtDNA mutations, 6470
osteoprotegerin survival factor, 1619
PARP-based gene therapy, 6879
PEITC-induced apoptosis
ERKs, 3615
PI3k/PTEN/Akt kinase and fatty acid synthase, LNCaP cells, 642
PRC17 amplification, 5420
prevention by toremifene, 1370
progression
gene expression profiles, 5325
preoperative RT-PCR-hK2 status and, 5974
selenoprotein-P downregulation, mice, 5325
RASSF1A methylation, 3498
-reactive CTLs, 5807
-reactive stroma
TGF- β and angiogenesis, 6021
recurrent
adenoviral double suicide gene therapy, phase I study, 4968
PKC ϵ , 2423
relapsed growth
AR mutations, CWR22 cells, 6606
retinol metabolism reduction, 1654
- RhoA-dependent cell proliferation, 2630
risk
AMACR sequence variants and, 6485
Stat3 activation, 6659
susceptibility
HSD3B genes and, 1784
- Prostate cancer gene 17 (PRC17)**
amplification, prostate cancer, 5420
- Prostate carcinogenesis**
chemoprevention by 9-*cis*-retinoic acid, rats, 5178
- Prostate-derived Ets factor**
NKX-3.1 interactions, 338
- Prostate-specific membrane antigen**
selective tumor infarction, 5470
- Prostate-specific RNA aptamers**, 4029
- Prostate stem cell antigen**
therapy target, 2546
- Prostate tumorigenesis**
chromosome 20q13 genes and, 6803
early telomere shortening, 6405
reactive stroma and, 3298
- Prostate tumors**
DDC^{PCa3} gene marker, 2695
progression to malignancy
FGFR1 phosphotyrosine 766, 1898
- Prostatic intraepithelial neoplasia**
FGF8b mouse model, 5096
inhibition by 9-*cis*-retinoic acid, rats, 5178
RXRα allele inactivation, prostate epithelium, 4812
- Proteasome**
nuclear
and drug resistance, 5008
- Proteasome activator PA28**
tumor epitope presentation rescue, melanoma, 2875
- Proteasome inhibitor PS-341**
adult T-cell leukemia therapy, murine model, 1083
tumor growth inhibition, myeloma, 4996
- Protein kinase**
RNA-regulated
translation regulation, 2272
- Protein kinase B**
Akt/PKB
and TRAIL resistance, non-small cell lung cancer, 4929
tumor progression, melanoma, 7335
- Protein kinase C α**
PDK1 mammary epithelial cell transformation, 3538
- Protein kinase C ϵ**
recurrent prostate cancer, 2423
- Protein kinase CK2**
NF- κ B activation promotion, breast cancer, 6770
- Protein kinase C ζ**
inducible chemoresistance factor, 1815
RhoA-dependent cell proliferation and apoptosis, prostate cancer, 2630
- Protein kinase D**
activation
neurotensin-induced, pancreatic cancer, 1632
- Protein phosphatase 1 α**
BRCA1 interactions, 6357
- Protein tyrosine phosphatase**
low-molecular-weight
 β -catenin interactions, cell-cell adhesion, 6489
- Proteomic profiling**
breast ductal carcinoma *in situ*, 6740
prostate cancer detection, 3609
- Proto-oncogenes**
cadmium-responsive, novel, 703
- PS-341**
adult T-cell leukemia therapy, murine

model, 1083
tumor growth inhibition, myeloma, 4996
Psoriasis
expression, mammary epithelial cells, 43
PTEN
hyaluronic acid-induced invasion inhibition, glioblastoma, 6318
PI3K/PTEN/Akt pathway
and fatty acid synthase, LNCaP prostate cancer cells, 642
TRAIL-induced apoptosis, non-small cell lung cancer, 4929
PTK787/ZK 222584
activity, multiple myeloma, 5019
tumor vascular bed effects, 4015
Pulmonary fibrosis
radiation-induced
genetic loci, murine, 3782
Pulmonary metastasis
CXCR4 expression and, murine B16 melanoma cells, 7328
prevention by angiotensin II type I antagonist, renal cell carcinoma, 4176
ZD6126 effects, lung adenocarcinoma, 3711
Purging
adenoviral, autologous PBSC transplantation, 5013
virus-directed enzyme prodrug therapy, neuroblastoma, 5001
Pyrimidine
regulation
uridine phosphorylase knockout and, 2313
Pyrimidine nucleoside monophosphate kinase
characterization and l-form deoxycytidine analogue monophosphate phosphorylation, 1624

Q

Quinazolines
apoptosis induction, prostate cancer, 597

R

²²³Ra
antitumor effects, skeletal metastases, 3120
Rac
survival regulation, glioma, 2131
Rad6
overexpression
chromosomal instability induction, 2115
Rad51
elevated levels, tumor cells, 219
Radiation
 α -particle
bystander effects
oxidative metabolism and, fibroblasts, 5436
radionuclide ²²³Ra antitumor effects, skeletal metastases, 3120
bystander effects
membrane signaling, 2531
chemoradiation resistance
mediation by EGFR, glioblastoma, 4307
chemoradiation response
p53 and, cervical cancer, 7364
G₂ delay
cdc2 regulation, 241
ionizing
endothelium response
PI3K/Akt signaling, 4671
-induced NO, endothelial
apoptosis induction, 1450
Ku G₂ checkpoint effects, 6031
mutagenesis, solid tissue, 1518
sensitivity
modulation by insulin, 3555

S-phase checkpoint
Brcal requirements, 4588
NF- κ B activation
inhibition by anti-Ras scFv, 2318
pulmonary fibrosis
genetic loci, murine, 3782
thyroid tumors
mtDNA deletions, 7031
tumor response
arsenic trioxide and, 4202
tissue-specific induction, 7316
ZD1839 effects, 4300
ultraviolet
carcinogenesis
inhibition by DFMO, *Xpa*^{-/-} mice, 1338
melanomagenesis
Ink4a/Arf deficiency and, 6724
p70^{S6K} phosphorylation, signal pathways, 5689
smoothed mutations, xeroderma pigmentosum basal cell carcinoma, 7186
ultraviolet B
flux
and melanoma risk, 3992
Radiation-induced fibrosarcoma RIF-1
tumor tissue
redox mapping, 307
Radioimmunotherapy
combined with cilengitide, breast cancer, 4263
pretargeted ⁹⁰Y-labeled DOTA-biotin, mice, 5755
Radioresistance
cyclin B1 and, head and neck squamous cell carcinoma, 6414
Ras-mediated, 4142
Radiosensitivity
tissue-specific induction, 7316
Radiosensitization
dodecafluoropentane, hypoxic tumor cells, 3626
rapamycin, U87 xenografts, 7291
Radiotherapy
combined with Ad5- Δ 24RGD, glioma, 5736
SU6668 adjuvant, 1702
Ral A
EGF receptor-regulated cell motility, 982
Raloxifene
apoptosis induction
androgen-independent prostate cancer, 5365
prostate cancer LNCaP cells, 3649
Raman spectroscopy
breast microcalcifications, 5375
RANTES
promalignant activity, breast cancer, 1093
Rapamycin
chemoresistance modulation, prostate cancer, 6141
radiosensitization, U87 xenografts, 7291
TSC renal tumor inhibition, 5645
Ras
anti-Ras scFv
radiation-induced NF- κ B activation inhibition, 2318
CD95 expression inhibition
reversal by farnesyltransferase inhibitors, 450
cell transformation
reversal by IND 12, 1718
-mediated radioresistance, 4142
micrometastasis growth regulation, 887
mutations, lung cancer and melanoma, 6997
organ specificity, mammary cancer, 1241
Raspberry extracts
effects on BPDE-induced AP-1 and NF κ B, 6857

RASSF1A gene
epigenetic inactivation, medulloblastoma, 5906
methylation, prostate cancer, 3498
silencing, thyroid carcinoma, 3698
RBKIN gene
amplification, retinoblastoma, 967
Receptors
advanced glycation end product-binding motif, amphotericin
metastasis blockade, 4805
androgen
cell proliferation, androgen-refractory prostate cancer, 1008
mutations, prostate cancer, 1496
transactivation by IL-6
mediation by p300, 5632
benzodiazepine
peripheral
ligands, apoptosis resistance reversal, 1388
chemokine CCR7
CD45RA⁺CCR7⁺ cytotoxic T lymphocytes, melanoma, 1743
expression, lymph node metastasis, 2937
chemokine CXCR4
and B16 lung metastases, murine, 7328
cell migration and adhesion regulation, small cell lung cancer, 6304
neutralization, non-Hodgkin's lymphoma, 3106
prostate cancer metastasis to bone, 1832
regulation by VEGF
invasion promotion, breast cancer, 7203
cholecystokinin B
missplicing, pancreatic cancer, 947
coxsackie adenovirus
expression, prostate cancer, 3812
endothelin A
blockade
growth inhibition, cervical cancer, 6381
epidermal growth factor
anti-EGFR therapy resistance
mediation by IGFR-1, glioblastoma, 200
and bladder tumorigenesis, 4157
 Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
-dependent angiogenesis, skin carcinogenesis, 3402
expression
head and neck squamous cell carcinoma, 7350
induction by *Egr-1*, hypoxia, 827
inhibition
antiangiogenic effects, 2554
effects, breast epithelial proliferation, 122
metastatic pancreatic cancer, 1996
molecular targeting, neutron capture therapy, 3159
mutations
asbestos-induced proliferation inhibition, lung epithelium, 4169
radiation and BCNU resistance mediation, glioblastoma, 4307
-regulated cell motility
Ral A, 982
signaling
inhibition by ZD1839, 5749
Nf1:p53 mouse tumor cells, 4507
signal transactivation, head and neck squamous cell carcinoma, 6329
truncated trEGFR
mitogenic blockade, pancreatic cancer, 5611
epidermal growth factor 2
human: See **HER-2/neu**

epidermal growth factor VIII
invasion gene activation, 3335

estrogen
βcx protein, ERα-positive breast cancer, 4849
inhibition by BRCA1
modulation by p300, 141
SERM-ER complexes
gene expression profiles, breast cancer, 4419

estrogen α
absent, mammary tumor onset delay, 2798
βcx protein, breast cancer, 4849
lung cancer, 2141

estrogen β, lung cancer, 2141
estrogen-related, breast cancer, 6510

fibroblast growth factor
FGFR4 Arg³⁸⁸ allele
and tumor progression, 840

fibroblast growth factor I
phosphotyrosine 766, prostate tumor progression, 1898

G protein-coupled
Kaposi's sarcoma-associated herpesvirus
viral
gene expression modulation, 4525
KiSS1, 5399

hBUBR1
inactivation, 13

IL-13 receptor α2
IL-4 signaling inhibition, glioblastoma, 1103

insulin-like growth factor I
anti-EGFR therapy resistance mediation, glioblastoma, 200
expression, prostate cancer, 2942
metastatic phenotype and, breast cancer, 6529
signaling blockade by proinflammatory cytokines, breast cancer, 4746

interleukin 4, pancreatic cancer therapy, 3575

laminin 67-kDa
and cell motility, 1321

lymphotoxin-β
angiogenesis induction, 4034

platelet-derived growth factor
antagonists, chemotherapy enhancement, 5476

prostaglandin E EP₄, colon carcinogenesis, 28

retinoic acid β
loss, lung cancer, 3945

retinoic acid β2
reactivation, breast cancer, 2455

retinoic acid γ
paclitaxel resistance and, ovarian carcinoma, 2192

retinoid-related orphan RORγ
-deficient mice
T-cell lymphoma, 901

secretin, pancreatic cancer, 5223

sigma-2
agonists, apoptotic pathway, 313

somatostatin subtype 2
sst2 gene transfer, pancreatic cancer, 6124

T-cell
human TCR-like MUC1-specific recombinant antibodies, 5835
-like telomerase-specific recombinant antibodies, 3184
transcripts, multiple melanoma metastases, 5664
ζ chain
granzyme B-mediated degradation, 4884

TRAIL decoy DcR1 and DcR2

hypermethylation, tumors, 2157

Trk
osteoblast inhibition, 986

tumor necrosis factor-Rp55 knockout mice
liver metastasis, 6682

vascular endothelial growth factor
metastatic pancreatic cancer, 1996
phosphorylation inhibition by green tea catechins, 381

vascular endothelial growth factor 2
DNAzyme, 5463

vascular endothelial growth factor 3
progression marker, cutaneous melanoma, 7059

Redox
mapping, RIF-1 tumor tissue, 307
tumor status
glutathione levels and, 307

Rejection
tumor
IL-12-induced
effector mechanism, 5069
IFN-γ, 4696

Renal cell carcinoma
adenoviral gene therapy, 4273
diagnosis
array-based comparative genomic hybridization, 957
families
FH mutations, 4554
hypoxia-inducible factor expression, 2957
hypoxia regulation of cyclin D1
VHL-mediated, 3014
IL-6 production, 932
metastasis
postoperative azotemia and, 5218
metastasis to lung
prevention by angiotensin II type I antagonist, 4176
TRAIL/Apo2L-induced apoptosis, 3093
VEGF₁₆₅b downregulation, 4123

Renal tumors
growth inhibition
rAAV-mediated tsFlk-1 expression, mice, 3077
tuberous sclerosis complex
inhibition by rapamycin, 5645

Reovirus
colon and ovarian cancer therapy, 1696

Resveratrol
mammary carcinogenesis inhibition, rats, 4945
and prostate cancer cells, S phase, 2488

RET
kinase inhibition by ZD6474, 7284
RET-MEN type 2A
function-impaired
repair, 2414
transformational inhibition by PP1, 1077

Retinoblastoma
Msh2^{-/-}*Rb*^{+/-} mice
cell lineage effects, 5134
Rb gene
and genetic stability, mouse, 2498
RBKIN amplification, 967
Rb protein
protection by adeno-associated virus, 2982
tumor formation, preclinical mouse model, 1862
tumor suppressor RB
transcriptional repression, profiling, 6587

Retinoblastoma 94
head and neck squamous cell carcinoma
treatment, 4637

Retinoic acid
receptor β
loss, lung cancer, 3945

receptor β2
reactivation, breast cancer, 2455

receptor γ
paclitaxel resistance and, ovarian carcinoma, 2192

9-cis-Retinoic acid
prostatic intraepithelial neoplasia inhibition, rats, 5178

Retinoid
acyclic
growth inhibition, hepatoma, 3997
COX-2 induction inhibition, 2522

Retinoid-related orphan receptor RORγ
-deficient mice
T-cell lymphoma, 901

Retinoid X receptor α gene (RXRα)
allele inactivation, prostate epithelium, 4812

Retinol
metabolism
reduction, prostate cancer, 1654
retSDR1 and, neuroblastoma, 1196

Retrovirus
gene therapy
bone marrow TGF-β signaling blockade, 7135
gene transfer, ovarian cancer, 6099

retSDR1
and retinol metabolism, neuroblastoma, 1196

Rhabdoid tumors
childhood atypical
workshop meeting report, 323
INI1 and SWI/SNF complex, meeting report, 323

Rhabdomyosarcoma
alveolar
fusion-negative, 4704

RhoA
-dependent cell proliferation and apoptosis, prostate cancer, 2630

RhoGDI2
invasion and metastasis suppressor gene, cancer, 6418

Rho-like GTPase
autocrine motility factor-induced changes, 4484

Ribonucleoprotein D
heterogeneous nuclear hnRNP
overexpression, mice tumorigenesis, 1489

Ribosomal phosphoproteins
breast
downregulation by GnRH, 1036

Ritonavir
antitumor effects, 6901
-boosted docetaxel exposure, mice, 6158

RK3E epithelial cells
GLI-regulated transcripts, 5867

RNA
antisense
bcl-xL expression downregulation, 2175
prostate-specific aptamers, 4029
small interfering siRNAs
DNA-PKcs silencing by, 6400

RNA polymerase II holoenzyme
BRCA1 and BARD1 and, 4222

RNA-regulated protein kinase
translation regulation, 2272

RNF6 gene
mutations
somatic, esophageal squamous cell carcinoma, 4191

Runx1/AML-1 gene
T-cell lymphoma role, 7181

S

S100A calcium binding proteins
overexpression, gastric cancer, 6823

SAGE: *See* Serial analysis of gene expression

S-3APG: *See* S-3-Amino-phthalimido-glutarimide

Saquinavir
apoptosis induction, 5230

Sarcoma
 β -actin/AUF1 transgenic mice, 1489
Ewing's

EWS and *EWS-FLI1* fusion gene
BARD1 interactions, 4583
EWSRI-CIZ fusion gene, acute leukemia, 5408

Kaposi's
-associated herpesvirus viral G protein-coupled receptor
gene expression modulation, 4525
oxytocin growth factor, 2406

metastasis
CD44 gene effects, 2281

soft tissue
chromosomal aberrations and, 3980
inhibition, 2034

synovial
gene expression
genome-wide analysis, 5859
SYT-SSX and cyclin D1 expression, 3861
SYT-SSX fusion and, 135

uterine
1,2-dimethylhydrazine-induced, p53 transgenic mice, 3024

SBEM gene
breast tumor biomarker, 2736

Schwannian cells
neuroblastoma, 2986

Scintimammography
Tc-MIBI
Pgpr/MPR expression and, 617

Secondary lymphoid tissue chemokine
combined SLC/CD40L-mediated immunotherapy, antitumor activity, 6545

Secreted protein acidic and rich in cysteine (SPARC)
glioma invasion promotion, 6270
induction by β_1 integrin, melanoma, 226
neuroblastoma tumor angiogenesis inhibition, 7357

Secretin
receptor, pancreatic cancer, 5223

SEI-1 oncogene candidate
identification, ovarian cancer, 7157

Selectin
tumor angiogenesis, nude rats, 6289

Selective estrogen receptor modulators
SERM-ER complexes
gene expression profiles, breast cancer, 4419
SP500263

effects against breast cancer, 1439

Selenium
cell proliferation modulation, prostate cancer, 2540
chemopreventive mechanisms, breast cancer, 708

Selenoprotein-P
downregulation, prostate cancer progression, 5325

"Self-" antigen
tumor expression
and CD4⁺ T-cell function, 5144

SEL1L
expression
and tumor cell aggressiveness, breast tumors, 567

Semaphorin 3B
tumor inhibition, adenocarcinoma, 542

Semaphorin 3F
tumor inhibition, 2637

Senescence

induction by DNA damage, tumor cells, 1876
p300 downregulation and, melanocytes, 6231
p38^{HOG} role, 5076

prostate epithelial cells
characterization by SAGE, 6255

Sensitivity

anticancer drug
expression profiles, 518
CCI-779, multiple myeloma, 5027
CHS 828, PARP-1 fibroblasts, 4206
cisplatin
transcription-coupled nucleotide excision repair and, 4899
photodynamic therapy
extracellular signal-regulated kinase and, 5528

SEPTIN6

MLL-SEPTIN6 fusion, infant t(X;1)(q24;q23) acute myeloid leukemia, 333

SEREX: *See* Serological identification of tumor antigens by cDNA expression cloning

Serial analysis of gene expression
epithelial senescence characterization, prostate, 6255

gastric cancer, 6823
pancreatic cancer, 819

Serological identification of tumor antigens by cDNA expression cloning
melanoma antigen isolation, 4836
new design, lung cancer, 1751

SGN-30
antitumor activity, Hodgkin's disease, 3736

SHP1 gene
aberrant methylation, leukemias/lymphomas, 6390

SHPS-1
and cancer dissemination inhibition, 3929

Sialyl Lewis antigens
COX-2 and, colon cancer, 1567

Sialyl Lewis X antigen
-dependent lung colonization, melanoma, 4194

Sigma-2
receptor agonists, apoptotic pathway, 313

Signal transducer and activator of transcription 3
activation, prostate cancer, 6659
downregulation by sulindac, oral squamous cell carcinoma, 1004
head and neck squamous cell carcinoma, 3351
modulation by p53, breast cancer, 376

Silibinin
growth inhibition, prostate cancer, 3063

Silica
dendritic-like cells, 1050

Simian virus 40
large T antigen
Kin17 interactions, 5425

Single nucleotide polymorphisms (SNPs)
hOGG1
and prostate cancer, 2253
MDR1, acute myeloid leukemia, 4955
MMP2
and lung cancer risk, 6430

2G
MMP-1 promoter
and gene expression, 7200

Skeletal metastases
²²³Ra antitumor effects, 3120

Skeletal muscle
ubiquitin-proteasome-dependent proteolysis, 2771

Skin

histone acetyltransferase and histone deacetylase regulation by polyamines, murine, 67
p16 expression
 α -MSH and, 875

Skin cancer

non-melanoma
XRCC1 and, 152
PUFAs and, HPV-16 transgenic mice, 433

Skin carcinogenesis

EGFR-dependent angiogenesis, 3402
enhancement by cyclin D1, 1641
inhibition by cyclooxygenase 2, mice, 2516

Skin tumorigenesis

e12S-LOX, mouse, 4610
JNK1, mice, 1343
reduction by COX-1 or COX-2 deficiency, 3395

Skin tumors

okadaic acid-induced promotion
blockade by TAM-67, 3044
phenotype
Gli2 NH₂-terminal fragment and, 5308

SLIT2 gene

tumor suppressor activity, 5874

SLUG zinc-finger protein

E-cadherin inhibition, breast cancer, 1613

Smac

apoptosis, prostate cancer LNCaP cells, 18

Smad

signaling alterations, breast cancer, 497

Smad4

anoikis induction, 6045

Smad2 (Madh2)

Apc/Smad2 compound mutant mice
invasive tumors, 5955
null mutation
and malignant intestinal polyp progression, *Apc*^{Δ716} knockout mice, 4558

Smad ubiquitin ligase Smurf2

expression, esophageal squamous cell carcinoma, 7162

Small cell lung cancer

cell migration and adhesion
regulation by CXCR4 and c-Kit, 6304
oxytocin functional signaling, 4623

Smokeless tobacco cessation

NNK metabolites, 129

Smokers, former

bronchial epithelium and sputum hypermethylation, 2370
p16, *DAPK*, and *GSTP1* methylation, 351

Smoking

bronchial epithelium and sputum hypermethylation, 2370
ERCC2 polymorphisms and, lung cancer, 1377
p53 mutations and, breast cancer, 1987

Smoothered gene

mutations, xeroderma pigmentosum basal cell carcinoma, 7186

Soft tissue sarcoma

chromosomal aberrations and, 3980
inhibition, 2034

Solid tissue

ionizing radiation mutagenesis, 1518

Solid tumors

cell killing by viral fusogenic membrane glycoproteins, 6566
drug resistance
nuclear proteasome and, 5008
growth inhibition by CSF-1 antisense, 5317
pediatric
MS-27-275 antitumor activity, 6108

Somatostatin

cytotoxic analogue AN-238
and colon cancer, 781

- receptor subtype 2
ssr2 gene transfer, pancreatic cancer, 6124
- Sonic hedgehog Shh**
 medulloblastoma induction, mice, 6385
- SOX10**
 tumor-associated antigen, 3020
- SP500263**
 effects on breast cancer, 1439
- SPARC: See Secreted protein acidic and rich in cysteine**
- Spectral karyotyping**
 sporadic ovarian cancer analysis, 3466
- S-phase kinase-associated protein 2 (Skp2)**
 deficiency, recovery from partial hepatectomy, 995
 expression, gastric cancer, 3819
- Splicing alterations**
 allele separation and, 4579
NFI, *NF2*, and *TSC2*, tumors, 1503
- Sputum**
 hypermethylation, smokers, 2370
- Squamous cell carcinoma**
 esophageal
p16 silencing modes, 4938
RNF6 mutations, 4191
 Smurf2 expression and, 7162
WWOX alterations, 2258
 head and neck
 combination IL-2 gene therapy and cisplatin, 4023
 EGFR expression, 7350
 gene expression profiling, 1184
 growth promotion by COX-2-derived *PGE₂*, 6706
 growth promotion by *K-ras*, 7154
 hypoxia-inducible factors, 2493
 lymphangiogenesis, 1315
*p53*₂₆₄₋₂₇₂-specific T cells, 3521
 radiotherapy resistance
 cyclin B1 and, 6414
 retinoblastoma 94 treatment, 4637
 Stat3, 3351
 treatment outcome
 pimonidazole binding and tumor vascularity and, 7066
 oral
 inhibition by curcumin, 5451
 Stat3 downregulation by sulindac, 1004
 progression
 gene expression and activity alterations, 3759
- Src kinase**
 activation by endostatin, endothelial cells, 5580
 activity
 homotypic adhesion disruption, colon cancer, 2669
 function-impaired RET-MEN2A repair, 2414
- SRPK1 gene**
 inhibition
 bleomycin resistance and, 4453
- SSX gene**
SYT-SSX fusion genes
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
- Stanniocalcin 2**
 expression, breast cancer, 1289
- Stathmin**
 and antimicrotubule drugs, breast cancer, 6864
- Stem cells**
 acute myeloid leukemia
*DT₃₈₈*IL3 cytotoxicity, 1730
 mesenchymal
 IFN- β tumor delivery, 3603
 mobilization by combination defibrotide and rhG-CSF, mice, 6152
- neural
 IL-12, glioma therapy, 5657
 peripheral blood
 autologous transplantation
 adenoviral purging, 5013
- STI-571: See Imatinib**
- Stress**
 cellular response
PCPH oncogene and, 2690
 oxidative
 expression profiles, breast cancer, 6246
- Stroma**
 epithelial neoplasia regulation, 79
 gene expression
 MMP-1 2G single nucleotide polymorphism and, 7200
 neuroblastic and Schwannian cells, neuroblastoma, 2986
 prostate cancer-reactive
 TGF- β and angiogenesis, 6021
 reactive
 and prostate tumorigenesis, 3298
- Stromal cell-derived factor-1/CXCR4**
 prostate cancer metastasis to bone, 1832
- Stromelysin-1 (MMP-3) promoter**
 mutations, MSI-H colorectal cancer, 3855
- SU6668**
 combined with B7.2-IgG fusion protein, breast tumor therapy, 5727
 tumor radiotherapy adjuvant, 1702
- Sucrose-rich diet**
 mutations, rat colon, 4339
- Sudan I**
 metabolism by CYP1A1, 5678
- Suicide gene therapy**
 carboxypeptidase G2
 prodrugs, 1724
 double
 adenoviral, locally recurrent prostate cancer, 4968
 inducible
 combined with photodynamic therapy, 1458
 nitroreductase
 bystander effects, 3D cell cultures, 1425
- Sulfonamide anilides**
 anticancer agents, 4325
- Sulfonate-derived methylating agents**
 DNMT1 protein depletion, 1592
- Sulforaphane**
 -induced Nrf2-regulated genes, identification, 5196
- Sulindac**
 Stat3 downregulation, oral squamous cell carcinoma, 1004
- Sulindac derivative IND 12**
 Ras-induced cell transformation reversal, 1718
- Superchemosensitization**
 Herceptin pretreatment, breast cancer, 5703
- Suppression subtraction hybridization**
 ovarian cancer libraries, 262
- Surgery**
 postoperative azotemia
 and metastatic renal cell carcinoma, 5218
- Survivin**
 microtubule stability regulation, 2462
- SW 480 cells**
 migration inhibition by GABA, 6467
- SWI/SNF complex**
 rhabdoid tumors, meeting report, 323
- Syndecan-1**
 prognostic value, lung cancer, 5210
- Synovial sarcoma**
 gene expression
 genome-wide analysis, 5859
- SYT-SSX* and cyclin D1 expression, 3861
SYT-SSX fusion and, 135
- Synthetic combinatorial peptide libraries**
 positional scanning format
 recognition by tyrosinase-specific CTLs, 2058
- SYT-SSX fusion genes**
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
- SZF1**
 DNA binding, 3773
- T**
- TAF15**
TAF15-CIZ fusion, acute leukemia, 5408
- Tag microarrays**
 expressed CpG island sequence, 3214
- TAM-67**
 okadaic acid-induced tumor promotion blockade, 3044
- Tamoxifen**
 combined with urokinase-derived $\Delta 6$ angiogenesis inhibition, breast cancer, 4678
 genistein interactions, breast cancer, 2474
 VEGF regulation, breast cancer, 4977
- T antigen**
 Kin17 interactions, 5425
- TAP: See Transporter for antigen presentation**
- TAT-ODD fusion protein**
 antitumor effects, 2013
- TBX2**
 amplification, *BRCA1*- and *BRCA2*-related breast tumors, 3587
- T cell factor**
 transcription
 regulation by Wnt-1, esophageal cancer, 277
- T cell factor-4**
 mutations
 frameshift, MSI-high colorectal cancer, 3009
- T cell receptor**
 human TCR-like MUC1-specific recombinant antibodies, 5835
 -like telomerase-specific recombinant antibodies, 3184
 transcripts, multiple melanoma metastases, 5664
- T-cell receptor**
 ζ chain
 degradation
 granzyme B-mediated, 4884
- TDAGS1/PHLDA1 gene**
 function, metastatic melanoma, 5920
- Technetium-99m methoxyisobutylisonitrile scintimammography**
 Pgp/MRP expression and, 617
- TEL-AML1**
 acute leukemia induction, mice, 3904
- Telomerase**
 activity
 MKT-077 and, 4434
 modulation by cytokines, multiple myeloma, 3876
 inhibition, NIH 3T3 cells, 2104
 inhibitors
 G-quadruplex-related, TRAP assay, 3365
 regulation by JNK, ovarian surface epithelial cells, 4575
 -specific TCR-like recombinant antibodies, 3184
- Telomerase reverse transcriptase**
 human hTERT
 COOH-terminal fragment polypeptide

- telomere dysfunction, HeLa cells, 3226
HLA DR7-restricted epitopes, 2600
- Telomerase RNA**
-transfected dendritic cells, 5041
- Telomeres**
dysfunction
 hTERT COOH-terminal fragment
 polypeptide, HeLa cells, 3226
early shortening, prostate tumorigenesis, 6405
short
 angiogenesis, mice, 552
- Telomeric repeat amplification protocol (TRAP)**
G-quadruplex-related telomerase inhibitor assay, 3365
- Temozolomide**
cell invasion reduction, glioma, 1915
- Tenascin-C**
isoform expression, breast cancer, 3289
microvascular cell migration promotion, 2660
- Teratocarcinoma**
flt-1 promoter transcriptional targeting, 1271
- Teratoid/rhabdoid tumors**
childhood atypical
 workshop meeting report, 323
- Testicular germ cell tumorigenesis**
FHIT, 512
gene expression profiling, 2359
- Testicular germ cell tumors**
DAD-R and, 1822
- Testis antigen**
gene expression, lung cancer, 3971
- 1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid (DOTA)-biotin**
⁹⁰Y-labeled
 pretargeted
 radioimmunotherapy, mice, 5755
- Tetranucleotide repeats**
mutations, DNA damage, 6052
- Tetrathiomolybdate**
tumor growth and metastasis inhibition, 4854
- Thiol antioxidants**
apoptosis induction, tumor cells, 1443
- Thioredoxin-1**
HIF-1 α increase, 5089
- 3D cell cultures**
bystander effects, 1425
- Thrombospondin 1**
and tumor vascularity, glioblastoma, 1191
- Thrombospondin 2**
cell-based antiangiogenic gene therapy, 2004
- Thrombotic infarction**
selective, 5470
- Thromboxane A₂ synthase**
gene transfer, colon cancer, 63
- Thymic lymphoma**
prevention by dexamethasone, *Atm*^{-/-} mice, 5153
- Thymidine phosphorylase**
2-deoxy-l-ribose functional effects, 2834
- Thymidylate synthase**
p53-regulated gene modulation, 2644
promoter polymorphisms
 and colorectal adenomas, 3361
- Thyroid carcinoma**
RASSF1A silencing, 3698
- Thyroid hormone**
receptor $\beta 1$
 gene inactivation, early stage breast cancer, 1939
- Thyroid tumors**
mtDNA deletions, 7031
- Tirapazamine**
topo II poison, 5248
- Tissue**
CPI-0004Na distribution, 2327
glutathione levels
 and tumor redox status, 307
microarrays
 candidate gene target validation, prostate cancer, 1256
- T lymphocytes**
activation
 apoptotic pancreatic tumor cells, 2347
 inhibition by CD40-expressing carcinoma, 2052
adoptive
 combined with lymphocyte transgene therapy, 2043
CD4⁺
 indirect tumor killing mediation, 2611
 "self"-antigen tumor expression and, 5144
CD8⁺
 antigen-presenting cell interactions, 5065
 -mediated tumor killing
 IFN- γ and, mice, 5058
 memory
 activation, 6438
epitope hierarchy, lymphoma
 subversion, 1116
helper
 CD4⁺
 EBNA1 peptides, 7195
 wtp53-specific, antitumor efficacy, 6187
 HPV16 E2-specific responses, 472
 NY-ESO-1 119-143 epitope, 213
leukemia
 adult
 PS-341 therapy, murine model, 1083
 lymphokine-activated killer-derived
 inhibition by HLA class I molecules, 480
lymphoma
 cutaneous
 Fas splice variant, 5389
 DNA vaccines against, 1757
 ROR γ -deficient mice, 901
migration to tumor masses
 CCR5, 3751
neoplastic
 Par-4 function, 1768
p53²⁶⁴⁻²⁷²-specific, head and neck cancer, 3521
receptor
 human TCR-like MUC1-specific recombinant antibodies, 5835
 -like telomerase-specific recombinant antibodies, 3184
 transcripts, multiple melanoma metastases, 5664
 ζ chain
 granzyme B-mediated degradation, 4884
 regulatory
 CTL inhibition, colorectal cancer, 5267
 synergy with anti-HER2 mAb trastuzumab, 2244
 tumor antigen response, poly-l-arginine vaccination, 1477
- Topoisomerase I**
mutations, novel, 3716
- Topoisomerase II**
hypoxia-activated poison tirapazamine, 5248
- Topoisomerase II-directed drugs**
resistance
 nuclear proteasome and, 5008
- Toremifene**
chemopreventive activity, prostate cancer, 1370
- Toxicity**
aflatoxin B₁, bronchial cells, 105
- antibody-dependent cellular cytotoxicity
 anti-adhesive antibody and, 6891
antifolate
 uracil misincorporation, 4909
CPI-0004Na, 2327
discodermolide and epothilone B, non-small cell lung cancer, 4081
DT₃₈₈IL3, acute myeloid leukemia stem cells, 1730
ET-743, female rat, 4256
GART inhibitor
 p53 independence, 5236
glycinamide ribonucleotide formyltransferase inhibitors, 5236
- Transcription**
-coupled nucleotide excision repair
 and cisplatin sensitivity, 4899
repression
 RB-mediated, profiling, 6587
-targeted chemotherapy agent ET-743, 3377
- Transcriptome mapping**
non-small cell lung cancer, 3340
- Transforming growth factor β**
and angiogenesis, prostate cancer-reactive stroma, 6021
bone marrow signaling
 blockade, cancer gene therapy, 7135
signaling
 early loss, endometrial carcinoma, 2778
- Transforming growth factor $\beta 1$**
germ-free TGF- $\beta 1$ -deficient mice
 colon cancer elimination, 6362
p53 damage response mediation, 5627
- Transgenes**
cancer-inducible
 expression by Grp94 promoter, 7207
- Translation**
regulation by caspases and RNA-regulated protein kinase, 2272
- Transplantation**
autologous peripheral blood stem cells
 adenoviral purging, 5013
- Transporter for antigen presentation (TAP)-1**
-deficient tumors, 2856
- Trastuzumab (herceptin)**
gastric cancer, 5813
phosphatidylinositol 3-kinase and Akt inhibition induction, 4132
pretreatment
 superchemosensitization, breast cancer, 5703
rapid accumulation and internalization, inflammatory breast cancer, 860
synergy with T cells, 2244
- Trk**
receptor
 osteoblast inhibition, 986
- TrkA**
angiogenesis inhibition, neuroblastoma, 1802
dose and function, 4867
- TrkB**
BDNF-TrkB-PI3K pathway
 protection against chemotherapy, neuroblastoma, 6756
chemotherapy resistance mediation, neuroblastoma, 6462
- TSLC1 gene**
DAL-1 association, lung cancer, 5129
- TSP50 gene**
activation, breast cancer, 290
- Tuberin**
14-3-3 interactions, 6475
- Tuberous sclerosis complex**
renal tumors
 inhibition by rapamycin, 5645
TSC2 gene

- aberrant splicing, tumors, 1503
- loss
 - HMGA2 expression and, uterine leiomyoma, 3766
- Tubulin**
 - new cancericidal ligand 3-iodoacetamido benzoyl ethyl ester, 6080
 - small molecule
 - 2-aryloindole inhibitors, 3113
- Tubulogenesis**
 - hepatocyte growth factor-induced N-WASP, 2503
- Tumor angiogenesis: See Angiogenesis**
- Tumor-associated antigen**
 - melanoma with vitiligo
 - isolation by SEREX, 4836
 - primed dendritic cells, cancer vaccines, 1884
 - SOX10, 3020
 - T-cell response, poly-L-arginine vaccination, 1477
- Tumor cells**
 - apoptosis
 - regulation
 - HERG K⁺ channel, 4843
 - CML28 overexpression, 5517
 - dissemination
 - inhibition
 - SHPS-1 and, 3929
 - MAGE-A expression, 251
 - E6/E7-immortalized
 - combination HPV-16 E7 and CpG-ODN immune therapy, 7234
 - endothelial
 - placental growth factor survival factor, 2749
 - extracellular membrane vesicles
 - angiogenic activity, 6312
 - furamidine analogue distribution, 7219
 - genomic instability-null, 6345
 - hypoxic
 - radiosensitization by dodecafluoropentane, 3626
 - RGD-peptide binding, 5139
 - senescence
 - induction by DNA damage, 1876
- Tumor cell vaccines**
 - fusion, melanoma, 5495
- Tumor growth**
 - angiogenesis dependence, review, 1931
 - APC mutations and, colorectal tumors, 363
 - assessment with PET, 5698
 - chromogranin A and, mouse models, 941
 - enhancement by complement inhibitor, breast cancer, 1110
 - fluorescence imaging, pancreatic cancer, 1534
 - GPIIb/IIIa and $\alpha\beta$ 3 integrins and, 2824
 - inhibition
 - AAV-encoded angiostatin, glioma, 756
 - adenoviral endostatin delivery, mammary tumors, 3934
 - allele-specific, 2024
 - combination pegylated IFN- α 2b and docetaxel, prostate cancer, 5720
 - combination urokinase-derived A6 and tamoxifen, breast cancer, 4678
 - CSF-1 antisense, solid tumors, 5317
 - ⁶⁴Cu-PTSM, 445
 - human anti-MUC18, melanoma, 5106
 - IL-12, mammary carcinoma, 747
 - mediation by CD4⁺ T-cells, 2611
 - metallothionein, 5370
 - PC-SPES, colon cancer, 5204
 - PS-341, myeloma, 4996
 - rAAV-mediated tsFlk-1 expression, renal tumors, 3077
 - S-3APG, mice, 2300
 - SPARC, glioma, 6270
 - sulfonamide anilides, novel, 4325
 - tetrathiomolybdate, 4854
 - thrombospondin 2, cell-based antiangiogenic gene therapy, 2004
 - vascular endothelial-cadherin antibody
 - E4G10, 2567
 - ZD1839, 5749
- prevention
 - FTY720, mouse breast cancer, 1410
- promotion
 - COX-2-derived PGE₂, head and neck cancer, 6706
 - fibroblast activation protein, 4767
 - morphine, 4491
- regulation
 - HERG K⁺ channel, 4843
 - IFN- γ -dependent phagocytic cells, metastatic mammary carcinoma, 4406
 - IGF-I, colon cancer, 1030
- Tumorigenesis**
 - AUF1/hnRNPd overexpression, mice, 1489
 - DNA polymerase β and, 3511
 - EGFR signaling, *Nfl:p53* mouse tumor cells, 4507
 - HIF-1 α , 2962
 - inhibition by *semaphorin 3F*, 2637
 - Myc-induced
 - inhibition by *E2f1*, 3276
 - p16^{INK4a} and p53 deficiency, murine, 2761
 - Rb-dependent
 - preclinical mouse model, 1862
- Tumorigenicity**
 - VEGF and, glioma, 1854
- Tumor immunity**
 - central nervous system
 - induction by *L. monocytogenes* vaccine, 2287
- Tumor infarction**
 - selective, 5470
- Tumor-infiltrating macrophages**
 - and tumor angiogenesis, 7042
- Tumor load**
 - reduction by vitamin D₃ compounds, Apc^{min} mice, 741
- Tumor masses**
 - T cell migration
 - CCR5, 3751
- Tumor necrosis factor**
 - receptor p55
 - TNF-Rp55 knockout mice
 - liver metastasis, 6682
- Tumor necrosis factor-related apoptosis-inducing ligand**
 - apoptosis
 - PI3K/PTEN/Akt kinase pathway, 4929
 - cytochrome *c* release
 - blockade by epidermal growth factor, 488
 - decoy receptors DcR1 and DcR2
 - hypermethylation, tumors, 2157
 - GFP/TRAIL fusion protein
 - targeted expression, hepatocytes, 3620
 - neural stem cell-mediated delivery, glioma therapy, 7170
 - TRAIL/Apo2L-induced apoptosis, colorectal cancer, 1583
- Tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand**
 - apoptosis
 - COX-2 and, colon cancer, 4903
 - sensitization by casein kinase II inhibition, 4180
 - apoptosis, renal cell carcinoma, 3093
 - combined with chemotherapy, colon tumors, 7448
- 5800
- Tumor-primed dendritic cells**
 - cancer vaccines, 1884
- Tumors**
 - Apc* and *Smad2* compound mutant mice, 4558
 - ARF^{-/-}Bax^{-/-}* mice, 2184
 - blood flow
 - antivascular therapy and monitoring, high-frequency Doppler ultrasound, 6371
 - colitis-associated
 - Msh2*-deficient mice, 2092
 - dormant
 - solitary cells and, 2162
 - eradication
 - CD8⁺ T-cell-mediated
 - IFN- γ and, mice, 5058
 - Hsp70 depletion, xenografts, 7139
 - focal adhesion kinase signaling *in vivo*, 2699
 - histone acetyltransferase and histone deacetylase regulation by polyamines, murine, 67
 - intra-tumoral oxygen distribution, photodynamic therapy, 7273
 - IRS-1 activation, 6035
 - large
 - immunotherapy
 - anti-4-1BB mAb and, 3459
 - liposome distribution, 6831
 - microenvironment
 - and tumor therapy, 1462
 - microvascular endothelium
 - heparin-binding VEGF substructure binding, 7118
 - NF1*, *NF2*, and *TSC2* aberrant splicing, 1503
 - progression
 - Akt role, melanoma, 7335
 - FGFR4 Arg³⁸⁸ allele and, 840
 - progranulin, 5590
 - radiation response
 - arsenic trioxide and, 4202
 - radiotherapy
 - SU6668 adjuvant, 1702
 - redox status
 - glutathione levels and, 307
 - rejection
 - IL-12-induced
 - effector mechanism, 5069
 - IFN- γ , 4696
 - RIF-1
 - redox mapping, 307
 - TRAIL decoy receptors DcR1 and DcR2
 - hypermethylation, 2157
 - vascularity
 - destruction by ZD6126, 7247
 - PTK787/ZK 222584 effects, 4015
 - reduction by TSP-1 overexpression, glioblastoma, 1191
 - and treatment outcome, head and neck cancer, 7066
- Tumor suppressor genes**
 - chromosome 3p21.3 homozygous deletion region, 2715
 - chromosome 15q15 candidates, B-cell lymphoma, 7175
 - X chromosome
 - MEF, 6579
- Tumor vaccines**
 - enhancement by immunized donor leukocyte infusion, 796
 - fusion, melanoma, 5495
 - photodynamic therapy, 1604
 - tumor-primed dendritic cells, 1884
- Tumor vessels**
 - anionic phospholipid exposure, 6132
 - phosphatidylserine marker, 6132

Tyrosinase

- specific CTLs
- PS-SCL recognition, 2058

U

Ubiquitin ligase

- Chfr activity, 1797

Ubiquitin-proteasome

- dependent proteolysis
- skeletal muscle, 2771

UCN-01: See 7-Hydroxystaurosporine

UL16-binding proteins

- recognition by NKG2D, tumors, 6178

Ulcerative colitis

- associated colorectal cancer
- HPPI aberrant methylation, 6820
- p14^{ARF} hypermethylation, 1148
- colonic mutated crypts, 2236

Ultrasound

- chemotherapy drug delivery, rat model, 7280
- high-frequency Doppler
- antivascular therapy monitoring, 6371

Ultraviolet B radiation

- flux
- and melanoma risk, 3992

Ultraviolet radiation

- carcinogenesis
- inhibition by DFMO, *Xpa*^{-/-} mice, 1338
- melanomagenesis
- Ink4a/Arf deficiency and, 6724
- p70^{S6K} phosphorylation, signal pathways, 5689
- smoothed mutations, xeroderma pigmentosum basal cell carcinoma, 7186

Upper urinary tract cancer

- microsatellite instability, 6796

Uracil

- misincorporation, antifolate toxicity, 4909

Uridine phosphorylase

- knockout
- and pyrimidine regulation, 2313

Urinary tract cancer

- upper
- microsatellite instability, 6796

Urokinase

- and tumor metastasis *in vivo*, 2390

Urokinase-derived A6

- combined with tamoxifen
- angiogenesis inhibition, breast cancer, 4678

Urokinase-type plasminogen activator

- predictive impact, breast cancer, 4617

Uroplakin II promoter

- human, identification and use, 3743

Urothelial neoplasia

- flat
- genetic alterations, 809

Uterine leiomyoma

- HMG2 expression and TSC2 loss, 3766

Uterine sarcoma

- 1,2-dimethylhydrazine-induced, p53 transgenic mice, 3024

Uterine tumors

- LMP2^{-/-} mice, 24

V

Vaccination

- CD40L-transduced lymphoma cell, 3195
- DNA
- B-cell lymphoma, 5845
- DNA electrovaccination, melanoma, 5489
- HLA-A*0201 HPV16 tumor model, 5792
- poly-L-arginine, 1477

Vaccines

- candidate chronic myelogenous leukemia
- rAAV dendritic cell-targeted, 3175

dendritic cell-based

- IL-18 gene-transduced, immunotherapy, 5853

DNA

- against T-cell lymphoma, 1757
- MHC class I and class II dual-specific peptides, 3630
- recombinant HSP110-HER-2/*neu* protein, 1737
- telomerase RNA-transfected dendritic cells, 5041
- tumor
- enhancement by immunized donor leukocyte infusion, 796
- fusion, melanoma, 5495
- photodynamic therapy, 1604
- tumor-primed dendritic cells, 1884
- tumor-primed dendritic cells, 1884
- vector-based
- combined with cytokines, 5770

Vascular endothelial growth factor

- autocrine regulation, prostate cancer, 854
- CXCR4 regulation
- invasion promotion, breast cancer, 7203
- DNA-binding protein B expression, 4985
- heparin-binding substructure
- glycosaminoglycans binding and tumor endothelium localization, 7118
- induction by desferri-exochelin, 6924
- in vivo* imaging, 5912
- isoforms
- and tumor vessel patterning, melanoma, 1838
- receptor
- metastatic pancreatic cancer, 1996
- phosphorylation inhibition by green tea catechins, 381
- receptor 2
- DNAzyme, 5463
- receptor 3
- progression marker, cutaneous melanoma, 7059
- regulation
- estrogen, breast cancer, 4977
- hormonal, breast cancer, 1948
- MT1-MMP, glioma, 580
- secretion by tumor-infiltrating macrophages and tumor angiogenesis, 7042
- signaling inhibition by ZD6474, 4645
- and tumorigenicity, glioma, 1854
- and tumor progression, β -cell carcinogenesis, 603

Vascular endothelial growth factor 165

- peritumor lymphatic drain, MR mapping, 6731

Vascular endothelial growth factor-A₁₆₅

- vascularity effects, melanoma brain metastases, 341

Vascular endothelial growth factor_{165b}

- downregulation, renal cell carcinoma, 4123

Vascular endothelial growth factor-D

- prognostic value, colorectal cancer, 1669

Vasculature

- antivascular liposomal doxorubicin effects, rat brain tumor model, 2561
- ionizing radiation response
- PI3K/Akt signaling, 4671
- tumor
- PTK787/ZK 222584 effects, 4015
- and treatment outcome, head and neck cancer, 7066
- VEGF-A₁₆₅ effects, melanoma brain metastases, 341

Vasculogenic mimicry

- hemodynamics, inflammatory breast cancer, 560

Vaults

- and drug resistance, murine, 7298

VG76e

- [¹²⁴I]iodinated-, 5912

Vinyl chloride

- induced N²,3-ethenoguanine
- molecular dosimetry and repair, rats, 5189
- rat brain and liver, 5183

Virosomes

- antirat neu, cancer therapy, 437

Virus-directed enzyme prodrug therapy

- neuroblastoma purging, 5001

Vitamin D₃

- adenoviral replication enhancement, 3084
- compounds
- tumor load reduction, Apc^{min} mice, 741
- differentiation
- blockade by leukemia-associated fusion proteins, 7050

Vitamin K₂

- and gap junctional intercellular communication, 4922

Vitiligo

- melanoma
- tumor-associated antigen, isolation, 4836

von Hippel-Lindau disease

- cyclin D1 modifier, 3803

von Hippel-Lindau gene *VHL*

- β 1-integrin fibrillar adhesion formation, 2929
- hypoxia regulation of cyclin D1, renal cell carcinoma, 3014

von Hippel-Lindau protein pVHL

- catecholamine regulation, PC12 cells, 1682
- neuroblastoma transformation to neuronal cells, 7004

von Hippel-Lindau tumorigenesis

- malignant conversion, 1952

W

Waardenburg syndrome type 4 gene *SOX10*

- tumor-associated antigen, 3020

Wall, Monroe E.

- in memoriam, 7377

Werner syndrome

- plasmid-based deletion assay, fibroblasts, 547

Wilms' tumor

- gene expression profiling, 6598
- WT1* gene

- p53 gene interactions, 6615

Wiskott-Aldrich syndrome protein

- neural N-WASP
- hepatocyte growth factor-induced tubulogenesis, 2503
- podosome formation, 669

WK175

- apoptosis induction, leukemia, 1057

Wnt

- Met expression regulation, colorectal cancer, 5126

Wnt-1

- T cell factor transcription regulation, esophageal cancer, 277

Wnt-5a

- loss of expression, invasive breast cancer, 409

WRN gene

- loss, effects, 547

WWOX (WW domain containing oxidoreductase) gene

- alterations, esophageal squamous cell carcinoma, 2258

X

X chromosome

- MEF tumor suppressor gene, 6579

Xeroderma pigmentosum

- basal cell carcinoma

SUBJECT INDEX TO VOLUME 62

smoothed mutations, 7186
Xpa^{-/-} mice
 UV carcinogenesis inhibition by DFMO, 1338
XPD
 cisplatin resistance regulation, 5457
X-ray cross-complementing group 1 gene (*XRCC1*)
Arg399Gln polymorphism
 and pancreatic adenocarcinoma risk, 4630
 camptothecin resistance, 459
 and non-melanoma skin cancer, 152

Y

Yeast cytosine deaminase
 expression under CEA promoter, 2337

YKL-40
 serum levels, malignant glioma, 4364
Yttrium-90
 -labeled DOTA-biotin
 pretargeted
 radioimmunotherapy, mice, 5755

Z

ZBRK1
 DNA-binding site, 3773
ZD1839 (Iressa)
 antiangiogenic effects, 2554
 EGFR signaling and tumor growth inhibition, 5749
 radiation response and tumor-induced angio-

genesis effects, 4300
ZD6126
 pulmonary metastases effects, lung adenocarcinoma, 3711
 tumor vasculature destruction, 7247
ZD6474
 RET kinase inhibition, 7284
 VEGF signaling inhibition, 4645
ZK 222584: See PTK787
***Znfn1a1/Ikaros* gene**
 alterations, murine lymphoma, 2650
Zoledronate
 osteoblastic *versus* osteolytic lesion treatment, SCID mouse model, 5564

